{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from utils.io import load_object, save_object\n",
    "from utils.evaluation import calc_eval_metrics\n",
    "from collections import Counter\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import colorcet as cc\n",
    "from statsmodels.stats.multitest import multipletests\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Manuscript Figures and Results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 2A. Accuracy of LLM across various prompt strategies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_data=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_mistnemo_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra0n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_1 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra1n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_2 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra2n1temp0.0_res_dict.pkl'))\n",
    "llm_mistnemo_res_dict_3 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_mistnemo/stra3n1temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                               0          1\n",
      "Basic_prompt            0.692308  69.230769\n",
      "Basic_prompt_condition  0.534188  53.418803\n",
      "Basic_prompt_system     0.645299  64.529915\n",
      "Basic_prompt_combined   0.512821  51.282051\n"
     ]
    }
   ],
   "source": [
    "plot_res = pd.DataFrame(\n",
    "    {\n",
    "    'Basic_prompt' : [calc_eval_metrics(llm_mistnemo_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_condition' : [calc_eval_metrics(llm_mistnemo_res_dict_1['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_system' : [calc_eval_metrics(llm_mistnemo_res_dict_2['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']],\n",
    "    'Basic_prompt_combined' : [calc_eval_metrics(llm_mistnemo_res_dict_3['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)['avg_partial_match_acc']]\n",
    "    }\n",
    "    )\n",
    "    \n",
    "plot_res = plot_res.iloc[0,:].to_frame()\n",
    "plot_res[1] = plot_res[0]*100\n",
    "print(plot_res)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [],
   "source": [
    "plot_res[1].rename(index={\n",
    "    'Basic_prompt':'(1) Basic prompt',\n",
    "    'Basic_prompt_condition':'(2) Basic prompt + condition',\n",
    "    'Basic_prompt_system':'(3) Basic prompt + system role',\n",
    "    'Basic_prompt_combined':'(4) Basic prompt + (2) + (3)'\n",
    "                          }, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 350x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res[1].plot(kind='bar', color=cols[3], width=0.6, legend=False)\n",
    "\n",
    "# add text\n",
    "for i, v in enumerate(plot_res[1]):\n",
    "    ax.text(x=i, y=v+0.05, s=f'{v:.1f}', ha='center', va='bottom', fontsize=10)\n",
    "\n",
    "# x, y label and ticks\n",
    "ax.set_xlabel('Prompt strategy', fontsize=11)\n",
    "ax.set_ylabel('Partial Match Accuracy (%)', fontsize=11)\n",
    "plt.xticks(rotation=45, ha='right')\n",
    "\n",
    "# borders\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# highlight first bar\n",
    "ax.patches[0].set_facecolor(cols[3])\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    if i != 0:  \n",
    "        patch.set_alpha(0.5) \n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig('./figures/Figure2_accuracyLLMprompt.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 2B. Accuracy of LLMs of various sizes across prompt strategies"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Statistical test on basic vs. combination prompts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load McNemar package\n",
    "from statsmodels.stats.contingency_tables import mcnemar\n",
    "\n",
    "# Function to create a contingency matrix for McNemar's test\n",
    "def create_mcnemar_table(y_pred_A, y_pred_B):\n",
    "    \n",
    "    # Convert to numpy arrays for easy element-wise comparison\n",
    "    y_pred_A = np.array(y_pred_A)\n",
    "    y_pred_B = np.array(y_pred_B)\n",
    "\n",
    "    # Compute contingency table values\n",
    "    a = np.sum((y_pred_A == True) & (y_pred_B == True)) # Both correct\n",
    "    b = np.sum((y_pred_A == True) & (y_pred_B == False)) # A correct, B incorrect\n",
    "    c = np.sum((y_pred_A == False) & (y_pred_B == True)) # A incorrect, B correct\n",
    "    d = np.sum((y_pred_A == False) & (y_pred_B == False)) # Both incorrect\n",
    "\n",
    "    # Create contingency table\n",
    "    table = np.array([[a, b], [c, d]])\n",
    "\n",
    "    return(table)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load LLM-only outputs and evaluate\n",
    "models = ['mist7B', 'mist8B', 'mistnemo', 'mistlarge', 'gptmini', 'gpt4o', 'o4mini']\n",
    "strategies = [0, 3]\n",
    "\n",
    "llm_output_dicts = {}\n",
    "llm_eval_res = {}\n",
    "partial_acc_dicts = {}\n",
    "\n",
    "for model in models:\n",
    "    model_eval = {}\n",
    "    for strategy in strategies:\n",
    "        output_key = f\"llm_{model.lower()}_res_dict_{strategy}\"\n",
    "        eval_key = f\"llm_{model.lower()}_eval_res_{strategy}\"\n",
    "        \n",
    "        # Load LLM outputs\n",
    "        path = os.path.join(root_dir, f'output/LLM_res_{model}/stra{strategy}n1temp0.0_res_dict.pkl')\n",
    "        llm_output_dicts[output_key] = load_object(filename=path)\n",
    "        \n",
    "        # Evaluate LLM outputs\n",
    "        eval_result = calc_eval_metrics(llm_output_dicts[output_key]['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "        llm_eval_res[eval_key] = eval_result\n",
    "        \n",
    "        # Save each model's results\n",
    "        model_eval[strategy] = {'partial_match_acc':eval_result['partial_match_acc'], 'avg_partial_match_acc':eval_result['avg_partial_match_acc']}\n",
    "        \n",
    "    partial_acc_dicts[f\"{model}_partial_acc_dict\"] = model_eval\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table for mcnemar's test\n",
    "mcnemar_tables = {}\n",
    "for model in models:\n",
    "    mcnemar_tables[f'{model}_partial_table'] = create_mcnemar_table(\n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][3]['partial_match_acc'], \n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][0]['partial_match_acc']\n",
    "    )\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Perform McNemar's test (use exact=True if b+c < 25)\n",
    "def conduct_mcnemar_test(table):\n",
    "    b, c = table[[0,1],[1,0]]\n",
    "    if b+c < 25:\n",
    "        result = mcnemar(table, exact=True, correction=True) \n",
    "    else:\n",
    "        result = mcnemar(table, exact=False, correction=True)\n",
    "    discordants = {'b':b, 'c':c}\n",
    "    return(result, discordants)\n",
    "\n",
    "# Print results\n",
    "def print_mcnemar_res(mcnemar_result, alpha):\n",
    "    significance = mcnemar_result.pvalue < alpha\n",
    "    \n",
    "    return f\"Significance: {significance}; Test Statistic: {mcnemar_result.statistic}; P-value: {mcnemar_result.pvalue}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Significance: False; Test Statistic: 2.938775510204082; P-value: 0.08647626549366548\n",
      "Significance: False; Test Statistic: 2.56; P-value: 0.10959858339911568\n",
      "Significance: True; Test Statistic: 38.20454545454545; P-value: 6.370385309896191e-10\n",
      "Significance: False; Test Statistic: 5.0; P-value: 0.30175781249999994\n",
      "Significance: False; Test Statistic: 5.0; P-value: 0.09625244140625\n",
      "Significance: False; Test Statistic: 3.0; P-value: 0.057373046875\n",
      "Significance: False; Test Statistic: 8.0; P-value: 0.38331031799316406\n"
     ]
    }
   ],
   "source": [
    "# Run McNemar and get accuracies\n",
    "model_labels = dict(zip(models, ['mist_7B', 'mist_8B', 'mistnemo_12B', 'mistlarge_123B', 'gpt4omini', 'gpt4o','o4mini']))\n",
    "\n",
    "mcnemar_result = {}\n",
    "accuracy = {}\n",
    "p_values = {}\n",
    "\n",
    "for model, label in model_labels.items():\n",
    "    # Run McNemar's test\n",
    "    mcnemar_result[f'{model}_mcnemar_res'], _ = conduct_mcnemar_test(mcnemar_tables[f'{model}_partial_table'])\n",
    "    print(print_mcnemar_res(mcnemar_result[f'{model}_mcnemar_res'], alpha=0.05))\n",
    "\n",
    "    # Get p-values\n",
    "    p_values[label] = mcnemar_result[f'{model}_mcnemar_res'].pvalue\n",
    "    \n",
    "    # Get accuracies\n",
    "    accuracy[label] = [\n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][0]['avg_partial_match_acc'], \n",
    "        partial_acc_dicts[f'{model}_partial_acc_dict'][3]['avg_partial_match_acc']\n",
    "    ]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot bar graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "(1) Basic prompt",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "(2) Basic prompt + (2) + (3)",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "3e75a9db-2574-4e6c-8960-aa5e95849575",
       "rows": [
        [
         "mist_7B",
         "32.05128205128205",
         "37.60683760683761"
        ],
        [
         "mist_8B",
         "44.44444444444444",
         "48.29059829059829"
        ],
        [
         "mistnemo_12B",
         "69.23076923076923",
         "51.28205128205128"
        ],
        [
         "mistlarge_123B",
         "67.09401709401709",
         "64.95726495726495"
        ],
        [
         "gpt4omini",
         "70.51282051282051",
         "67.09401709401709"
        ],
        [
         "gpt4o",
         "75.64102564102564",
         "72.22222222222221"
        ],
        [
         "o4mini",
         "69.23076923076923",
         "67.09401709401709"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 7
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>(1) Basic prompt</th>\n",
       "      <th>(2) Basic prompt + (2) + (3)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>mist_7B</th>\n",
       "      <td>32.051282</td>\n",
       "      <td>37.606838</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mist_8B</th>\n",
       "      <td>44.444444</td>\n",
       "      <td>48.290598</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mistnemo_12B</th>\n",
       "      <td>69.230769</td>\n",
       "      <td>51.282051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mistlarge_123B</th>\n",
       "      <td>67.094017</td>\n",
       "      <td>64.957265</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gpt4omini</th>\n",
       "      <td>70.512821</td>\n",
       "      <td>67.094017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gpt4o</th>\n",
       "      <td>75.641026</td>\n",
       "      <td>72.222222</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>o4mini</th>\n",
       "      <td>69.230769</td>\n",
       "      <td>67.094017</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                (1) Basic prompt  (2) Basic prompt + (2) + (3)\n",
       "mist_7B                32.051282                     37.606838\n",
       "mist_8B                44.444444                     48.290598\n",
       "mistnemo_12B           69.230769                     51.282051\n",
       "mistlarge_123B         67.094017                     64.957265\n",
       "gpt4omini              70.512821                     67.094017\n",
       "gpt4o                  75.641026                     72.222222\n",
       "o4mini                 69.230769                     67.094017"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_models_acc=pd.DataFrame(accuracy)\n",
    "all_models_acc.rename(index={\n",
    "    0:'(1) Basic prompt',\n",
    "    1:'(2) Basic prompt + (2) + (3)'\n",
    "    }, inplace=True\n",
    ")\n",
    "\n",
    "all_models_acc=all_models_acc*100\n",
    "all_models_acc=all_models_acc.transpose()\n",
    "all_models_acc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pval_to_stars(p):\n",
    "    if p < 0.001:\n",
    "        return '***'\n",
    "    elif p < 0.01:\n",
    "        return '**'\n",
    "    elif p < 0.05:\n",
    "        return '*'\n",
    "    else:\n",
    "        return ''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_res=all_models_acc\n",
    "\n",
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [5, 5]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, [cols[3], cols[25]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(kind='barh', color=row_colors, width=0.6, legend=False)\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_width() # bar length (horizontal position)\n",
    "    y = bar.get_y() + bar.get_height()/2 # center the bar (vertical position)\n",
    "    ax.text(x+0.02, y, f'{x:.1f}', ha='left', va='center', fontsize=9)\n",
    "    \n",
    "# add p-value significance\n",
    "yticks = np.arange(len(plot_res.index))  \n",
    "bar_height = ax.patches[0].get_height()\n",
    "n_bars = plot_res.shape[1] # bars per group (i.e., columns in plot_res)\n",
    "bar_offsets = np.linspace(-bar_height/2, bar_height/2, n_bars, endpoint=False) # offsets per bar within group\n",
    "\n",
    "for i, (label, pval) in enumerate(p_values.items()):\n",
    "    if label not in plot_res.index:\n",
    "        continue\n",
    "    row_idx = plot_res.index.get_loc(label)\n",
    "\n",
    "    # get the bars for this group\n",
    "    bar_group = ax.patches[row_idx * n_bars : (row_idx + 1) * n_bars]\n",
    "    if len(bar_group) < 2:\n",
    "        continue\n",
    "\n",
    "    bar1, bar2 = bar_group\n",
    "    y_pos = yticks[row_idx] + np.mean(bar_offsets[:2]) + bar_height / 2\n",
    "\n",
    "    # place to the right of the longer bar\n",
    "    x_pos = max(bar1.get_width(), bar2.get_width()) + 1.0\n",
    "\n",
    "    # convert p-value to stars\n",
    "    sig = pval_to_stars(pval)\n",
    "    if sig:\n",
    "        ax.text(x_pos, y_pos, sig,\n",
    "                ha='left', va='center',\n",
    "                fontsize=11, fontweight='bold', rotation=90)\n",
    "\n",
    "    \n",
    "# x, y label and ticks\n",
    "ax.set_xlabel('Partial Match Accuracy (%)', fontsize=12)\n",
    "ax.set_ylabel('')\n",
    "ax.tick_params(labelsize=11)\n",
    "for spine in ax.spines.values():\n",
    "    spine.set_visible(False)\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=\"Prompt strategy\", \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          )\n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# set background and grid color\n",
    "ax.set_facecolor('white')\n",
    "ax.grid(axis='x', linestyle='--', color='lightgray', linewidth=0.8)\n",
    "\n",
    "# save\n",
    "save = True\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/Figure2_accuracyPromptLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3A. Impact of RAG integration on LLM performance with unstructured and structured database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load RAG-LLM and baseline results\n",
    "base_model='gpt4o'\n",
    "rag_unstruc_res_dict_0 = load_object(filename=os.path.join(root_dir, f'output/RAG_res_{base_model}/unstructured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "rag_struc_res_dict_0 = load_object(filename=os.path.join(root_dir, f'output/RAG_res_{base_model}/structured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "llm_res_dict_0 = load_object(filename=os.path.join(root_dir, f'output/LLM_res_{base_model}/stra0n5temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "-----First iteration-----\n",
      "Unstructured: 0.7948717948717948, 0.9017094017094017, 0.49424603174603166\n",
      "Structured: 0.9444444444444444, 0.9529914529914529, 0.793091168091168\n",
      "LLM-only: 0.6153846153846154, 0.7521367521367521, 0.44864672364672314\n"
     ]
    }
   ],
   "source": [
    "# Evaluate RAG-LLM output from the first iteration\n",
    "unstruc_results = calc_eval_metrics(rag_unstruc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "struc_results = calc_eval_metrics(rag_struc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "llm_results = calc_eval_metrics(llm_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "\n",
    "print(\"-----First iteration-----\")\n",
    "print(f\"Unstructured: {unstruc_results['avg_exact_match_acc']}, {unstruc_results['avg_partial_match_acc']}, {unstruc_results['avg_precision']}\")\n",
    "print(f\"Structured: {struc_results['avg_exact_match_acc']}, {struc_results['avg_partial_match_acc']}, {struc_results['avg_precision']}\")\n",
    "print(f\"LLM-only: {llm_results['avg_exact_match_acc']}, {llm_results['avg_partial_match_acc']}, {llm_results['avg_precision']}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate evaluation metrics for the RAG-LLM output from all iterations\n",
    "all_results_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_exact_acc_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_partial_acc_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_precision_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_recall_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_f1_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "avg_specificity_ls = {'unstructured':[], 'structured':[], 'llm':[]}\n",
    "\n",
    "for i in range(5):\n",
    "    try:\n",
    "        unstruc_results = calc_eval_metrics(rag_unstruc_res_dict_0['full output'][i], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "        struc_results = calc_eval_metrics(rag_struc_res_dict_0['full output'][i], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "        llm_results = calc_eval_metrics(llm_res_dict_0['full output'][i], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "        \n",
    "        all_results_ls['unstructured'].append(unstruc_results)\n",
    "        all_results_ls['structured'].append(struc_results) \n",
    "        all_results_ls['llm'].append(llm_results) \n",
    "        \n",
    "        avg_exact_acc_ls['unstructured'].append(unstruc_results['avg_exact_match_acc'])\n",
    "        avg_exact_acc_ls['structured'].append(struc_results['avg_exact_match_acc'])\n",
    "        avg_exact_acc_ls['llm'].append(llm_results['avg_exact_match_acc'])\n",
    "        \n",
    "        avg_partial_acc_ls['unstructured'].append(unstruc_results['avg_partial_match_acc'])\n",
    "        avg_partial_acc_ls['structured'].append(struc_results['avg_partial_match_acc'])\n",
    "        avg_partial_acc_ls['llm'].append(llm_results['avg_partial_match_acc'])\n",
    "        \n",
    "        avg_precision_ls['unstructured'].append(unstruc_results['avg_precision'])\n",
    "        avg_precision_ls['structured'].append(struc_results['avg_precision'])\n",
    "        avg_precision_ls['llm'].append(llm_results['avg_precision'])\n",
    "        \n",
    "        avg_recall_ls['unstructured'].append(unstruc_results['avg_recall'])\n",
    "        avg_recall_ls['structured'].append(struc_results['avg_recall'])\n",
    "        avg_recall_ls['llm'].append(llm_results['avg_recall'])\n",
    "        \n",
    "        avg_f1_ls['unstructured'].append(unstruc_results['avg_f1'])\n",
    "        avg_f1_ls['structured'].append(struc_results['avg_f1'])\n",
    "        avg_f1_ls['llm'].append(llm_results['avg_f1'])\n",
    "        \n",
    "        avg_specificity_ls['unstructured'].append(unstruc_results['avg_specificity'])\n",
    "        avg_specificity_ls['structured'].append(struc_results['avg_specificity'])\n",
    "        avg_specificity_ls['llm'].append(llm_results['avg_specificity'])\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(e)\n",
    "        continue"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average exact acc: {'unstructured': 0.7931623931623932, 'structured': 0.941025641025641, 'llm': 0.6170940170940171}\n",
      "Average partial acc: {'unstructured': 0.9076923076923077, 'structured': 0.9529914529914529, 'llm': 0.7538461538461538}\n",
      "Average precision: {'unstructured': 0.4916625966625965, 'structured': 0.7969210419210417, 'llm': 0.4379059829059824}\n",
      "Average recall: {'unstructured': 0.8535612535612538, 'structured': 0.947008547008547, 'llm': 0.7058404558404553}\n",
      "Average f1: {'unstructured': 0.5715557851455293, 'structured': 0.8427215804138882, 'llm': 0.5087986087986094}\n",
      "Average specificity: {'unstructured': 0.9658298602884694, 'structured': 0.9916636892004626, 'llm': 0.9759272458748841}\n"
     ]
    }
   ],
   "source": [
    "print(\"Average exact acc:\",{key: np.mean(value) for key, value in avg_exact_acc_ls.items()})\n",
    "print(\"Average partial acc:\",{key: np.mean(value) for key, value in avg_partial_acc_ls.items()})\n",
    "print(\"Average precision:\",{key: np.mean(value) for key, value in avg_precision_ls.items()})\n",
    "print(\"Average recall:\",{key: np.mean(value) for key, value in avg_recall_ls.items()})\n",
    "print(\"Average f1:\",{key: np.mean(value) for key, value in avg_f1_ls.items()})\n",
    "print(\"Average specificity:\",{key: np.mean(value) for key, value in avg_specificity_ls.items()})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Run statistical test to compare performances"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "RAG-LLM unstructured vs. LLM-only - across five iterations - mcnemar's test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table\n",
    "exact_table_ls=[]\n",
    "partial_table_ls=[]\n",
    "model_A='unstructured'\n",
    "model_B='llm'\n",
    "\n",
    "for i in range(5):\n",
    "    exact_table_ls.append(create_mcnemar_table(\n",
    "        all_results_ls[model_A][i]['exact_match_acc'], \n",
    "        all_results_ls[model_B][i]['exact_match_acc'] \n",
    "        )\n",
    "                          )\n",
    "    \n",
    "    partial_table_ls.append(create_mcnemar_table(\n",
    "        all_results_ls[model_A][i]['partial_match_acc'], \n",
    "        all_results_ls[model_B][i]['partial_match_acc']\n",
    "        )\n",
    "                            )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "unstructured_vs_llm:\n",
      "Exact: Significance: True; Test Statistic: 153.37591240875912; P-value: 3.170431977463823e-35\n",
      "Partial: Significance: True; Test Statistic: 129.19758064516128; P-value: 6.1392583682076796e-30\n"
     ]
    }
   ],
   "source": [
    "exact_result_ls=[]\n",
    "partial_result_ls=[]\n",
    "exact_result_pval=[]\n",
    "partial_result_pval=[]\n",
    "exact_result_bc=[]\n",
    "partial_result_bc=[]\n",
    "pooled_exact = np.array([[0, 0], [0, 0]])\n",
    "pooled_partial = np.array([[0, 0], [0, 0]])\n",
    "\n",
    "for i in range(5):\n",
    "    # run mcnemar's test separately\n",
    "    exact_result, exact_bc = conduct_mcnemar_test(exact_table_ls[i])\n",
    "    partial_result, partial_bc = conduct_mcnemar_test(partial_table_ls[i])\n",
    "    exact_result_ls.append(exact_result)\n",
    "    partial_result_ls.append(partial_result)\n",
    "    \n",
    "    # pool matrix\n",
    "    pooled_exact += np.array(exact_table_ls[i])\n",
    "    pooled_partial += np.array(partial_table_ls[i])\n",
    "\n",
    "    # mcnemar's p-values\n",
    "    exact_result_pval.append(exact_result.pvalue)\n",
    "    partial_result_pval.append(partial_result.pvalue)\n",
    "    \n",
    "    # get discordant (b,c) values (if b > c, model A is better)\n",
    "    exact_result_bc.append(exact_bc)\n",
    "    partial_result_bc.append(partial_bc)\n",
    "\n",
    "# run mcnemar's test on pooled matrix\n",
    "pooled_exact_result, pooled_exact_bc = conduct_mcnemar_test(pooled_exact) \n",
    "pooled_partial_result, pooled_partial_bc = conduct_mcnemar_test(pooled_partial)\n",
    "\n",
    "print(f'{model_A}_vs_{model_B}:')\n",
    "print(f'Exact: {print_mcnemar_res(pooled_exact_result, alpha=0.05)}')\n",
    "print(f'Partial: {print_mcnemar_res(pooled_partial_result, alpha=0.05)}')\n",
    "\n",
    "all_mcnemar_results = {\n",
    "    f'{model_A}_vs_{model_B}': {'exact': pooled_exact_result, 'partial': pooled_partial_result}\n",
    "    }"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "RAG-LLM structured vs. RAG-LLM unstructured - across five iterations - mcnemar's test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table\n",
    "exact_table_ls=[]\n",
    "partial_table_ls=[]\n",
    "model_A='structured'\n",
    "model_B='unstructured'\n",
    "\n",
    "for i in range(5):\n",
    "    exact_table_ls.append(create_mcnemar_table(\n",
    "        all_results_ls[model_A][i]['exact_match_acc'], \n",
    "        all_results_ls[model_B][i]['exact_match_acc'] \n",
    "        )\n",
    "                          )\n",
    "    \n",
    "    partial_table_ls.append(create_mcnemar_table(\n",
    "        all_results_ls[model_A][i]['partial_match_acc'], \n",
    "        all_results_ls[model_B][i]['partial_match_acc']\n",
    "        )\n",
    "                            )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "structured_vs_unstructured:\n",
      "Exact: Significance: True; Test Statistic: 103.80350877192983; P-value: 2.23409161233704e-24\n",
      "Partial: Significance: True; Test Statistic: 16.588957055214724; P-value: 4.642052747520578e-05\n"
     ]
    }
   ],
   "source": [
    "exact_result_ls=[]\n",
    "partial_result_ls=[]\n",
    "exact_result_pval=[]\n",
    "partial_result_pval=[]\n",
    "exact_result_bc=[]\n",
    "partial_result_bc=[]\n",
    "pooled_exact = np.array([[0, 0], [0, 0]])\n",
    "pooled_partial = np.array([[0, 0], [0, 0]])\n",
    "\n",
    "for i in range(5):\n",
    "    # run mcnemar's test separately\n",
    "    exact_result, exact_bc = conduct_mcnemar_test(exact_table_ls[i])\n",
    "    partial_result, partial_bc = conduct_mcnemar_test(partial_table_ls[i])\n",
    "    exact_result_ls.append(exact_result)\n",
    "    partial_result_ls.append(partial_result)\n",
    "    \n",
    "    # pool matrix\n",
    "    pooled_exact += np.array(exact_table_ls[i])\n",
    "    pooled_partial += np.array(partial_table_ls[i])\n",
    "\n",
    "    # mcnemar's p-values\n",
    "    exact_result_pval.append(exact_result.pvalue)\n",
    "    partial_result_pval.append(partial_result.pvalue)\n",
    "    \n",
    "    # get discordant (b,c) values (if b > c, model A is better)\n",
    "    exact_result_bc.append(exact_bc)\n",
    "    partial_result_bc.append(partial_bc)\n",
    "\n",
    "# run mcnemar's test on pooled matrix\n",
    "pooled_exact_result, pooled_exact_bc = conduct_mcnemar_test(pooled_exact) \n",
    "pooled_partial_result, pooled_partial_bc = conduct_mcnemar_test(pooled_partial)\n",
    "\n",
    "print(f'{model_A}_vs_{model_B}:')\n",
    "print(f'Exact: {print_mcnemar_res(pooled_exact_result, alpha=0.05)}')\n",
    "print(f'Partial: {print_mcnemar_res(pooled_partial_result, alpha=0.05)}')\n",
    "\n",
    "all_mcnemar_results[f'{model_A}_vs_{model_B}'] = {\n",
    "    'exact': pooled_exact_result, 'partial': pooled_partial_result\n",
    "    }"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Adjust p-values from all comparisons"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[3.170431977463823e-35,\n",
       " 6.1392583682076796e-30,\n",
       " 2.23409161233704e-24,\n",
       " 4.642052747520578e-05]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_pvalues=[]\n",
    "for comparison, output in all_mcnemar_results.items():\n",
    "    all_pvalues.append(output['exact'].pvalue)\n",
    "    all_pvalues.append(output['partial'].pvalue)\n",
    "all_pvalues"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([1.26817279e-34, 1.22785167e-29, 2.97878882e-24, 4.64205275e-05])"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# multiple test correction\n",
    "_, p_corrected, _, _ = multipletests(all_pvalues, alpha=0.05, method='fdr_bh')\n",
    "p_corrected"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Raw: 3.170431977463823e-35, 6.1392583682076796e-30\n",
      "Adjusted: [1.26817279e-34 1.22785167e-29]\n"
     ]
    }
   ],
   "source": [
    "print(f\"Raw: {all_mcnemar_results['unstructured_vs_llm']['exact'].pvalue}, {all_mcnemar_results['unstructured_vs_llm']['partial'].pvalue}\")\n",
    "print(f'Adjusted: {p_corrected[0:2]}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Raw: 2.23409161233704e-24, 4.642052747520578e-05\n",
      "Adjusted: [2.97878882e-24 4.64205275e-05]\n"
     ]
    }
   ],
   "source": [
    "print(f\"Raw: {all_mcnemar_results['structured_vs_unstructured']['exact'].pvalue}, {all_mcnemar_results['structured_vs_unstructured']['partial'].pvalue}\")\n",
    "print(f'Adjusted: {p_corrected[2:4]}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plot bar graph"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Using acc results from all five iterations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "LLM-only",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Unstructured RAG-LLM",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Structured RAG-LLM",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "19f7535b-3e5d-492d-9d08-7a5c8cd4309c",
       "rows": [
        [
         "Exact match accuracy",
         "61.70940170940171",
         "79.31623931623932",
         "94.1025641025641"
        ],
        [
         "Partial match accuracy",
         "75.38461538461539",
         "90.76923076923077",
         "95.2991452991453"
        ]
       ],
       "shape": {
        "columns": 3,
        "rows": 2
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LLM-only</th>\n",
       "      <th>Unstructured RAG-LLM</th>\n",
       "      <th>Structured RAG-LLM</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Exact match accuracy</th>\n",
       "      <td>61.709402</td>\n",
       "      <td>79.316239</td>\n",
       "      <td>94.102564</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Partial match accuracy</th>\n",
       "      <td>75.384615</td>\n",
       "      <td>90.769231</td>\n",
       "      <td>95.299145</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                         LLM-only  Unstructured RAG-LLM  Structured RAG-LLM\n",
       "Exact match accuracy    61.709402             79.316239           94.102564\n",
       "Partial match accuracy  75.384615             90.769231           95.299145"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# compute means and standard deviations\n",
    "means = {\n",
    "    'LLM-only': \n",
    "        [np.mean(avg_exact_acc_ls['llm']) * 100, np.mean(avg_partial_acc_ls['llm']) * 100],\n",
    "    'Unstructured RAG-LLM': \n",
    "        [np.mean(avg_exact_acc_ls['unstructured']) * 100, np.mean(avg_partial_acc_ls['unstructured']) * 100],\n",
    "    'Structured RAG-LLM': \n",
    "        [np.mean(avg_exact_acc_ls['structured']) * 100, np.mean(avg_partial_acc_ls['structured']) * 100]\n",
    "        }\n",
    "\n",
    "stds = {\n",
    "    'LLM-only': \n",
    "        [np.std(avg_exact_acc_ls['llm']) * 100, np.std(avg_partial_acc_ls['llm']) * 100],\n",
    "    'Unstructured RAG-LLM': \n",
    "        [np.std(avg_exact_acc_ls['unstructured']) * 100, np.std(avg_partial_acc_ls['unstructured']) * 100],\n",
    "    'Structured RAG-LLM': \n",
    "        [np.std(avg_exact_acc_ls['structured']) * 100, np.std(avg_partial_acc_ls['structured']) * 100]\n",
    "        }\n",
    "\n",
    "\n",
    "# convert to dataframe\n",
    "plot_res = pd.DataFrame(means, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "# Convert stds to DataFrame for error bars\n",
    "error_bars = pd.DataFrame(stds, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "plot_res"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 450x370 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [4.5, 3.7]\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, ['0.8', cols[23], cols[6]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(\n",
    "    kind='bar', \n",
    "    yerr=error_bars,\n",
    "    capsize=4,\n",
    "    color=[row_colors[name] for name in plot_res.columns], \n",
    "    width=0.6, \n",
    "    legend=False\n",
    "    )\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_x() + bar.get_width() / 2\n",
    "    y = bar.get_height()\n",
    "    ax.text(x, y+2, f'{y:.2f}', ha='center', va='bottom', fontsize=9)\n",
    "    \n",
    "# x, y labels, ticks, grid\n",
    "ax.set_xlabel('')\n",
    "ax.set_ylabel('Accuracy (%)', fontsize=12)\n",
    "ax.tick_params(axis='x', labelsize=10, rotation=0)\n",
    "ax.tick_params(axis='y', labelsize=11)\n",
    "ax.set_facecolor(color='white')\n",
    "\n",
    "# borders\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "    \n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=3,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure3_accuracyRAGLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3B. Impact on other evaluation metrics: precision, recall, f1, specificity"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from math import pi\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# metrics\n",
    "metrics = ['Exact accuracy', 'Partial accuracy', 'Precision', 'Recall', 'F1 Score', 'Specificity']\n",
    "\n",
    "# llm-only model (averaged across five runs)\n",
    "values_llm = [\n",
    "    np.mean(avg_exact_acc_ls['llm']),\n",
    "    np.mean(avg_partial_acc_ls['llm']),\n",
    "    np.mean(avg_precision_ls['llm']),\n",
    "    np.mean(avg_recall_ls['llm']),\n",
    "    np.mean(avg_f1_ls['llm']),\n",
    "    np.mean(avg_specificity_ls['llm'])\n",
    "    ]\n",
    "values_llm = [value*100 for value in values_llm] \n",
    "values_llm += values_llm[:1] \n",
    "\n",
    "# unstructured model (averaged across five runs)\n",
    "values_unstruc = [\n",
    "    np.mean(avg_exact_acc_ls['unstructured']),\n",
    "    np.mean(avg_partial_acc_ls['unstructured']),\n",
    "    np.mean(avg_precision_ls['unstructured']),\n",
    "    np.mean(avg_recall_ls['unstructured']),\n",
    "    np.mean(avg_f1_ls['unstructured']),\n",
    "    np.mean(avg_specificity_ls['unstructured'])\n",
    "    ]\n",
    "values_unstruc = [value*100 for value in values_unstruc] \n",
    "values_unstruc += values_unstruc[:1] \n",
    "\n",
    "# structured model (averaged across five runs)\n",
    "values_struc = [\n",
    "    np.mean(avg_exact_acc_ls['structured']),\n",
    "    np.mean(avg_partial_acc_ls['structured']),\n",
    "    np.mean(avg_precision_ls['structured']),\n",
    "    np.mean(avg_recall_ls['structured']),\n",
    "    np.mean(avg_f1_ls['structured']),\n",
    "    np.mean(avg_specificity_ls['structured'])\n",
    "    ]\n",
    "values_struc = [value*100 for value in values_struc] \n",
    "values_struc += values_struc[:1]\n",
    "\n",
    "# radar chart setup\n",
    "angles = [n / float(len(metrics)) * 2 * pi for n in range(len(metrics))]\n",
    "angles += angles[:1]\n",
    "\n",
    "# set up the plot\n",
    "plt.figure(figsize=(5, 5))\n",
    "ax = plt.subplot(111, polar=True)\n",
    "\n",
    "# plot the models\n",
    "ax.plot(angles, values_llm, color='0.8', linewidth=2, linestyle='solid', \n",
    "        label='LLM-only')\n",
    "ax.plot(angles, values_unstruc, color=cols[23], linewidth=2, linestyle='solid',\n",
    "        label='RAG with unstructured database')\n",
    "ax.plot(angles, values_struc, color=cols[6], linewidth=2, linestyle='solid', \n",
    "        label='RAG with structured database')\n",
    "\n",
    "# Annotate each metric value\n",
    "for i in range(len(metrics)):\n",
    "    ax.text(angles[i], values_llm[i] - 15, \n",
    "            f\"{values_llm[i]:.0f}\",\n",
    "            color='grey', fontsize=9, ha='center', va='center')\n",
    "    ax.text(angles[i], values_unstruc[i] - 8, \n",
    "            f\"{values_unstruc[i]:.0f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "    ax.text(angles[i] - 0.08, values_struc[i] + 8, \n",
    "            f\"{values_struc[i]:.0f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "\n",
    "# Labels and ticks\n",
    "ax.set_ylim(0, 100)\n",
    "ax.tick_params(axis='y', labelsize=9)\n",
    "ax.set_xticks([])\n",
    "for i, metric in enumerate(metrics): # Manually set the position of the labels outside the chart\n",
    "    angle = angles[i]  \n",
    "    if angle == 0:  \n",
    "        ax.text(angle, 160, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "    else:\n",
    "        ax.text(angle, 130, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "\n",
    "# Create a custom legend\n",
    "from matplotlib.lines import Line2D\n",
    "handles = [Line2D([0], [0], color=col, linewidth=2) for col in ['0.8', cols[23], cols[6]]]\n",
    "legend = ax.legend(handles, ['LLM-only', 'RAG with unstructured database', 'RAG with structured database'], \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=1,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=11\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# Save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure3_ragllmPerformance_radar.jpeg', dpi=600, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'exact_match_acc': 18.642241379310338, 'partial_match_acc': 4.990583804143116, 'avg_precision': 62.08697739680385, 'avg_recall': 10.947930574098763, 'avg_f1': 47.44345212065604, 'avg_specificity': 2.674780515097881}\n",
      "Precision: 49.17 to 79.69\n",
      "F1-score: 57.16 to 84.27\n"
     ]
    }
   ],
   "source": [
    "# Calculate percent increase of evaluation metrics\n",
    "def perc_increase(old, new):\n",
    "    if old == 0:\n",
    "        if new == 0:\n",
    "            return 0  \n",
    "        return None  \n",
    "    return ((new - old) / old) * 100\n",
    "\n",
    "perc_increase_ls=[]\n",
    "for i in range(len(values_unstruc)):\n",
    "    perc_increase_ls.append(perc_increase(new=values_struc[i], old=values_unstruc[i]))\n",
    "\n",
    "print(dict(zip(['exact_match_acc', 'partial_match_acc','avg_precision','avg_recall','avg_f1','avg_specificity'], perc_increase_ls)))\n",
    "print(f'Precision: {values_unstruc[2]:.2f} to {values_struc[2]:.2f}')\n",
    "print(f'F1-score: {values_unstruc[4]:.2f} to {values_struc[4]:.2f}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WilcoxonResult(statistic=15.0, pvalue=0.03125)\n",
      "WilcoxonResult(statistic=15.0, pvalue=0.03125)\n",
      "WilcoxonResult(statistic=15.0, pvalue=0.03125)\n",
      "WilcoxonResult(statistic=15.0, pvalue=0.03125)\n"
     ]
    }
   ],
   "source": [
    "# Compare statistically\n",
    "from scipy.stats import wilcoxon, ttest_rel\n",
    "\n",
    "print(wilcoxon(avg_precision_ls['structured'], avg_precision_ls['unstructured'], alternative='greater'))\n",
    "print(wilcoxon(avg_recall_ls['structured'], avg_recall_ls['unstructured'], alternative='greater'))\n",
    "print(wilcoxon(avg_f1_ls['structured'], avg_f1_ls['unstructured'], alternative='greater'))\n",
    "print(wilcoxon(avg_specificity_ls['structured'], avg_specificity_ls['unstructured'], alternative='greater'))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 3C. Accuracy of RAG-LLM across therapies, diseases and genomic alterations"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Get exact match accuracies from the first iteration"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create df for plotting\n",
    "plot_df = moalmanac_data\n",
    "plot_df['RAGLLM_struc_res'] = struc_results['exact_match_acc']\n",
    "plot_df['RAGLLM_unstruc_res'] = unstruc_results['exact_match_acc']\n",
    "plot_df['oncotree_code'] = plot_df['oncotree_code'].fillna('Any solid tumor')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Accuracy across cancer types"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure subplots\n",
    "fig, axes = plt.subplots(nrows=2, ncols=1, figsize=(8,5), gridspec_kw=dict(height_ratios=[1, 1]))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create accuracy dataframe \n",
    "df_all = pd.DataFrame()\n",
    "for col in ['RAGLLM_unstruc_res', 'RAGLLM_struc_res']:\n",
    "    df = pd.crosstab(plot_df['oncotree_code'], plot_df[col])\n",
    "    df['accuracy'] = df[True] / (df[True] + df[False])\n",
    "    df_all = pd.concat([df_all, df.rename(columns = {'accuracy':col})[col]], axis = 1)\n",
    "\n",
    "# add counts (number of relationships)\n",
    "group_cnt_df = pd.DataFrame.from_dict(Counter(plot_df['oncotree_code']), orient=\"index\", columns=[\"Number of relationships\"])\n",
    "df_all=df_all.merge(group_cnt_df, left_index=True, right_index=True)\n",
    "\n",
    "# sort by number of relationships (descending) \n",
    "df_all = df_all.sort_values(by=\"Number of relationships\", ascending=False)\n",
    "\n",
    "# create a mapping of names to colors\n",
    "struc_unstruc_colors = dict(zip(df_all.columns[0:2], [cols[23],cols[6]]))\n",
    "num_rel_color = cols[7]\n",
    "\n",
    "# create bar plot\n",
    "df_all[['RAGLLM_unstruc_res', 'RAGLLM_struc_res']].plot(kind='bar', color=struc_unstruc_colors, \n",
    "                                                        width=0.6, legend=False, ax=axes[1])\n",
    "df_all['Number of relationships'].plot(kind='bar', color=num_rel_color, width=0.6, legend=False, ax=axes[0])\n",
    "    \n",
    "# x, y label and ticks\n",
    "axes[0].set_ylabel('Number of entities', fontsize=12)\n",
    "axes[0].set_xticks([])\n",
    "axes[1].set_ylabel('Accuracy', fontsize=12)\n",
    "axes[1].set_xlabel('Cancer type', fontsize=12)\n",
    "axes[1].tick_params(axis='x', labelrotation=45, size=5)\n",
    "for label in axes[1].get_xticklabels():\n",
    "    label.set_ha('right') \n",
    "    label.set_rotation_mode('anchor')\n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(axes[0].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "for i, patch in enumerate(axes[1].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# change background and grid color\n",
    "for ax in axes:\n",
    "    # change background color\n",
    "    ax.set_facecolor('white')\n",
    "    # change grid color\n",
    "    ax.grid(visible=True, axis='y', color='lightgray', linestyle='dotted')  \n",
    "\n",
    "# Save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure3_cancerAcc_heatmap.jpeg', dpi=600, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "RAGLLM_unstruc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "RAGLLM_struc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Number of relationships",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "perc_increase",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "oncotree_term",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "oncotree_code",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "3f8d1df8-ef1a-467f-b942-8223e43fe384",
       "rows": [
        [
         "30",
         "0.1",
         "1.0",
         "10",
         "900.0",
         "Melanoma",
         "MEL"
        ],
        [
         "28",
         "0.5",
         "1.0",
         "36",
         "100.0",
         "Prostate Adenocarcinoma",
         "PRAD"
        ],
        [
         "10",
         "0.6666666666666666",
         "1.0",
         "6",
         "50.000000000000014",
         "Cholangiocarcinoma",
         "CHOL"
        ]
       ],
       "shape": {
        "columns": 6,
        "rows": 3
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>RAGLLM_unstruc_res</th>\n",
       "      <th>RAGLLM_struc_res</th>\n",
       "      <th>Number of relationships</th>\n",
       "      <th>perc_increase</th>\n",
       "      <th>oncotree_term</th>\n",
       "      <th>oncotree_code</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.100000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>10</td>\n",
       "      <td>900.0</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>MEL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>36</td>\n",
       "      <td>100.0</td>\n",
       "      <td>Prostate Adenocarcinoma</td>\n",
       "      <td>PRAD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.666667</td>\n",
       "      <td>1.0</td>\n",
       "      <td>6</td>\n",
       "      <td>50.0</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>CHOL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    RAGLLM_unstruc_res  RAGLLM_struc_res  Number of relationships  \\\n",
       "30            0.100000               1.0                       10   \n",
       "28            0.500000               1.0                       36   \n",
       "10            0.666667               1.0                        6   \n",
       "\n",
       "    perc_increase            oncotree_term oncotree_code  \n",
       "30          900.0                 Melanoma           MEL  \n",
       "28          100.0  Prostate Adenocarcinoma          PRAD  \n",
       "10           50.0       Cholangiocarcinoma          CHOL  "
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# calculate percentage increase\n",
    "df_all['perc_increase'] = df_all.apply(lambda row: perc_increase(old=row['RAGLLM_unstruc_res'], \n",
    "                                                                 new=row['RAGLLM_struc_res']), \n",
    "                                       axis=1)\n",
    "\n",
    "df_all_perc=df_all.sort_values(by=\"perc_increase\", ascending=False)\n",
    "\n",
    "# top cancer types with percentage increase >= 30 and number of relationships >= 5\n",
    "df_all_perc.loc[(df_all_perc['perc_increase'] >= 30) & (df_all_perc['Number of relationships'] >= 5), :]\\\n",
    "    .merge(plot_df[['oncotree_term','oncotree_code']], \n",
    "           left_index=True, right_on='oncotree_code', how='inner')\\\n",
    "               .drop_duplicates()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Accuracy across therapy types"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "# clean therapy strategy names\n",
    "plot_df['therapy_strategy_2']=plot_df['therapy_strategy'].replace(r'inhibition|targets|signaling','', regex=True).str.replace(r'\\s+', ' ', regex=True).replace(r'chemotherapy|Chemotherapy','chemo', regex=True).str.strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAr8AAAKbCAYAAAD8JOLOAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/OQEPoAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzde1gUZf8G8Ht2ERDlIB7whIdMUzMzNZQyj5ivlae01Ep9Sau3RFPfSsuzVmYHs9KyMssO/rJ6KyvNVEzNtFQSTUWiUBEFxBAQhYXd+f7+WHacZXdhV1nAuD/XtZePuzszz70z8+WZ2dldRUQERERERETVgKGyO0BEREREVFE4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqg4NfIiIiIqo2OPglIiIiomqDg18iIiIiqjZ8KrsDVZ2qqjh9+jQCAwOhKEpld4eIiIiIShARnD9/Ho0bN4bBUPq5XQ5+y3D69GmEh4dXdjeIiIiIqAwnT55E06ZNS30OB79lCAwMBGB9MYOCgiq5N0RERERUUm5uLsLDw7VxW2k4+C2D7VKHoKAgDn6JiIiIqjB3LlHlB96IiIiIqNrg4JeIiIiIqg0OfomIiIio2uDgl4iIiIiqDQ5+iYiIiKja4OCXiIiIiKoNftXZ5dgywb3nRa30bj+IiIiIyCM880tERERE1QYHv0RERERUbVTaZQ8XL17Ep59+CpPJhDvuuAPNmzevrK4QERERUTVRIYPf8ePH49dff8WhQ4cAAIWFhejevbv2/+DgYGzduhU33XRTRXSHiIiIiKqpCrns4ccff8Tdd9+t/X/NmjU4dOgQPvnkExw6dAgNGzbE/PnzK6IrRERERFSNVcjgNz09HS1atND+//XXX6Nr164YPXo02rdvj4ceegi//vprRXSFiIiIiKqxChn81qpVC9nZ2QAAs9mMbdu2YcCAAdrjgYGByMnJqYiuEBEREVE1ViHX/Hbu3Bnvvvsu+vTpg2+++Qbnz5/HoEGDtMf/+usvhIWFVURXiIiIiKgaq5DB73PPPYcBAwaga9euEBGMGDECERER2uNfffUVbr311oroChERERFVYxUy+O3atSuOHj2KXbt2ISQkBL169dIey87OxmOPPWZ3HxERERGRN1TY9/zWr18fQ4YMcbg/JCQEjz/+eEV1g4iIiIiqsQr7hTeLxYJPP/0UjzzyCIYNG4bff/8dAJCTk4Mvv/wSGRkZFdUVIiIiIqqmKmTwm52djVtvvRX33Xcf/u///g/ffPMNMjMzAQC1a9fG5MmT8dprr1VEV4iIiIioGquQwe+MGTNw+PBh/PDDD0hOToaIaI8ZjUaMGDECGzZsqIiuEBEREVE1ViGD36+//hqTJk1C//79oSiKw+Nt2rTB8ePHK6IrRERERFSNVcjgNycnBy1btnT5eFFREcxms8fznTdvHhRFsbu1bdtWe7ygoAATJ05E3bp1Ubt2bQwfPpzXFhMRERFVYxUy+G3VqhV+++03l49v2rQJ7du3v6x5X3/99UhLS9NuO3fu1B6bOnUqvv32W3z++efYvn07Tp8+jbvvvvuylkNEREREV78K+aqzCRMmYPr06ejduzf69esHAFAUBSaTCQsWLMDGjRvxzjvvXNa8fXx80LBhQ4f7c3Jy8N5772HNmjXo27cvAOD9999Hu3bt8Msvv6B79+6XH4iIiIiIrkoVcub38ccfx9ixYzF69Gi0adMGAHDfffchMDAQixYtwsMPP4zx48df1ryTkpLQuHFjXHPNNbj//vuRkpICAIiLi0NRURGioqK057Zt2xbNmjXD7t27Xc7PZDIhNzfX7gYAqqpq/6owWtsw6to+l9qKD9Til1ZVVe0DfhaLxe22iDi0AbjdtuuvF9rMxEzMxEzMxEzMxExVLZM7KmTwqygK3n33XezYsQNjx47FwIED0alTJzz88MPYtm0b3nrrrcuab7du3fDBBx9g48aNeOutt3Ds2DHcdtttOH/+PNLT0+Hr64uQkBC7acLCwpCenu5ynosWLUJwcLB2Cw8PBwBtmoyMDGQEWn+KOS2oDzJr3wwASA25HVkBHQEAKSGDkF2zHQDg2LFj2gA6OTkZeXl5AKyD9vz8fABAYmIiTCYTACAhIQFmsxmqqiIhIQGqqsJsNiMhIQGAdXCemJgIAMjPz0dSUhIAIC8vD8nJyQCA3NxcHDt2DID1a+ZsBwRZWVlITU0FAGRmZiItLe1SpuJrodPS0rSvoUtNTUVWVpY1U0oKsrOzmYmZmImZmImZmImZqlwmWw53KGIbVv8DZGdno3nz5liyZAlq1qyJ6Oho7YWziYiIQJ8+fbB48WKn8zCZTHbT5ObmIjw8HOfOnUNISIj1qGXrozDAop3ptbZ9AIi1rfgAosIQ9Q5UVdU+jGexWGAwGNxqA9YjI33baDRqR2NltUUEBoNBO8oq7zYzMRMzMRMzMRMzMVNVyZSdnY3Q0FDk5OQgKCgIpflHDX4B4Oabb0ZUVBT69++Pfv36aYNWm+bNm2PKlCmYOnWqW/PLzc1FcHCw/Yu5ZYJ7nYla6WHviYiIiMhTTsdrLnjlA28tW7aEwWDA0aNHUaNGDbRs2dLp9/vqKYqCv/7664qWm5eXh7/++gtjxoxBly5dUKNGDcTGxmL48OEArKfQU1JSEBkZeUXLISIiIqKrk1cGv7169YKiKNppadv/y9sTTzyBQYMGoXnz5jh9+jTmzp0Lo9GI0aNHIzg4GOPHj8e0adMQGhqKoKAgTJo0CZGRkfymByIiIqJqyiuD3w8++KDU/5eX1NRUjB49Gn///Tfq16+PHj164JdffkH9+vUBAK+++ioMBgOGDx8Ok8mEAQMG4M033/RKX4iIiIio6quQa34//PBD9OzZEy1atHD6+IkTJ7B9+3aMHTvW213xGK/5JSIiIqraPLnmt0K+6iw6Ohq7du1y+fgvv/yC6OjoiugKEREREVVjFTL4Levk8oULF+DjUyE/NkdERERE1ZjXRpwHDx5EfHy89v+ffvoJZrPZ4XnZ2dlYsWKF9stvRERERETe4rXB71dffYX58+cDsH6N2dtvv423337b6XNDQkLw4YcfeqsrREREREQAvDj4ffjhh3HXXXdBRBAREYEFCxZg4MCBds9RFAW1atVCq1ateNkDEREREXmd10acjRo1QqNGjQAAP/74I9q1a4cGDRp4a3FERERERGWqkNOtvXr1qojFEBERERGVyiuD3z59+sBgMOCHH36Aj48P+vbtW+Y0iqIgNjbWG90hIiIiIgLgpcGviEBVVe3/qqqW+fPGFfBbG0RERERUzXll8Ltt27ZS/09EREREVBkq5EcuduzYgczMTJePnz17Fjt27KiIrhARERFRNVYhg98+ffpg8+bNLh+PjY1Fnz59KqIrRERERFSNVYmfNzaZTDAajRXRFSIiIiKqxrz2VWcpKSk4fvy49v+jR486vbQhOzsbb7/9Npo3b+6trhARERERAfDi4Pf999/H/PnzoSgKFEXBc889h+eee87heSICo9Ho8qePiYiIiIjKi9cGv/feey86dOgAEcG9996LyZMn47bbbrN7ju3njTt16oSwsDBvdYWIiIiICIAXB7/t2rVDu3btAFjPAvfs2RMtW7b01uKIiIiIiMpUIT9vPG7cuIpYDBERERFRqSpk8AsACQkJeP/995GcnIxz5845fAMEf96YiIiIiLytQr7q7KOPPsINN9yAN954A3/++SdUVYWI2N30P4d8OV544QUoioIpU6Zo9xUUFGDixImoW7cuateujeHDhyMjI+MK0xARERHR1apCzvzOmzcPN910E77//nvUq1ev3Oe/d+9evP322+jYsaPd/VOnTsX69evx+eefIzg4GDExMbj77rvx888/l3sfiIiIiKjqq5Azv6dPn8aDDz7olYFvXl4e7r//frz77ruoU6eOdn9OTg7ee+89LFmyBH379kWXLl3w/vvvY9euXfjll19czs9kMiE3N9fuBkA7M62qKlRYf5BDhVHX9rnUVnygFr+0trPcAGCxWNxui4hDG4Dbbbv+eqHNTMzETMzETMzETMxU1TK5o0IGvx07dsTp06e9Mu+JEyfizjvvRFRUlN39cXFxKCoqsru/bdu2aNasGXbv3u1yfosWLUJwcLB2Cw8PBwCkp6cDADIyMpAReCsAIC2oDzJr3wwASA25HVkB1jPPKSGDkF3T+k0Xx44d0wbQycnJyMvLAwAkJSUhPz8fAJCYmAiTyQTAem202WyGqqpISEiAqqowm81ISEgAYB2cJyYmAgDy8/ORlJQEwHoQkJycDADIzc3FsWPHAFh/RCQlJQUAkJWVhdTUVABAZmYm0tLSLmUqvhwkLS0NmZmZ1kypqcjKyrJmSklBdnY2MzETMzETMzETMzFTlctky+EORWzDai/6+eefcc899+CLL77ALbfcUm7z/fTTT/Hcc89h79698Pf3R+/evdGpUycsXboUa9asQXR0tPbC2URERKBPnz5YvHix03maTCa7aXJzcxEeHo5z584hJCTEetSy9VEYYNHO9FrbPgDE2lZ8AFFhiHoHqqpqP/RhsVhgMBjcagPWIyN922g0akdjZbVFBAaDQTvKKu82MzETMzETMzETMzFTVcmUnZ2N0NBQ5OTkICgoCKWpkGt+Fy9ejODgYNx2221o3749mjVrBqPRaPccRVGwbt06t+d58uRJPP7449i8eTP8/f3Lra9+fn7w8/NzuN/2Qlv/tZ5aN+DSKXYDzJfaYnaYDoBd5sttK4riVltRFIfle6PNTMzETMzETMzETMxUVTK5o0IGvwcPHoSiKGjWrBny8vJw5MgRh+fYXmR3xcXF4cyZM+jcubN2n8ViwY4dO7Bs2TL88MMPKCwsRHZ2NkJCQrTnZGRkoGHDhpedhYiIiIiuXhUy+D1+/Hi5z7Nfv374/fff7e6Ljo5G27ZtMX36dISHh6NGjRqIjY3F8OHDAVivH0lJSUFkZGS594eIiIiIqr4K+5GL8hYYGIgOHTrY3VerVi3UrVtXu3/8+PGYNm0aQkNDERQUhEmTJiEyMhLdu3evjC4TERERUSUzlP2U8mGxWPDpp5/ikUcewbBhw7Sztjk5Ofjyyy+98uMTr776Ku666y4MHz4cPXv2RMOGDfHll1+W+3KIiIiI6OpQId/2kJ2djX/961/Ys2cPateujQsXLmDz5s3o27cvLBYLmjdvjrFjx+L555/3dlc8lpubi+DgYPtPD26Z4N7EUSu91zEiIiIiAuBivOZChZz5nTFjBg4fPowffvgBycnJ0I+3jUYjRowYgQ0bNlREV4iIiIioGquQwe/XX3+NSZMmoX///k6/1aFNmzZe+VAcEREREZFehQx+c3Jy0LJlS5ePFxUVwWw2u3yciIiIiKg8VMjgt1WrVvjtt99cPr5p0ya0b9++IrpCRERERNVYhQx+J0yYgFWrVmHt2rXa9b6KosBkMmHmzJnYuHEjHnnkkYroChERERFVYxXyPb+PP/44Dh8+jNGjR2u/tnbffffh77//htlsxiOPPILx48dXRFeIiIiIqBqrkMGvoih49913MW7cOHzxxRdISkqCqqpo1aoV7r33XvTs2bMiukFERERE1VyF/sJbjx490KNHj4pcJBERERGRpsJ+4Y2IiIiIqLJx8EtERERE1QYHv0RERERUbXDwS0RERETVhlcGv6+//jr++OMPb8yaiIiIiOiyeWXwO3XqVOzbt0/7v9FoxJo1a7yxKCIiIiIit3ll8FunTh1kZGRo/7f9qhsRERERUWXyyvf89u7dG/PmzUN8fDyCg4MBAB9++CF++eUXl9MoioLXXnvNG90hIiIiIgIAKOKF07JnzpzBlClT8OOPP+LMmTMAyj77qygKLBZLeXfliuXm5iI4OBg5OTkICgqy3rllgnsTR630XseIiIiICICL8ZoLXrnsoUGDBlizZg3S0tJgsVggIvj444+hqqrLW1Uc+BIRERHRP0uFfNXZ+++/j1tuuaXc5/vWW2+hY8eOCAoKQlBQECIjI/H9999rjxcUFGDixImoW7cuateujeHDh9tdi0xERERE1YtXrvktady4cVr7yJEjOHHiBACgefPmaN++/WXPt2nTpnjhhRfQunVriAhWr16NIUOGYP/+/bj++usxdepUrF+/Hp9//jmCg4MRExODu+++Gz///PMVZyIiIiKiq49Xrvl1Zt26dZg2bRqOHz9ud3/Lli2xZMkSDB48uFyWExoaipdeegkjRoxA/fr1sWbNGowYMQIAcPToUbRr1w67d+9G9+7d3Zofr/klIiIiqtoq/ZrfkjZs2IDhw4cDAJ5//nl89dVX+Oqrr/D8889DRHD33Xdj48aNV7QMi8WCTz/9FBcuXEBkZCTi4uJQVFSEqKgo7Tlt27ZFs2bNsHv3bpfzMZlMyM3NtbsBgKqq2r8qjNY2jLq2z6W24gO1+KVVVVX7sJ/t+md32iLi0Abgdtuuv15oMxMzMRMzMRMzMRMzVbVM7qiQwe/ChQvRsWNHHDx4ENOnT8fgwYMxePBgTJ8+HQcPHsQNN9yA+fPnX9a8f//9d9SuXRt+fn74z3/+g6+++grt27dHeno6fH19ERISYvf8sLAwpKenu5zfokWLEBwcrN3Cw8MBQJsmIyMDGYG3AgDSgvogs/bNAIDUkNuRFdARAJASMgjZNdsBAI4dO6YNoJOTk5GXlwcASEpKQn5+PgAgMTERJpMJAJCQkACz2QxVVZGQkABVVWE2m5GQkADAOjhPTEwEAOTn5yMpKQkAkJeXh+TkZADWo59jx44BALKzs5GSkgIAyMrKQmpqKgAgMzMTaWlplzIVXwudlpaGzMxMa6bUVGRlZVkzpaQgOzubmZiJmZiJmZiJmZipymWy5XBHhVz2UKtWLTz//PN4/PHHnT7+2muv4ZlnnsGFCxc8nndhYSFSUlKQk5ODL774AitXrsT27dsRHx+P6Oho7YWziYiIQJ8+fbB48WKn8zOZTHbT5ObmIjw8HOfOnUNISIj1qGXrozDAop3ptbZ9AIi1rfgAosIQ9Q5UVYWiKNpXuRkMBrfagPXISN82Go3a0VhZbRGBwWDQjrLKu81MzMRMzMRMzMRMzFRVMmVnZyM0NNStyx4q5ANv/v7+2sjfmaysLPj7+1/WvH19fXHttdcCALp06YK9e/fitddew8iRI1FYWIjs7Gy7s78ZGRlo2LChy/n5+fnBz8/P4X7bC23913pq3YBLp9gNMF9qi9lhOsD6M89X2lYUxa22oigOy/dGm5mYiZmYiZmYiZmYqapkcoeh7Kdcub59++K1115zeq3tr7/+itdff93u2twroaoqTCYTunTpgho1aiA2NlZ7LDExESkpKYiMjCyXZRERERHR1aVCzvy++OKLiIyMRI8ePRAREYHrrrsOgHUwumfPHjRo0MDlZQilefrppzFw4EA0a9YM58+fx5o1a7Bt2zb88MMPCA4Oxvjx4zFt2jSEhoYiKCgIkyZNQmRkpNvf9EBERERE/ywVMvht2bIlDh48iEWLFuH777/H2rVrAVi/5/fxxx/HjBkz0KBBA4/ne+bMGYwdOxZpaWkIDg5Gx44d8cMPP6B///4AgFdffRUGgwHDhw+HyWTCgAED8Oabb5ZrNiIiIiK6elTY9/xerfg9v0RERERVW5X7nl8iIiIioqqAg18iIiIiqjY4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqw+uD34sXL6JLly5YsWKFtxdFRERERFQqrw9+AwICcOzYMe1n8oiIiIiIKkuFXPbwr3/9Cz/88ENFLIqIiIiIyKUKGfzOnj0bf/zxB8aMGYOdO3fi1KlTyMrKcrgREREREXlThfy88fXXXw8AOHLkCNasWePyeRaLpSK6Q0RERETVVIUMfufMmcNrfomIiIio0lXI4HfevHkVsRgiIiIiolJVyvf85uTk8BIHIiIiIqpwFTb43bdvH/71r38hICAAdevWxfbt2wEAZ8+exZAhQ7Bt27aK6goRERERVVMVMvjdtWsXevTogaSkJDzwwANQVVV7rF69esjJycHbb79dEV0hIiIiomqsQga/zzzzDNq1a4cjR47g+eefd3i8T58++PXXXyuiK0RERERUjVXI4Hfv3r2Ijo6Gn5+f0299aNKkCdLT0yuiK0RERERUjVXI4LdGjRp2lzqUdOrUKdSuXbsiukJERERE1ViFDH67d++OL774wuljFy5cwPvvv49evXp5PN9Fixbh5ptvRmBgIBo0aIChQ4ciMTHR7jkFBQWYOHEi6tati9q1a2P48OHIyMi4rBxEREREdHWrkMHv/PnzsW/fPtx55534/vvvAQAHDhzAypUr0aVLF2RmZmL27Nkez3f79u2YOHEifvnlF2zevBlFRUW4/fbbceHCBe05U6dOxbfffovPP/8c27dvx+nTp3H33XeXWzYiIiIiunooIiIVsaCtW7fi0UcfRVJSkt39rVq1wsqVKy/rzG9JmZmZaNCgAbZv346ePXsiJycH9evXx5o1azBixAgAwNGjR9GuXTvs3r0b3bt3L3Oeubm5CA4ORk5ODoKCgqx3bpngXoeiVl5uFCIiIiJyk9PxmgsV8gtvANC3b18kJiZi//79+PPPP6GqKlq1aoUuXbqU208f5+TkAABCQ0MBAHFxcSgqKkJUVJT2nLZt26JZs2YuB78mkwkmk0n7f25uLgBo1yxb/zXCAAtUGAGguO0DQKxtxQcQFYbi5yuKAkVRYLFYYDAY3GrblqVvG41GiIhbbRGBwWDQ+l3ebWZiJmZiJmZiJmZipqqSyZMfT6vwX3i76aabcM8992DkyJHo2rVruQ18VVXFlClTcOutt6JDhw4AgPT0dPj6+iIkJMTuuWFhYS6/XWLRokUIDg7WbuHh4dq8ACAjIwMZgbcCANKC+iCz9s0AgNSQ25EV0BEAkBIyCNk12wEAjh07pg2gk5OTkZeXBwBISkpCfn4+ACAxMVEbcCckJMBsNkNVVSQkJEBVVZjNZiQkJACwDs5t1zXn5+drZ9Lz8vKQnJwMwDpgP3bsGAAgOzsbKSkpAICsrCykpqYCsJ4lT0tLu5Sp+DrotLQ0ZGZmWjOlpiIrK8uaKSUF2dnZzMRMzMRMzMRMzMRMVS5TySsLSlNhlz2YTCa8++672LBhA44fPw4AaNGiBe644w5MmDAB/v7+VzT/Rx99FN9//z127tyJpk2bAgDWrFmD6OhouzO5ABAREYE+ffpg8eLFTvtZ8sxveHg4zp07h5CQEOuRy9ZH3TvzG/UOj9iYiZmYiZmYiZmYiZm8nCk7OxuhoaFuXfZQIYPf1NRU9O/fH4mJiWjUqBGuvfZaAMCff/6JtLQ0tGnTBlu2bNEGrZ6KiYnBunXrsGPHDrRs2VK7f+vWrejXr582cLVp3rw5pkyZgqlTp5Y5b17zS0RERFS1VblrfidOnIgTJ07gs88+0z54ZvP5559j3LhxmDhxItatW+fRfEUEkyZNwldffYVt27bZDXwBoEuXLqhRowZiY2MxfPhwANbT6CkpKYiMjLyyUFeKA2giIiKiClchg9/Y2FhMnTrVYeALAPfccw9+++03vPHGGx7Pd+LEiVizZg3WrVuHwMBA7brc4OBg1KxZE8HBwRg/fjymTZuG0NBQBAUFYdKkSYiMjHTrmx6IiIiI6J+lQga/th+hcKVhw4YIDAz0eL5vvfUWAKB3795297///vv497//DQB49dVXYTAYMHz4cJhMJgwYMABvvvmmx8siIiIioqtfhQx+o6Oj8cEHH+Chhx5CQECA3WN5eXl4//33MX78eI/n687lyv7+/li+fDmWL1/u8fyJiIiI6J/FK4PfL7/80u7/N910E9avX4+2bdti3Lhx2gfekpKS8OGHHyI0NBQdO3b0RleIiIiIiDRe+bYH21dT2Gatb7vsSPFXWVQ1Xvu2B37gjYiIiKhcVPq3Pfz444/emC0RERER0RXxyuC3V69e3pgtEREREdEVqfCfNyYiIiIiqiwV8m0PALBz506sWrUKycnJOHfunMM1wIqi4MCBAxXVnX8GXjdMRERE5JEKGfwuWbIETz75JPz9/XHdddchNDS0IhZLRERERGSnQga/L730Em699VZ8++23CA4OrohFEhERERE5qJBrfi9evIj777+fA18iIiIiqlQVMvjt06cPfv/994pYFBERERGRSxUy+H3jjTcQGxuLl19+GVlZWRWxSCIiIiIiBxUy+A0PD8cjjzyCGTNmoH79+qhVqxaCgoLsbrwkgoiIiIi8rUI+8DZnzhw899xzaNKkCbp27cqBLhERERFVigoZ/K5YsQJ33nknvv76axgM/F0NIiIiIqocFTISLSwsxJ133smBLxERERFVqgoZjd5111346aefKmJRREREREQuVcjgd+7cuThy5Agee+wxxMXFITMzE1lZWQ43IiIiIiJvqpBrfq+77joAQHx8PN5++22Xz7NYLBXRHSIiIiKqpirs2x4URSn3+e7YsQMvvfQS4uLikJaWhq+++gpDhw7VHhcRzJ07F++++y6ys7Nx66234q233kLr1q3LvS9EREREVPVVyOB33rx5XpnvhQsXcOONN+LBBx/E3Xff7fD4iy++iNdffx2rV69Gy5YtMXv2bAwYMABHjhyBv7+/V/p0Vdkywb3nRa307jyIiIiIKkiFDH69ZeDAgRg4cKDTx0QES5cuxaxZszBkyBAAwIcffoiwsDB8/fXXGDVqVEV2lYiIiIiqgAoZ/C5YsKDM5yiKgtmzZ5fbMo8dO4b09HRERUVp9wUHB6Nbt27YvXu3y8GvyWSCyWTS/p+bmwsAUFVV968RBligwggAxW0fAGJtKz6AqDAUP19RFCiKAovFAoPBYG0rNWAQMxQILIovDFKkaxdal6X4wiCiLddoNEJELrWhQFV8YJSiEm0DRDHAIGaoMACqCoPBoGW41HaWw1kmOEyrZbLLUVqmSzlsX3nnNFMpbRFxkaN82k7XUxltZmImZmImZmImZqr8TJ58bqxCvu1h3rx5Lm/z58/X2uUpPT0dABAWFmZ3f1hYmPaYM4sWLUJwcLB2Cw8Pt5tfRkYGMgJvBQCkBfVBZu2bAQCpIbcjK6AjACAlZBCya7YDYB2E2wbQycnJyMvLAwAk1RuL/BoNAQCJ9cfD5FMHAJAQ9hjMhtpQFV8khD0GVVVhNpuRkJAAwDo4T0xMBADk12iIpHpjAQB5vs2QHGod0Of6tcKxOsMBANk12yElJQUAkJWVhdTUVABAZmYm0oL6WDMF3lp2ppQUZGdnO2YKHYU832ZlZzKboaoqEhISHDNtn47Ew/HAlgnI3zEHSYf2AFsmIO+nZ5F8cCewZQJyd76IY8eOWTNlZ9tn+u1rYMsEZO5ZhbR9nwFbJiBj78fI2PsxsGUC0vZ9hsw9q6yZUlO1bxZxmUm/npKSkJ+fb82UmKgdGCUkJJSeSb+e8vORlJRkXU95eUhOTraup9xc15n06yktzbqeMjKQkZFhXU9pacjMzGQmZmImZmImZmImk0nL4Q5FpPiUXAVTVRUnTpzA8uXLsWPHDnz//feoW7fuZc9PURS7D7zt2rULt956K06fPo1GjRppz7v33nuhKArWrl3rdD7OzvyGh4fj3LlzCAkJsR65bH3UvTO/Ue+4PrqJfdS9M799l2uvl8OR2ZaH3Dvz23eF8yMwpzmcZIp62/URm12OUs786nI4HLFteQiqUgNGKSz9bLbLHI/BAHMpOYrbTnI4zcQja2ZiJmZiJmZipqsqU3Z2NkJDQ5GTk4OgoCCUptKu+TUYDGjZsiVefvll3H///Zg0aRLWrFlTbvNv2NB6BjIjI8Nu8JuRkYFOnTq5nM7Pzw9+fn5O+3vpX+updQMunWI3wHypLWaH6QDAaDReakuRrl3oul38LRm2aRVFudSGaPOxb6tQpHgjgwrY9V3fL2c5XGRymNZZjlIylchhlwmiPb/UTC5zmMvIYSnx/DIyOemjp2279VRK2/YtKO7060razMRMzMRMzMRM1SGTOwxlP8X7evbsiQ0bNpTrPFu2bImGDRsiNjZWuy83Nxe//vorIiMjy3VZRERERHR1qBLf9rBv3z67owB35eXl4c8//9T+f+zYMcTHxyM0NBTNmjXDlClT8Oyzz6J169baV501btzY7ruAiYiIiKj6qJDB74cffuj0/uzsbOzYsQNffvklJkxw8/tidfbt24c+ffpo/582bRoAYNy4cfjggw/w1FNP4cKFC3j44YeRnZ2NHj16YOPGjfyOXyIiIqJqqkIGv//+979dPlavXj3MmDEDc+bM8Xi+vXv3Rmmf11MUBQsWLHDrq9aomuMPfhAREVULFTL4tX1dhp6iKKhTpw4CAwMrogtERERERBUz+G3evHlFLIaIiIiIqFRV4gNvRFSMl04QERF5ldcGvx07dvTo+Yqi4MCBA17qDRERERGRFwe/oaGh2hcklyY9PR2JiYluPZeIiIiI6Ep4bfC7bdu2Uh9PT0/H4sWL8fbbb8NoNGLMmDHe6gpR9VFVvrXiSudRFfpARET/SBV+zW9GRgZeeOEFvPPOOygqKsIDDzyAmTNnolWrVhXdFSIiIiKqZips8Gs706sf9M6aNQvXXHNNRXWBiIiIiKo5rw9+09PT8cILL+Ddd99FUVERxowZg1mzZqFly5beXjQR0ZXh5RdERP84Xhv8pqWlaYNes9mMsWPHYubMmRz0EhEREVGl8drgt1WrVjCZTOjUqROeeeYZtGzZEufOncO5c+dcTtO5c2dvdYeIiIiIyHuD34KCAgDA/v37ce+995b6XBGBoiiwWCze6g4R0dWJl00QEZUrrw1+33//fW/NmoiIiIjosnht8Dtu3DhvzZqIiIiI6LJU+Pf8EhFRBasK31pRFfpARATAUNkdICIiIiKqKBz8EhEREVG1wcseiIio+qgKl19UhT6Uxzx4GQpdparFmd/ly5ejRYsW8Pf3R7du3bBnz57K7hIRERERVYJ//JnftWvXYtq0aVixYgW6deuGpUuXYsCAAUhMTESDBg0qu3tERETVV1U4g10e86gKfSiPeVSFPpTXPErxjz/zu2TJEjz00EOIjo5G+/btsWLFCgQEBGDVqlWV3TUiIiIiqmD/6DO/hYWFiIuLw9NPP63dZzAYEBUVhd27dzudxmQywWQyaf/PyckBAGRnZwMAVFUFLlhggAUqjNZ5wgIVPgDE2lZ8AFFhyM2FqqpQFEX7BTuDwWBtXxQYxAwFAoviC4MU6dqF1mUpvjAUL19VVRiNRojIpfaFIqiKD4xSBIGiaxsgigEGMUOFAcjOhsFgsPa9+DVwncNJpuIc+mm1THY5arjOpMthMBjsM10ogqrUgFEKS+QokcllDhUGmEvJUdx2kkNrX1ShiAoFaokcJTLl5NitS7tMFwqhKr66HC4ynTunrUsRse/LhcLi/iqlZyreHp3lgKgwQIWq+LjOVCKHXabiHPrt0GkmXQ799ikixTkMgLYdusjkKscF1XF/cpaplBzKhULH/clZJhc5VFWF8UKh4/7kLJOrHHb7mZMaoc+Um1tGDhc1wtYuM0cpNcLWdivHZda9C4Wl1whdDoca4TKHi0we56jgunehjBpha+fkONaIqlT3LpRRI3Q5HGqErS8X1dJrhJs5Kr3uaTnKqHul5agKde+ilF4jbJlKzWEpvUbYMrmVw/26ZxuniQjKJP9gp06dEgCya9cuu/uffPJJiYiIcDrN3LlzBQBvvPHGG2+88cYbb1fZ7eTJk2WOD//RZ34vx9NPP41p06Zp/1dVFVlZWahbty4URanEnhERERGRMyKC8+fPo3HjxmU+9x89+K1Xrx6MRiMyMjLs7s/IyEDDhg2dTuPn5wc/Pz+7+0JCQrzVRSIiIiIqB8HBwW497x/9gTdfX1906dIFsbGx2n2qqiI2NhaRkZGV2DMiIiIiqgz/6DO/ADBt2jSMGzcOXbt2RUREBJYuXYoLFy4gOjq6srtGRERERBXsHz/4HTlyJDIzMzFnzhykp6ejU6dO2LhxI8LCwiq7a0RERERUwRQRd74TgoiIiIjo6vePvuaXiIiIiEiPg18iIiIiqjY4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqg4NfIiIiIqo2OPglIiIiomqDg18iIiIiqjY4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqg4NfIiIiIqo2OPglIiIiomqDg18iIiIiqjY4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqg4NfIiIiIqo2OPglIiIiomqDg18iIiIiqjY4+CUiIiKiaoODXyIiIiKqNjj4JSIiIqJqg4NfIiIiIqo2OPglIiIiomqDg18iIiIiqjY4+CUiIiKiasOnsjtQ1amqitOnTyMwMBCKolR2d4iIiIioBBHB+fPn0bhxYxgMpZ/b5eC3DKdPn0Z4eHhld4OIiIiIynDy5Ek0bdq01Odw8FuGwMBAANYXMygoqJJ7Q0REREQl5ebmIjw8XBu3lYaD3zLYLnUICgri4JeIiIioCnPnElV+4I2IiIiIqg0OfomIiIio2riqBr87duzAoEGD0LhxYyiKgq+//rrMabZt24bOnTvDz88P1157LT744AOv95OIiIiIqqaravB74cIF3HjjjVi+fLlbzz927BjuvPNO9OnTB/Hx8ZgyZQomTJiAH374wcs9JSIiIqKq6Kr6wNvAgQMxcOBAt5+/YsUKtGzZEq+88goAoF27dti5cydeffVVDBgwwFvdJCIiIqIq6qo68+up3bt3Iyoqyu6+AQMGYPfu3S6nMZlMyM3NtbsB1h+7sP3raVtEAAAWi8Xttog4tAG43b6S/jITMzETMzETMzETM12NmdxxVZ359VR6ejrCwsLs7gsLC0Nubi7y8/NRs2ZNh2kWLVqE+fPnO51XSEgIMjIyAACNGjVCWloafHx8EBYWhtTUVAQEBKBevXpISUlBUFAQQkNDcezYMdSrVw/BwcFITk5Gw4YNERgYiD8OH0a9wkL4qSpO1qyJsIIC1Lv5ZiQkJOC6666DwWBAQkIC2rVrB1VVkZiYiA4dOsBkMiE5ORnt27dHfn4+UlJS0LZtW+Tl5SE9PR0bHl6NBp3C0azvddi3ZAsaR16Dmx/uixYtWiArKwsXL15Es2bNkJmZiYtpaahbWIhzNWoAAOoUFWF3fBpM2fk49v0hdHjwFuQc+xt3zxnjMtOfhw8jpLAQNVUVp/z9Ua+wEGue/Bq9XhyOfUs240J6Lvq9McrjTD88+jFC2zZE67tvwq/Pf48GncIREROFVq1aITs7G7m5uU4zmc1mNGnSBBuXfQkASPoqHm1H3wxTdj4GPzXK5Xr68/ffEWQ2I8BiQZq/P0IKC/Hpk1/j1gWD8fuqn5F7/G/0enE42t7QDv7+/m6vp80T1yCoRV3c8OCt+HnONwht2xDdpw1A69atkZubi7Nnz5aZKX7dLzj6f3vRelgnLdOIjx91uu0l//47Asxm1LZYkO7nhyCzGWuf+ArdnhmIpC/3I+toOm5dMBjtu3RAQEAAEhMTcc0119hlurB/P1IDAtD04kWoioLTNWsidtKnqNUwCF2n9cf2p/6HoBZ1ETl9oN22p89U/++/kWc04qKPDxqYTMj18UHi4XQcWrULLQd2gF9ITRz9v724d81Et/enj4YvQddpUUjZmogz8SfR7ZmBuL57RwQGBiIpKQnNmjWzy1R48CBSAgLQOD8fBhGkBgRg25NfwMe/BnosHKJlumX2XS73p7Bz53DRaESujw8amkzIMxqRlJyF+De3I7zPdQhuWReHVu3CqE8nadteyRphOXMGIUVFyPT1hZ+qIshsxv4TOTiz/yRO707WMo1+9RG7GuEsk2097Zy9DuaCIvR+aYRdJlf7U+PcXOQbDMj29UWjggJcNBpxISTE7f0pIyMDhenpqFNUhL99fWEUQUhREfYmnkXOsb9x8sdEdHqsF87sP4l7nn/Qad2ThAStRtjq3u7nv9dqhD6Tq/2paV4eTAYDzvr6oklBAfINBhw7Z9JqhK3ujfnfNLcy2dbT5pXfelT3nK2nd+98/orq3pG4Q1qNsNW9f3/9pMsakZOaivqFhciuUQMWRUHdwkLs/CWlQuuevkY0u3gRhYqCVPhoNcJW9x78ZrpDjSht2/vu5c+0GmGre3dMHnFFf3NL25/Ko+5lHD+u1Qhb3duyMVGrEba6N+DhIR6NIyqj7nny98lV3SuZ6ZN7lmo1wlb3OvS8yaP1VFbdS0pKcnt8qIhtWH2VURQFX331FYYOHeryOW3atEF0dDSefvpp7b4NGzbgzjvvxMWLF50Ofk0mE0wmk/Z/25cmnzt3DiEhIdpRi8FgcLutKAoURYHFYoHBYICiKMjeswcKAAWAWvxvcESE9hzAemSkbxuNRu1ozFV7WdRcKAYFio8BaqEFitGAmE3znPYrd98+GADYNgAFwOpZ661HVGYVhhrW+U7evMBlJmc5Ppj+DYz+PrCYLIAIjP4+mLhhrkeZbDkMPkZYCs1QDApiNs93+3V/o/8c6zLKyGFru8zh5wO1yAJRL+XQr8uyMmk5ahhhMVlzTNw0T3uOiJSZafm/5kMtssDgY9AyTYpd4FkOXx+o5uIcfj6Y+P1ch23S1s7duxdSPC2Kt4/V078BFAVGPyMsBY459LlFBHn79kGKp7VtYx/OWg+1yALFx7o8tcjiMoez9hv95sDga4SYVWsOXx9M3Og6x/m9e7XXwD4HYPTzgaXADCgKYjY7z6GqKi7ExTnmmL3eum+5meP8vn1260MBsHr2eohFIBZVyzQ5dqHTHM7ay/rPBQTW/azADChAzOb5HuUI7NrVozrmNIe+XvgaIRbB5C0LnNY9/fqwzWf1jG+1GmExmQEBYrbMd7k/Ocvx0ewNWo2w1T1PtiuDwYA3bp/rUd1ztm5e7zv7iure8oHztRphq3uTty50WSP09dv2eqye+Z1WIyqi7uXFxWn7lrY+5m7QaoSt7k3eutChRpS2Pl7vP0fbt2x1b1IpOTxZT96qezl79zqsjw9mfqflsNWLSZvmezSOqIy658nfJ49z6OpezMZ5Hq2nsupednY2QkNDkZOTU+bvMvyjz/w2bNhQOxqxycjIQFBQkNOBLwD4+fnBz8/P4X7bDq//vWhP20aj8dL9+nnr2vrnOGsrilJmW1SBFBa/FWBRXfbd9j/910GrRRanbZf5XOSwFJjt2rYvnfYkk6gCS6FZa3uyDlSzWj45TO7ncJVJVNHmI6rYPcc2v9Iy2fqvz+RxjkJdDlMZ6wP224TWFtHWa8kczjLp56Pg0noQs6odcHm6D6mFl9alpbDs9aF/DS7l0G2f4jqHs9dD0fXB3Ry2afV90efQt8varrR28YIv5XCjRpTI4WlNc5qjyHkOt+ue7S1NXb0os0aUyKGvEba65/F25WHdc7VurqTu6WuELVNpNUJfv22vR0XXPf16sP2rrxG2+biqEa76pd+33Kp7Hq4nb9Q9Z+tDn+Oqq3tu/n263BxqocXtv6da2826545/9DW/kZGRiI2Ntbtv8+bNiIyMrKQeEREREVFluqoGv3l5eYiPj0d8fDwA61eZxcfHIyXFep3T008/jbFjx2rP/89//oPk5GQ89dRTOHr0KN5880189tlnmDp1amV0n4iIiIgq2VU1+N23bx9uuukm3HTTTQCAadOm4aabbsKcOdbrO9PS0rSBMAC0bNkS69evx+bNm3HjjTfilVdewcqVK/k1Z0RERETV1FV1zW/v3r21r71wxtmvt/Xu3Rv79+/3Yq+IiIiI6GpxVZ35JSIiIiK6Ehz8EhEREVG1wcEvEREREVUbHPwSERERUbVxVX3grarI3bPH4b6giIhK6AkREREReYJnfomIiIio2uDgl4iIiIiqDV72UE5e6zPL4b7Hf3y2EnpCRERERK7wzC8RERERVRsc/BIRERFRtcHBLxERERFVGxz8EhEREVG1wcEvEREREVUbHPwSERERUbXBwS8RERERVRsc/BIRERFRtcHBLxERERFVGxz8EhEREVG1wcEvEREREVUbHPwSERERUbXBwS8RERERVRsc/BIRERFRtXHVDX6XL1+OFi1awN/fH926dcOePXtKff7SpUtx3XXXoWbNmggPD8fUqVNRUFBQQb0lIiIioqrkqhr8rl27FtOmTcPcuXPx22+/4cYbb8SAAQNw5swZp89fs2YNZsyYgblz5yIhIQHvvfce1q5di2eeeaaCe05EREREVcFVNfhdsmQJHnroIURHR6N9+/ZYsWIFAgICsGrVKqfP37VrF2699Vbcd999aNGiBW6//XaMHj26zLPFRERERPTPdNUMfgsLCxEXF4eoqCjtPoPBgKioKOzevdvpNLfccgvi4uK0wW5ycjI2bNiAO+64w+VyTCYTcnNz7W4AoKqq9q8UP1cFtLahhhGKj/XlNPgaoRgNl54v1mdZLBatrZ9W37Y9R0Qc2gDcaisGBQZfo7VtNNj13a5dvExxlUPXLjltWTmM/j6Aomjty8mkGBQYfX20tsscTtoGHwMMbuTQ2q5y+PlAMdjn8HQ9KQYFRr9LOfTPcSeToYbRIZPHOXx1Ofwcc9hl0k1ra1s7r1jXq5MczjLpp5Xi9QAAio9Ba7uzLu3Wq6/xUg7f0nPoXwP7HNByQHGdQ2uXzOHrWQ6n9UJXI/SZXOUo2Yb16boc8DiHJ6+7t+qevkbYMpVZI0rk0NcI27rxeLvysO65WjdXUvf0NcKWqdQaoV+XtvVR0XXP2frQ1QhbJlc1wlW/9PuWW3XPw/XklbrnZH3oc1x1dc/Nv08e59DVPU/Xk7t1zx1XzeD37NmzsFgsCAsLs7s/LCwM6enpTqe57777sGDBAvTo0QM1atRAq1at0Lt371Ive1i0aBGCg4O1W3h4OABoy8jIyEB2jRoAgHO+vsgpbrcf0w1Nb2sNAOg4oQcaRbQAABw7dkwbQCcnJyMvLw8AkObvj0KD9eU/VbMmiooLZkJCAsxmM1RVRUJCAlRVhdlsRkJCAgDr4DwxMREAkJ+fj6SkJABAXl4ekpOTAQD1OzZF55g+AIBGES2QkpICAMjKykJqaioAIDMzE+d8fQEA2TVqaJnajOiMFv3bO2RKSUlBdna2Q6YMf38UFOfQZ+qxYAhqhQUCAHq/NKLUTH/v24ejR44gd88enI2Lwx+HDwMA6rQJQ9cn+muZjh07Zu1vdrbLTGlpaQCAVoM6otWgjg6ZUlNTkZWV5ZDpjJ8f8o1Gh0zdZ96BwGahWiaTyeTxegpsForuM+/QMtnWU25urluZ2ozo7JApLS0NmZmZDpnO+vnhQnEOfaauT/RHnTZhWqb8/HwAQGJiokMmAZAaEAABYFEUpAYEAABqhQWix4IhWiZn254+0wWjEWf9/AAA53180H5MNwBAi/7ttUwZGRnIyMgoNZN+PXWO6YP6HZtqmWz7U1JSktNMqQEBsCiKlsno7wO/4Jro/dIILVNZ+1O+0YgzxTkuGI3oOKEHAKDpba21TPptr2QmW43429cX532sRVtfI/SZ9DXCVaaEhAT4BdeE0d8HvV8aoWUqq0YUGAzI8PfXMnmyP3mr7ulrhC1TWftTocGAtOIcBQaDXY2w1T13M9nWk6d1z9V68qTulVxP+hphy1Rajfi7uH7n1Kih1fKKrnsla0SRotjVCFsmVzXC1XrS1wh36p6n68kbdU9fI2x1T18jrra65+7fJ1d1z1mmknXP0/VUVt2z5XCHIrZhdRV3+vRpNGnSBLt27UJkZKR2/1NPPYXt27fj119/dZhm27ZtGDVqFJ599ll069YNf/75Jx5//HE89NBDmD17ttPlmEwm7cUGrBtAeHg4zp07h5CQEKiqivP79kGB9YhKKb6tnrXeevRoVq1HNBbB5C0LoKoqFEWBUnykZTAYoCgKsvfs0aa1zSc4IkJ7DlB81k/XNhqN2tGYq/ayqLlQDAoUHwPUQgsUowExm+bBYLh0BtjWzt23DwZcOtp3yFHDOt/Jmxc4TGvL5CzHB9O/gdHfBxaTBRCB0d8HEzfMdZkpZ88e6xk1XDpaXT39G+uZHB8jLIVmKAYFMZvnO83hrP1G/znWZZSRw9Z2mcPPB2qRBaJeyqFfl2WtJ9v6MNQwwmKy5pi4aZ72HBEpM9Pyf82HWmS5dPbDrGJS7ALPcvj6QDUX5/DzwcTv5zpsk7Z27t69EGgH2dr6gKLA6GeEpcAxhz63iCBv3z5tXdrW64ez1kMtskDxsS5PLbK4zOGs/Ua/OdZ9y6xac/j6YOJG1znO792rvQb2OaxntiwFZkBRELPZeQ5VVXEhLs4xx+z11n3LzRxO68Xs9RCLQCyqlmly7EKnOZy1l/WfC4j1DIg1BxCzeb5HOQK7dnV7fyqPuqdfH7b5rJ7xrVYjLCYzIEDMlvku9ydnOT6avUGrEba658l2ZTAY8Mbtcz2qe87Wzet9Z3tU90qup+UD52s1wlb3Jm9d6LJG6Ou37fVYPfM7rUZURN3Li4vT9i1tfczdoNUIW92bvHWhQ40obX283n+Otm/Z6t6kUnJ4sp68Vfdy9u51WB8fzPxOy2GrF5M2zXc7B1A5dc+Tv08e59DVvZiN8zxaT2XVvezsbISGhiInJwdBQUEojU+pj1Yh9erVg9Fo1I4sbDIyMtCwYUOn08yePRtjxozBhAkTAAA33HADLly4gIcffhgzZ87UdmI9Pz8/+BUftenZnmswGLSNSj+1WnTpdLtaaHGYDgCMxUfYJafVt/XPcdZWFKXMtqgCKe6DWFS7vuv7ZfufgkvschQ5z2HXdpHDUmC2ayu2twKdZdL1Qd8WVWApNGttVzmctVWzeql9JTlM7uewy1RifdjmI6rYPcc2v9Iy2fqvz+RxjkJdDpP76wP6toi2XkvmcJap5Hq15RDzpbfQ3VmXdutVt29ZCsteH/rX4FIO3fYprnO42j5tfXA3h9N6Uei8XpS1XWnt4gVfyuFGjSiRw5P9yWt1z/aWpq5elFn3SuTQ1whb3fN4u/Kw7rlaNx7VvRLrSV8jbJlKqxH6+m17PSq67unXg+1ffY2wzcdVjXDVL/2+5Vbd83A9eaPuOVsf+hxXXd1z8+/T5eZQCy1u/z3V2m7WPXc4jv6qKF9fX3Tp0gWxsbHafaqqIjY21u5MsN7FixcdBrjagOTqOOFNREREROXoqjnzCwDTpk3DuHHj0LVrV0RERGDp0qW4cOECoqOjAQBjx45FkyZNsGjRIgDAoEGDsGTJEtx0003aZQ+zZ8/GoEGDPDpCICIiIqJ/hqtq8Dty5EhkZmZizpw5SE9PR6dOnbBx40btQ3ApKSl2Z3pnzZoFRVEwa9YsnDp1CvXr18egQYPw3HPPVVYEIiIiIqpEV9XgFwBiYmIQExPj9LFt27bZ/d/Hxwdz587F3LlzK6BnRERERFTVXTXX/BIRERERXamr7swvUVWVy18OJCIiqvJ45peIiIiIqg2vDH6d/eAEEREREVFl88plD5GRkbj22msxZswY3H///bjmmmu8sZh/nNf6zHK47/Efn62EnhARERH9M3nlzO/HH3+M1q1bY+HChWjdujVuvfVWrFixQvt9ZyIiIiKiyuCVwe99992H9evX4/Tp03jttdcgInjsscfQuHFjDB06FF988QUKCwu9sWgiIiIiIpe8+oG3evXqISYmBrt27UJSUhJmzpyJo0ePYuTIkWjYsCEefvhh7Ny505tdICIiIiLSVNi3PdSsWRMBAQHw9/eHiEBRFKxbtw69evXCzTffjCNHjlRUV4iIiIiomvLq4Pf8+fN4//33ERUVhebNm+OZZ55BixYt8MUXXyA9PR2nT5/G2rVrcebMGURHR3uzK0RERERE3vm2h3Xr1uGTTz7Bd999h4KCAtx8881YunQpRo0ahbp169o9d8SIETh37hwmTpzoja5QNcAflyAiIiJ3eWXwO2zYMISHh2Pq1KkYO3YsrrvuulKff+ONN+L+++/3RleIiIiIiDReGfxu3boVvXv3dvv5ERERiIiI8EZXiIiIiIg0Xrnm15OBLxERERFRRfHK4HfWrFno1KmTy8dvuukmzJ8/3xuLJiIiIiJyySuXPXzxxRcYNmyYy8fvuOMOrF27FnPnzvXG4omIqAz8OXUiqq68cuY3JSUFrVq1cvl4y5YtceLECW8smoiIiIjIJa8MfmvXrl3q4PbYsWPw9/f3xqKJiIiIiFzy2gfe3n77bZw6dcrhsZMnT+Kdd95Bnz59vLFoIiIiIiKXvHLN78KFCxEREYHrr78e48ePx/XXXw8AOHToEFatWgURwcKFC72xaCIiIiIil7wy+L3uuuvw008/YdKkSXj11VftHuvZsydef/11tGvXzhuLJiIiIiJyySuDXwDo2LEjtm/fjrNnzyI5ORkAcM0116BevXreWiQRERERUam8cs2vXr169bRfcCuPge/y5cvRokUL+Pv7o1u3btizZ0+pz8/OzsbEiRPRqFEj+Pn5oU2bNtiwYcMV94OIiIiIrj5eO/MLAKmpqdi/fz9ycnKgqqrD42PHjvVofmvXrsW0adOwYsUKdOvWDUuXLsWAAQOQmJiIBg0aODy/sLAQ/fv3R4MGDfDFF1+gSZMmOHHiBEJCQi43EhERERFdxbwy+C0oKMC4cePwv//9D6qqQlEUiAgAQFEU7XmeDn6XLFmChx56CNHR0QCAFStWYP369Vi1ahVmzJjh8PxVq1YhKysLu3btQo0aNQAALVq0uMxURERERHS188plD8888wy+/PJLPPfcc9i2bRtEBKtXr8amTZswcOBA3HjjjThw4IBH8ywsLERcXByioqK0+wwGA6KiorB7926n03zzzTeIjIzExIkTERYWhg4dOuD555+HxWJxuRyTyYTc3Fy7GwDtzLWqqpDi56qA1jbUMELxsb6cBl8jFKPh0vOLB/4Wi0Vr66fVt43+PoByqS0iEBGtz+60FYMCg6/R2jYa7Ppu1y5eprjKoWuXnNa9HIrTHA6Ziqct2VYMCoy+PlrbnRy2tsHHAIMbObS2qxx+PlAM9jkAOOQQkdJz+F3KoV9nLjPp2oYaRodMHufw1eXwc8xhl0k3rT4HFMW6Xp3kcJap5Othy6H4GLR2abmdtQ2+xks5fEvPoX8N7HNAywHFdQ5X26e2b7mZw2m90NUIfSZXOUq29TXClumycxgNWtvjHFdY9/Q1wpbJaY0oJYe+RriTw+l25WHdc7VuPKp7Jdr6GmHLVGqN0L0GlVb3nK0PXY2wZXJVI1z1S79vuVX3PFxPXql7TtaHPsdVV/fc/PvkcQ5d3fN0Pblb99zhlcHvF198gejoaEyfPl37mrMmTZogKioK3333HUJCQrB8+XKP5nn27FlYLBaEhYXZ3R8WFob09HSn0yQnJ+OLL76AxWLBhg0bMHv2bLzyyit49lnXP+G5aNEiBAcHa7fw8HAA0JaRkZGB7OKzyOd8fZFT3G4/phua3tYaANBxQg80imgBwPqDHrYBdHJyMvLy8gAAaf7+KDRYX/5TNWuiqLhg9n5pBPyCa8Lo74PeL42Aqqowm81ISEgAYB2cJyYmAgDy8/ORlJQEAMjLy9M+WFi/Y1N0jrF+j3KjiBZISUkBAGRlZSE1NRUAkJmZiXO+vgCA7Bo1tExtRnRGi/7tHTKlpKQgOzvbIVOGvz8KinPoM/VYMAS1wgK1TGazGaqqIiEhwSFTkaLgVM2aAIBCgwFpxT+AUqdNGLo+0V/LdOzYMWt/s7PtMv1dnCOnRg0tU6tBHdFqUEeHTKmpqcjKynLIdMbPD/lGo0Om7jPvQGCzUC2TyWQCACQkJDhksigKUgMCHDIFNgtF95l3aJls6yk3N9dlJv16ajOis0OmtLQ0ZGZmOmQ66+eHC8U59Jm6PtEfddqEaZny8/MBAImJiQ6ZBEBqQAAEsMtUKywQPRYM0TI52/b0mS4YjTjr5wcAOO/jg/ZjugEAWvRvr2XKyMhARkZGqZn066lzTB/U79hUy2Tbn5KSkpxmSg0IgEVRtExGfx/4BddE75dGaJnK2p/yjUacKc5xwWhExwk9AABNb2utZcrMzERaWprTTLYa8bevL877WIu2vkboM+lrhKtMCQkJdjXClqmsGlFgMCCjeN/KNxrtaoQtU8ltT5/JG3VPXyNsmZzVCH0mfY0oMBjsaoQtU2n7k7P15Gndc7WePKl7JdeTvkbYMpVWI6pC3StZI4oUxa5G2DK5qhGu1pO+RrhT9zxdT96oe/oaYat7+hpxtdU9d/8+uap7zjKVrHuerqey6p4thzsUsQ2ry5G/vz+WLVuGCRMm4OLFi6hduzbWrVuHQYMGAbB+aG3BggXaC+WO06dPo0mTJti1axciIyO1+5966ils374dv/76q8M0bdq0QUFBAY4dOwZj8Q6+ZMkSvPTSS9oKK8lkMmkvNmDdAMLDw3Hu3DmEhIRAVVWc37cPCqxHVErxbfWs9dajR7NqPaKxCCZvWaBd9qEUH2kZDAYoioLsPXu0aW3z+WD6NzD6+8BiMgNiPbqZuGEuAOvRk9Fo1I7GXLWXRc2FYlCg+BigFlqgGA2I2TQPBsOlM8C2du6+fTDg0tG+Q44a1vlO3rzAYVpbptJzWAARhxwGg8EuU86ePdYzUbh0tLp6+jfWMzk+RlgKzVAMCmI2zy8zh20+q2d+Z11GGTlsbZc5/HygFlkg6qUc+nWpz5S7d6/rHDWMsJisOSZumqetMxFxmknfXv6v+VCLLJfOfphVTIpd4FkOXx+o5uIcfj6Y+P1ch23S1rblsF2gZMsBRYHRzwhLgWMO/XYoIsjbt89ufQiAD2eth1pkgeJjXZ5aZHGZw1n7jX5zrPuWWbXm8PXBxI2uc5zfu1d7DexzWM9sWQrMgKIgZrPzHKqq4kJcnGOO2eut+5abOZzWi9nrIRaBWFQt0+TYhU5zOGsv6z9XqxHWHEDM5vmXl8NogGJUoBZeRg4P6p5+fdjms3rGt1qNsNW9mC3zHWpEaTk+mr1BqxG2uufJdmUwGPDG7XM9qnvO1s3rfWd7VPdKrqflA+drNcJW9yZvXeiyRlSFupcXF6ftW9r6mLtBqxG2ujd560KHGlHa+ni9/xxt37LVvUml5PBkPXmr7uXs3euwPj6Y+Z2Ww1YvJm2a73YOoHLqnid/nzzOoat7MRvnebSeyqp72dnZCA0NRU5ODoKCglAar1zzGxYWhr///hsAEBAQgDp16iAxMVEb/Obm5qKgoMCjedarVw9Go9FhwJyRkYGGDRs6naZRo0aoUaOGNvAFgHbt2iE9PR2FhYXwLT5a1vPz84Nf8VGbnm2HNxgM2kalP22uFl063a4WWhymA2DXD/20+ralwGzXtl0jbZtWUZQy26IKpLgPYlHt+q7vl+1/l67CLpGjyHkOu/Zl5rDLpOuDvi2qwFJo1tru5LBNq5q1N3uuLIepnHKYLuXQrzPb/Fz2y2DQ+q/P5HGOQl0Ok/s5oG+LaOu1ZA5nmUq+HrYcYr70FnppuZ219fuWpbD0HCVfg0s5dNunuM7har3a+uBuDqf1otB5vXCVw6FdvOBLOdyoEa5yWFSI5TJzXGnds72lqasXTrfJUnLoa4St7nm8XXlY91ytG4/qXon1pK8Rtkyl1YiqUPf068H2r75G2Objqka46pd+33Kr7nm4nrxR95ytD32Oq67uufn36XJzqIWWMnNcbt1zh1cue+jWrRt27typ/X/QoEF46aWX8Mknn+Cjjz7Cq6++iu7du3s0T19fX3Tp0gWxsbHafaqqIjY21u5MsN6tt96KP//8UzvyAIA//vgDjRo1cjrwJSIiIqJ/Nq8MfidPnoxrrrlGu3xg4cKFCAkJwZgxYzBu3DgEBwfj9ddf93i+06ZNw7vvvovVq1cjISEBjz76KC5cuKB9+8PYsWPx9NNPa89/9NFHkZWVhccffxx//PEH1q9fj+effx4TJ04sn6BEREREdFXxymUPPXr0QI8ePbT/h4eHIyEhAb///juMRiPatm0LHx/PFz1y5EhkZmZizpw5SE9PR6dOnbBx40btQ3ApKSl2p9jDw8Pxww8/YOrUqejYsSOaNGmCxx9/HNOnT7/ykERERER01Sn3we/FixfxwAMPYPjw4bj//vu1+w0GA2688cYrnn9MTAxiYmKcPrZt2zaH+yIjI/HLL79c8XKJiIiI6OpX7pc9BAQEYMuWLbh48WJ5z5qIiIiI6Ip45ZrfHj16uPzhCSIiIiKiyuKVwe+yZcvw008/YdasWdqXIRMRERERVTavDH5vvPFGpKamYtGiRWjevDn8/PwQFBRkdwsODvbGoomIiIiIXPLKtz0MHz5c+/JiIiIiIqKqwiuD3w8++MAbsyUiIiIiuiJeueyBiIiIiKgq8sqZ3w8//NCt540dO9YbiyciIiIicsorg99///vfLh/TXwvMwS8RERERVSSvDH6PHTvmcJ/FYsHx48fx5ptvIiUlBatXr/bGoomIiIiIXPLK4Ld58+ZO77/mmmvQt29f3HnnnVi2bBmWL1/ujcUTERF5Te6ePZU6PRFdmUr5wNtdd92FtWvXVsaiiYiIiKgaq5TB719//QWTyVQZiyYiIiKiaswrlz3s2LHD6f3Z2dnYsWMHXn/9dQwdOtQbiyYiIiIicskrg9/evXs7/YU3EYHRaMQ999yDN954wxuLJiIiIiJyySuD3x9//NHhPkVRUKdOHTRv3hxBQUHeWCwRERERUam8Mvjt1auXN2ZLRERERHRFvPKBt2PHjuHbb791+fi3336L48ePe2PRREREREQueeXM7xNPPIHc3FwMGjTI6ePLly9HSEgIPv30U28snoiIiIjIKa+c+d29ezf69+/v8vF+/frhp59+8saiiYiIiIhc8srg99y5cwgMDHT5eO3atfH33397Y9FERERERC55ZfDbrFkz/Pzzzy4f/+mnn9C0aVNvLJqIiIiIyCWvXPM7evRoLFy4EBEREYiJiYHBYB1jWywWLFu2DGvXrsXMmTO9sWiiq1runj2V3QUiIqJ/NK+c+X366afRp08fTJkyBY0aNULPnj3Rs2dPNG7cGFOnTkWvXr0ue/C7fPlytGjRAv7+/ujWrRv2uDlY+PTTT6EoCn9ZjoiIiKga88rg18/PD5s2bcJ7772HiIgInD17FmfPnkVERARWrVqFLVu2wM/Pz+P5rl27FtOmTcPcuXPx22+/4cYbb8SAAQNw5syZUqc7fvw4nnjiCdx2222XG4mIiIiI/gG8ctkDABgMBkRHRyM6Orrc5rlkyRI89NBD2jxXrFiB9evXY9WqVZgxY4bTaSwWC+6//37Mnz8fP/30E7Kzs8utP0RERER0dfHKmd+srCwcPHjQ5eO///47zp0759E8CwsLERcXh6ioKO0+g8GAqKgo7N692+V0CxYsQIMGDTB+/Hi3lmMymZCbm2t3AwBVVbV/pfi5KqC1DTWMUHysL6fB1wjFaLj0fLE+y2KxaG39tPq20d8HUC61RQQiAovFAgButRWDAoOv0do2Guz6btcuXqa4yqFrl5zWvRyK0xwOmYqnLdlWDAqMvj5a250ctrbBxwCDGzm0tqscfj5QDPY5ADjkEJHSc/hdyqFfZ876UnI+hhpGh0we5/DV5fBzzGGXSTetvi9QFOt6dZLDWSZXORQfg9Z2mcNF2+BrvJTDt/Qc+tfAPge0HFBc53C1fWr7lps5nNYLXY3QZ3KVo2RbXyNsmS47h9GgtT3OcYV1T18jbJmc1ohScuhrhDs5nG5XVaDu6WuELZOrGlFl6p6zHLoaYcvkqka46pd+33Kr7rlYT+7uT+VS95ysD32Oq67uubGeLiuHru55up7crXvu8Mrgd+rUqXj44YddPv7II4/giSee8GieZ8+ehcViQVhYmN39YWFhSE9PdzrNzp078d577+Hdd991ezmLFi1CcHCwdgsPDwcAbRkZGRnIrlEDAHDO1xc5xe32Y7qh6W2tAQAdJ/RAo4gWAKy/dmcbQCcnJyMvLw8AkObvj8LiDwKeqlkTRcUFs/dLI+AXXBNGfx/0fmkEVFWF2WxGQkICAOvgPDExEQCQn5+PpKQkAEBeXh6Sk5MBAPU7NkXnmD4AgEYRLZCSkgLAelCSmpoKAMjMzMQ5X18AQHaNGlqmNiM6o0X/9g6ZUlJStLPm+kwZ/v4oKM6hz9RjwRDUCgvUMpnNZqiqioSEBIdMRYqCUzVrAgAKDQak+fsDAOq0CUPXJ/prmY4dO2btb3a2Xaa/i3Pk1KihZWo1qCNaDerokCk1NRVZWVkOmc74+SHfaHTI1H3mHQhsFqplMplMAICEhASHTBZFQWpAgEOmwGah6D7zDi2TbT3l5uY6zXTex8cuU5sRnR0ypaWlITMz0yHTWT8/XCjOoc/U9Yn+qNMmTMuUn58PAEhMTHTIJABSAwIggF2mWmGB6LFgiJbJ2banz3TBaMTZ4subzvv4oP2YbgCAFv3ba5kyMjKQkZFRaib9euoc0wf1OzbVMtn2p6SkJKeZUgMCYFEULZPR3wd+wTXR+6URWqay9qd8oxFninNcMBrRcUIPAEDT21prmTIzM5GWluY0k61G/O3ri/M+1qKtrxH6TPoa4SpTQkKCXY2wZSqrRhQYDMgo3rfyjUa7GmHLVLJG6DN5o+7pa4Qtk7Maoc+krxEFBoNdjbBlKlkjXGWyraeqUPf0NcKWyVWNqCp1r2SNKFIUuxphy+SqRrhaT/oa4U7dc7We3N2fyqPu6WuEre7pa8TVVvfcWU+l1T1nmUrWPU/XU1l1z5bDHYrYhtXlKDw8HI8++iieeeYZp48vWrQIK1aswIkTJ9ye5+nTp9GkSRPs2rULkZGR2v1PPfUUtm/fjl9//dXu+efPn0fHjh3x5ptvYuDAgQCAf//738jOzsbXX3/tcjkmk0l7sQHrBhAeHo5z584hJCQEqqri/L59UGA9olKKb6tnrbcePZpV6xGNRTB5ywKoqgpFUaAUH2kZDAYoioLsPXu0aW3z+WD6NzD6+8BiMgNiPbqZuGEuAOvRk9Fo1I7GXLWXRc2FYlCg+BigFlqgGA2I2TQPBsOlM8C2du6+fTDg0tG+Q44a1vlO3rzAYVpbptJzWAARhxy2b/+w9T1nzx7rmShcOlpdPf0b65kcHyMshWYoBgUxm+eXmcM2n9Uzv7Muo4wctrbLHH4+UIssEPVSDv261GfK3bvXdY4aRlhM1hwTN83T1pmI2PUlb98+uxwC4MNZ66EWWS6d/TCrmBS7wLMcvj5QzcU5/Hww8fu5DtukrW3LUXyQreWAosDoZ4SlwDGHfjsUkVJzKD7W5alFFpc5nLXf6DfHum+ZVWsOXx9M3Og6x/m9e7XXwD6H9cyWpcAMKApiNjvPoaoqLsTFOeaYvd66b7mZw2m9mL0eYhGIRdUyTY5d6DSHs/ay/nO1GmHNAcRsnn95OYwGKEYFauFl5PCg7unXh20+q2d8q9UIW92L2TLfoUaUluOj2Ru0GmGre55sVwaDAW/cPrdC657THHM2aDXCVvcmb13oUCOqUt3Li4vT9i0tx9wNWo2w1b3JWxc61IjS1sfr/edo+5at7k0qJYer9eTu/lQedS9n716H9fHBzO+0HLZ6MWnTfLdzAJVT99xdT5eVQ1f3YjbO82g9lVX3srOzERoaipycHAQFBaE0XrnmNzMzE/Xq1XP5eN26dcv8kFpJ9erVg9Fo1I4sbDIyMtCwYUOH5//11184fvy43U8s21aCj48PEhMT0apVK4fp/Pz8nH4Yz7bDGwwGbaPSnzZXiy6dblcLLQ7TAYCx+Ai75LT6tqXAbNdWbG+hFU+rKEqZbVEFUtwHsah2fdf3y/Y/BZfY5ShynsOufZk57DLp+qBviyqwFJq1tjs5bNOqZu3NnivLYSqnHKZLOfTrzDY/fV9KzsfWf30mj3MU6nKY3M8BfVtEW68lczjL5CqHmC+9he4yh4u2ft+yFJaeo+RrcCmHbvsU1zlcrVdbH9zN4bReFDqvF65yOLSLF3wphxs1wlUOiwqxXGaOK617trc0dfXC6TZZSg59jbDVPY+3qypQ9/Q1wpbJVY2oKnVP338th65G2Objqka46pd+33Kr7rlou70/4crrnrP1oc9x1dU9N9bTleRQCy1l5rjcuucOQ9lP8VyjRo2wf/9+l4/HxcWhfv36Hs3T19cXXbp0QWxsrHafqqqIjY21OxNs07ZtW/z++++Ij4/XboMHD0afPn0QHx+vXc5ARERERNWHV878Dh06FMuXL8fAgQMxePBgu8fWrVuH999/H48++qjH8502bRrGjRuHrl27IiIiAkuXLsWFCxe0b38YO3YsmjRpgkWLFsHf3x8dOnSwmz4kJAQAHO4nIiIiourBK4PfefPmYcuWLRg2bBhuvPFGbbB56NAhxMfHo3379pg/f77H8x05ciQyMzMxZ84cpKeno1OnTti4caP2IbiUlBS7U+xERERERHpeGfwGBwfjl19+wYsvvogvv/wSX3zxBQCgVatWmDNnDp566im7D5V5IiYmBjExMU4f27ZtW6nTfvDBB5e1TCIiIiL6Z/DaadJatWph/vz5+P3333Hx4kVcvHgRe/fuxfXXX4/77rsPjRo18taiiYiIiIic8tovvNmICGJjY/HJJ5/gq6++wvnz51GvXj3cd9993l40EREREZEdrw1+4+Li8Mknn+DTTz9Feno6FEXBqFGjEBMTg+7du2tfcUFEREREVFHKdfCbnJyMTz75BJ988gmSkpLQpEkT3H///YiIiMDIkSMxfPhwp19LRkRERERUEcpt8BsZGYk9e/agXr16GDFiBFauXIkePaw/mfnXX3+V12KIqBrI3bOnsrtARET/UOU2+P3111/RsmVLLFmyBHfeeSd8fLx+OTERERERkUfK7dseli1bhkaNGmHYsGFo2LAhHnnkEfz4448QkbInJiIiIiKqAOU2+H3sscewc+dO/PXXX5gyZQp++ukn9OvXD02aNMGcOXPsfieaiIiIiKgylPv3/LZs2RKzZs3CkSNHsHfvXowaNQrbtm2DiOCxxx7Dww8/jO+++w4FBQXlvWgiIiIiolJ59beAu3TpgiVLluDkyZPYtGkTBgwYgLVr12Lw4MGoV6+eNxdNREREROTAq4NfbSEGA6KiovDBBx8gIyMD//d//4d+/fpVxKKJiIiIiDQVMvjV8/f3x8iRI7Fu3bqKXjQRERERVXMVPvglIiIiIqosHPwSERERUbXBwS8RERERVRsc/BIRERFRtcHBLxERERFVGxz8EhEREVG1wcEvEREREVUbHPwSERERUbXBwS8RERERVRsc/BIRERFRtXHVDX6XL1+OFi1awN/fH926dcOePXtcPvfdd9/Fbbfdhjp16qBOnTqIiooq9flERERE9M92VQ1+165di2nTpmHu3Ln47bffcOONN2LAgAE4c+aM0+dv27YNo0ePxo8//ojdu3cjPDwct99+O06dOlXBPSciIiKiquCqGvwuWbIEDz30EKKjo9G+fXusWLECAQEBWLVqldPnf/LJJ3jsscfQqVMntG3bFitXroSqqoiNja3gnhMRERFRVXDVDH4LCwsRFxeHqKgo7T6DwYCoqCjs3r3brXlcvHgRRUVFCA0Ndfkck8mE3NxcuxsAqKqq/SvFz1UBrW2oYYTiY305Db5GKEbDpeeL9VkWi0Vr66fVt43+PoByqS0iEBFYLBYAcKutGBQYfI3WttFg13e7dvEyxVUOXbvktO7lUJzmcMhUPG3JtmJQYPT10dru5LC1DT4GGNzIobVd5fDzgWKwzwHAIYeIlJ7D71IO/Tpz1peS8zHUMDpk8jiHry6Hn2MOu0y6afV9gaJY16uTHM4yucqh+Bi0tqc5DL7GSzl8S8+hn9Y+B7QcUFzncLV9avuWOzlc1QtdjdBncpWjZFtfI2yZLjuH0aC1Pc5xhXVPXyNsmZzWiFJy6GuEOzmctatC3dPXCFsmVzWiytQ9Zzl0NcKWyVWNcNUv/b7lVt1zsZ7c3Z/Kpe45WR/6HO7WC6fbZ2XUPTfW02Xl0NU9T9eTu3XPHVfN4Pfs2bOwWCwICwuzuz8sLAzp6eluzWP69Olo3Lix3QC6pEWLFiE4OFi7hYeHA4C2jIyMDGTXqAEAOOfri5zidvsx3dD0ttYAgI4TeqBRRAsAwLFjx7QBdHJyMvLy8gAAaf7+KDRYX/5TNWuiqLhg9n5pBPyCa8Lo74PeL42Aqqowm81ISEgAYB2cJyYmAgDy8/ORlJQEAMjLy0NycjIAoH7Hpugc0wcA0CiiBVJSUgAAWVlZSE1NBQBkZmbinK8vACC7Rg0tU5sRndGif3uHTCkpKcjOznbIlOHvj4LiHPpMPRYMQa2wQC2T2WyGqqpISEhwyFSkKDhVsyYAoNBgQJq/PwCgTpswdH2iv5bp2LFj1v5mZ9tl+rs4R06NGlqmVoM6otWgjg6ZUlNTkZWV5ZDpjJ8f8o1Gh0zdZ96BwGahWiaTyQQASEhIcMhkURSkBgQ4ZApsForuM+/QMtnWU25urtNM53187DK1GdHZIVNaWhoyMzMdMp3188OF4hz6TF2f6I86bcK0TPn5+QCAxMREh0wCIDUgAALYZaoVFogeC4ZomZxte/pMF4xGnPXz0zK1H9MNANCif3stU0ZGBjIyMhwy/e3ri/M+Pg6ZOsf0Qf2OTbVMtv0pKSnJaabUgABYFEXLZPT3gV9wTfR+aYSWqaz9Kd9oxJniHBeMRnSc0AMA0PS21lqmzMxMpKWlOc1kqxH6TPoaoc+krxGuMiUkJNjVCFumsmpEgcGAjOJ9K99otKsRtkwla4Q+kzfqnr5G2DI5qxH6TPoaUWAw2NUIW6aSNcJVJtt6qgp1T18jbJlc1YiqUvdK1ogiRbGrEbZMrmqEq/WkrxHu1D1X68nd/ak86p6+Rtjqnr5GuFP3XGWqjLrnznoqre45y1Sy7nm6nsqqe7Yc7lDENqyu4k6fPo0mTZpg165diIyM1O5/6qmnsH37dvz666+lTv/CCy/gxRdfxLZt29CxY0eXzzOZTNqLDVg3gPDwcJw7dw4hISFQVRXn9+2DAusRlVJ8Wz1rvfXo0axaj2gsgslbFkBVVSiKAqX4SMtgMEBRFGTv2aNNa5vPB9O/gdHfBxaTGRDr0c3EDXMBWI+ejEajdjTmqr0sai4UgwLFxwC10ALFaEDMpnkwGC6dAba1c/ftgwGXjvYdctSwznfy5gUO09oylZ7DAog45DAYDHaZcvbssZ6JwqWj1dXTv7GeyfExwlJohmJQELN5fpk5bPNZPfM76zLKyGFru8zh5wO1yAJRL+XQr0t9pty9e13nqGGExWTNMXHTPG2diYhdX/L27bPLIQA+nLUeapHl0tkPs4pJsQs8y+HrA9VcnMPPBxO/n+uwTdrathzFB9laDigKjH5GWAocc+i3QxEpNYfiY12eWmTxOIfB1wgxq9Ycvj6YuNF1jvN792rT2uewntmyFJgBRUHMZuc5VFXFhbg4xxyz11v3LTdyuKwXs9dDLAKxqFqmybELneZw1l7Wf65WI6w5gJjN8y8vh9EAxahALbyMHB7UPf36sM1n9YxvtRphq3sxW+Y71IjScnw0e4NWI2x1r7Qcztpv3D63Quue0xxzNmg1wlb3Jm9d6FAjqlLdy4uL0/YtLcfcDVqNsNW9yVsXOtSI0tbH6/3naPuWre5NKiWHq/Xk7v5UHnUvZ+9eh/XxwczvtBy2ejFp03y3cwDAG/3mVHjdc3c9XVYOXd2L2TjPo/VUVt3Lzs5GaGgocnJyEBQUhNL4lPpoFVKvXj0YjUbtyMImIyMDDRs2LHXal19+GS+88AK2bNlS6sAXAPz8/OBXfNSmZ9vhDQaDtlHpT5urRZdOt6uFFofpAMBYfIRdclp921JgtmsrtrfQiqdVFKXMtqgCKe6DWFS7vuv7ZfufgkvschQ5z2HXvswcdpl0fdC3RRVYCs1a250ctmlVs/Zmz5XlMJVTDtOlHPp1Zpufvi8l52Prvz6TxzkKdTlM7ueAvi2irdeSOZxlcpVDzJfeQvc0h37fshSWnqPktJdy6LZPcZ3D1Xq19cGtHK7qRaHzeuEqh0O7eMGXcrhRI1zlsKgQy2XmuNK6Z3tLU1cvnG6TpeTQ1whb3Ssth7N2Vah7+hphy+SqRlSVuqfvv5ZDVyNs83FVI1z1S79vuVX3XLTd3p9w5XXP2frQ53C3XjhrV0rdc2M9XUkOtdBSZo7LrXvuMJT9lKrB19cXXbp0sfuwmqpaP7ymPxNc0osvvoiFCxdi48aN6Nq1a0V0lYiIiIiqqKvmzC8ATJs2DePGjUPXrl0RERGBpUuX4sKFC4iOjgYAjB07Fk2aNMGiRYsAAIsXL8acOXOwZs0atGjRQrtut3bt2qhdu3al5SAiIiKiynFVDX5HjhyJzMxMzJkzB+np6ejUqRM2btyofQguJSXF7hT7W2+9hcLCQowYMcJuPnPnzsW8efMqsutEREREVAVcVYNfAIiJiUFMTIzTx7Zt22b3/+PHj3u/Q0RERER01bhqrvklIiIiIrpSHPwSERERUbXBwS8RERERVRsc/BIRERFRtcHBLxERERFVGxz8EhEREVG1cdV91RldkrtnT2V3gYiIiOiqwjO/RERERFRtcPBLRERERNUGB79EREREVG1w8EtERERE1QYHv0RERERUbXDwS0RERETVBge/RERERFRtcPBLRERERNUGB79EREREVG1w8EtERERE1QYHv0RERERUbXDwS0RERETVBge/RERERFRtcPBLRERERNUGB79EREREVG1cdYPf5cuXo0WLFvD390e3bt2wZ8+eUp//+eefo23btvD398cNN9yADRs2VFBPiYiIiKiquaoGv2vXrsW0adMwd+5c/Pbbb7jxxhsxYMAAnDlzxunzd+3ahdGjR2P8+PHYv38/hg4diqFDh+LQoUMV3HMiIiIiqgquqsHvkiVL8NBDDyE6Ohrt27fHihUrEBAQgFWrVjl9/muvvYZ//etfePLJJ9GuXTssXLgQnTt3xrJlyyq450RERERUFfhUdgfcVVhYiLi4ODz99NPafQaDAVFRUdi9e7fTaXbv3o1p06bZ3TdgwAB8/fXXLpdjMplgMpm0/+fk5AAAsrOzAQCqquJ8Xh4UACoApfhmUsyACMSsQvE1AhZBbm4uVFWFoihQFAUWiwUGgwGKoiC7eB76+RSYTTD4+0A1mQEBDP4+2vJVVYXRaISIaO2cvDwIrEcwUnwrMJugGBTAxwAptEAxGpCdnQ2DwQBVVbXXTVVV5ObladPCWY4aRkAu5dBPa8tUeg4LIOKQw2Aw2GUqLYfiY4RaaIZiUNzKYZuPCUUAUGYOW9tlDj8fSJEFol7KoV+X+ky5peWoYYRqsuY4d+6cti5FxK4vecXz0M/HpJghRRYoPgYtk217dDuHrw/EXJzDzzGHvm3LoRRvF7YcUBQY/IxQCxxz6LdPESk7h6JAiiwe51B8jYBZtebwLT3H+bw8bVr7HIDBzwdqgRlQXOdQVRUXnOUwmK37lhs5XNYLgxmwCMSiaplyc3Od5nDWLrCYtBphzYHLz2E0AEYFUngZOTyoe/r1YZtPgaVQqxG2unfu3DmHGlFajkKDRasRtrpXWg5n7Yque05zGC1ajbDVvZycHIcaUZXqXl5enrZvaTl8LFqNsNW9nJwchxpR6vpAkbZv2epeaTlcrSd396fyqHs5rtaHPoeieJQDqJy65+56uqwcurpXWo7LqXu2/V7ENqophVwlTp06JQBk165ddvc/+eSTEhER4XSaGjVqyJo1a+zuW758uTRo0MDlcubOnWvbdnnjjTfeeOONN954u4puJ0+eLHNMedWc+a0oTz/9tN3ZYlVVkZWVhbp160JRFKfT5ObmIjw8HCdPnkRQUNBlLbcqzKMq9KE85lEV+lBV5lEV+lAe86gKfagq86gKfSiPeVSFPlSVeVSFPpTHPKpCH6rKPKpCH8pjHlWhD+7OQ0Rw/vx5NG7cuMz5XTWD33r16sFoNCIjI8Pu/oyMDDRs2NDpNA0bNvTo+QDg5+cHPz8/u/tCQkLc6mNQUNBlr9iqNI+q0IfymEdV6ENVmUdV6EN5zKMq9KGqzKMq9KE85lEV+lBV5lEV+lAe86gKfagq86gKfSiPeVSFPrgzj+DgYLfmc9V84M3X1xddunRBbGysdp+qqoiNjUVkZKTTaSIjI+2eDwCbN292+XwiIiIi+me7as78AsC0adMwbtw4dO3aFREREVi6dCkuXLiA6OhoAMDYsWPRpEkTLFq0CADw+OOPo1evXnjllVdw55134tNPP8W+ffvwzjvvVGYMIiIiIqokV9Xgd+TIkcjMzMScOXOQnp6OTp06YePGjQgLCwMApKSkaJ9EBYBbbrkFa9aswaxZs/DMM8+gdevW+Prrr9GhQ4fKikBEREREleiqGvwCQExMDGJiYpw+tm3bNof77rnnHtxzzz1e7hURERERXQ2ummt+qzI/Pz/MnTvX4YNyV9s8qkIfymMeVaEPVWUeVaEP5TGPqtCHqjKPqtCH8phHVehDVZlHVehDecyjKvShqsyjKvShPOZRFfpQXvPQU0Tc+TZgIiIiIqKrH8/8EhEREVG1wcEvEREREVUbHPwSERERUbXBwS8RERERVRsc/P5D8HOL/0wmk6myu0DkVaxdpKeqamV3ocowm82V3YV/LA5+/yFycnJQUFCAvLy8yu7KP0ZBQUGl/mFOSEjA+PHjkZeXB4vFUmn9sLncP0p//vknvv3223LuzZXhH9jKl56ejoKCAiiKUtldKRccxF+5o0eP4uOPP64SB/2VXSMOHjyIe++9Fzk5OZXaD5vK3r7Le/kc/P4DfP755xg9ejQ6deqECRMmYO/evZc1n7/++gvfffddOffOc5W9kwFAXFwcBg8ejLS0tErrwzvvvIOzZ8+idu3aMBqN5TLPyynoJ06cgNlstvv1RHfl5+fj9ttvR3JyssfTlnQlBwA//PADPvjgA7z11lsAAIPBUCW2M08dP34cv/32G1JTU6vEAOFypaSk4LbbbsPRo0cruyvIz8+/7G3h/PnzyM3NRWZmJhRFuSq3qariwIEDaN++Pc6ePVtu3+V6uUREq3f79+9Hfn5+hS7/wIEDiIiIQIcOHRAcHFyu83ZnG7X9ndCfeVYUpUIPCGzLys/Ph9lsxvnz57XHymM/4+D3Cp04cQLvvfce5s+fj/379+PChQsVuvy3334b48aNQ5cuXRAREYHDhw/j4Ycf9viPSnx8PK677jpkZGR4qadls23stjNBlfWHJD4+Hj179kT79u3RuHHjK57f5ebIy8tDYGDgZS/3o48+wuTJk/Hkk09i48aNAODxAPbAgQNo1aoVPv/888vqg5+fH3x9fdGiRQsAl/9axMfH44UXXsDFixc9nvbpp5/Go48+ilmzZuHxxx/HbbfdBrPZXOmDFU+X/dFHH2HgwIGIiopC165d8cILLyArK6tC+1Be88jOzkZRURFatmx5xX9QryTD0aNHMXToUGRmZno87ZEjRzBs2DD07NkTXbt2xffff+/xNmV77qlTp3D69GkkJSV53A8AOH36NHbs2HFZ05aXKzk4jY+Pxy233IKnn34a06ZNs3vMk+3D9nrm5+cjNzf3svoiItrfoP/+97+IiYnxaPu40nV68OBBREZG4r///S8WLFig3e/pfmLrx4kTJ3D06FEkJiYCQJnvtKiqCoPBgD/++AMPPfQQ7rrrLkRHR8NiscBgMHjUj7179+LTTz/Fl19+iTNnzrg9na0PCQkJGDNmDG655RaMGTMGW7dudSuDW4QuW3x8vISHh0uHDh2kZs2aEhISIq+//rqYTCa351FYWHjZy//oo49EURTZunWrdt/HH38stWrVkvfff9/t+Rw8eFACAgLkqaeeuuy+iIioqnrZ0yYlJcns2bNl3Lhx8tFHH0l6errH8zh79qwcPnxYfv/998vux5EjR6R27dry3HPPicjlZbp48aKcO3fObjuwWCwez2fixInyyCOPiIhIUVGRR9M+8cQT0rhxYxk+fLg0atRI2rZtK+vWrfNoHgcOHJCaNWvKzJkzPZrORlVVyc/Pl+uuu062bdum3eepAwcOiKIo8vTTT3s87eOPPy6hoaGyc+dOSUpKks8//1xCQkIkOjra43nZXM66PH78uCxbtkyee+45+fjjjz2e/u233xZ/f395/fXXJTY2VkaNGiVBQUHavDx5XU0mkxQUFGj/N5vNHvUlLy9Pzpw5IxcvXtTu8+Q1sVgssnHjRmnUqJHdPDyRm5srZ86ckb///vuyprd55ZVXpFevXh5Pt3//fgkMDJQpU6bIq6++KnfccYcoiiK//fab2/OwrbOvv/5abr75Zmnbtq20bt1annrqKY/+hhw6dEi6du0qPXr0kF27dnmcReTSNnC5NVy/Da1bt04++ugj2bRpk+Tm5pY5bUJCgtSoUUNeeuklu/v/97//edQHW9+//fZbueOOO+Taa6+Vf//73/Lee+95NB+b1NRU6d+/v+zYscPjPlzuOj18+LD4+vrKk08+aXf/6tWr5ccff/S4H//73/+kbdu20qhRI2nVqpXceeedcv78ebvn6Nn24/j4eKlbt67cd999cv/990tISIj069fP7eWLiKxatUoaNWokHTt2FEVRZMiQIXLw4MEyp7P1Yf/+/RIUFCSPPvqoTJkyRbp06SLXXHONHDlyxKN+uMLB72U6ePCg1KpVS+bNm6f9Ibj33nulbt26cuLECbfmkZiYKDNmzLiswdqJEyfk+uuvly5dusiZM2e0+1VVlWuvvVZef/11t+Zz5MgRqVevnjzwwAMiYi1inhbAvLw8u+V7Kj4+Xho0aCCDBg2SDh06aH9ULly44PY8fv/9d+nUqZO0bdtWFEWR6dOnS1pamkf9OHjwoNSpU0dCQkLsDig8+cN++PBhGTJkiHTo0EGGDBkiX331ldvT/vXXX/Lvf/9b+/8999wjU6ZM8bgPTzzxhNStW1f7Q7xjxw7x8/OT6dOni8ildVTaPBMTEyUkJEQmT56s3efuuj1+/Li27NOnT0tQUJBHhVtv//79UrNmTXnmmWccHiurP++8844oiiJ//fWXdl9eXp4MHjxY+vfv79G2+sEHH8iHH37o9rL1Dh48KI0bN5bbb79dbrjhBmnWrJlHBxSffPKJKIoin376qd39rVu3llGjRrk9HxGRZcuWyeDBg6VXr16yYMEC7X538xw+fFgGDhwobdu2lb59+8onn3zi9rKzs7O19rp16yQ8PNyudrjr0KFD0rNnT+nYsaPUr19fli5dajdvT8yaNcvjwe+RI0fE19dXXnzxRe2+//3vf+Lj4yNLly7V7rPtX6W9tj/88IPUrFlT3nrrLUlKSpI333xTFEWRDRs2uNWXQ4cOSZ06deTJJ5+87IP+pKQkmTdvnpw8ebLM/jqjf/6QIUOkefPm0rZtWzEajTJixAjZvHmzy2lNJpNMnjxZFEWRQ4cOafe/8MILoiiKxMfHe9SX7777Tnx9fWXGjBmyePFiufPOO6Vz584eH8C//PLL0qlTJ+nXr5/HJ2KuZJ2+//77oiiKLF++XBukvvDCC2I0GuXXX3/1qB/btm2TmjVryooVK2T79u3y1VdfSZs2bSQiIkI76HS2rn///XcJCAiQefPmiYjIhQsXZMqUKWI0Gt3+u7hy5Urx8fGRzz//XHJycmTt2rViMBg8Gpf4+fnJ888/r923dOlSURRFvv/+e7fmURYOfi/DqVOnRFEUGTlypN39Bw8elNq1a7u1cv78808JCwsTRVFk0qRJcvToUY/78c4770i/fv3knnvukT/++ENERNasWSNGo1Hi4uLKnD4+Pl5q1aolTZo0kaZNm8qePXtExLMzQadOnZLBgwfL559/rt3nSfG07WgLFizQzm4OHDhQGjduLJmZmSJS9sDPlmP69Omyfft2ef7558VgMMgHH3zgdj/i4+MlICBARo0aJSNHjpTevXvLt99+61Gm+Ph4CQkJkQcffFAWL14sTZs2lQ4dOtgV9dKsW7dOateuLffee6+IWP+Q2Aa/7nrvvfdEURS7sx1paWkSGBgow4YNk7S0NIezyCVfX9tZLUVR5KmnnpKMjAy3l3/x4kUZM2aMtGzZUhsAh4SEyO7du0XEs20rKSlJfHx85Nlnn7Xr5zvvvCN79+4tddrCwkJ57733pFGjRvLQQw/ZPTZs2DAZNGiQ22fTFy1aJIqiyG233Sb/93//p93vzjZx/Phxueaaa2T69OmiqqpkZGTIq6++KrfeequcPn3areWPGDFC6tWrJ998843dYHHQoEHywAMPuH2WcOrUqdKoUSOZPn26DBs2TBRFkfnz57s1rYh1+w4ODpaHHnpI3nrrLWnTpo1ce+21btWas2fPSvPmzeXVV18VEesAoWPHjmIymbRtwp0DPNvB+rRp0+T777+XWbNmSVBQkGzfvt3tHPrX64knnpABAwaIiHvr02QyySOPPCKKosiff/6p3T937lxRFEWio6Nl06ZNbr0mIiKTJ0/W3tGwbSu2d3vKkpWVJREREfLEE084PKY/sy/iOltSUpLUq1dP6tSpIzNmzJDU1NRSn1+aWbNmSbt27eTEiROSn58ve/fulcjISBkyZEipr8f+/ftl1KhREhYWJikpKfLWW29J3bp15YcffnB72aqqyvnz52XQoEEya9Ys7f4zZ87Is88+K507d/boQG3nzp3SpEkTCQ4Odrt+21zJOhUReemll0RRFFm5cqUsWLBA6tWrJ5s2bfKoDyIizz77rAwdOtTuvuPHj0urVq1k+PDhTqfJzc2Vbt26SaNGjezut23zn332md1278yaNWtEURS7kwXJyclSp04dGTt2rMO73SW3tfPnz8uAAQOkYcOG2rhGRGT27NmiKIosXLhQfv/9d4d+eLrNcvB7mbp16yatW7eWH3/8UTuK2r59u9SsWbPMI7SLFy/KhAkT5L777pPly5dL06ZN5dFHH7UbALu7IleuXCk9e/aU6OhoeeONNyQoKEhWrVpV5jz27NkjgYGBMmvWLDl27Jjcc8890qBBA20A7O6Zxj179ki/fv2kX79+dm+ru9P/9PR0CQ4OlqioKLtBUXR0tBiNRtmzZ48UFhY69EU/74SEBPHx8bEreH/99ZfUq1dPRowY4bBMZ4OvY8eOiaIo2tnFn376SYYMGSK9e/eW7777zq1Mhw4dktq1a8ucOXO0+z799FOtYOiVzHPu3DkREcnPz5f//e9/0qxZMxkxYoQ88MADMmrUKFm4cKEsXLhQ3njjDXnllVdkwYIFMnPmTFm9erVDP7777jvp0qWL3H///bJ//34REenUqZMEBgbKvffeK61atZI77rhDJk+eLPv27XN42/i3334TPz8/efnll2XTpk3awZknA+AffvhBhg8fLp07d5YvvvhC+vbtK+vXr5eTJ0/KkSNH5K+//pJTp07Jn3/+Kdu2bXN61s5sNstzzz0ngYGB8sorr2j3P/fccxISEuLW27vnz5+XNWvWSJMmTWTMmDEiIrJkyRKpVauWJCYmupXlxx9/lE6dOsmCBQvkrrvukj59+siaNWu0x0vbT8xmsyxevFgGDhxol3Hv3r0SGBhY5pk6/fZ29913yw033KBd5rBx40ZRFMXtM+pPPPGE1KtXT3vb8fTp09K6dWvp2bOnW5fnHD58WKsXNhs2bHA40HI1j/T0dJkyZYrUqVNHVq5cKZs3b5auXbtKVlaW9hz9vql/N8vm3Llzctddd8mjjz5qd//AgQNl9OjRIlJ23fnrr7/kP//5j7b9TJo0SZvW1veioiKn747Y3omKi4uTYcOGSZMmTeTMmTPy5ptvSmBgoDz11FPyxBNPyIgRI8TPz09GjBghDz30kKSkpDh9bfLz8yUiIkJee+01ycnJkSZNmsjDDz+sLfutt96SjRs3usySlJQknTt3tnsredeuXfL888/LtddeK4MHD5aVK1e6fE3Onz8v9957r4wePVqeeuopuemmm+TJJ5+87AHwPffcIxMnTrTL+dtvv0mzZs20d5309K/FoUOHZPjw4RIQECD+/v4eXT5io6qqREREyH//+1+7+zMzM6VPnz7y2GOPOZ3O1Ta/Z88eqVu3rgwdOtShRulfm/JYpxaLxW77t535NhqNHl+uZjN+/Hjp1KmT9n/bwf5HH30k7du31870l9zG3333XWnWrJn2LuTLL78s/v7+MmzYMBk6dKh06dJFbrzxRnn++edlw4YNDicRbIPfBQsWaPvM0KFDRVEU6du3r0RFRcns2bO1WlZQUOCwDj744AO5/fbbZejQoZKeni6vv/661KpVS+6++26JiYmRjh07SqNGjWTixIny3HPPXdbBGge/HtIftfTq1UvCw8PlwIED8ueff0qjRo1k2rRpZc7j/Pnz8vHHH8tHH30kIiJffPGFNGnSxGEAXFJycrIcOnTIrpiKWAfAt9xyixiNRu2tTIvF4nKDUFVVunbtKv/5z3+0+w4dOnTZA+CdO3fKsGHDpFevXnY7qn56s9ksCQkJDtMOHz5cbrjhBm3A/sorr4iPj49ce+21MmrUKGnVqpWMGjVKvvrqK20wp7ds2TJRFMVuQPLss8+KoijSs2dPee6552Tt2rUuBxonT56Un3/+2eGswE8//SRDhw51awBsNpulS5cu0rBhQ7uzBE8//bQoiiJvvPGGxMbGOlyGoaqqxMXFScOGDbW39/Lz8+Wzzz6T66+/XhRFkU6dOkmPHj3k2muvlRtuuEFuuOEG6dixo3Tp0sXuj97HH3+svd4//PCDdO/eXUaMGCGtW7eWQYMGaYOJPXv2yIcffijt27eXunXr2g3W09PTpVOnTnbXm61bt+6yBsBbt26VESNGSHh4uCiKIk2bNpVatWqJv7+/BAQESO3atSUgIEDq168vx48fdzqPEydOyJw5c+S6666T5cuXy9KlS6Vu3bqlvrNScpvNzc2VTz75RBo1aiTt27eXevXqaWcJ3TkLffToUZkyZYpkZmZKSkqK3HHHHQ4DYP02UXL7+Oabb+ze6rNYLHL+/Hlp1qyZ04Pk0oq47Q/P1KlTJTAwUHtno6z9dMuWLaIoit0Zwvz8fO06wLi4OIdr8fT9KCwslNtuu03q1q0r+/bt0+6fOXOmKIoiixcvlnXr1jlc7lUyS1pamsycOVOCg4MlMjJSWycRERESGRkpN9xwg3Tp0kVuuukm6dWrl8P1wLZLLmxvvdr+6D755JMyZMiQUl8Dmx9//FECAwNlzJgx8scff8j48eMlJibG5fNty/jtt9/k7rvv1gaG8fHxctddd0mtWrWkZs2aDm/Pb9myRebMmSOtW7eW5ORk+fvvv7W3z//3v/9pz3/hhRdk1KhR0qhRI/nPf/6jvWb5+fkSHR0t8+bNc/m5kMOHD4ufn5/2d2TZsmXSrVs3ufXWW2Xq1KnSq1cv6dy5s8t3SfLz82XJkiXauxnPPfecwwBYz9W2aTabpbCwUAYOHCgPPvig9rrZXruXXnpJmjVrJjk5OaKqqt1gSd8+ePCgREdHS3BwsLY9uvs3yGKxyIULF2TkyJEyatQoyc3Ntevv008/Ld26dXM4I66f/2+//SabNm2SlJQU7aDs559/lpCQELn33nslJyfH7nUoj3Va8ppo/bq2XS5hG0h76ocffpBWrVo5/G377rvvpEWLFpKSkqLlP3TokHzzzTciYr007KOPPpKGDRvK9ddfL/Xr15cdO3Zon+HIzMyUKVOmSL9+/aROnTraO7QHDx7UDqRtn0eaP3++DB06VDp06CD79u2TgwcPyv/93//JvffeK02bNpUGDRpolwrt27fP7vK2//u//5N+/fpJ+/btpVatWnbvHpw4cULWr18vt99+u7Rr187l35DScPDrJttGWfIo57bbbpOwsDAJCwuzG0w622nPnj2rtfVnPEREPvvsM4czwGazWTvt/9FHH0m7du20QYSt4Nl8+OGHEhkZKaNHj9beDnDWhxMnTsjXX3+t/V+f5/Dhw24NgJ194OWnn36SYcOGSe/evR3OAJtMJpk0aZIMHDhQcnNz5cCBA7Jy5UrtOffff7906NBBRowYIaGhofLTTz9pZyRXr14tU6ZMEV9fX+nevbv2Gp45c0br2/z588XHx0e+/vprWbx4sYSEhMiKFStk5cqVMmfOHLn22mulXbt20r17d1mzZo1WjPbv3y+NGze2ez30eXfu3KkNgF1dApGYmCgHDx6UvXv3Sps2bWTUqFFy/PhxefHFF6V27doyZMgQmTdvntStW1duvfVWiYqKkmXLlsmxY8ckPj5eAgMDZerUqXav7/nz52Xt2rVy0003aW/JllxX+fn5WnvKlCkSEhJiVwA2btwoXbp0kcaNGzsdLBYVFcnPP/+s/T8pKUm+/PJLiY2N1TLaBodlDYDPnj0rCQkJDgdusbGxcu+990qzZs3kjTfekNTUVElISJDff/9d9u/fL4mJidrZBz3963vy5EmZOXOmtGjRQhRF0c7YORu4vvfeezJ58mQZO3as7NixQ3uN8vLy5OOPP5brrrvO7vpOdy/B0J/1+fPPP50OgPVnKv/44w/56quvxGw2260nfa42bdrYvVWvX0e7d++W1atXy1tvvaW9K2AzfPhwURRFJkyYoG2rZQ0Q/vjjD5kyZYpcf/312lnazp07S6tWreQ///mP9OvXT9q0aSNRUVHy0ksvOX2L+sCBA9KhQwcZPHiwHD16VBYvXiyBgYEyatQoeeGFF6Rx48Zyyy23SLdu3WTx4sUu3yo+deqUzJs3T0JDQ6Vp06aycuVKmTFjhjz99NMyd+5cmTdvnsydO9duen3d1O+Htv3h9ddfd3h7t2R9PXnypDaA+PHHH6V58+YSExMjPXr0kNatW8t///tfGT9+vDz22GMyadIkeeSRR2TUqFEya9YsiYuLkxo1ajh8CCkuLk7uv/9+CQ0N1eq02Wy2Wx+FhYWSmZkpHTt2lFdffVVWrlwpiqJoZ72+/vpradmypXTp0kWbh8lkkmeeeUaaNWsmSUlJTl9HEes7iI8//rjUrFlT2rdvLzVq1JDnnntOO0mQlZUlAQEB8tprr9lNp68jeXl5dtvls88+qw2AT506pfVHP0hztd+8++67oiiKbNmyxe7+pUuXSt++faWwsFAOHz4s48ePl+XLlzudx8GDB2XEiBESFhamDdqdLc/W58zMTCkoKNAGtRs3bhSDwSBz5syx22/Hjh0ro0ePtsuuzz19+nQJDw+X+vXrS6NGjeSee+7Rlv/zzz9LnTp1ZPTo0do8y2OdHj58WBo3bixTp06Vn3/+WbukSb/9LF68WBRFkZdfftnlhwdtOf744w/Zu3evtr+cPHlSRowYIXfccYc2XigsLJQZM2ZI165dtUFrfHy8KIpid33thQsX5MMPP5Q2bdpInz59tPv1r5/JZNLm8eabb0r79u3tLlNYvXq1KIoitWrVcjg4vHjxoqSnp8uiRYvEbDZLfHy8+Pn5Ofwt/PTTTyUyMlJuueUWu78vtn7k5uZq10Z7ioNfNyQmJsrDDz8sQ4YMkccff9zhWr3Bgwdr37rg6g/R2bNnpXv37nYFVD/AELEfAB88eFCmTp0qkZGR8tprr4mvr6+sWrVKNmzYICNHjpSAgACHDeq9996TXr16yejRo52eQf77779l0qRJct1118lbb72l3e9qAGw7y1Py7akBAwbIddddJ3fddZfdH+2ff/5ZOwNsO4osKiqSmJgY8fHxkd9++03i4+PF19fX7oyjiPVSB0VR5L///a/TazEPHjyonY3Yv3+/tGvXzm7wYLseyGAwaAM4m2PHjsnWrVvlrrvu0t7ujo+PF39/f5kxY4bDsvTrxDYAjoqKcvj08f79+yUgIEA7s/fTTz9Jy5Yt5frrr5eQkBC7t6RTU1Nl586d8q9//Uu6desm69evd/pBLtugPy8vTz777DNp0qSJDBs2THvcVuRtBW/q1KkSEhIiBw4ccMixadMm6datm9x77712n1gueSbpt99+E0VR5O2337a7X1VVbd27GgD//vvvctNNN2kfNJw9e7bdGe7Y2FgZMWKEdO7cWbvut+RrbGMymbR1r3/85MmTMmvWLLn22mvtPmSkf85///tfadiwoTzwwAMSFhYmTZo00bZBEesBxSeffCKNGzeWsWPH2mV0l215f/31l9xxxx3St29fWbt2rSQmJkrr1q21y1tsH+D57LPPHNaX7cxvkyZNZOfOnSJyads9efKk9paj7YzL9ddf73BpyogRI+TGG2+UNWvW2A2uS5OYmCjTpk2TNm3aSIMGDWTo0KHaH9Nz587JH3/8IePGjZN27drJ+PHjneY+ePCgtG3bVtq0aSMhISF2g5y///5b4uLiZNSoUXLLLbfYfciwpJSUFFmwYIEEBwfLF198UWq/bXWz5FvZ+pr04osvSrdu3bTX+Pnnn5cnn3xSOwu1f/9+adiwod2HT7ds2SItWrQQg8EgLVq0kFGjRkmfPn3k9ttvl7vvvlsGDBgg//rXv+Tzzz+XgIAAl980sn//fhk8eLA0adJEG7A7q1/z5s2Thg0biqIosmzZMrvH3nrrLWnVqpX06NFDhg4dKkOGDJF69eq5fOtfv82eOHFC1q1bJy+99JLdpTwWi0XS09OlR48e8uWXX2r3Jycny4wZMxzeddD3WT8APnbsmDz++OPSr18/MZvNdvvcu+++K2+88Yb8/PPP2nb44IMPSs2aNbX94o8//pDrr79eHn30USkqKpLx48dL+/btpXv37nLbbbfJ0qVLHc7aHThwQEaMGCFNmjSxqxklff3119q8HnjgAe3v8urVq8VoNMqwYcPkwQcflPHjx0vt2rVdftPAm2++KfXq1ZPY2FjJyMiQ1atXy1133SW9evXSDiR++eUXrb7ZXOk6/fDDDyUsLEx69uwpI0eOlM6dO8v27dsdXo9FixaJr6+vLFy40OVA78svv5Tg4GBp2bKlhISEaGfzjxw5IiNHjpQWLVrItddeK71795Y6depof9vj4+OlZs2adpcz2WRlZclHH30kjRo1svsgdsnPGLz99tuiKIrTb+dYu3at9rrpD2L1B4ml9UHEega4b9++dt8WUdo72+7i4LcM8fHxEhoaKmPHjpWBAwdKy5YtpV+/fpKdnW334vfq1UuaNWsm27Ztc1r80tLS5IknnpAOHTrYfcik5Er87LPPpHnz5tKyZUvx9/fX3sLXD+g++ugj8fHxcfoVLu+++660a9fObicVsV4bO3z4cNm6das8/PDDEhkZKW+++ab2eMkB8OjRo8VoNNrtrPHx8dpXj7z//vvStWtXueuuu+yWs337du0M8JdffilPPvmk1KxZUxv41qxZ0+UfkrFjx0q7du1k1apVdkfB+tfHdoTo7Bqyl19+WRRFsTsr7mwHsX24reTA98CBA04/PPTzzz9L3759ZdCgQVrxKTkP23L27dsnrVq1kttuu81lsf3ll1/Ez8/P4QBg9uzZ0qZNG+06qfz8fPn888/l2muvlf79+zvMZ8qUKVK3bl27M3UWi0U+/vhjrT8bN26Ubt26yciRI+Wnn35ymIdtAO/s2xRsuWzzWrdunfj6+kp0dLScOXNG+6DhU089JVu3bpW5c+eK0Wi0+1CYiPVM29ChQ+Xmm2/WBnwlHT16VHr27CkzZ850OpBPSUmRmTNnynXXXad9DZ0t71NPPSUhISFy+PBhEbl0LbntG0xs9NcA33nnnU77URZbwU5OTpZBgwZJ9+7dJTAwUP71r3/ZPW/ChAlSq1Yt+fTTT+3eITGbzZKdnS2NGzeWgwcPyuLFi6VWrVqyb98+efvtt8XX11fWrl0rGRkZsmrVKu2bS0Ts/+gMHTpUOnXqJCtXrnS6zRYUFMjp06ftzn799ddfMm3aNAkLC5PFixdr9+sPhvR/oJzlPnz4sNxwww1y8803a+8OlRQXF1fmoPbUqVPyzDPPSGBgoN2BuH57Eym9btosWbJEevbsKSIic+bMEUVRtEFLaQe5P/30kzbwdXam+sSJE2I0GrU/yraB37PPPqtdpmVbxuDBg6VFixYOJyT0r1vt2rUlNDRUXnvtNYdLoL777jtZtGiRDB8+XBYtWuRwTfrhw4clJiZG/vzzT4d3A1yZPXu2XHfdddplcgcPHpRWrVrJPffcY/eal+yrLWPXrl2lTZs2UqtWLYdLJ4YOHSotW7aUhg0byk033SRPP/205Ofny/nz5+W///2v1KxZU5o2bSrXXHON3Vn55cuXS5cuXcRiscjSpUvl3nvvlfr168vLL79sd4CelJSkvSNRUFDgUMcPHz4sDRo0kMWLF8v06dOld+/e0q5dO+0EyebNm+Whhx6S22+/XcaMGWN32Zv+QLSoqEgeeOABh0tfNm7cKLfddpvd36pDhw5JUVFRua3TxMREefDBB2Xbtm2SkZEh//nPf+TWW2+V/v37y4oVK+xOss2dO1fq1KnjcCBs+xBt165d5c0339ROmhmNRm1AnpGRIT///LM89dRT8uabb2r9OHDggNSuXduh9r/55ptaFtslEI0aNXI4KBYRWbFihfj4+DgMfA8dOqS9TrYzwM8884zWf9s6sH3NasmB75tvvmn3mRbbAHj48OGXdT24Mxz8luLQoUPi7+8vCxcu1O576KGH7K5J0g8a+/btK7Vr13Y6yBCxnsGaO3euXH/99XZvMZQc4EVFRUmdOnVkz5492hlR/dsJd911lyiKIg8++KAsWLBAtm7dane93caNGx3OrK1atUq6desmIta3Rx588EHp3r27ywHwgQMHJDo6utQdZfPmzdKjR4//Z++rw6JM27e/oaSkZ+ju7lJUFAUJEUEBAxREscFARQRFUGxF18LErrVdc6011wIDATFQMFAEJSTn/P7g99zv88wMiIq76noex3u86zDzxJ3nfcV54d69e4zF5dy5c+jXrx/k5OQgJiaGmzdvkoQZ3on2559/MqzUAwcOhImJCTZt2sR3ys3OzoaUlBSfbA2dXCQlJUFYWJixOVHgcrkoKCiApKQkscBTEzQlJQWdO3cmrj7q+xSuXr1KXPTZ2dkCCeOxY8fw/v17XL16FXp6eggNDWXESFLtm5KSwuceTEtLg7KyMokvpseJbd26FZaWlowQASoejL5pNzY2wsbGBlFRUYzYNioG2MPDg7EAU3J9vAvPrl27iDuLty327NkDBQUFXLhwASIiIoxDVl5eHuTl5QXKb50+fRpdu3ZFly5d8PHjR76EkRkzZoDNZiMlJYUkDu7atYtxjSdPniAhIQHm5ubkmSmCSE8qfP78OdTU1ODt7U02Q2o+VFRUYN26dRg7dizfMzZH5nhBPTuVEEhPtqITyZiYGCgrK2P37t184Q/29vbo0KED2rVrh+vXr5Nr0eXMXr16BSkpKRJHSScnXC4Xbm5uJJGPjsWLF8PPzw+ysrLQ0tJC586dcfXqVdI2EyZMgLGxMZYvX05+w+sN4D3A0/999+5dmJiYoFevXozQGeo7ycnJYLFYfIcgXrx48YKQ1ZZ0yZtbNynSv3LlSgwcOBCzZ89Gu3btGFYtQYfcrKwssmacOXMGOjo6GDBgAF9OwdGjR6Gurs4gb3PmzIG0tDRf0lJ2djbc3d1hZmaG2tpaPrJWVlaGW7duISUlBZqampg7d65ACS1BHpGGhgY4OjqShKHBgwfzyd7R+++vv/7CxIkTISsrS97pwYMHYLPZmDJlSouycPR+trGxgby8PO7cucMYezk5OfD29sabN2/w7t07JCUlwdnZmSFPefPmTZw/f57hnaOu0blzZyxZsoQ88/79+yEmJgYlJSWEh4fj0qVLqK2txcuXLxlrHr1N79y5w+jXy5cvo0uXLjA0NCS/ofq4uYRO6v6DBw9Gnz59+Ly2kydPhp6eHt/hkmqjr+lTCv3792ccnJ8+fQpdXV2wWCx4e3tj5MiRePz4MQBmKA/VFnV1daiqqkJ8fDxjv0xISICQkBBWrFgh0DtUUlICISEhvqRwKsyCfhCprKzEtm3bICYmxkgapKy6dM8CAPj6+mLUqFGM+27evBnCwsIYM2YMCT8qKyuDmZkZzM3NGb+fM2cO2WPo2LVrF+zs7DBw4MDP0sFuDr/IbzN49+4dHBwcYGhoyLehsVgsbNu2DW/evOHTqfTx8SFElRqgvEH+VKA4nVRT2Z7U9SnrV1FREfr16wd5eXk8fPgQAwcOhJGREXbu3IkVK1Zg+PDh4HA4sLGxQffu3RlJZfRJN2fOHNjb25PPCgoKPkmAqQFWXl4OTU1NODg4MN514sSJUFRUhIqKCjQ1NRki2OfPn8eAAQNw//59NDQ0oHv37pCVlWW4sZKTk6GhoYG8vDzGwjN48GBwOByGBfPFixdESoiOmTNnYvLkyYw+mjFjBiQkJBjvRWHJkiXgcDiYPn06+c2cOXMgLy8vMDaWd+F69uwZlJSUiBwZhZSUFGhoaBAyevHiRejp6WHgwIGEeFDgcrkYMWIEpKSkcOXKFcyfPx8KCgoC5Wzq6+vR0NDAiPeqra3FnDlzYGJiwtDhdXBwgKenJ1lc6M++d+9eotsINI0rFouFAQMGMO5HZRkLivuk+qisrIzEudFP/BSp9/DwwNy5c3Hw4EEGOb9+/TpfsiYFysNy584dXLhwAePGjYOBgQGCgoKwe/duMs9evnxJBM/fvn2LDx8+QEdHBx07dsSjR49QV1cHOzs7KCsrw93dHQ4ODnB2dkZERASuXLmCJ0+e8PUF0ER8qdi61iA/Px+ysrLo3bs3IRONjY0MdRIqGVNBQQE7d+4kB5J3795BVlYWoqKiyM7OBpfLxZo1a2BmZsYgs0FBQRASEkLnzp0RHh6Ofv364eLFi3zubTomTZoEFRUVLFiwADt37sT06dNhbW0NOTk54il68uQJJk6cCFNTUwYBBpqsWbx9RI2jwsJCEspDhUD06dOHFDChIz4+HqKiooy4aEF4/fo1UlJSGOvW56ybALB8+XKwWCy0b9+eEN9PHXKfP39O7nPmzBkYGhrC39+f4a2pqqrCoUOHYGhoiMDAQMybNw9sNrvZhEt6MjKdnPDGak6bNg2ampqYP38+sbClpaW1WAAgMzMTSUlJOHjwIBYuXEiS9lJSUhgu5C1btsDX1xdubm4MA83QoUMRFRXFIJAfPnxAYWEhbty4wXjGmpoaDB06FCIiIrhz5w5jHSkuLsa1a9fQr18/cs+amhqkpKTAyckJMTExAmNT6WoGixYtQmBgIPnbyJEjoauri507d8LJyQmamprw9vYWmEh69uxZLFiwAJGRkQyVDi6XiytXrpADiKBcAiqZDQCmTp1KZCTT0tKgpqbGFwqyY8cOuLq6kvndln1K7T1Pnz6Fk5MTkXUbMmQI9PX1cezYMSxcuBAGBgbQ09MTmPB26NAhBAQEwNraGvb29nzSXwkJCRAXF8fixYv5eEptbS2Cg4OhrKxM5nRaWhoUFBSILjO9/aurq0koC/X7Pn36wMDAgDHH+/btC1NTU0LY6evTihUr0KFDB3Ldt2/fYs6cOWCz2ZgxYwaAJvLNK3NHv8aePXu+KLlNEH6R32ZQX1+PxMREdOrUibhElixZgnbt2sHDw4NIOZmZmWHNmjV8Vo7Hjx9j8+bNfIN28eLFkJOTw6BBg2BqasogJEBTHNPt27cZC87Lly+JLqeOjg7fxLt58ya2b9+OPn36MH5HP3nNmjUL3bt3B/C/wUQRYN4QCF7CV1FRgblz50JMTIxkZqalpUFGRgY7duzA9evXsWzZMiK2Luj+lCyPp6cn7t69i7S0NLDZbBw9elTgfaOjoxmTuby8HB07doSJiQmxMlNJN/RrUKCknaiF68mTJzh9+jQaGxsxe/ZsODg4IDk5GSkpKVBSUhK4ofFmBlPXcXR0hL+/P3Hhp6WlMa5BvcfFixchJyeHIUOGIDs7GxkZGYxrRUVFgcViQVxcnC9OGWjaqBcsWCDQcvD+/XssW7YMVlZWGDZsGAlBoawD1ALz/v17vt9Tf7OysoKZmRl5j3nz5rWoKdnY2Ih79+4hOTkZlZWVmDp1KkRFRXH8+HGSaLhixQqsXr0aU6ZMgb6+PszMzPjiDgVdF2jqM2r8UJnFQkJC0NbWhoGBAXbv3o0HDx6gvr4eJSUlhBi9f/8eurq6cHBwgKWlJby9vVFRUYHKykp8+PAB6enpRGqHHjLBi8WLF0NMTAyLFy9u9jsUysvLER0djTdv3kBbW5tR3ABoypxXVFTE33//jeHDh/OFQNDdj0DTWNu4cSMcHR0xYMAA9O7dG7a2tjh16hSePn2KTZs2YdCgQdDR0YGEhASDtFLtt3XrVmhpaTFc1I2NjXj+/Dl69eoFWVlZYonLy8vDxIkTIScnR/qbqqRHj6umxsrTp08hIyOD8ePHk/F09+5dKCsro3///uS96GNtypQpzRLgmpoaTJgwAX/++Sdjk/2SdXPz5s1QUFBgVH5qzSGXHmJx7NgxWFtbIzc3F8+ePSMkqba2FgcPHoSFhQXDW9Nc4hT931R+hqWlJWbOnMmQ50tISICenh4iIyPJOiBIzYbC+fPnYWBgQLwTT548IbGWnTt3RmpqKp4/f47nz5/j2rVrjLj8mpoaODs7M9rs6NGjiIqKgqysLISFheHr68s48M6ZM4ePDPbv3x8aGhrQ1taGtbU142+1tbVITU2Fi4sLwsPDUVtbi9raWoGFiigDwp49ezBy5EioqqqSQ0t1dTUOHTokUEv28OHDaNeuHaytrWFsbAwlJSWGRxQArl27BhsbGzg6OjLGYmVlJYyMjGBpaYnIyEjIyMgwiGm3bt2gq6uLU6dOoaioCOXl5STOlD5OvrRPy8rKUFRUxDh8U0aNvn37YsaMGRgyZAhUVVUZHihq/vLi6tWrkJSURGRkJAICAiAiIoKEhAS+fKTx48dDSUlJYKhMY2Mj+vfvDyUlJQwdOhRsNpusBfQxfeXKFYEHmpcvXyI4OBidO3fG9u3bERgYCCsrK0J86YdYypBG/wxoyhVYvHgxZGVl4ebmBg6HI3Av/JxiUa3FL/IrANRmUl9fj9mzZ6NDhw5wcnKCnJwc/v77b9KRN2/exMyZM2FhYQFNTU28evWKdOrYsWOhqKiIjIwM4o6gm/NLS0sxY8YMmJiYMCotNeeSKioqwrBhwyAtLU3IX3MSOA0NDcRiTA3mGTNmkKIcdEsBFXfUoUOHFq1eNTU1JKbW09MTKioqjNNZRUUFbG1tGZYrSi+T2hgfPXoEKysr6OnpQVZWVuBEa8lF9OHDB3Tt2hVGRkaIiYmBkpJSi9WDKNd9cXExlJSUYGhoiIMHD6KxsRGzZs0iVYioUAP6hpaYmIjevXsLDKzPz89Hz5494e/vj2HDhoHNZgsUZH///j0KCgqIVZHFYjE0a7lcLqZMmQIRERG+31Oi+YI2RDqxXbp0KUxMTMDhcMhGQ43Pd+/eQVlZWaAIPgVHR0eYmZlh5MiRUFRUFLjwXL16FeXl5QKzguPi4sBisSAiIsL324cPH+L48ePw9PRsVleX3rZbtmyBrq4umS/R0dFQVVXF6dOnMXbsWKipqcHe3h6VlZVk/FJz4P3796SMJt0VT8enCmMA/6si1BwBzsnJIQddLpeLDx8+YNy4cVBQUCAJg5QFhV7RKSoqCnJycgLlyagxX1NTg/Xr18POzg7i4uICk1Zv3bqFHTt2CCRfo0ePZiSm0FFcXAxHR0eG9yYvL48QU6qSnqCkk1evXkFDQwPR0dF8ChP379/HiRMnMG3aNDx9+pTPEh0XFwdRUVGG3FJdXR1JCuQd35+zbtJjgCmy9yWHXGreUHJmffr0YUhWfvz4Efv374epqSkjVrwlAnzgwAFIS0tj/PjxSE9Ph7m5Ofz8/BhJmPPnz0ffvn3RrVs3gXHuvJgwYQLc3d3J84aGhsLAwAAjRoxAjx49wGKxkJqaKrCIzdChQ+Hh4YELFy4gOTkZenp6CAsLw5YtW3DlyhUoKSnxqVnQ1+Lly5fD1NQUhw4dQkxMDLS0tBAcHMxwP9fW1iIuLg4zZ87EgwcPMGDAALi4uCAqKop4v6h2WrhwIcTExKCnpycwsZoXHz58wPjx47FhwwbU19cjOzsb3bp1g6amJp835/r168Q6uHPnTtJejY2NkJGRgaSkJBkHVFs1NjbCx8cHWlpaUFFRgY2NDaysrMj6wuVyv7hPqYqEenp6sLCwYOz3QFOYIIvFAofDEegB4cWjR4+QmJjIKAedmpoKLS0tpKam8sUeC9LMptDY2EiIOj0PgMKUKVOgoqLCp/JD9dXLly8RFBQEdXV1qKmpkb6gj8GQkBBidBC0n5aWlmLJkiVQVlZmhMxR449KCG4riy+FX+S3GVCDvq6uDmlpaTA0NISfn5/AWJNnz54JTBSJioqCoaEh9uzZQ+Su6LFiL168wKxZs6CsrIy5c+diy5Yt6NChA2bPno0PHz7wLWLFxcUICgqCnJwcCfpujiw+evQIrq6u8Pb2xs2bNxEfHy8wPhBoOhX37t0bvXr14pMIoj9DTU0N0tPTISkpSapm0d1ZAQEBmDx5MomtnTFjBkaPHo1Lly6R7zx+/BgODg6wtbVlkBRBE/3Nmze4evUqI8C9oqICPj4+YLFYWL16tcD34cXZs2chJCQER0dH+Pn5Yd++feByuZgzZw4sLS0xdepUhpU6KSkJ4uLijHhdXuTl5aFHjx6QkJAghwa6hSAhIQGqqqpkAw8KCoKpqSlfxjDQFEcuJSVFZJySkpLQrl27Fqsi8RJgKysrhtReSUkJzM3NGfFkz549w7p165CRkcEoU9mpUyewWCxSfYuOqVOnwszMDH/99RckJCSIe4qOOXPmgMVitbrKX2VlJd68eSNwLnl7e2PSpEkYNGgQVFRUGOTo8uXLWL16NR4/fsy4PnWdDx8+QF9fH05OTsjKyiLf4Z0jn5IGoxNg+n1ycnLA4XDg5eWFR48eEWtvUVEREhIS0L59e/j6+kJZWZkcZng3ATU1Nbx//x6FhYWMuGrqPhQBdnBwQEhICBmXgtqKujZ1yLS3t0dMTIzAd2xoaMCCBQugqKjIp+F6//59SEhI8G3Kly9fRlVVFW7evImMjAy+PqXCPKh4VENDQ0yaNIkvVnvChAmEAFPqL1QSrCB8zrpJVf/jcrlffMj19/fH7du3wWazER8fzwhToixp1dXVOHjwIAwNDRlzitK4pV83JycHJiYmJKmsvr4eioqK0NDQQPfu3RmHooqKCj49Y/o8peePnD17Fl5eXnj9+jUGDx4MZWVlYu1++/Yt1qxZQ5I+eXHo0CF07dqVyHJu2rSJQRojIyPh4eEhMFl7/vz5SE1NJSSvrq4Oa9euJWOUPjYp2SoFBQWEhoYiLi4OkpKS6NatG4OUXbx4EQoKCkQerKU5eePGDXA4HDg6OjLyJB4/foyuXbtCQ0NDIDHavHkzrK2tCeEqLi6GoqIidHR04ODgQBRJ6Pc+ceIEMjMzsWXLFjQ0NBC94i/t09u3bxPCvG3bNvTr1w+SkpIkXIySQxwwYAAp3tJSWzx58gQODg5QUVFhGCGAJu+uhoYG0tLSms1dEYS6ujoMGTIE8vLyDANGUlISpKSkmi3aRT3n69evERISAmdnZ2RmZpLPGxoa4O3tDX19/WYNdRRKSkqwZMkSyMnJMRLBExISSEJwW+MX+f0/5Obm4tChQwILMdTX12POnDlwdXXF6NGjiQvgUx0KAGFhYVBUVIS0tDQx3dNPP0VFRZg7dy5ycnJI8LuNjQ18fX0RHR2Np0+fMhakFy9eIDAwEIqKip+sJPfw4UN4eXkhMDAQ9vb2sLOzQ3h4OIYMGYLIyEgMHDgQgwYNwrBhw+Dn50fcK48fP+bbwCh8+PABS5Ys4SNLCQkJYLPZRPfWwMAAMTExDGsyRQQLCgpgZWUFT09PhhwYL9Ho0qUL/Pz8GNJUQBPh69GjB/T09FplMQGaFncbGxsEBQWhS5cu2L9/P7hcLmbNmgUHBwdiHZ0zZ84niS+FgoICeHp6wtvbmxGcn5iYCHFxcVy/fp3IhaWkpCAgIADbtm1Du3bt+Ajw8OHDIS8vj969e7d6sgsiwGPHjiVWULpG8O3bt6GtrQ0nJycoKipCX1+f4Y6m9E4vXLhAFi/qPXbs2AElJSWYmpqS7/OO/cmTJzfr4qb36/379+Hh4QFLS0uYmpriyJEjjAo/mZmZkJGRgZmZGSG+1N82bdoEFosFIyMjJCYmCixXSoVAODs782XetwTeDYcqMUqN8QcPHkBXVxe9evXCvXv3ICkpCRUVFbLxU8lb0tLSpMoV9e508v3ixQscPnwY0tLS6NevHxYvXsxHbGtqarBu3To4OjoiODiYEGBBB9309HRySAoKCoKVlRWZZ7yb3oULFyAkJMSIw66oqICjoyP09fUZmrIpKSmwtbVtNkabjvnz52Px4sU4efIkyUofOHAgVqxYQZ5hxowZEBcXJ+oYnyr/29p1k+4e/9JD7qFDh6Cjo8Mnp0aFelEHGYoAm5mZwdXVFUBTwqWenh5pc6qYT1JSEiorK/Hs2TPo6upizJgxuH79OuTl5dGjRw/GQZGO7OxsvnlKT+bs3LkzhISESHElQXj58iWOHz+OZcuWYf369YR0VlVVIScnh89QU19fj379+mHixIl88yArKwvq6upgsVgM/faPHz9i7dq1cHJyQmhoKBnDd+7cgaysLCMpmdoveJMEBw8eDEdHx0/qtFZVVaF37958xYyAJjLYo0cPSEpKChyr1JyhhydUVFTA3NwcdnZ2xEVPoba2ltGnlLzbl/RpXl4e2rVrxzhUXr58WWBuweLFi8FmswWGOADMubxw4UJoaWmhe/fufM8/e/ZsSEpKYtGiRZ9VSr6xsREDBgyAnJwcrl27huTkZEbyaEu/A5q8Q0FBQXBzc0NmZia4XC569eoFY2PjZmsk8IIKgZCTk8PcuXOxaNGiVu/FX4Jf5BdNoQYaGhqws7ODj48PJk6ciCdPnvBlhqakpMDFxQXjxo3ji0l7//49Hj58iO3bt+PKlSuMQTlq1Cioq6tj48aN5Hf0hZwapEuWLIG/vz8aGxtx6NAhBAYGQl9fH+PGjWPEYZaXl6Nz587w9PT85Lvl5ubC29sb0tLSUFRUxIgRI+Dp6QkvLy8EBQXB398fPXv2JBaD9+/fQ0NDAzIyMrCzs0NmZiafDFBFRQUJgcjIyMD8+fMhLi6OmzdvIjc3FwoKCoiPj2cM9k2bNmHKlCnE6pSfnw8rKyv4+Pjwufzv3LkDBQUFTJ8+naFicfv2bbKQV1RUwN3dHTo6Oi0milBxu0ePHsWQIUNw4sQJBAYGomPHjgzrkKurK8zNzVs14emgQiC8vLxw69YtzJs3T+CELSsrg6amJlatWoUdO3ZARESEz4o6dOhQCAkJfZaUC50Ap6enE9c/fWxQcmZTp05FVVUVTp06ReS+6GE2FAm6desWEhMT0a5dO2zfvh2SkpJwd3eHmpoaI8GOd3GdMmUKpKSkBCptAE0bqaysLEaMGIG1a9eSCon0A2dFRQVMTEwQHR3N9/ucnBxERERgzpw5mDNnDpSUlBASEoJVq1YxSE1ZWRl0dXWhra0tcEOk5jVd8ojCzp07yRxNT0+HiIgI4uLiYGhoCG9vb9KWbm5uMDExYWR3P3/+HImJiWjfvj3DK0H3jnC5XCxatAiqqqr4448/oKOjg379+pE1hSIR1dXVWL9+PZycnODh4SHwoB0bGwsWi0VCStLT06GkpISFCxcKJMzbtm1Dp06d+OL/MjIy4OzsjKioKJSUlGDp0qWQl5dnWLNawtmzZyEjI0PCSl68eIGZM2dCQkICzs7OyMjIQF5eHhYvXgxRUVHG+G6LdZOOLznkLlmyBF5eXgxr2dy5c9G+fXt069YNEhIShLhVV1djz549cHBwQGFhIU6cOAEbGxs4OzuTpKIPHz7g2bNn4HK5GDx4MMLDwwnB8/HxgYKCAgYOHChQzaa5eUq9/9WrV2FsbNysOgaViOjs7AwOhwNxcXGoq6sjISGB0YYU6urqkJCQAHV1db7EY6CJ5B4+fBgmJiaE8NP/RulSr1ixAjU1NVBVVYWamhrDg0iFuOzZswd///03WZOvX78OXV3dFvMBKNTW1sLX1xcqKip84UsFBQXw9/dnxP/S5/alS5fAYrGwYMECst69ePECFhYWcHR0RF5eHj5+/IiQkBAkJia2SZ/W1dVh+PDhUFRUZBiSZs+eDRaLhbCwMOzcuZNRPdTR0ZHP0EN/DzoB/u2332BhYYGYmBg+ArxgwQK+WOjWoLGxEWFhYWCxWJ/0PPL+DmgiwH379oW7uzv09PRgZGTUauJLobS0lHjeWCzWNyO+wC/yS+Dn5wdPT0/cuHEDLi4u8PLyQt++fZGfn08mTG1tLebOnQtDQ0PExcWRwZibm4s+ffrA3Nwc0tLSEBISQqdOnRgLVHh4OAwNDZGRkUEsx4LcERYWFox4w23btpGYytDQUKxfvx4fP35EVVVVq0s/Pnz4EL6+vujRo0eLRBFoIg79+/fHtm3bsGrVKlKmcd68eQyN1vr6emIdowbpx48fERoaisjISMZgpya8kZEREhISCAF++PAhNDU1ERgYSOKyiouLYW5uzlfphVIhiI+PJ5aLiooKeHh4QEZGhuHue/bsGd+CWlJSAhMTE/z2228oKSlBYGAg3NzcCAGeNm0azMzMPstaSCE/Px9+fn7gcDgQFRXF7t27kZ6ezkjAAZqynEeMGIGGhgZkZGRAWFiYQYAbGhpajM9qDnQCnJqayojde/r0KZSUlNCvXz/GbxwdHWFkZITy8nJGX1EhEO3bt8eWLVsgKiqKmTNnoqGhAWvWrIGSklKLBHj06NHgcDh8h8O7d+9CWlqaEVN65MgRsFgspKWlMb67du1aWFlZMfqCclt6eHiQxMH8/HzMnj0bjo6OsLW1RWZmJiFW5eXlLcY6C2o/ivDQF31KscHb25voVM+aNQuPHj2CiIgInzzaixcvSAgEb4IjXb7OzMwM+/fvR3l5OTIyMhAQEAB9fX1MnjyZzDOqzYcMGcI316dMmQIlJSWGxODHjx/h6uoKJSUlLF68mJFs9OrVK1hZWTGs0nRs3LgR9vb2cHR0RPv27ckztFZIftKkSRg4cCAh3SEhITAxMUF4eDg6d+4MUVFR7Nixg3HYast182sOuf7+/gwvyatXrzBmzBicOnUKFRUVGD16NNq1a0fiRGtrawnJaWxsxLlz5+Dg4AB7e3uG1b2xsRGdO3dmzPHhw4dj1apVfIcyKgmspXkKNIUMubi4EP1Zels8ePAA8vLymDJlCp4/f47S0lI8efKEhOKMGDGCMSZ27NiByMhIqKio4NatW4y5/P79e8Zh4MSJE9DT02Mo+gBNhwG62sepU6cgISGBqKgoNDQ0YN68eZCQkED37t0RGxsLKSkp9OjRA0OGDMHevXthaWnJCL+gq6+sXLkSS5cuZSQo9uzZE2pqanwE+FPkKiUlBaKioli8eDFZm16+fAkrKyuw2WySREeptbRFn2ZlZSE8PBwdO3bEoUOHsGTJEsjKymLs2LFYuXIlOnfuDAMDA9ja2iIwMBBRUVEC2+LUqVMYPHgwevfujVGjRpHnX7p0KWxtbTFu3Di+uOcvRX19PaZOndpqjyoFOgHu0aMHOnfu/NnEl0JJSQlWr179RQT+c/CL/P4fbty4AW9vbyIMf/78eUREREBSUhLBwcHk9MblcrFixQpy2srKygKbzcaYMWNw9OhRlJSUYOvWrXB2doaqqiqjjOOQIUNgZmaGZcuWoaKiAsXFxSgsLGS4odLT08kC2NjYCFtbW/Tu3RtnzpxBSEgIFBQUiO4n9Z3WIC8vD15eXvDy8uLTz+PdTNLT06GlpYWKigp8/PgRR48eRa9evaCpqYmIiAjcuHGDnIjXrVtHLHfV1dUwMjIicVGNjY3466+/ICoqijNnzhDrS3x8PHHvPHnyhFEN6tChQ7C3t0dubi55twULFkBKSgqxsbEQFhbGtGnTSJt9+PABvXr1Ii7bZ8+eQVFRESwWCz4+Pgx5lkOHDqFTp04oKSlBTk4OAgMD0bVrV+zevRtcLrdZgf/WIDc3F/7+/sTKwGKx4Ofnh169euH+/fuorKzE3bt3oaCgQAjT2rVrIS4uzpdowtun1KLbEujEin4dQeoUVIyuk5MTevXqhYiICEKWGhoaEBERgVu3buH8+fMMolteXt4qAiwoOSI0NJRUMaMwdepUsFgsTJ06Fbt378arV6/w4cMHvHnzBvLy8gJLoO7YsQPq6uqEoObm5kJGRgY2NjZwd3cn1Yh42wFoijNcsWIFBg4ciKSkJFy9epU8++LFiyEvLy8wcfGvv/7CrVu3ICUlRbRFnz17Rmre09sf+LR+LZfLRVpaGqKiohifi4iIwNraGqKiooiOjsbatWv52hH4XzIk/ZBMWYyrqqqIy9zV1RULFixAXFwcrK2t4ePjA6BJsmzZsmVITU1lkHeqnKm3t7dAK1pL2LNnD1xdXUlylbKyMvEY5ebmYsmSJQwP0tesmxTa4pBbU1ODnj17kkQbetlUCmVlZbCyskLv3r0ZY51ulTt79iwhS9TaWFJSgh49emDgwIHYsWMH4uPjoaamJrBEeGvm6eDBg7Fr1y5s3LiRT46QitvklYIEmtaEsLAwKCgokFChS5cuITo6GoMHD2astUCTB6pbt26QkpLC2LFjSS7C0aNHYWJi0qzHkWq706dPQ1hYGJaWluBwOIw43UePHmHz5s2ws7NDp06dBHpm9u7dCwUFBfj7+6N79+7Q19cnISkfP36Ej48PtLW1BVZ/o3tIeNfMWbNmkXlDP5zPnz8fy5cvJ7HzVCGLr+1ToOnQP3DgQBgaGkJMTIwRflFZWYnS0lJMmjQJwcHBAuO19+/fD2lpaYwZMwYZGRlgs9lwdXUl91uyZAkcHR0RGRlJ4p5535ue1NdatPTd5tYD6jfl5eVknvAmhbY2FONznvVL8Z8lv0VFRdi5cye2b9+OW7duETkYehD5sGHDoKKigqioKLRr1w6Ojo6MzYyqTpKYmMg3IK5evUqCvekbar9+/WBvb4+MjAzY2NiAw+FARUWFLOL379+HiooKtm3bBmdnZ3Tu3JlRbYVXd/FzQFkoXVxc+LRnAeagDgoKYsg3+fn5wdjYGHZ2dkTijZrIlDUhLy9PYG13+kY64/+KGdDj2OiYOHEidHV1yb/r6+uxZcsWouqwfft2sFgsTJo0idyX/txPnz6Fg4MDXF1dYWdnh6ioKGhra2PNmjXYtWsX/Pz8iDv3/v376N69O3x8fL64PjgddXV14HK5mDx5MnnGAQMGwN7eHgEBAfjrr78wbNgwhIWFEXK2YsUKKCkp8RWVePHiBQ4cOMB3j3v37vElyAgCvU3o6hRRUVFgs9nYs2cPCgsLsX//fqSmpkJZWRkcDgcDBgwQuLjRrcuCCPCnTvevX7+Gi4sLzM3N8f79eyJTN2HCBMTHx8PNzQ1GRkbo0KEDVq9ejfDwcCxYsACJiYmYMGECbt26hdraWlRWViIoKAjHjx9HYWEh2Gw2OQw+ePAAy5cvF0gAUlJSiGWzS5cukJaWhoaGBuLj49HY2Ig1a9bwjVsKz58/h6SkJMOSzOVyYWRkRNYDXrfkmzdvkJycjAcPHuDWrVvYv38/du/eTcbs+fPnISUlReKabWxs0KlTJ7x69QrHjh0jZVF5+yI2Nhbi4uJwd3eHp6cng/xRBPjjx49ITU1Ft27doKGhgT59+pDEsLt378LU1BRRUVECZd82bNgAe3t7DB06lGFVbg2oeFQ1NbUWPShfs25SIRtfc8i9evUqtm/fTsbs7NmzISQkxMihoPfnhw8fEBwczCdnR0d9fT3Onj0LOzs7hrXw8OHDsLW1hZGREQwNDVsMafrUPJ01axaUlJTg7OwMFovFiHeurq6GtbU1kanjDQ2pr6+HoaEhOQABTVY63nUvNDQUpqamOHv2LE6fPg0tLS306NGDhOT88ccfMDY2ho2NjcB3oEjL+fPnISYmBg8Pj2aNCrxrHtC0JqurqxPpzVu3bkFaWppo8gJN66yrqytMTU3JOsqrJrNq1SoMGzYMsbGxJKkOYBJg3uRuentRbfa1fQo0zbkBAwbA0tKSEbNMj/UXJKv5+vVr2NnZEYWgsrIyqKurY/To0Yx5M2vWLHTu3JmvwEZKSgrxJFLt9PLly1aHM9XU1DCuSbWNINkzCvTnamxsxG+//caXm1FcXIx9+/a1SaGKr8F/kvxmZ2dDT08PZmZmEBYWhrGxMf766y8cO3YMBgYGKCkpQUREBFRVVUmYwI0bNxAZGUksjC9evICGhga6du1KrkuP7QOaJEwUFRUxefJkxv3nzZsHMTExLFu2DMuXL0ffvn0hKSlJ1A+oCkndunUjCwTvJvGlBPjBgwfo27cvI5aWF1wuF3FxcSSrOSIiAsrKyuTd9+7di7CwMOTk5JByvk+ePEFJSQk0NTUZSYHU9ajnzc3NhaurKyOLOT8/nxCPmTNnQl9fHyUlJYw4Sfr/R0VFwc3NTeCCQV0vMDAQAQEB2LdvH/bv3w93d3ei9ers7EwmXm5ubrNJBl+D8ePHQ0ZGBhcuXMCFCxcwb948qKioQFlZGVpaWoyFn1ferrGxEfHx8fD19WXEi82YMQO6urp8Wo6tAaVOIS4uzpDIofD27Vvs2bOnVa4mOgHmDU9pCW/evIGdnR2kpaX5MouBpjCIqVOnQl9fH9HR0VBWVkbHjh0hLi4OHR0dEh83efJkqKqqQl5eHpGRkc0eXKjxMn78eFI9j9oMXr16hd69e0NTUxOzZs1q1prx8OFDJCcnM0gmRYyMjY35Mq6p96A2/A0bNpAysNLS0nByciL9PXnyZPTp0weGhobo2LEjY0yUlJTwjfvhw4dDVlYWT548wZ07d9CnTx906dKFcUji3VDoFq6cnBzIy8tj+vTpDMv49u3bsWzZMvLvdevWwc7ODsOHD29VGBD1fEePHoWRkRFJUBPUpl+zbtLH/ZcecinPDN2yfO3aNZiamsLe3l5glb/p06dDX1+fT7/0yZMnePDgAcOiffHiRdjZ2cHW1pa0/ePHj1FUVNSqkKZPzdM3b95g165dDG8Z0ESU9PX1yW/oFlBqTFBFE5pbP65cuQJLS0ty7bVr10JGRobMU+q9f//9d76+oUA/BJ88eRLCwsKIiopi3JP6jqDx8ccff5BKpE+ePIGWlhZDxYYimrW1tcRqPHr0aEYVw+TkZEhJSWHIkCGwt7eHubk5o5JZamoqREVFMWvWLGLR/RZ9Sm+LvLw8DBgwAB07dmSU7W3JaFBUVARLS0tUVlaSqpXDhw9ntBUF3rLHb9++hZeXF5ydnQmBLSgogIaGBkPHuyWEhoaid+/eKCwsJO1Ded5aU2L71atXGDVqFAIDA0ky4PPnzyEjIyNQNeifxn+O/FJJBZMnT0ZxcTGOHDkCd3d32NjY4Ny5c6Rqia6uLrEE0KU7gKaJ9+bNG/j5+aFLly5Eu5P+XWqwREdHw87ODvX19airq8OWLVvAYrEYG39hYSE0NDSIxercuXPQ0NAgxRu+lOg2h5ZOXNRzV1RUQF9fHxoaGiQmjA5K0qZ9+/ZEXgloSjiRkpLC/v37BZLTKVOmwM3NjbhtKCkYajM6ceIESaTjfSYut6l8bHR0NCZOnNii2gaV6EdpzFZWVuLKlSvw8/PDli1bGNf9VhgxYgSkpaUJOXn06BHWrFnDVwddEF69eoXY2Fj0798fp0+fxty5c8HhcIgL8ktAV6egHz5ao1rCi/fv32Pt2rUkbKG1KCkpgZeXF1RUVMgBjNfFNWHCBMjJyRErd1VVFQwNDdGpUycATRuGg4MDunfvLrB0Jx3x8fFo3749g9RT8+nt27fo06cP1NXVSdwifUzcvn0bsrKyRL+XAtVePXr04CMB06ZNg6qqKp49e4bVq1dDTEwMW7ZswYMHD5CRkQEtLS3069cPDQ0N2L9/PyQkJODv78+w5vNaT4Ami03fvn0ZCSCXL19GYGAgHwFuaGjgs/y9f/8ePj4+iI6OZqwnaWlpEBYWhpWVFUO9hSLt48aNa7WF5tWrVzAwMBCoFQx83bopCJ97yD1+/DikpKRIvCwdGRkZ0NPTg7a2NrZv346cnBxSCEJGRga3bt1iSBnu3bsX2tra0NfXh7CwMMLCwogb/q+//iJeBkGVuT6FL52nDg4OcHFxIf/m3TdmzZoFa2vrZq9z9epV2NvbA/hfQRDK+v7q1StSfIQ+XwXpVdOLhJw+fRoiIiKIjo7mk9gThNOnT8Pb2xt37tyBpqYmhg8fTq577do1xMbG8smaXb58GcbGxggICMCRI0fg4+NDVIQ+fvyILVu2wMLCgpFMNm3aNHTs2JFh4W+LPuWdd8+ePSMJwFQIRJcuXfjyAQThw4cPMDc3x4oVK6Cnp4fo6GjSd48fP4a7u3uzBYmAJiIfGhoKNzc33Lp1C9ra2hg6dGir971nz57B0dERgwcPRmNjI/bt2wd5efkWPSC8yM/Px5QpUzBgwACsWrUKWlpaGDVq1GfHAX8L/KfIb3NJBRkZGWjfvj0KCwtJclZzmY7Pnz9H3759kZWVhRcvXhAhb0ELOQAEBweTGKmqqioMGDAALBaLJBNQ3+3QoQPDihYcHExOwP8U6GL7QJMUEG/FKGriUIeIadOmMT5//fo1fH19weFwsHnzZkJyHz9+jAkTJqB9+/YkmD4rK4tkN1Oora1FRESEQFmbhoYGxMfHQ1VVtdmiCXTk5+fD09MTnp6ejGS9fxKjR4+GuLg49u7d2+rfUGOipKQE06ZNg7W1NaSlpclC9zXxUHR1iq9tk/LycmzatKlVBSzoi11paSns7Oxgbm7OkNficrnIyMhglE2mfrdgwQIYGhqiuLgY9fX1GDduHLy9vVu0Ip06dQosFotxOONVeHj79i3k5OT4LNjU2JwyZUqz7z9kyBD4+/uTf1PSWdevX8fx48f5tI8bGhoQGhrKKDTRq1cvRgxlcxsTl8sl85JOaq5cuSKQAPNep6ioiC+zfteuXVBUVERmZiZGjRqFDh06MOKIt2/fzpdJ/ils2bJFoDbo16ybLaG1h9y7d+9CQkKCoSEKgIQVAE3JxV5eXmCxWJCSkoKRkRE8PDzIdShcvHgR0tLSWL16NbKysnDy5ElYW1vD39+fWI7PnTsHAwMDuLu7f9Eh+1PzlK4FTB3cdu7cCVFRUYalFPhfuw4bNgyRkZGora0VuIZcvXoVHA4HY8eOBYfDYVTOPHr0KHx9fXH//n0SfkQHNSafPn0KCQkJTJ06ldzjzJkzYLFYGDduHONgJqhdbt68CQ6Hg3bt2vEpvowbNw4+Pj7E6rhhwwby37du3YKhoSG8vLzg4ODA8OZVVlbit99+g52dHfHkXrp0ifEcX9qn7969w6NHjxgaxtSa9PTpUygoKDCS4+/du4devXqhZ8+ejLLogpRnKE1sWVlZeHt7M9oiPj4e9vb2LR4o6uvrUV1djV69eqFdu3akAE5r9g+qP58/fw5nZ2d07doVUlJSfIaA1qC8vBwjR46EhIQEI7H0n4jrbQn/KfJLTyqgn6hPnjwJBQUF5ObmoqysDM7OzgKrnQBN1jtnZ2f4+Pjg3r17ZCF3dXVlLOQNDQ148+YN+vbtSzYULpeLwsJC9OrVC0pKSsS18vvvv0NISIiRiHbu3Dm+8r/fAtQgp59UZ86ciaqqKly9ehXt2rUj4ubUBKUOEcHBwYxrLV68GJMmTcKDBw/g5eUFYWFhaGlpwcbGBvb29jAyMiIxjrzkmcKZM2ewfft29O7dG0JCQhg1ahS2bduG5cuXY+DAgZCXl/8sKTD6JkLv838SY8aMgbi4uMAYXkGgL4bTp0+HuLg4unbtyud6/1LQY78FJY18Dng3MLp1jAK1GRQWFpL4uzdv3sDBwYGUlKVQUlICVVVVdO/eneFyDw8PZySe5OfnQ1xcnOGu50VtbS2ioqLQoUMHzJ8/ny9GnLKiBAcHEyLd2NjY7Ng8efIkw4I8fvx4dOzYEQCzMEpjYyNWrFgBY2NjREVFMTwgkyZNgouLC4k3PHr0KBwcHBhFR+hozutD/5yyAHft2rXZMUZ5VOihFaWlpcSS/Pz5c0RHR0NbW7vFqomfQlFREdzd3flCib523WwJnzrkFhUVQUpKCgEBAYzP58yZAyEhIYaho6qqCn///TeOHDmC3NxcjBgxAiIiInjz5g1p8+TkZHTr1o3xbDdu3ICZmRmGDh0KoGnMX7x48bMPD7zvJWieCtICPnjwIKqrqzFq1Ci0a9cO4eHhKCoqQmVlJV6+fInExETIysri/v37jPH4+vVrhiV41KhRYLFYJGkZaIrRtLGxwciRI5GTk4O+ffvC2dkZAwcOZCR6vXz5Eurq6hg5ciRfJcDz588z1G8oi/yVK1ewceNG7NixgzzX+vXrSbW6u3fvIj8/H5MmTYK8vDyJQ09PT0doaChjHly/fp0UEtq5cyejLR8/fgxxcXHs2bMHMTExpE+ptelL+vTu3bvo0KEDdHR04OTkROKUgab4XCUlJQwbNoxv/Obk5KC4uBgPHz5k9MXx48cxduxYhIWFkX3y7t276Ny5M9zc3LB06VLs3r0bo0aNgoyMTIshSVSfPn36FCoqKjAwMICTkxMJj/iU5ZXysgJN4S/CwsJwdXVlxAC3pngG0GRgUFZWJqoWdM/nt/a+toT/FPkF/keGPD09kZOTg4qKCrDZbOK+rKmpwfDhw9GpUyeBdcmpa3h5ecHT07PFhXzq1KkwNjbmkyEpKiqCr68vVFVVsXTpUigoKBA3CLVYlJWVYdSoUW0e8vDq1StcvHgRJ0+eJBOAWoiePHkCDoeD2NhY8hwxMTFwcHBgnGwFZSanpaWhffv2DNmbjIwMxMfHY9iwYdi6dStxhTVHnpOTk6Gjo4NHjx4hLy8PycnJUFBQgKysLExMTBAaGtpsBaOW0JZk70sRExMDFovF0HX8FFJSUsDhcLBr1y5MmDABAwYMaLb4yOeiNbHfn4u8vDyMGTMGffr0ISLu1Dh6+vQp0QmmFry3b9/CwMAArq6uqKurI+Px9evX0NDQIElL1NiiNgRqUe3Xr5/A2MOPHz+SWLy6ujqMHDkSDg4OWLBgAaPUKfXdLl26MFQcBI3NlJQUoklMPX9mZiY8PDwwYcIEPn3oqqoqrF27FnZ2dhgwYACAJku0sLAwI1bv9evXkJGRwcyZM/neg37AobL8CwsLyfvzWoCDgoJgbm4u0GtVUFAAaWlpgfF+1H0OHToEJyenr5YYai4U5WvXzZbQ0iH3w4cPsLW1hbu7O5l/CxYsgJKSEnHrCzpMXrlyBRoaGuSwTXnrpk6dCjc3N/I7atweOHAA7dq1YySifS1456kgLWA1NTWSyPbkyRNMmzYN0tLSkJWVBZvNhpubG/T09Pis3sOHD4e1tTW6d++O9PR0cLlcvHjxAv7+/hATE0NMTAyio6NhaWkJX19fZGVlQU5ODuHh4Zg9ezZUVVXJ2Kbef/bs2QxCQ1eqWb16NQmrAJos1TIyMjAyMoK2tjacnZ3J/Jw3bx6UlJTA4XBgZWUFCwsLgaF3QFPxFupQl52dDWNjY3h6ejL2IkoFZO7cuW3Sp1lZWSQR79ixY8STQR3Oy8vLsXPnTsa4orfL77//zigccvr0aYiJiSEoKAgWFhZo3749UXu5fv06Ro0aBVVVVdjZ2ZGwkE/h0aNH0NHRwYgRI/Do0SOEhoaiY8eOrYo9p5519+7dkJWVxdy5c2Fvb48hQ4Z8Vo7Mo0ePoKamhpiYGDx48ABTp05FcHCwwGJI/zT+c+QXaFoovb290aVLF8jLy5NMUqrDr1y5AmVlZb4a2bzXaG4h37NnD+bMmcPI5uZFUVERAgMDwWKxSPA3rxWWQlsR4Dt37sDKygr6+vpQUFCAu7s72UjLy8uhqKiIqKgoxiTNyMiApaUlX8YuPTN52LBh4HA4LW4kdDRHnpWUlPgs3S9fvsSTJ09QWlrabIJba/AtyN7nYsqUKQIrCArCH3/8ARkZGdIer1+/RkxMDLy8vD5Z2a+1aMtsW0q6KiAgAKGhoRAVFSXJN69fv4a2trZAK0hpaSnDOkYnwGpqamCz2QySQrdY8OooA03SP56entDU1MSkSZPw7t071NfXY/jw4XB0dGQQYKDJXerq6kqStFoam5TeKIXDhw8LFISn3rG6uhpr1qyBvb09OnToACkpKeJCpyd5Xb58uUVLTEBAALS1tYmk2/Lly8k78CaKpaenC7zG27dvYWdnB2tr62Y9IFOmTEHPnj0FZsG3Fb523fzUtXkPuVT7vHv3Dm5ubnB3d8fgwYOhoKBA4kLpOH/+PGnbgoICqKurY/v27Th69CjxPBw4cAAsFotvvTt37hxMTExaFdv6OaDmaUtawIaGhox+e/78OVauXInU1FQcOXIE06ZNg76+PvFoJiQkwMTEBGvXrkVgYCCcnJzIPlhXV4c5c+agZ8+eiIiIwPz58wV6QzZt2oQ+ffqguLiYEbMuaP1vbGzE/v37YWBgAE9PT1RXVyM8PBybN2/Gu3fv8OeffxIFBar97927h4sXL+LWrVsMwka//smTJ6Gnp4cZM2aQPer69eswMjKCs7MzUlJSsGvXLvTq1QumpqbIy8v76j7Nzs6GjIwMoy1ycnJga2uL8+fP4/Tp06TPWtoLAwICwGaz8ccff2Dy5MmMwjjjxo2DoqIiVq9ezZAQq66u/qTaD2W1NTAwwKBBg8jnT58+hY+PD7p3786nTiMIZ8+eZeTjFBcXw8HBAf7+/s1Ku9FRX19P1I2od8jPz8eYMWMQHh7eomrEP4H/JPkFmjqhW7du0NbWxvnz5wEwVQl4M/CbuwbvQh4eHg4FBQWIiop+sjrJ06dP0bdvX3A4HLKRt7WllwIVwzh58mRkZ2cjPT0dLBYLEyZMIN85deqUwAnR3CGAykyWkJDgK9fYGlclnTyz2Wyy8NB/+yWW3ubQ1tIqVF99i9il+/fvk3enJz3xxh9+D8jOzoaEhATZDBobGzFmzBjExsaitrYWjx49IslUrXFzUUTwzZs3MDExgZGRESM2mHeOUNeMjY2FqqoqJk6ciIiICEhISJDFv7a2lhBgyvpZU1MDKysrhIWFMa7X0tikY/v27QgNDRV4oOElwJaWlgyrl6B5LkiP88qVK+jWrRuKiorw9u1bDB06FE5OTowwDt5rvXv3Dnfv3sWqVatw6NAhEpN969YtyMjIoEOHDnzW5wkTJkBGRqZVFqWvxdeumy1B0CGXToC7du0KFouFlJQU8neqr6ZNmwYTExOy3pWUlCA+Ph5GRkZgsVhEnrGhoQEjR46EtLQ0/vjjDxIuM3XqVFhYWHyVXnhL+JQWsJ+fH4YMGYJly5bh7du3jHFRXFyM2NhYODs7Y8aMGRg7dixRR6iqqsKcOXNgZ2fH8MxQFvzXr19DR0eHJJxSiI6OhoqKCjQ1NWFsbIyYmJhmvaVAE6n+448/YGJiAhcXF/Tu3ZthUb158yZsbGxgaGjY7HUErR9jxoyBk5MTZs2aRdr+5s2bMDMzA4vFQkBAACZNmoT6+nqUlJRgypQpX9yn1dXV0NfXh7a2NuMZpk+fDklJSejp6YHNZsPIyIiEGDSnuwsAffr0AZvNhoODA6N8NPA/Arx27Vo+NYfWgK7SQOHZs2etPpzt3buXGAWosVRYWIiIiIhW73m88mtA06HyS4o5tTX+s+QXaJIx+trkH/pCfv/+fRQXFyMqKkqgVUoQioqK4OfnBxUVlc+uqtJaPH78GGJiYox66+/fv4eysjIRd+dFawWpm8tMbg3JEUSe6TGj06dPh4aGBsrKyv7V2CBeTJ8+nRAKyhr94sULvtrurUFr30tQ4YvvAc1Zo0JCQmBtbQ1DQ0P07duX4dZuDagNoqSkBOrq6ujcuXOLB6EJEyZAUVGRQd4oNQrK/Ukphbi6umLWrFkwMjIicn4As00/NTZnzJgBQ0PDFmM6BVmABw4c2OKhiT7nysvL8ffff2PUqFHks9raWowYMYLPik1d68GDB+jZsycsLS0hISEBKSkpyMjIEHml8+fPQ1FREcrKyvDw8ECfPn3QvXt3aGlpfVYs/dfia9fNliDokEs3anTp0gVubm44dOgQaTeqnPeECROwfv168rtly5aBxWJBW1sbO3bsIJ8/fvwYY8aMAYvFgo2NDZycnKCgoPDN27C1mt1UWWSqaAPwv8p1Tk5O0NTUZIzdDx8+YM6cOXBycuLTkX348CGGDBkCS0tLrFu3DkBTNUQqQez8+fMIDw+HiooKQ1OXDup69fX1OHr0KJycnCAlJUVIHTW3bt68CUdHR3A4HL7wGV6VCvozjhs3Dvb29gwCfPfuXcjJycHPz4/0aUNDw1f36YEDByAtLY2xY8cCaPIMycrK4vfff0dBQQGOHz8ONTU1BAUFtdiXFMLDw8FisbBo0SK+dxw/fjxYLBY2bdr0WWu+oFyMrwWvd+pzjT7fy55F4T9NfoG2iQfNz8+Hj48PnJ2dcf/+/c8eFEVFRXBxcYGvr+8X3b8lUBn0qqqqjNKmaWlpYLFYsLe3R2JiIhISElBYWPhFroivURCgk2d6wl9iYiJJIPqeUF5ejpCQEFhaWhICXFBQADU1NYFFA3hx48YNXL16lU9Q/0dFc2ECkpKSSElJwdq1a2FqagpDQ8PPLh1NJ8AaGhrNupQLCgrAYrEwbNgwxu+ysrKgoqKC8+fPkzauq6vDiBEjiEWIgqA+aGlsioqKNqsIQwcvAXZ0dIS3t/cn+zwsLAwmJiZgs9no3LkzX7uMGjUKTk5OSExMJGQvKyuLaC9TLv0TJ05gwIABEBERIcmBjx49IiEOfn5+mDdv3lclZn0pvnbd/FzwhkB06NABZ86cIUmlFy9exJAhQxgxzwsWLMC8efMwevRo2NnZEfJH4cSJE1i4cCF+++23No31bQmt1ex++PChwOqLsbGxkJWV5YuXpwiwtrY2n4cpLy8PY8eOhZmZGfz9/cHhcBiJkbW1tWCz2QxPIgW6hi5l8Tt69Ch0dXX5rMlAk6RZ586dSXvyzrP09HQEBwdjwoQJDA8GRYBTUlIIAb5x4wYGDx6M/Px88hxt0aeHDh2CmJgYbG1tweFwGJJjdXV16N27t0C1EnoyHT3ELzQ0FHJycjh8+DAfAZ46deon1Y3aonrb15DrL3mOfxv/efILtE086IMHDxAYGNisdimF5gZNSUnJNxs4lZWVWLlyJaytrTFu3DjMnTsXioqKWLJkCc6dO4ekpCRSDUpfX5+R6dtafM0hgk6eb926hXnz5n2XxJfCixcvMHz4cNjY2OD8+fPQ0dFBVFTUJ/svMTERJiYm4HA4YLPZ+O233/6hJ/624LVG0eO/gSZXGYvF+iKZHIrIvnz5kiFZRuHcuXN4+/Yt1q5dCzExMcycOZP0w8yZM8HhcMhGSBGBuro6hoWqpX5ri7FJJ8CLFy8W6Dak/3vevHkwMjLCjh07EBoaCm1tbcTGxjJi/err6xEaGkryBbKzsyEtLU00bOnXe/36NSH8X6Pk8C3w4MEDBAUF/WOx+HQC7O7uDklJSUhLS5P+pJfCzszMJH2XlZWFqKgogWTp30BrtIDpxHfOnDmEKL558wYxMTFwcnLiK9JSXl5O1H14kZubi7Fjx0JOTo5R3bG2thZVVVXo1q0bw0tC//99+/bBxsYGq1atQnl5Oerq6nD06FEYGxvDw8OD716UR23p0qVQUlIizz5z5kwoKipi0KBB6NChA4yNjRn9Qb1XXFwc0eOl4uvbuk//+OMPyMnJMarmUdceMGAAoqKiSMlk+t/27t0LDQ0NjB49mqF0ExQUBAUFBYEEmPf6t2/fxp49e7B9+/bPKnpEXxcKCgpw8+ZNBvdojbeXeoZr164hPT0dK1euZKz3PwoB/kV+/w9tEQ9aW1uLmpoaknhAH/iCSjkKQlsNnKKiImzbtg2bNm1CeXk5KisrsWzZMlhYWIDFYgkUxz5y5AhmzJjBqG7zOfiaQwRFnjkczlfH/X1rNDQ0oLGxEQMGDICoqCj69+8PoOW+i4mJgby8PM6cOYNjx47B398f4uLiAitK/YhoLkygrq4ORUVFsLa25lOqoNqRDkGHQ153G/Wd/Px86OvrEyvnmjVrICQkhGXLlmHu3LmQl5cnB7HmFvfWzDfescnbZ62xmFDfqamp4dP0pJPaVatWYdKkSWR+1tfXY8aMGXBxccH48eMZrmDq9+/evQOHwyEWYkGaoQUFBbC1tUWPHj1QW1vLaId/2x35T5c5pRPgwMBA3LlzhxHmxeVyMWDAAFhYWDASjrKzswlZ+twwnm+Bljxu9D4NCAiAiYkJNm/eTDx7r169wtixY+Hs7Iy5c+cKvL6guUERYCpZjkJiYiLU1NQEWkr/+OMPiIuLY+nSpURdAQAhwCYmJgz9VzouXbqEsLAwWFhYYPfu3Zg6dSp519zcXMTGxkJdXZ1BXsPDwxEZGclIKv1WfXr06FG0a9cOo0ePJoQ9MTERCgoKAnMBqLLma9euJfOe3ldBQUFQVlbG3r17myXAe/bsAZvNhomJCXR0dCAjI4M9e/Z8ch7R7zNt2jTY2tpCVlYWXl5eGDZs2GfNw99//x0yMjJwd3eHvr4+1NTUGOFZPwIB/kV+2xCNjY2YNm0aunbtysiG3LdvH0JDQ7+oLO2X4O7duzAzM0OfPn0QGxtLFrwPHz5g+fLlsLS0ZJRJ/BoVBV58zUaWm5sLf3//Lybf/wTo+omqqqowMzODhYUFKQkqKGufSkqhL/zp6ekQFRUVqO/6IywcgtBSmICuri6ePXuGhw8fMgpHUO+6a9euL3IbT548maFGkpGRAWFhYbBYLBw/fhxA25A73rFZU1ODw4cPk82V6vfHjx83W26ZDuqZ1q1bhy5dugBosjbq6upCRkaGQWaqq6sxY8YMuLq6YsKECXzZ3jU1NSRmdePGjYzr0zFhwgQYGxv/42TzW6K5vv0UuaeTInqC2smTJ3HmzBmUlZVh4MCB6NChA1atWsUgSyNGjICurm6z8a3/JD7lcaO8Ta9fv+Y7FFHeFGdnZz5N65ZAEWBjY2Ns374dCxYsgLi4OF94QmNjI6qqquDr68tXVY+aL3V1dTh+/DjYbDZ69+4t8H7Xr19HeHg4zMzMYGxszCjtXFBQgNjYWGhoaDBitanwCi6X+8379PDhw2jXrh3i4uKQkJDAJ3tIPQfQ1B9UEm5zB/Ju3bpBT09P4DqSlZUFBQUFbNy4EW/fviVWfAkJCaID/6n9Y+7cuVBSUsKZM2dQUVGBsLAwyMjI4PLly61634cPH0JVVZWoQLx69QpbtmyBrKwsxowZ06prfA/4RX7bGH/++SfCwsIQGBgI4H/6fXQZk2+JBw8eQFFREQkJCYwqPNSE+PDhA5YtWwZra2si3g18WvT6n8KXlNr9p1FQUED0E6niADY2NgLjsl69eoXAwEDo6OgQa15DQwPs7OwgJCSEQYMGITU1FRs3bmwxU/pHQXNhAlTSSHZ2NlgsFkkWAUCSdFoTQ0uB2kxevnyJfv36MTa+HTt2QFhYGGlpaW16kKCPzaVLl6JHjx7YvHkz+Xznzp1gs9mflbRVUlICc3Nz7Ny5E3V1dVizZg20tbXh4+PDmJMfP37EzJkzoaenh23btgFo8u7s2rULO3fuJDJnQkJChABToNqKXpTjZ8OKFStIX1PtVlxc/MmDdFlZGTgcDubNm4fDhw9DSEiIFAp5+/YtQkJC0LFjRwZZunXrFmJiYv6VOGlBaMnjFhISQogtnfBTKCkpQXh4uECd6ZZAWV0lJCQgLCzcrKeuvr4elpaWWL58OQB+YkZ5RE+dOsV3+KU/55UrVxAeHg5RUVE+VYSCggJMnDgRwsLCOHToEOnTuXPn/mN9euTIEbBYrBarwwLAoEGD0L17d4HvSE94b05L98iRI7C2tkZpaSnjt2PGjIGiomKLKgpcLhfv37+Ht7c3iek+ceIEsUQDTevMp9bMCxcuQF9fn2HMq6mpwaZNm6Cjo/OvFZP6XPwiv22MxsZGnD9/HsOGDYOLiwukpKTIZvWtUVVVhaCgIAwePJixcfLGHFEWYDs7Oz4x/19oHpRr1MbGhiHuTmmVdujQAXV1dXyWpuvXryMiIgIWFhbYt28fXF1d4e7ujn379iEzMxMxMTGQlZWFs7MzbG1tW6Wh+D3jUyEs169fh5ycHKZMmYKVK1dCUVGRkbjyOeByuZg6dSpfcsm6desgKiqKlJSUbyIfWF5ejilTpqBfv344cuQI9uzZAzk5uRYrztFBLzCTnJyMkSNHAmiaw2vWrIGNjQ0GDRrEePaqqipi3cnOzoaenh5MTEwgIiICMzMzrFu3DkuWLAGLxSLqDtRYLC8vR79+/Uihg3871KEtUVVVBREREfTt25dYtZ8+fQoOh0NioptDTU0NNm/eDDExMbRr146E5tCrU1HFAdasWUP643uzngt6npqaGpiYmDAOmvQ9gEq6pWJj6X9vDe7fv/9J7fL6+nqYmJgwkq0pcvXo0SMsW7aMT1e6OfJ17do19OvXD0ZGRnx68Lm5uUhPT0dDQ8O/1qfnzp1rMTGNy+WScIMnT54wquC9f/8ekZGROH36dIv32Lp1K9q1a0cMW5TX9smTJ9DU1OTTIuftz5qaGnTs2BF///03Dh06BGlpaZLjU1tbi3Xr1jGKgwjC3bt3ISsry7dmU9Xk/im+87X4RX7bEPSNKjU1FaKiorC1tWXU8P6WKC0thaGhIcMKRgf9/h8/fsT8+fPh5ub2j4Vj/AgoLS39pOLFmzdv+BaVV69etVgU5dq1awgPD4eMjAwsLCz4/v7ixQusW7fus9yP3zOaC2Gh5khRUREkJCQYyWOfIqnNxQfX1dXB0NCQr4IVVSa1tWWlWwt6FcbU1FR06NAB4uLipLzpp+Z5cnIy5s2bR57/77//BofDIZqalZWVWLVqFezs7BAWFsbXLlTBgcmTJ6O4uBiHDx+Gh4cH7O3tkZWVhenTpzMIMNBU1MDAwIDhMv4ZQI971tLSwqBBg/D48WNoaGhgxIgRrVpzr1+/Tqx2dL1yOlkaOHAgTE1NsWHDBgA/zuEhKSkJ1tbWfITm6tWr8PHxYXgp6EaS1u5VLXnqqGusXbsWHA6HrwDLpEmT0KFDBwb5pbdrZmYmlixZwjhQXrt2DYMGDYK5uXmzB+aGhoY261PeWPCvxatXr8DhcBAQEICCggIiRTd9+nQYGhoyrPeC7vfu3TvY2NggPDycERZRVFQEQ0NDRkIrvQ8pDlJVVYUuXbrAw8MDCgoKjJLMjx8/hqenJ4O8CnqGFy9ewMPDA+Hh4QxpydraWjg7O2Pz5s2f2yz/Cn6R3zYENVAOHz4MaWlpxMXFISwsDEFBQYwYpG+F69evQ0ZGhsR+Nbcwbdq0CbW1tfjw4cM3reb0o+HmzZtgs9ktJqG1Rj/x6tWr2LdvH1auXMnQ/s3OzkZ4eDhMTEwYZY6pfqJf60eN+6WDd/zR32nx4sWQlZWFtLQ0Q8WhufCbzMxMHD9+nO/v1Ma0Y8cOBAYGEisU1ZZUAZu2BvUcW7duhZiYGOzt7bFt27ZPFj6JiYmBpKQkIR3Ucy5cuBCOjo6EnFIWYDs7O/j4+JDvNaervGbNGkhLSyMvLw/19fVITEwEi8XC3r17sWDBAkhISHxR1bQfAfQxoaKiAklJSURHR7f691wuF3/99Rc2btwIISEhRgEMagyXlZUhOjr6s0oufw+4cOEC3NzcEBgYiCNHjqC6uhq3b9+GtbU1SdQFgC1bthB3NT0m+NatW1+9Zz1//hxTpkwBm81GREQEkpKSMHjwYMjKyjLGJP0+cXFxkJWVhZOTE2RkZNCtWzcSFnbt2jWEhYXBysqKeEJ48TV9GhcXh6VLlwL43/ry/PlzpKamflVoGnWtu3fvQlVVFTY2NrC3t4evry+fnjDVFlevXsWaNWtw+PBhYpletWoVOnTogAEDBuDNmzcoLCxEUlIStLS0SLgEff2ZO3cugoKC8OzZMwBNh20lJSV069aNtEd5eTl8fHzQpUsXPrJ/5swZzJkzB7NmzSIW5wMHDsDExAQDBgzAnj17kJubi7i4OLDZ7B9mjvwiv22MQ4cOgcVikdPkX3/9hbCwMLi7u6OsrKzN70cX3i8vL4eysjJGjBhB/s67CR86dAienp6tVp/4ryArKwvt27dn6FR+yaI/bdo0GBsbw8TEBDIyMhAWFoajoyNJAKMIsJmZGUNS6EexJLUF0tLSoKCggAsXLuDevXtQUlJiuEV5QSUM6uvr49y5cwItxPn5+XB1dSUuvJakxNoKu3btgpycHJYuXYr4+HgEBwdj8+bNzVqw4+PjoaSkRPSO6X2em5uLvn37MhQxqqursWjRIiQmJpLP6LrK9Ni6kydPMop8VFZWIikpiVi/vmf1lK8F1d5VVVVQU1ODtLQ0goKCmp1T1OdFRUUMqanGxkb89ttvEBISYkiAZWRkEEWRHxHHjx9Hnz59ICcnBxUVFejr65OcFOB/BUdGjx5Nkp6ePXsGSUlJUg75a1FSUoLdu3eTkK/g4GDcvXtX4HfLysrg5+eHO3fu4MOHD7h16xb09fXRsWNHYu38+++/4evri4EDBwJouz6tq6vD8uXLoaurS6QZnz59CjabzUjU/VJQz/n27VssW7YM48ePx/z58xna0hQOHz4MUVFRODg4gMViYdCgQcjNzUVDQwMyMjJgZ2cHYWFhmJubQ0NDQ2CscVxcHNTU1LB+/XpGlczMzEyIiIigQ4cOcHNzQ6dOnWBtbU0OBtSc+uOPPyAhIYFOnTpBXV0dOjo6ZP06dOgQfH19IS0tDSMjIxgYGPyjhXK+Fr/Ibxvj1KlThPhSOH36NJKTk9t8A87Ly8OYMWPQp08fUrI1OjoaqqqqfM9AISEhAQMGDGAkw/3XIahuPcCMhWsNEhMToaSkhHPnzqGsrAzl5eXYv38/TE1Noa2tTRbbv//+GxERETA3N+eT//rZceXKFb5ywbdu3eJz01O4ePEi7O3tsWHDBri7u0NLSwtnz54V6Irctm0bX5W3r0FLBxJKV5dK5Hn//j2mTp2K7t2788XdAU2HIhaLhalTpwIQTManTJkCKysrxmd06zld4q1nz57w9PRETk4OKioqwGaz+YoWlJeXY/ny5W1SNe17B6W+MmHCBLx58wbq6uoICQlp9iCyd+9eaGlpQUNDAxYWFjhz5gxp6xUrVkBYWBhDhgzBiBEjICEh0WJc6/cK+vh99eoV7ty5gz179jCUWOi6xqGhoYiLi8OBAwegpaWFkSNHfpN4eeB/8bXXr19nfL5o0SJYWVnB39+focJx//596Ovrw83NjRDgnJwcxjxqqz6trq7GunXroK+vj7S0NGhra2PEiBFtlhT+qTalwk7Cw8NJovzFixeho6ODoKAgUumyvr4eBw8exKVLlwQW/zl48CDU1dUZBZWqq6tJUl9eXh4SEhIQHx+PNWvWkPejv+e0adNIYuCrV6/g5eUFVVVVcph+//49CgoKkJ2d/V2ULP4c/CK/3xCCNs+2IsBZWVlgs9kICAhAaGgoREREkJGRgcePH8PMzAxGRkZYvHgx+f7z588xceJEsNns71pK7J/G69evoampSVxAFNLS0uDn59dqGbhbt27B2tqaxFzR+z4/Px8WFhawsbEhC9+NGzfQu3dvQob+SxDkFnv69KnA7/79999ISkoiC2uXLl2aJcANDQ0YPnw4ZsyY8VXyfTdu3CDztDkCnJ+fj0uXLgH435wuLy/HypUr+eY4ldA4evRoiIqK8hU3oX/fzc1NYNw373Pk5+fD29sbXbp0gby8PGJjY8nf6JvrzxA+8ylUVlbCxcUFI0aMIP3+7t07SEhIYPDgweR7VBvev38furq6WLBgAc6ePYsePXpAS0uLoZW6d+9eUo3vewsXoXv7PtW/vMnOdDQ2NjI+f/DgAXr16gVpaWn06dOH7xoUmiNvn5KXoz8rl8tFcnIyn/rI0aNHoaenBw0NDWJ8oPebsbExjIyMGBq5jY2N36RP58+fDxERESJFyPsOvO9JXzM+59DA20evXr1CWVkZ4uPjGQoQly5dgp6eHoKCgvgODYKwbNkydOjQAUDTYT0tLQ2GhoaQkJDA+PHj+Z4f+B/xffr0KTGu0ZPwqqqq0LNnT6iqqn6WOs/3iF/kt5UQtMj8W67q7OxsSEhIkE2ysbERo0ePJlm9t27dQocOHaCkpAQrKys4OTnB3d0durq6391C/m8jNzcXAwcOhKWlJdF4pAokCCoE0hyoeu501xIdJ0+ehIiICEPyrjnC97OAd360hojxfqe+vp7PokAnwNT337x5g8bGRmRkZKBjx44Mq9HnICEhAYaGhjhy5MgnCTAdzRXPmDJlCmRkZIg1mgrhoCea0L+/fv36VmuC5+fno1u3btDW1mbENv+XQmgoXLp0ibw3tYGXlZXxuZOvXr2KzMxMxMXFMT4PDAyEtrY29u7dSwqJVFRUfLceMnquBt078CXPS/2+vLwcbDYbBgYGGDVq1CcL8HypvBwFKtkL+N+BuKGhAX/++SfYbDYjNINelS04OJgx39qyT6m2eP78OdTU1ODu7g4dHR1GQQ9B82vFihVYvnw5oy8KCwuxfv16RmGaT2HPnj0wNjYGh8OBlJQUX+GNK1eukKIgnyKf586dg6ioKHr37g0dHR0MGjQIa9aswZYtW8BisZr1kO3duxdsNhvm5uZgsVhYsmQJ472qqqrg5+cHcXHxzy5Z/z3hF/ltBegb8uPHj1FWVkZOnt/KLdQcmkt4CQkJgZWVFQwNDREeHo7k5GTs3LkTw4cPR0REBNauXfvTk60vxf379xEdHQ1zc3MEBgby1WpvCZQsWUZGBtq3b08SInjHRXV1NTQ0NJCcnMx3jZ+BrBw7dgyrV6/G77//jlevXn2Te9AX4M6dO0NLSwsXLlzAnTt34ObmRpJfFi9e/MUuuDdv3qBz587o2LEjDh8+/FkEmBdLliwBh8NhaIdWV1cjLS2NjwDTdYv19PQwe/bsVt3j4cOHzVb5+hnR2gNVc+uyvb09WCwWvL29+dzYgYGBMDAwwNatW79rze2Kigo4ODjwafOmp6cjLi7uiyS7Hj16BHV1dcTGxuLChQsIDQ3FuHHjmh1TXyMvx4sDBw4wqo5yuVycOnUKioqK6Nu3L/lecxbotu7TgoICaGpqYvTo0aisrMSGDRtgaGjYrIxhXV0dxowZg379+hGS/Pr1a8jJybWYyyDovnp6epgzZw5WrVoFCwsLdOvWjS+M6q+//oKdnR0JdeC1qFP/rq2txZ49exAUFITMzEySDPfixQu4uLgwYq6pts3Ly4OtrS0WLFiAkydPolevXlBUVMSxY8f4Dll9+/YVGKv8o+AX+f0MJCYmQl9fH+bm5hg8eDAZfP8kAaYnvFALU1paGiQlJZGSkoK1a9fC2NgY5ubm/4lYv68BfaG8d+8eRowYARkZGUyaNIl83hLpiY6ORnh4OIAmpQgZGRnMmjWL/J2XONnY2GDJkiVt+QrfBaZOnQp1dXVYWlqCxWKhf//+30xSi76xd+vWDWpqapCXl0ePHj2++tqUy7yiogKdOnVCt27dcOjQoS8mwDNmzCCbN/25myPA1Dpy+vRpxMbGtjp041NVvn5UvHjxAocPH8aRI0c+6+DOSwZ4P/P29oaCggLOnDnDt3Z3794dVlZWn5Q7/DdRV1eHLVu2wMTEhOR6zJs3D1JSUl+UmPfx40cEBARg8ODBpJ0uXboEHx8fTJo0ic9y2RbycrzX69+/PxQVFRlSXadOnYKSkhJCQkL+0T4dOXIkQkJCyH2qq6uxYsUKWFtbo6ysjLEOUP9dVVWFadOmISwsDPPmzYO6ujrGjRvX6jjh27dvY9KkSYzwpb///htdunSBn58fHwGm+oTeBunp6YiIiECnTp2wb98+Ypih2qOhoQGVlZXw8fFBp06d+Prp2rVrSEtL41NK6dWrF9hsNv74448foghVa/GL/LYA+iDfv38/qbmdmJiI7t27w97enujy/ZMEmEp48ff3R1RUFDgcDiOB6OnTp81alv7reP78Oe7evUvICH0BoAiwqakpqYADCG672NhYyMjIkMD/d+/ekTrne/fu5fv+o0ePYG5uzlB4+BkwadIkKCgo4OrVq6ivryeJJXSJty8FvW/obl5qrhUUFIDFYiEsLEzgb770Xn/++SdSUlIgJiYGBwcH/PHHH60mwHTLy9ChQ0k2Oi8oAiwiIsIXAlFfX//Z5KulKl8/Iu7cuQN9fX1YW1uDxWLB09OzVcSO6h8qCYd+6KAfJpydnWFgYICLFy/yjZnmqmt9T6iuriYucm9vbygpKTVbIOHp06ctHkbr6+tJEhUdV69eFZhIRf2GwpfIy/GCy+UiLCwMsrKyDAJ8+vRp/L//9/8wffr0f7VPP378SLRyeUG/1+jRoyEpKQl3d3fybJ9ak96/f4/g4GAoKCjA19eX8berV6+ic+fOCAgIYFS2412Hpk6dCjabjcTERAwdOhSGhoaYMGEC6ffq6mps3rwZnTp1gr29PSGx9GcLDQ0Fi8WCjY0N37v26tULampqOHDgwHdTDfZr8Yv8tgJ79uxBamoqI+7n1KlT8PDwgJ2d3b9CgPPy8tCjRw9ISEgQEW8ul4u6ujoUFRXB2tq6TQjIz4SSkhLIycmhe/fu6Nq1K27dusVXTS07OxvR0dEwMTFptlLNjBkzIC4uTvqdWkjy8/PBZrOhr6+P+fPno6GhAW/evMGDBw9gYWHBiGH7GUBJadFdo+fPn4eIiAiSk5MFul+bE5Ln/TevTmV8fDwJNQKaPCAcDgc9e/Ykn7VFcld8fDzYbDYWLVqEGTNmQFdXF7a2tjh69GirCDA9VjckJISRcMULugX4U5WdWoPvrerYl4JSX4mPj8erV6+wf/9+tGvXjiFD2BJev34NFosFFRUVhmYrb785OjrCwMAAly5d+qESA+nPOmDAAAgLCyMqKkrg30tLS6GsrEwKqLQGnxPj3lp5udbelyLA9Plw/fp1vHjx4h/p0y/5DdUWpaWlUFNTg52dHfr27YsNGzYI1HAXhGvXriEkJARsNpvkntD/ZmVlhdDQUIHxylu3boWenh6JAb548SJYLBYMDQ0xZswYPHv2DB8/fsSWLVsQHx8vUNWBwsiRI8HhcLBy5Uq+A3iXLl1gaGj43cbBfy5+kd9P4O7du7CxsYGUlBRf5bTTp0+je/fucHR0/FfqvBcUFMDT0xPe3t4M+ZrExETo6uoSUetfaMLDhw+hoqKClStXYubMmbC3t4ePjw/Wr1/PkDXLzs7GqFGjwGazsXv3bsY1pkyZAhaLBVdXV0ZiB50Au7i4oH379uBwONDT04ONjQ0jRvtH2mhbAlVKlx7KQVnqAgMDYWNjg6SkJLKYN0fOampq8OzZM7x48YKv6EpycjLat2/PF4NdUFDAEK7/kjbl1brOz8+HpqYmoyJcaWkpbG1tYWlpybAAC8L+/fshJCREtFIHDRpEknDo7kLeksU/mzfga/Dw4UNIS0tj2LBhjM9NTU1hZ2fHt/HSlQ/oCAoKQmhoKFauXAl9fX306NEDaWlpfLHgLi4ukJeXx9WrV9v+Zb4xFixYAHl5eZKkuWDBAvI3qk1evHgBFRWVbxIC97nycq0BRYAVFBQYhYCApvjdL+3TR48eYe7cuYiOjsbJkycZ1dHaAoWFhVBQUEBMTAwqKiqQkJCA0NBQrFixgo9kUn1DyWFS7ZWTk4N+/fqhU6dO2LFjB+M3N27cEBj6w+VysXfvXqLHfODAAcjJyWHDhg2YP38+xMXFMW7cOD5+Qj1TUVERioqKGHvZoEGDYGxsjA0bNvDNt5+JU/wivzwQJP2xefNmWFpawt7enm9z/vPPP2FtbY2IiIh/8jEJqBAILy8v3Lp1C/PmzYO4uPgPJTb9TyItLQ1eXl4AmuLaMjIyoKWlBXd3dyQkJBBXVWFhIWJiYlBQUEB+O378eCgqKmLx4sXo1asXvL29GQssvXTmqVOnSAw2PSTlZyC+dCtSeno6WCwWZs+eDQcHB/Ts2RN5eXl48uQJNm3ahLCwMCgpKUFVVVWgpvG6devQt29fSElJQV5eHkZGRjh8+DCApjAUHR2dZsuYUviSNh08eDBDChBo6nMdHR0SX0eNhTdv3pCKSLt27Wr2fnfu3EHfvn2hqqqKv//+G6NGjSKKLFSMHpfLRXV1NbhcLh/5/hnGxtfiwIEDEBYWRlxcHFFOoRQynJycMHDgQKSmpmL79u0Amq8iuHjxYowaNQpAk1t5/vz56N+/P1RUVLBo0SLGYcrHx6dZlZbvFQkJCZCXl8eff/4JoMk7aWBgwCiIAjSp2airq7dYev1L0Fp5OaDlcd2cJ8jPzw+enp6M339pn2ZlZUFdXR3u7u6wsLCAmJgYKbXcFnOuoaEBycnJGDlyJBmPVVVViImJwZAhQxghBPQqsB07doS1tTVMTU2xfft21NfX486dOwgJCYGbm5vA9VJQe718+RKvX7/Gy5cv4ejoSDzBFRUV0NDQgIqKCmOto65x4MABODg4wMTEBIaGhkQtCmgiwCYmJti0aVObHxS+F/wivzTQJ0JtbS2RS+Jyufj999/h4OAAPz8/PgJM1wX9N0AlvHA4HIiKiv7U1Zy+FNSEv379Onr06MHQSfTx8YGuri6MjIygp6eHsLAwFBQUMPp0wYIFYLFY5IS8f/9+eHp6wsfHh0GAW7J6/Axx1zExMdDU1GTEAi5duhQsFgs6Ojp8MYI1NTUoLi5mSLxRmDJlCgwMDDBz5kwcOnQIK1asgKenJ4SEhLBs2TJUVlY2G3P4tVi7di3ZqKjFvaysDDo6OkQDE2g6/NbX16Njx44QFxf/ZPZ2Tk4OgoODoaSkBDabDV1dXWhra0NDQwOmpqYwMDCAuro62Gw2o+LUfx10crZ161aoq6tj2rRpmDhxIhQUFLBz505cvnwZmzZtwsCBA6GiogI9PT2MGTNG4Nqbn58POTk5UqULAPr06YP27dvD29sbampq6NWr1w8r1TRx4kSGx6C2thaZmZmYNGkSSkpKiJUwNzcXsrKy30TpR5C8XHl5OUMBgN43W7duxbx58zB+/HjcvXu3RfUF3tAn4Mv6NDs7G1JSUkhMTERVVRWqq6vh7u4OdXV1UnG1LfZuuvWZul51dbVA1Zk//viDVM/Ly8vDwIEDISUlReQKb968iQEDBsDCwgK///47+R39oFdaWsrHQ7KysqCvr0+8wLm5uYiIiMCaNWv49qUTJ05AQkICq1atwqNHj5CRkQEWi8XweoWHh4PD4WDr1q0/xd7Fi1/k9/9AnwBpaWnw9fWFuro6YmJiyGDasWMHOnToAD8/P4Gliv9p2TM6cnNz4e/v/6uARSvg6+uLXr16AWiyAKqqqhL94+nTp8Pb25thCeJyubh06RKfrMuBAwcEEuCfFbGxsZCVlRVIGFavXg0Wi4V58+YxLB28Lj9qnsXGxkJeXh5XrlxhzJuioiKMHj0awsLCZCFuy4WX91pr167FyJEjCTnYsWMHREVFSRY90DSvIyIi8NdffzU7x+kb07179xAVFQUhISEEBwfj8OHDSE9Px/Lly7Fq1SqsW7eOkT/wX8ft27ehra3N8JBs3ryZHOY3btzI+H5tbS2KioqQlJQk0GJLjbGFCxcSNZYhQ4ZATU0N+fn5KC4uxsGDB2Fvb//NVEm+FVqaC/X19SgvL4eFhQWGDx+O4uJiPH78GAoKCgJlsZqTyPrUPT9XXg5oKrOrqqqKyMhIuLm5QU9PD4sWLfpk8hR1ry/p05KSEggJCSEoKIhxzYCAAMjKyqKoqEigokpbrDfN1QWoq6tDUFAQ4uPjATQd+gwNDfmSBa9du4bIyEg8ffqUb/wnJSXBysoK1tbWjKqOly9fhpGREdLS0nD+/Hn4+fkx3p3eP7GxsaTA0tOnT6Gnp4cRI0aQ56QwfPhwhvfzZ8Iv8suDhIQEKCsrIyMjAydOnICysjK6deuGkpISNDQ0YNu2bXBzc4OLi8t3J4fzM8mQfC2ePXuG/fv3Y82aNXj79i1jQufm5qJbt26wsbGBiooKn6WcbpHgXcQaGxsZnx08eJAQYHoZyZ8NU6ZMgby8PCMrnMvlIi8vj/ybigGeO3dui6WhKTc2lYHNG7dZXFwMPz8/aGlp8SUktjWmTZsGS0tLTJkyBcXFxQCaKjsJCQkhICAAY8eORadOnWBmZkb6ndpEDhw4gOPHjwu8bnZ2NiIiIsDhcFosjftfD3XIysqCuLg4IQP0cbB7926oqKhgwoQJjINna7PNT548CTMzM7i4uEBbW5uvaMO/aaygozVJoJ+DZcuWQVtbG+PHj8fGjRthYWGB169f4/3793j37h3Ky8vJ/x48eICamhoyDr9UXq4l7N27F5qamuTQfOrUKbBYrM9KwqPwuX0aHBwMDoeDM2fOAPjf3NbU1ERYWBjU1NSQkJCA/fv3kzCkbzkn6+vr4erqiosXL+L9+/dQVVXF8OHDyd+3bdtG4nNrampw4cIFsFgsTJw4EUCTkUFZWRlLly5FQkICpKWlERoaSn4/ceJE6OvrQ1NTE66urgIT7hoaGuDi4oJFixbh/fv3UFdXx/Dhw8l3Vq1axVCW+Fnxi/zSkJOTAwsLCyKpc/XqVYiJiWHDhg3kO1wuF+vWrUN0dPR/fuP6XpGdnQ19fX3Y2NhASEgIVlZW+OuvvwCAxFr26NEDcnJyDLc6b3/SF1LeuCf6Bnzw4EH07NkTPj4+jMTDnwWHDh3ik86rr6+Hubk5FixYwGgLKgY4ISGBoc5AB6US0ZIayebNm9G+ffs2jcVsbr6mpKTAxsYGcXFxhGyfOXMGfn5+CAgIQFhYGJ800OHDh4kskJeXF06ePMlX3OPOnTvo168flJWViWfgeyFc3wOysrIgISFBiC8FenLW5s2biWbql4yFqKgoSEhICPTMfA+uXPozbNmyhZFg+znPd+/ePUYC6Lp166ClpYWuXbuCxWJBQUEBbDYb6urqUFBQgLy8PJSVlWFgYEAUSr5UXu5TWLlyJVG62bZtG2RkZMhaUllZ+dn9+qk+zc3NxebNmwE0zdeBAwdCUVERkZGRUFZWxrFjx/Du3TuUlZVh9erVROKra9euxGtVVFT0zfJmAgMDERAQAB0dHYwaNYokAldUVKBXr15IT08nBoH6+nps27YNEhISmDx5MjZs2MCQ0jx37hxfMZB79+7hzp07fNX36FiwYAGCg4OhoqKCESNGkLFWU1ODyMhIJCUloba29ruYI98Kv8gvDQ8ePICNjQ2AptOqtLQ0Vq1aBaBpku7fv59xSgZ+WW6+N1Cln5OSkvDs2TPcuXMHCgoKjMUBaLI+SEtLE1LMC/qkHzduHLp164aoqCjG93kJsJ2dHUk2+Nng7e0NTU1NXLx4ER8/foSTkxM8PDyIhZc+D1JTUxnauxQeP36MwsJC3L9/H0uWLIGQkBCfS4+6TlZWFlgsVpvVj6c/3507d8gGQX9ma2trxMXFEYs076ZB//fp06dhZmaG3NxcTJgwAQEBAUTjmU7ecnNz0a9fP7BYrB/Oxf4t8fDhQ4iLi2P69OkA/jffUlNT4evry4gB3rJlC3R0dDB06NBWtyHV3ydPnkSHDh1IYtj3ul5T3pBu3boxLKKtIR+3b99Gu3btkJaWxvh8w4YNkJOTg6urK+bOnYsTJ07gzJkzOHDgAA4ePIhz584Rz83XystRENS+CQkJCAkJwd9//4327dszDtFr167FjBkzWlV9rTV9SrUFvRobl8tFVFQU8UrxoqGhAY8fPyZjq7KyEkFBQejYsSMjN+RzQR10y8vLGZ6wffv2kUMGHdOmTYOBgQGx/NLJ69atWyElJQURERE+KTSKAAcHB/ONF+rQXlJSwjicHzlyBHp6erCzs0Nubi6AJuI7bdo0aGpq/nAJoF+C/yz5FURgc3NzoaKiglmzZkFOTg4rVqwg37ly5Qp69uz5yXrnv/DvgSruQa+SAzSJnxsbG/PVJ+/VqxdiY2ObtVACwNixY2FoaIjk5GQYGhqiS5cuDMJGJ0Q/o8IGfTH19vYGh8OBkZERevbsydduzcW5AU3WVVtbW7Rv3x5ubm5Yv349sRJnZmaS71KxhytWrGCQ67Z6h6lTp8LY2BhKSkrQ0tJi6KPOmjULdnZ2mDx5Mp48edLsNSj4+/tj5MiRAJqUItavXw89PT1YWlpi2rRpeP36NbhcLp4/f95sadT/IhobG4meMl0mb86cOZCVlSWhJPTxtGbNGpiZmX126ezq6mq4uLigd+/ebfHo3wSnT5+GtbU1EhMT4enpCU9PT1KqG2iZAGdlZRHSKgiZmZnQ0NDAlClTmi2A0lbycvT+OnfuHCFQ9+7dA4fDAYvFIhZZoEkBxcfHByNHjvwsC2NzfZqVlQUpKSkSy0pHXV0dIiIiGAoZ1D0FeWN27twJb29v+Pr6ftaef/LkScbhd9++fXB3d4exsTFSU1Px6NEj1NXVISkpCSYmJujevTvi4uIQHBwMeXl5soeUlpaSa9y6dQtcLhe7du2CvLw8hg4dyndfKjwiKSkJGzduZISs7Nu3D0ZGRjA2NkbXrl3J3zZs2AA9PT106NABvXr1Qu/evaGkpPRT7mOC8J8kv/SJtnHjRmzevJlIEU2YMAEiIiIMAlVTUwM/Pz/06tXru7Uc/EJTNrC8vDx69+5NlDrmz58PFosFDoeD6Oho9OnTB7t27UJ1dTXi4uL4RLt5F8IRI0aQWN63b98iMDAQnTp1YoTC8MZa/wyuomPHjmHp0qU4ePAgo7xpcHBwq+P1qHaIjY2FoqIiMjMzMXfuXLIZnDhxAsnJyQwCDDS5HB0dHflkm74WCxcuhIKCAs6ePYvz589j27ZtUFBQYCSFpKamQl1dHb/99hvf73///XeGReTkyZPw8/MjlprKykpISEhgwIABUFdXh5OTE7p06cI4JPxaP5pQXFyMmJgYODs7Y9WqVZg3bx4UFRWbjaEGwEgybs0co9p69+7d0NTURGlp6Xc5N7OzszFmzBi8e/cOubm56N69e4sEmHqvO3fuQEJCAjNmzGBcb/v27UQuEGgKgVBTU8OkSZOIlY9+va+Vl+O93tSpU2Fra4u1a9eioqIClZWVWLBgATQ1NZGQkICioiJcvHgR3t7esLS0JAaE1syN5vr0zp07aN++PfEkULhy5QqxKjc2NmLQoEGQk5MjMcAt3ff3339Hjx49GASY/p51dXVYv349bt++DS6Xi3v37hFFmGfPgHy9bgAAvhhJREFUnuHWrVuQl5fH1KlTMXHiRKiqqqJ///64f/8+ampqsH//fgQEBMDb2xtjx44luQEnT57EwIED8ezZM4wdOxZycnIoLy9HbW0ttm3b1qxF/vbt2ygrK4OysjLs7OxQXFyM7OxscDgcpKamYsOGDXBwcICuri7xqJ08eRLz5s1DcHAw5s+fz8jh+NnxnyO/9IH+7Nkz6OnpwdnZGb///jsaGxuJm1JRUREpKSlITExEjx49YG5uLrAk4C98X7h//z7U1NTQp08fJCUlQVFREfv378f169dx7do19O3bF46OjhAVFUVKSgojk5Xer9u2bcP27dv5Ssa+ePECgYGB6NKlC4MA/0yYOXMmHB0dERUVReLL6BZub29vqKio4Pjx459MPpo1axaEhIQY4uiU1M/69evR2NiI6dOng8VikXhHMzMz+Pv7k+9/KWHhnad9+/blI9SXL1+GlJQUkpKSyGeZmZl8h6Dnz5/Dz8+PYbkqLS2FoaEh0tPTUVFRATabTcoZl5eXY9GiRQKtUL/QhJcvX2LMmDEwNjaGiIgIscjRx1RSUhKxdFH9SS9NTvVTS7HURUVFba5z25bgcrkM2aq7d+8SAkyXuqIO9EBTFTtDQ0M4OTkxrjV79mxIS0vzues3bdoEcXFxJCQkkPZra3k5oKm/lJSUcO7cOUYoQ1lZGRYuXAg2mw1FRUVYWVmhZ8+eZE+lDohf0qf19fXw8vICi8VitOOsWbMgIyPD8OI0NjZi8ODBYLFYOH/+PHmP58+fY/fu3dizZw9jT9i/fz8hwPSE5pqaGowYMQIKCgqMAhKbN2+GlpYWJk+ejHnz5jFCUU6dOgVLS0uEhIQQdSFB2Lp1K6ytrWFpaQlFRUUGIaVigFsKSXn8+DEsLS3RsWNHHDx4kLHm1dXVoVOnTtDW1m6zkLIfFf858kthwoQJ6Nu3L1xdXaGkpARtbW1izXr06BFmzZoFMzMz+Pn5Ydy4cS2WBPyF7wv37t2Dvr4+WCwWIzmAwtu3b7Fq1SrGokJfzH18fKCmpgYZGRmwWCxMmTKF8fuXL18iKCgIpqamRJvxZ8HUqVPB4XBw5coVYhFvbGzE6tWrGRJnPXv2hJqaGk6cONHsnCgrK4O9vT1cXFz4FnuKNALAhw8fkJiYCCEhIbRr144UIaHu/SWgE2YqTtvGxoYR5kBtrpMmTULPnj35khp5N9/4+HjY2dkxPjt8+DD09PQgLi6OgQMHMnICeKWkfoEfr169wrhx42BlZcUXL5+UlARxcXGGGsuKFSswevRohrfm6dOnmDlzpkBN1R8N1JijE+CDBw/i4cOHMDExIRbd4uJihIWFoVOnTqTdFi5cCCUlpWaL6mzcuJFYfttaXg5oCp+wtrYm13z9+jWuXbuG6dOn4+jRowCa1oRLly4xdNSXLVv21X1aUFAAY2NjuLm5obGxEfPmzQOHwxFYIKexsRHDhw8n4QnZ2dnQ1taGs7MzhIWFERISwjB47Nu3j88CPHr0aEhJSZGxSW/nzMxMaGpqQlVVlS8c5cSJE7CwsEBYWBhj7+BdH8LDw8FiseDv788nsUkRYCkpKURGRgpsj+fPn8PY2BgsFoscyClQBNjIyIhUo/wv4j9Jfjds2AB5eXlkZWXh9evXKC8vh5ubG0xMTHDgwAGymX9qM/yF7w/UIpKTkwNNTU34+PiQBbQ1OpY3btyAj48PXrx4gQcPHmDEiBFwcnIi5SMpFBUVEfL2s+DQoUPQ19dnuAQbGhrg6OgIFouFsWPHMnSkvb29wWKxcPfu3WavmZeXB19fX3h6euLixYsAmuJ/paWlSWIZ0BQykJCQwKgO1RbEd/r06TA0NERJSQkWLlwIa2trxvtRz+Pm5ibQncsb79ihQwdStQ1oCrWxtLQk5aupZ/5FdlsPygLs7OxMEpJSU1P5iG9jYyN+++039OvXj1jUS0tLoaioSGKvv1d8znigvnvv3j14eXmhY8eOkJWVhZeXF0pKSogFuLCwECNHjkTHjh3h5eUFRUVFnDt3ju96lFGHnkz6LeTl3r59C3NzcyxatAhXr17F4MGDYWVlBXt7e77QJvp1v7RPebWJHz9+DF1dXWJdPnXqVLO/pbcFFTP94cMH/PXXXxASEiJeCAp79uxBjx494OfnB39/f0hKSjIsp7z9S8Xn9uzZkxw4KJw6dQrq6uoYNmwYo/Ij0ERMuVwu0tPTsWDBAjg5OSE8PJwYD+hxyhkZGXB3d+dbc6g16/nz53BxcYGhoSGxZtOLklhaWsLW1pYR1vZfwn+S/CYlJaFLly6or68nhLaurg6Ojo7Q19fH7t27+cSvf21m3z+oBZpyod29exdqamro2bMnw2VIB71+fFJSEuzt7RmJH8XFxWRjphc+oONnGRupqano0qULysvLyYLq5OQELy8vbNiwARoaGhg3bhxDJaE16hZUCe7evXsjKioKbDabSCjRN9WW9JW/BNevX0fv3r0J6f7777/Ro0cP9OvXj5RCfffuHTw9PflKsgJN4R/UoYd6zk2bNiE0NJRB3FNTU8HhcIhM2s8yHv5JUAS4U6dOcHJy4iO+FOrr67Fu3TqEhYVh1KhRUFNTQ0xMzA+jcd7ainLUGKJkBvv374+HDx9CV1cXw4YNI4l/T58+xahRo6CsrMxIhKLmD2U9p1zzbSUvJ2h+vnnzBiNHjoSVlRVEREQQExODo0ePgsvlolevXnweNApf0qePHz/G3LlzSWwshSdPnsDJyQmGhobNrvkUHjx4ABERERKaQLW5h4cHZsyYgfj4eKL2BDTFANvZ2TES0+i/+/PPP5GUlET+vXPnTqipqWHcuHF81tszZ84QdQl6W/JWbdu0aRPs7e0xePBgxtjh9ThSPObUqVOYMGECIebPnz+HqakpnJycSDvRCfC3qPz3o+A/RX6pQTZlyhRYWVmRzymydPbsWYiIiMDNzY3hDvqF7xe88WFPnz6FjY0NKcZw7949aGtrw9XVlZFBy+Vy8f79e4iJiWHp0qUAmlz+urq66Nq1K+MeL168wNixY+Hi4sKXUPEzgLKgeHl5MUIOgKaYWEpxYf/+/ZCTk8OYMWP4pIk+RVbz8vLQo0cPSEhIEMLcXNZ4W5DHzMxMeHl5oUuXLgzFiOPHj8PX1xfKysowNzeHlZUVLC0t+cTg6+vrYWxsTOKQqc+Liopgbm6O1NRUcs2ioiK4uroiLS3tV1jUV+Dly5eIiIiAgYGBwJhI+riYP38+JCUlYWdnR4oNfe+5GBcvXgSLxWKU520JeXl5kJeXR0BAABobG4k+toeHB8aOHUtiXp8/f46RI0fCxcUFCxYsIL+fPn064xDRVvJy9HbOycnB3bt3CdF88+YN7ty5wxdP6urqyng2Cl/Sp3fu3IGpqSliY2MZyX5ULPOTJ0+gr6+Pjh07ksI1vGhsbMTcuXPBYrFw+vRp8jmV6BcaGgobGxtISEiQymdAU9iCIMK4d+9eyMvLY/jw4Qx1CCqWujU61bNnz4aTkxO8vb0xe/Zs8nlmZiYcHR0RGhqKffv2oWfPnjAyMuJbJ3///XdISEggJSWFEfNNJ8D0wkL/dfzU5Le5xTA3NxcSEhKIi4tjfH7y5ElERkbC2dkZLi4u/8Qj/sJnorCwELt27UJ6ejpx11CEo7CwEGpqaoxqNUBTTJepqalAqZ8NGzagd+/eePnyJd6+fYu0tDSw2Wy+sfHixQsMGjQIM2fO/IZv98+D7uGIjIyEmZlZsxsGAISEhGDs2LFfdK+CggJ4enrC29ubWGO/FdauXQsDAwPIycnxxbU9evQIZ86cwaxZs7Bx40aB8fzl5eVQUlISqLl68uRJGBgY4NKlS+Rzd3d3TJo06Zu+038BvHqkdFAH3NevX0NdXR3u7u7o27cv4uPjGfHp3zNmzpyJdu3ataq89cuXLxkeiZs3b0JOTg7du3eHl5cXYmJiSFtRIRDOzs5YsWIFkpOTGcS3reTl6OtqUlISDAwMoKurCwUFBezevZsRKlhZWYl79+6hZ8+esLGxEXgw/Nw+ffDgAeTl5REfH89QUcnMzERGRgYhzRQB7tKlC8NLQ8ebN28wbtw4iIqK4urVq1i+fDnk5eWJN7CsrAzjxo2DsrIyw9vFi+zsbLDZ7GYPNVu3boWOjg4iIyMZBwn6e61cuRIKCgqYN28eQkNDYWlpSco4A00KHt27d4eRkRG6dOnCZxXPy8uDrq4uQ0OZfo/nz5/DwsICRkZGjMJO/2X8tOSXPrCOHDmC5cuXY9euXcR1sHbtWkhISGDMmDHIz89HXl4efHx8MGvWLDx58gQsFgvHjh37tx7/FwQgOzsburq6sLOzg5ycHExMTMgC+PHjR3h6ejarGUlZBQAQ0gI0WRHc3d2xc+dOAE0bzuzZs2FmZsbnpqOq/wA/x8k5JiYGoaGhZK7s378fLBYLixcvZnyPetdHjx7B1dW1VRt3c8jPz4ePjw969uzJF1f3pWhJqsjMzAzBwcEtZlcD/PH8Hz58gK6uLl+FKyozPzo6GvPmzSP35g2T+oVvg8LCQsjKymLcuHGoqanBxo0bERoainHjxrWqUML3gFmzZkFYWLjZefTgwQNGeVkul0vITmJiIiZOnIjExETY29sjNjaWQYDHjBkDDocDMTExvrCRL5GXo695dMycOROqqqo4evQoamtrERAQADabjZUrVxICun79evj7+6Nr167k+QXlzbS2T6uqqhAQEICIiAjG+kvJJQoLC2P16tWEgD99+hQKCgro2bMn47709aK8vByjRo0Ci8WCqKgoUXSgvrNlyxZoa2szQit4sXfvXnTs2BEVFRV8JdAptKRT/eeff2LevHk4dOgQgKa1Z+3atTAyMmIUC3r69CkePnwosHLbqVOnYGRkxLBK8+5RT58+haOjI5+G+X8VPy35pTBp0iSoqqrC2toapqamYLPZxJqzc+dOKCsrQ1VVFWpqarC1tUVNTQ0KCgqgp6f3yQ3zF/45ULFqCQkJePXqFR4+fAgNDQ1GidxHjx590vIzbtw4uLi4MOLBFi5cCFVVVeL2e/XqFWbPng0LCwuBUlU/A/GNjY2FnJwcsrOzyWf19fUYPnw4REREsHTpUlLrvq6uDnl5eTA1NWVo4n4p8vPz4ejo2GwM9eeA3t+HDh1CZmYmFi9eTA47u3fvhp2dHYYMGcKImRPUh6tXryYW/+rqamhqapLYvoaGBsZv1q9fD3V1dWJV+pXo9s9gw4YNGDNmDMNav3LlSgwZMuSHUntISUkRSIBzcnKgpKQEX19flJaW8sWRr1u3Ds7OzqioqMDSpUvh4ODAIMBPnjxh6Pny4kvl5ei4c+cOunbtShQcDh06BDk5OfTo0QPCwsJYuXIl6uvr8fr1axw7dowQweZCglrbp6WlpTA1NWUkzl28eBHt27fHjRs3MGPGDIiKimLVqlUk1KmwsJDE29ITu+jvVVpaiunTp0NISIjkAlB/nzhxIjp37swXi0vHypUrwWazyZ5CXwPOnj1L/k0dJOh/v3jxItTV1aGoqMiI46UIsLGxscB8BN5+2b9/PzQ1NQn5pf/97Nmz5CD0K2n/f/ipye+uXbugpKSEK1euoL6+Hnl5eZg0aRKEhYWJZMy7d+9w9uxZXLp0iQyY+Ph4mJubf9fakP8l8MaqUejYsSMSEhIQFhaG7du3t3g6B5osne3btyckiH5K79+/P5KTkwlpKikpwezZs6GoqIhdu3Z9g7f69xATE8NHfIGmTaeoqAjDhg0Di8WCs7MzhgwZgoCAAFhYWCAgIIB892vdy209t+Li4qCjowN3d3dYW1tDQ0ODSJxt27YNDg4OiIyMbLZcaWVlJSZNmgQDAwPMmTMHZWVlUFRUxJUrV5q9Z0REBAICAv6z2dLfCi0dIOgWdroFrDkL5fcE3jmTlJQEYWFhrFu3DkCTxVdXVxe9evVCfn4+9PX1YW5ujoMHDzLIbNeuXTF58mQATSTa2dkZEydOxIsXLwB8muB8rrwcLwoLC7Fu3To0NDTg/PnzUFVVJdVQfX19weFwMG/evGatrbxobZ/euXMH7dq1Y8Tovn//nhFLS2mG83ps7t+/D09PT8THx6Oqqorckxprb9++xejRoyEiIkLCHqZPnw4pKSmyTjb3DqdPn4aOjg4yMzNJqAZ13X79+pGkWd5x/fz5c1RVVSE5ORmKiooYNWoU4+8VFRVYv349ZGVlGTkGgvD48WNISEgwlGgoxMbGIikp6YdJCv2n8FORX97BOWfOHPTo0YPxWWlpKUaOHAknJyeyWFC4d+8eIiMjIS8v/8vq+52guVi1tLQ0CAkJoX///nB2doaYmBhiY2P5pKkozJ49G2JiYnwZrxSWLVsGLy8v4rIDmgga5Yr6WRAfHy9Q+N3Hx4eEflRVVWH79u3w9fWFra0thg8fzogla8u4yrawlG7YsAHKysrkUHP48GGwWCyGksfWrVuhpaXFSCThvf+zZ8+QnJwMMzMzREZGwtjYGNHR0YiLi8O4ceMwadIkxMfHY+zYsejXrx/mz5+PoKCgFqXefqFlNGcxb+24+F4t7bxzhP7vffv2kUP2rFmzICYmhpkzZ8LQ0BDe3t5obGzEtGnTICUlBRUVFdja2qJfv34YOXIkPnz4gPXr1yMiIoJcIzU1FUZGRoiPj+fzUDSH1sjL8UqJ0UF5hYYMGYJhw4ahvr4ejY2NiIqKgomJCdzc3MhzfG4f0b9PPyQXFBRAXFwcc+bM4fseRbTz8vLg4uLCKEjB5XIxc+ZMWFpawsHBAd26dcOoUaP4lDdKS0sxatQoSEpKwt/fn+j43r59+5OenZCQEKirq2PdunV49uwZXr58ifj4eKioqAi0wu/evRteXl7gcrl49eoVUlJSYGhoyEde379/j8OHD7fKYrt+/XqIiooiLi4Od+/eRU5ODiZPngw5OTlSPe4X/oefhvzSB+XatWuRk5ODVatWQUNDgy/O5vfffwebzeYLPv/rr78wefJkhpbpL/z7EBSrxmazcezYMdLvY8aMQfv27QXGM02YMAEsFgssFotY8ngXZi6XC2trawwfPlzgM3zviTStwb1796Curo5u3bqRz2pqamBnZwcPDw8G8QeaNhR6rDTwfbQD7waUmJhI4rN37twJGRkZIlFEtx4dP36cbxMpLy9HdXU1sQQVFhZixowZMDAwAIvFgpeXF9zd3eHi4oKOHTuiQ4cOcHd3Jxng69ata9El+gvNgxpLDx8+xLhx49C/f39Gpb3vYay1Fp8ieNTf586dy/A+AU0HcxaLBR8fH/JZUVERYmJiEBAQgMjISJw6dQoODg7w9/eHh4cHWCwWo8LkggULPjuWs7XycgBw9OhRHDhwgOGar6yshJubGyM5OCgoCPfv3ydKLlwul2/Otdb1ThXioOv1RkVFoX379rh69SqA/4VSUO0bFxeHrl278smcHTx4EJ07d8aHDx9w9OhRDB06FPLy8pg4cSKjEFJdXR2GDRuG9u3b4+bNm9i/fz/Mzc2xatUqcg/6uKS/S0REBExNTSEpKQl7e3toaGgwJNHo2L59O8TFxcnB+cWLF0hJSYGpqSkSEhIE/uZT7dbY2Ijdu3dDXl4eGhoaMDAwgLGxcbPP8F/HT0F+6YNx8eLFUFNTw82bN3HhwgVYWVlhzpw5DAJ8+/ZtmJmZ8VlsuFwu32b/C98H6LFqwsLCJFaNSng7evQo9PT0+E7ZlIv//PnziImJgZiYGInroguGA02yXt27dxcoFP+j48KFCwCarAPOzs4ICwtDVVUVXFxcGBbvlixW3xvorsVRo0bhwoULaN++PbFSc7lczJo1CykpKYzfUf29cOFCeHp6wt7eHpGRkSgrKwPQdNiaMWMGbG1tP6nu8SuG7stALzLA4XDQu3dv9OzZEyIiIowqfD8C6MT36tWryMjIwNChQzF//nyGB3HRokWQl5cn6w8ddIJHtU1xcTFGjx6NDh06kMPc0aNHMXHiRLBYLEa+w5dCkLzc2LFjGcolsbGx4HA4UFFRgYWFBSZOnEj+FhMTA0lJSQwdOhQODg4wNzcn1ufGxkacPn0ao0aNwoABAzB79mwSw/upecNbiIPCzZs3YWtrC1lZWZw6dYokxBUWFiIuLg4yMjLNKjP06NEDo0aNIu7/S5cuQV5eHkJCQvDz88PGjRtRWlqKmpoaYtl+/fo1goKC0KlTJ6xevVpg9Ub6u2RlZWHPnj04ceKEwHwA+u/69OmDvn37knd49eoVUlNTYWFhgTFjxrTYPi2huLgYly9fxpUrV5pVTvmFn4T8Urh79y6ioqIY9dCnTZsGCwsLTJo0CZcvX0ZOTg68vLzQqVOn73pj/wV+tBSrRlmG6Va4hIQEaGpqkkX97du3iI6OFkiAgaaNICQkBLNmzfr2L/MP4s8//4S8vDyys7NRU1ODjIwMODg4QFJSkhEWRLVFaWkp+vTpw1fh8N/GhQsXiP72yJEjifvz0KFDsLGxgYiICENu6MOHD/Dz8yPxkXRMnjwZysrKWLVqFSZPngxbW1tG8hFlATYyMkJiYiL5nH44/l5d7t87qHa7c+cOJCUlSSx/aWkp+vfvDwkJCdy6dUugpe17A30MpKamwtHREdbW1nBxcYGoqCj09fXJ4WvRokWMeFVB4H3XFy9eYMyYMbC3t2eEffFq734N6PJy7969Q2xsLExNTZGamopnz56hQ4cOyM7ORk5ODhYvXgwDAwPGAWXSpEkICgpCZGQkQ9Vh//79EBcXx7Bhw+Dl5QVHR0eGckJzBLi5QhzUO//555/o2rUrWCwWHB0d4eDgAFdXV+jp6Qm0clJtevDgQfTs2ZMQ8GHDhkFfXx8nT55ESEgI9PX1YWtrS96B+v+qqir0798fHh4eWLNmjcBx2ZoxSk/443K5WLlyJezs7Bjhl69fv8bkyZMxYMCAX+vLN8YPS34XL17MsNDt27cPCgoKUFVV5StQkZKSgi5duoDFYsHKygouLi5kYH/PC+sv8ENQrBpVLpdKTOByubh//z4kJCQYsmYAiExVcwT44MGDkJKS+qlipHJycqCgoIBFixYBaLKWr127Fra2tggMDGRsQu/evYOlpSWcnZ3/rcflA5fLRUlJCZycnODv74/g4GBISkqS/i4sLERISAisrKywceNG1NbW4t69e/Dx8YG9vT1flnl6ejp0dHQYLl5PT09s27YNVVVVDGtScnIyTE1NMWHChH/uhf8DKCsrg4mJCSwsLBifDxo0CO3atcPFixf5cjK+N9DXjfHjx0NZWRmHDh0icaqPHj1Cjx49oKWlxScf+Dmg1jwnJydGzPq38jpQng9zc3P07dsXERERZJ8sKyvDypUroa+vzwgRoyd91tfX482bN7C1tWWUhafKNevq6jZbfa2lQhze3t7EO1NSUoJVq1Zh+PDhCAsLw4YNGz5Zrezdu3cwNjbG8uXLMWbMGKiqqpKCFLW1tcjKymKEjlD3zsvLw/z586GmpgZjY2Ns2LBBoAW4JaxduxaqqqrYunUr8TjX1dXB0NCQUUSDes4vjZf+hdbjhyS/169fh66uLvr3709ifwBg+PDhEBYWRlxcHF+maFlZGa5du4asrCyBOnm/8OOgNbFqubm54HA4AuPg6ASYcjfSE0X27dv3ydKYPwqod0pOToaGhgYJC/n48SPWrVsHBwcH9OvXD0DTQm5qagpPT0/y++/pcHjnzh1oaWlBWFiYT1D+3r17CAkJgba2NuTl5WFjY4POnTvz6YtWV1cjJSUF6enpDPJgaGgIa2trWFlZwcbGhmykz549w4QJE5otzfoLrQfd/fvhwwekpqZCSUkJycnJAIB58+ZBTEwMHh4e8PPzg5WVFby9vbFmzRo+ZZLvCVOnToWMjAzy8vLIZ9TYKioqQs+ePaGjo9OicsinQK15HTt2ZMRFtyXoc/39+/dISkqCjo4O3NzcGN8rLy/HqlWrYGRkRNYOCtR68/TpUygrKzM0hBsaGpCdnQ17e3v89ttvjO9T929NIY7mnrk50O+xbds2sFgshkewJYJ54MABiImJYdq0aZg0aRJMTExgbW3NsAAL+j3vc2VnZ2PEiBGwt7eHsbExEhMT8ejRI2zbtg2+vr6MOGlBz/0LbY8fkvwCTRndzs7OGDBgAMMCHBERAT09Paxbt65Ft+33tKn/wufjU6VQHz58CB0dnWYltd69e4cRI0agXbt2RPaOws9yKOLVkzQxMcHWrVvJZzU1NVi3bh2cnJzQp08fGBsbf3fEl/4M+fn5cHZ2JhZr3s3w7du3ePjwIfbs2YObN28KPORyuVy8fPmSuD4bGxuJ2/TYsWM4cuQIPDw8YGlpSdaPn624yb8Bqi/u37+PdevWgcvl4u3bt1i4cCFkZWXRqVMnKCsr4+TJk6ivr0dJSQlycnIQEhICGxsbqKmpfZdyZn/88QdYLBYjtIbXKlhYWAgJCQlG+MyX4OXLlxgyZAi6d+/e5ofz7Oxs0r5Tp07FmTNn8Pr1ayQlJUFWVpaPcJeXl2PBggUIDg4WuE7U1NTA0dGRL3SBy+XCxcUFo0ePFvgcX1KIg7quoP+mDiHv379HWVkZnjx5AnNzc6Ix3pz1nMvloqysDM7OzowSyqWlpQgICIClpSU2bNggkADT2+O3334jMnBA0yF906ZNMDQ0RLdu3WBkZAQ2m40dO3bwXecXvi1+OPJL16rLzMyEk5MTQkJCGKfqQYMGwcjICOvXr//u4hZ/oe3AWwp19erVpDTvn3/+CQ6Hw5eJT19cSktLERwcjIiIiH/mgf8h0OXe6It7cHAwn5uZIsDq6uro3bs3+fx7I75nz54l73Ljxg24ubnB39//k5sidY05c+YQazF9DBQWFmLChAkMYpWZmQl1dXU+r8GvjenLQE9uY7FYDFd4aWkpFi9eDA6Hg/79+5PPqb7mcrkoLy//bkMg3r9/jwEDBqBTp05YtmwZXzgd9W9/f3/06dMHjY2NXzW3Xr161aZJTI2NjXj06BFYLBZmzZqFkSNHQkpKirjmX758iaSkJJiamhILPYXKykpirWxsbER9fT05aNbV1ZGCQryJeYGBgUhISOCzdFJobSGO4cOHNytB1tDQQL7/5MkTODo6krVi+vTpUFdX/6RKS0NDAxwdHUnMNjUm3717BwMDA1hZWWHp0qXN9mdcXByRVywsLOR7x8OHDyMkJARiYmIwMzNrtgzzL3wb/FDklz7AZ86ciejoaOjo6IDFYiEgIAAXL14kfw8LC4OpqSmWLVvGqAH+Cz8niouLYWVlBX19fbx9+xZZWVmQl5dHaWlpi7/7UUqithbJycnw9fXFwoUL+RblGzduQE9Pj1h/qcX848ePDO/J90B86XM9ISEBenp6pHIU0GTJdnNzQ58+fUilKQ8PDyxfvlzg9caPHw8Wi8WoDkUnWMD/3nvHjh0C5ZJ+4fNBtent27chKSkpUIS/uLgYixYtgqysLINgfW+i/PQxWVtbS9aWDx8+YPDgwXB2dsby5cv5CHBlZSVcXFy+2vL7LbFnzx6IiYlBQkKCKMNQ71tcXEwIMK9yCkVgjxw5gqCgIAQEBGD37t0AmqzDPj4+cHJywrhx47Bz506MHj0aMjIyn8ypaE0hDipe9+HDh5gwYQKGDh3KR9AfP34MVVVVREVFMciwlpYW0tPTmz3QcrlcVFZWwsPDA6GhoeQzas2IioqCoqIiAgICBJLoVatWgc1mt1gshMKePXtgb29PZOR+HbL/GfxQ5JfCkiVLICMjg7Nnz+L+/fvIzMyEiYkJQkJCcPnyZfI9X19fhIaG/hpM/xFcunQJ7u7uMDc3x/bt29GtWzesWbMGZ86cwfHjx7Fv3z6cOHECf/75J5YsWcIgvj/DGDl69Cj69esHX19faGpqwsTEBPPmzSPlPauqqtC5c2eEhISQ3/C6/b4H4kvH9OnToaSkhIsXL/KR0StXrsDDwwPm5uYwNTWFoaEhH2F6/PgxCgsLkZOTgyVLlkBISAgbN24EwK/1DDRZZGxtbTF+/Phv+2L/ITx48AAiIiJYsGAB4/OdO3eS8VZaWopFixZBTk7uu1RboY+R9PR0+Pn5wcDAALNmzUJVVRUqKysRFhYGFxcXBgEGmnJUXF1dGUVXvhc0NjaCy+Xi+PHjaNeuHVgsFlJSUojUF4WioiLMnDkTcnJyZP5QOH/+PGRlZREeHo4+ffqAxWIRicAPHz5g6tSp6NixIwwNDdG5c+dWF5BqqRAHRXyzsrLAZrMREBAANzc3tG/fnlEOOCkpCWFhYXxhCZGRkYzKcNTfS0pKUF5eTspKX7p0CaKionwHl7Fjx2LVqlXE00gHVSZ+6tSpAJrG/8aNG+Hk5IQuXboQxQ+6JbtLly4ICwtrVbv8QtvghyS/QUFBGDZsGOOzvXv3QllZGX369GEQ4E9VZvmFHx90Anf58mUiAs9isWBhYQF5eXkoKSlBXl4ebDYbHA4HQUFB/+ITtz3q6+sREfH/2TvvgJza/49/TkM7TamkRNLQoCFFssrMyIjIFklklj2yZzbZW2Zm9ko8djKSZCakiPZ4//7od5/nPorvMzzuO67XP7jOcF33uc457/O5PqMvn4Lo2bNn6N27N+zs7KCqqorQ0FDEx8fjjz/+QOXKlcvNNSptPH36FI6Ojnz2lnfv3uH27du8TyJQ6kO3efNmzJ8/n3+ZiP6cMWMG7O3toaamBjc3N6xfvx5Lly4tYwEGSpcyT548ibp166Jdu3Z8O3tu/Dvy8/MxevRocBzHCxagtNgDx3ECy9iHDx+wePFicBzHix1p4OusDgYGBhg2bBi6du0KeXl5DBkyBECppdPPzw8NGjRAREQEgNIASxsbG/Tu3Vsiff8W3/rIFQWETZw4sczHZlZWFtatW1fmg/ngwYOCEr7r16+HrKwsLxhFv9/bt2+/WYHzW5QX3CwqUS5KlSfyR3737h06dOgAXV1dPHjwgP+/xftbno+vqH/R0dFwdnaGnZ0djI2NsWrVKnz+/Blbt26FnJwcOnbsiJCQEAwYMAAqKiplXBnECQkJgaamJpYvXw5nZ2e0bt0aEydOROPGjVG3bt0ygbh9+vRB//79f5l4k4pAhRK/ohu2V69e6NGjBwDhZJ40aRLU1dXRqlUrQb4/abNmMX4M4v7c4tf40qVL6NSpE3R1dfmv+/T0dOTm5uLTp098sBPwa4mb9+/fQ19fX7D0n5SUhMWLF8PKygqGhoZwc3ODoaEhRo0aJfUFXZ49e4bKlStjx44duHXrFvr16wdra2vUrl0bcnJy5fr7ip4HI0aMgLa2NjZv3ow5c+agSZMmMDc3R0xMDKZNmwaO47BlyxYApXPnyJEj8Pf3F6RvYs+NH8OdO3fg7+8PbW1tPHz4EKtWrYK2tnaZlJRA6Rxevnx5uSVhJU1ISAi0tbUFRRQWLVoEjuP4crpZWVno1asX3NzcMHfuXNSpUwdeXl78/tLwvBGf1xcvXsSRI0fw6tUr/t5Zt24dOI7DlClTeAtwt27dcOnSJQB/Cspbt27hyJEj8PPzw5IlSwT/x/r16yEjI4Pp06f/a0FXXnBzeno6LC0tUbduXcG+fn5+kJOTw/nz58u4vH3vfj5+/DiUlJSwZMkSJCYmIjQ0FBzH8S4g165dg7e3N5o2bYqWLVuWKY38NYmJiejXrx9MTEwwd+5cvt+nT5+Gu7s737eSkhLcvHkTqqqq//OcjB+LVIvfb03WJUuWQEFBQZDmDCh9EDVs2BDDhg1jL65fnClTpqBTp0585aOvo30vXbqERo0awdramg8k+LrCjjS8iP4tovGIXlxr166Fr68vnjx5ItgvOTkZhw8fRqNGjcBxHIYOHfrT+/o9vnW/BgcHo3LlylBWVkZwcDCio6MBoExZVXGmT58OGRkZPpk+UBqVr6ysjPXr16O4uBgTJ04UCOC8vDxBqir2/PhniM9H8ViLR48eoWfPnlBSUkKlSpW+u/QtLb+9+PPhwYMH4DgOI0aMAPDn/Xbt2jVUrVoVcXFxfL9FPsAcx0ldEKk4o0aNgqGhIZSVleHi4oIlS5bwH8SRkZG8tdPR0RE1a9YUuHIcPHgQsrKysLW15WNuvnYB2LhxIziO4zMr/Bu+Dm5OTU3F6NGjYW1tzfv5zps3D/Ly8rxAbdiwIVq0aIG9e/d+t8RvcXEx/P39eTeFZ8+ewczMjF9FE80D0Xz+OzFE4oG0xcXFaNmyJTp37lzm3SNukGH8HKRW/Io/KKKjo7Fnzx5BCUgfHx/o6Ojg9OnTeP36NbKzs9G+fXusXbu2QlQGYvxz3rx5g7p166Jfv36wtLRE+/btMXXqVHz69Infp6SkBLGxsXB3d4eFhUW5vlkVnYCAAMycOVPQdvv2bTg6OvL16r+2uhQVFfEWHEA6PgC+tkTt3bsXly5d4q9nbGysYHm8qKgIjRo1wtKlS8ucKzMzE/Xr10eDBg3KCCwzMzP+mKysLEyePBkyMjJ8OWQR0vCbVERE1zE5ORljx46Fj48P9u/fz2+/f/8+Bg8eDDU1Nd5wURGe0ZcuXUJGRgYWLVqESpUqCQKwJk+ejKpVq/KWPJEozsrKwoYNG/j9pGGc4vP6/PnzcHBwQGxsLO7fv48+ffrAxcUFM2bM4AXwnj17EBAQgKCgIBQWFqKkpASFhYV49eoV2rRpg3Xr1uHFixfYtm0bOI7DqFGjyoi4bdu28S4I/wbR75ebm8u7TqSnp2PKlCmwtLRE48aNoaOjg7NnzyI3Nxfv37/H9evX0alTJ1hbW8PAwEDwfhAnNzcX9vb2OHjwIL58+QIDAwMMGjSI/72WLVsmCND7VpaKb5GdnY29e/eiefPmsLGx4T8ixI0x7Jnz85FK8Ss+EUJCQqCrqwsDAwNYWVnx1VAKCwvh5+cHFRUV1KxZE7Vq1YK5uTn/smeT6demX79+6NmzJwBg5cqVaNmyJczNzTFjxgzBisDNmzdhZmZWbonbikxISAiUlZV5i4b4fF+0aBEMDAzK+KRJe3DbmDFjYGxsDAMDA5iZmcHS0lKw/J2dnY27d++ibdu2sLW1/eZyamJiItq0aYOWLVvyGWBEVQDF0wl9+fIFwcHBUuePWRERzaW7d+/C1NQUI0aMwNatW8vsl5CQAD8/P2hra/NLytI2D8W5f/8+atWqxfuZzp8/HzIyMti0aRPmzp0LTU3NMkJe2u+zffv2YcCAAYLCLZ8+fUJgYCAaNGiAmTNn8gLt68ptFy5cwODBg9GuXTuBJTYqKgocxyEkJOSHWzFFv19iYiIGDx4Mb29v7Nu3D0CpBXjKlCkwNDQUpMoT59mzZ4JUeaJnpXjAc3BwMDp27AhDQ0MMHTpUMP5OnTohPDy83Kpuoo+Cr/sqTnx8PCZOnAg/P78ycQkMySGV4lfEkydP4O7ujvj4eDx58gTLly9H7dq1BdGchw8fxvbt2xEZGclPqP+q7CNDsog/iF+/fg17e3ucPn2av+7jx48Hx3FQVVXFsGHD+BRYv1r+xBEjRkBLS+ubS8fZ2dno1asX5s+fL6hcJ81ERkZCS0sLsbGxePv2LS5evIi2bdtCW1sbycnJAEqDWr28vNCkSZMyASNf8/jxY3h5ecHb2xsDBgyArq4uzp07B0D44snLy/tvB/YbkZiYCF1dXYSGhgquy8KFCzF8+HD+3w8ePICfnx+qVq3K53CVZgICAuDo6MhbHBcsWMAH1Ir8lqX5HhMXZDk5OWjevDmUlJQEgZ3AnwLY1dUV48ePL/fe2r17N5SUlKCurs5/vIiIioqCvLw8Bg0aVCZbxL/te3x8PPT19TFq1ChBcQngTwFsYWEhKEhRXkyD6LgTJ05g/Pjx/IrSjh07UKdOHTg4OPCpy0pKShAaGgpTU1P+GST+Wy5evBj+/v5wc3PDggULBNkjvubdu3f8/830iXQgteJ3/fr1aNGiheBrKSsrC5GRkahduzb8/PzKPY5NrF+TAwcOICgoCAUFBSgpKcHnz5/Ru3dvhISEACgtQ1u1alUMHz4chw4dQuPGjaGioiIIxJDmF9RfZeHCheA4DgkJCXxbcXEx+vTpIxDD8+fPR5MmTfh7R9qsT18zcuTIMsVGUlJS0LJlS7Rv3x5FRUVISUnBqVOn+Hv8f1lPEhMT0aJFCygpKfFL1d9asvwV5oYkycvLQ58+fdC9e3eBT+SMGTOgqKgIjuPQv39/vv3Bgwfw9vaGqakpcnJypPL3F90zL168QMeOHQXVEUVBYaIyvRWBgwcPIjc3F6mpqfD19YWZmRnWrl0r2CcrKws9e/YULPt/TXR0NPT19dG3b98yLg3btm2DpqbmDy3E8ezZMxgbG2PUqFGCdvF3vUgA16lT53+mytu3bx9UVVUxefJkgZ//1KlTUbduXTRs2BABAQHo2LEjtLS0yvUXHjduHHR0dLB8+XJMmjQJlpaWaN68+f8sqiWN8/x3RSrFb3Z2NkJDQ2FsbAxnZ2fBts+fP2P9+vWwsLAo8+XK+HVZvnw5PD09BUtVp0+fhr6+Pnbt2gV9fX307t2b356eno7Y2FhJdfc/IScnB/3790fdunWxcOFCvt3W1hatW7cuU7DD1tYWgwcP/tnd/J+UJ8QDAgJga2tbpn3JkiUwNzcvU9r2r4r5J0+eoGXLlmjVqpWgCA7jx5KVlQVLS0uBP+z169dhb2+Po0eP4siRI6hcuTL69evHb3/8+HGF8MUvLCzEiBEjBMFrQKl7kZycXJlMB9KGeBU3USxAamoqOnXqhMaNGwt8k4HS968o/29JSQnu37+P06dP4+DBg7w1NSoqCtWqVUNAQECZghVZWVk/rN9AaV5lLy+vb5aqF/HmzRtMnz4dVapU+WaqvJs3b0JPTw+bNm0qt88nTpxAQEAA2rZti/Hjx5ebdeTatWuwsLDgq8rGxMRAUVGRPycTuBUDqRC/5U2W1NRUzJo1C5qammX8NT9//oyIiAh0795d6i1ajB9DcXExbG1ty6Si8vPzA8dxCAgI4MXf1/PpV5ojr1+/xogRI+Di4oKZM2fCwcEBbdu2FVQZEllEzp07B09PT0Hpb0nzdXCbyIK9b98+2NraYuPGjQLL4fHjx1G3bt1/5bry+PFjtG7dGl5eXhVimb0i8PU9lpiYiCpVqvC+mCUlJcjMzBRk3Dh06BA4jkNkZORP7ev/4utMMeVt+/TpE4yMjMpkLhDlJS4vbZu0MWTIEHh4ePBWWXEB/LUYFAVj7du3DzVr1oS1tTXs7e1haGjIp+QSCeBhw4YJVqJ+tPjr2rUrmjVrVu428Qwb+fn5ePPmDebMmVMm240IUS7f7Oxs5OXlYevWrWjevDns7Oy+aSj4ejX51KlTsLCwAFDqiqWmpsZnHcrOzsaBAwf+pwWYIXkkLn7FX4YZGRnIzc3l/fBSU1MxY8YMWFpaIjQ0VHCc+FLZryRuGH9y4cIF5Ofn88vb165dQ9OmTXnfTaDUPUZNTY0P7voV58KzZ8+QkJDAv7TS0tIQFBQEIyMj1KhRgxf9Xz+kX758CW9vb0RFRf30PpeH+Etx3LhxsLCwwKZNm5CTk4O8vDx06dIFDRs2xJIlS5CamopXr17xVtt/+0J9/PgxHB0df0japd8d0T2WmpqKp0+fAih96ZuamsLHx+ebxyUkJMDDw4Mv4yoNiM+rHTt24Ny5c2WeIaL7auPGjfDx8SkjrMrLNy1Jvu6/6Pl54MABWFtb4+bNm/y21NRU+Pj4wMLCgo+REBEbGwt1dXWsW7cOQKnVlOM4LFq0iN8nKioKSkpKCAkJ+eHlqEXjaN++PVq3bs23l/csGD16NJ8G8Wt3KPH99+7dCyMjI4wfPx4ODg5o164dBg4ciAULFqB69erfvZaieXvx4kW4ublhx44dUFdXF2SLOX36dJnqcQzpRKLiV/wmnT9/Ppo1awZnZ2f079+fXw579eoVL4AnTJhQ5hxsieHXZOXKlahTp46gLS0tDb6+vggPDxe0N2zYUOBP+CuxcOFCdOjQAV27dhUs27958wbDhw+Ho6OjYInv6xdfYmKiINJZGpg7dy6qVKmCCxcuCCo+5eTkwN/fH3Z2dpCTk4OtrS3q1avHv1T/7YfN/1o2ZfxvRNfg1q1bqFq1qkAszJw5EyoqKpg9e7bgGNEzOiwsDM7Ozj/UH/RHER4eDo7jULduXcTFxZX7XklISICTkxOfxULaszqcOHGC/zgR4erqijZt2gjaXr58ibCwsDLjWbt2Le+m8vTpU1SvXp2vZgf8Of79+/fzJdT/Dd/6/SIiIqCiosK7bABCgfvx40e0a9cOhw8fFhz3LW0wduxYeHt7Izg4mLdif/jwAfb29oI0kAcOHOA/5kaMGAEHBwc+XZqdnV0Zn+/c3Fy0bt0aPj4+UjcXGGWRmPgVn5ihoaGoUqUK1qxZg5UrV6JevXqoX78+v9T56tUrhIeHQ1tbG6tXr5ZUlxk/kcWLF/MPafEH3dGjR6GoqCgoYT1//nyYmJgIghd+BcaOHQsTExNER0fzVaWKi4sFH4ZBQUFwdnYWCA5p+iAUFzqiQMUmTZqUydEr8iUsLCzEixcvsGfPHpw5c+YvB7f9HaTp96lIiF7od+7cgYqKCkaPHi3YnpSUhJYtW6Jq1aqYOHEigNLrlpiYiBEjRkBNTU0qq1hduHAB9vb2WLduHRwcHGBubi4QwOLzZdWqVdDT0/vmsrokEe/n1atXYW1tDTU1NcyfPx+nT58GUOqf6uLiwsdDfG2tFRfAISEh8Pb2xps3b2BkZCQIgtu5cycmTpz4w0Se6DzPnz/H7t27sXTpUj67zx9//AFLS0s4OTnh2LFjZY6dMmUKbGxsBP7jon5evHgRo0ePxqhRo7BmzRp++9c5fydNmgQzMzO8evWKP/7EiRNQUlKCjY0N1NXVcf/+fX7/Bw8ewNzcHA0aNMDGjRuxbt06NG/eHNbW1hUmyPh356eL369ToERHR8Pa2prPlRgdHQ1VVVXUqFFDMBmfP3+OTZs2sWwOvwlhYWHo2LEjAJR5CY0ZMwb+/v58Yvnk5GRBKqVfgSVLlkBXV1fgr1tcXIxmzZrB1taWDzJ59eoVhg8fDmdnZ4SFhUmqu+XSvn17RERECNo+fPiA6tWrY8eOHQCEL9ucnJxyP2DYPS95xPP4KikplZlrovl47949dO3aFfLy8qhRowZq1qwJFxcXWFhYfLeqmySJjY3FhAkTeL/5evXq8QL469yu+fn58Pf3x6xZs374Mv+/QVxoiay96enpWLZsGRo1agRTU1P069cPu3btQo0aNbB48WJ+/299DJ46dQoeHh7Q1tbmV9ZE/8/w4cPRt29fwcrNv+373bt3UaNGDdSrVw8aGhowNzfn/f/37t0LQ0NDmJmZYe7cuUhMTMSBAwcwcOBAaGholPtRtW/fPmhpaaFTp07w9/dH5cqVy8zb7du3IzAwENra2uVmdfD29gbHceW6XSQlJaFFixawtraGq6sr/P39/2cKRob08FPFb6NGjTB58mRBW0xMDB/QduTIEWhra2P58uU4e/YstLS0UK9ePTx79kxwDJtYvyYi6yZQWsSiffv25e535MgReHh4CPYXUdGteiUlJUhPT0fLli0FL6ji4mLUr1+fT6nj6uoqEMC9e/fG1KlTJdTr8tmxYwdv0RW3tNjY2KB79+78v0Uvv9u3b2PatGlS56bBKOXRo0dQU1NDUFCQoF2UYkrkVvLu3TtcunQJ48aNw6hRoxAVFcUbMaSRvLw8vH37lv93SUkJL4CvXLnCP1NEH9tLliyBh4fHNyuG/WzEhe/UqVPRqlUrgYX05cuXiI2NhbOzM7p27QqO46Crq8sHqYnGl5iYiBs3bvDi+e3bt2jXrh2qVauG3bt3Ayg1XoWFhaFKlSo/tHLbnTt3oKSkhAkTJiAtLQ1JSUmoVq0adu3axe97+vRptG/fHoqKilBVVUXNmjXRsmXLct8D169fh5GRER+I9vjxY2hoaJQp7b5gwQJ06dJFYNUVZ/369VixYgW0tLQEzyzxlajPnz8L5gIrYFEx+Kni98aNG3wwm3g6lDdv3iA3NxceHh78C/zLly9wdHSEiooK73dT0YUN49ucOHECurq6fHDFsGHDeGtDeVVxfHx80LhxY/7fv9LcSElJgYqKisCH7ejRoxg0aBC+fPmCY8eOoX379qhXrx7va/d1aWdpYvHixQgKCuKXinfu3AkjIyPBsnleXh68vLzQrl07qes/o5RVq1aB4zgsXLiQd2eZPXs2dHV1+WCpin7txK25IgH8xx9/4N69e3B3d+dF5axZs35YIYcfhSj37NGjR8v1b8/OzsbVq1cRFhYGJSUlPq92UVER9u3bBw0NDZiamkJJSYl3L3z58iXc3d1hZWUFfX19NGnSBEZGRuVaSf8pSUlJUFRU5F1lRLi6umLChAno1asXduzYgY8fP6KoqAiPHz9GTEwMnj59WiYFIlA6Bzdt2sQ/X168eAETExMMHDgQ69evB8dxAguwKDPD99wUjh07Bg0NDYEABkoNMV//34yKwU8Tv+LCJTw8HJ06dRKkwXny5AkMDAz4lDFpaWno2rUrzpw5w3xnfgPi4+MREBAACwsLbNmyBePGjUNoaCgyMzN5368vX74gMzMTQKkfWJMmTbB582YJ9vq/4f79+5CTkyvj3yZesWjr1q2oWrVqmQhtaXz4Llu2DFWqVMGECRPw5s0bfPnyBQsXLkTVqlXh7OwMb29vODs7o27duoK69wzpY8aMGTAyMsKyZcsQFhYGbW3tctN8led/WVEQv88cHR1hamoKLS0ttGzZkm+XtjGdO3cOpqamfMWy3NxcvH79Gvv27SvXNcHW1hZEhG3btuH169ewsLDA2rVrcePGDcyaNQscx/GBxenp6bhw4QLmzJmDI0eOlCmb/m8oLi5GaGgodHV1BStds2fPhoyMDHx9feHs7Aw5OTmMGDHiL6cQ+/TpE65evYqCggK0aNECffr0AVA6L42MjMBxnMBVTlxj7Nq1C3PnzsWkSZOQnp4OoPR6Hz9+nHejuHfvHjw9PeHp6Sl1c4Hx15BIwNv58+f5ij+i5bDs7Gy4urrCw8MD0dHRaNasGZo2bVpuPW3Gr8m9e/cQGBiIunXrQkFBARoaGtDX14eOjg4MDQ1RpUoV6OjoQE1NDYGBgQgNDcW6det+ibmxZcsW/mMwPT0d9erVQ5s2bfigT1HCeZHLz6VLl9CkSRPcvXtXYn0uj5iYGD712qRJk/jAtuXLl8PAwADjx4/H+/fvUVxcjBs3bqB///4IDAzEtGnTWN17KUbc1Wzq1KnQ0tKCkpISvywtLgCmT5+Onj17CvI1Syvizw5xK6JovPfv3wfHcYKKotL4vDl//jxMTEyQkpKChw8fYty4cTA1NYWenh5MTU15A4Lo3rp+/Tr09PSgoKCAiIgIBAYGCsa1bNkycByHWbNm/eduhq9fv0ZwcDCcnZ2xatUqzJ07F7q6ujh+/Dg/r4YNGwY1NTWkpKQIjhUv315eOePnz5/Dzs6OL8WckZGBPn36YMeOHeXGF4wbNw5GRkZo1qwZ3NzcoK+vz8cjlZSU4Pz58zAwMIC5uTmcnJzYx3oF5j8XvzExMfjjjz8AlEavi9IyXbhwAfLy8ujbty9vJTh48CBcXV1Rq1YtNG/e/IelOGJIJ5cvX8axY8cEFs74+HgEBQWhWrVqcHd3x+XLl7Fr1y5s3rwZ+/fvx8GDB/kyo1++fMG7d+8k1f0fRnBwMDiOE1hUpk2bhkqVKmHs2LFl/CVfvHgBW1tbBAQE/Oyufpe0tDTY2NjA2toagYGBUFBQEAQ5RURE8AL4W0UrmD+/9CL+HF64cCGqVKmCuXPnCny0J0+eDI7jfuiy+I+gvOIV4uOZN28epk2bxotEoDSQVldXF61ateLbpPVddOvWLTRq1Ag2NjbQ0tLCgAEDsGHDBjx+/Bi6urrYvn07AGHQsLq6OgIDA8FxHCwtLflVNRHLli1DpUqVMGXKlP/8Q+bNmzcYNmwYzM3NISsryxejEf2/R48ehampKV9x7c6dOwJXr6NHj8LPzw+enp5YsGAB7t27B6DUhUxeXh7h4eH4/Pkzxo8fD3t7e95/G/jzNxF9oIvyIB84cAAcx8HAwECQWz4rKwtXr17l5wL7WK+Y/KfiNy0tDW3atEHdunXh5+cHeXl5QVTm+fPnIS8vD39/f355oaCgAE+fPmUT6xcnNDQUderUQbVq1WBpaSmo237//n0MHz4c5ubmUlOg4b9ixIgR0NLSKteC6+fnBzk5Ofj4+ODcuXO4ffs2tm/fjjp16ghydUqL1aGkpAQ3b96ElpYWFBUV+XRK4i/OZcuWoVq1apgwYQJLBF8BERd/06ZNQ7Vq1XhhMWPGDCgqKgqKKEgS8fuisLAQr1+/xvv378ssnU+fPh2qqqo4deqUoP3hw4eC3PLSKnxFnD9/HitXrsTRo0d5YZieno769evzrimi32TatGm8UWrGjBngOA4bN24sc8758+dDS0uLfz//l6SlpWH48OGwsbERlMkGwFuGMzIyEB0dLYgPuXTpEuTk5DBkyBC0a9cOjRo1Qu3atfmcvQsWLADHcahVqxZ0dHRw69YthIeH48CBA/z509PTMW7cOD6H86FDh6Cmpobly5ejQ4cOMDQ0FOQAFiHtc4Lxbf5zy+/169dhbGwMOTk53mJXUFDAi9oLFy6gUqVK6NOnTxlfIjaxfk0mT54MPT09XLlyBUlJSRg3bhyaNWsmeFnFx8cjMDAQlpaWZWrP/yqMGjUKGhoaAuFbVFQk8H0LCwuDhYUFOI5DpUqV4OzsLIi2l4Z7RPy6XblyBZaWlrCysoKDgwO/lCwKdAVKLSwcx7Gc3RWUrwWwqakpnJ2doayszPucShrxOblx40Z0794dqqqqqFKlCmxtbflqXXfu3IG+vn65+WPFkYb77FuU9/Gbn5+P169fo23btnB2dha4Bxw+fBje3t78+xgoXe6Xl5fnLcTiiJdO/68RWYCdnZ35VeIZM2ZAVVVV8Jzs2bMn6tSpg40bNyIoKAhz587lt/3xxx/o1asX6tSpwwcE37lzB9HR0Xjx4gUeP34MCwsLtGvXTlCk5cKFC3jx4gXu378PMzMzLFu2DEDpijTHcZCRkZG6FQ3GP+c/E7+iG+3Bgwdo3Lgx3N3d4eDgwOctLSoq4t0aLl68CI7jMGPGjP+qOwwpISYmBmZmZoJlpJMnT6Jjx47YsWMH/+UNlPoADxs2DBoaGrzP1q+CKHJeZB0FSu8Je3t7ODk5CYJUnj17hitXriA2NlaQ9k8aXsjiL97hw4ejc+fOePDgAeLi4uDg4AB7e3teAIvve/ToUebiUIERn3uTJk2Crq6u1BSwEJ9n48ePh5mZGcLCwhAVFYV58+bB1dUVCgoK2LBhAz5//vxDA7j+K8q71791/+fl5WH16tXw9PQU+KUWFRXh4MGDUFBQwKJFi3jXABEiAbxz584fP4C/gUgAN2rUCE5OTlBUVOQ/qsSfGb169YK1tXW5BpKrV6+iQYMG3/zAvnr1Kpo0aYI2bdqUCRres2cPXF1deXeeU6dOITg4GDNmzGAr0b8QP1z8llcXvbCwEJcuXYK3tzfs7e0FiftFD6r79++zifUb8OTJE2zevJlfRisuLoa5uTlq164NGxsbmJmZwcLCgp8X8fHxv2RGh7i4OKirq/OBNKI8vq1bt+aXLL93P0iLq4OIly9fwsPDg7eoAaXLsI6OjgILsL+/P79cCTAfX2nhW9dBfJ59/WwX//fPtA7+VUaMGAFNTU3ExcUJUpilpKSgd+/eUFRU5H1LpeFD8luI9+3hw4e4ceMG0tPTv/t8OHbsGFauXCmokPjmzRs4OTlh4cKF3zz/+PHjwXGcoJSwJHjz5g369u2LWrVqlSmOIj5XhwwZAo7j0K9fvzJ5lz08PNC1a1dBm/hvdvPmTTRu3Bht27YVWP4XL14MJSUlpKSk4M2bN2jXrh2GDRtW7jkYFZcfKn7FH5S7du3CunXrBJa8s2fPokOHDnBwcODL03bu3JlfXgDYxPpVEQU4FRQUCHxAO3fujBYtWuDNmzf49OkTHj58CH19/TIPaEC6X1B/lRkzZmDWrFkASgWwhoYGfHx8UL9+fXh5efH5r0X30ufPn3Hjxg2pE7vizJs3Dw0aNICXl5fAN7C4uBgXLlyAk5MTtLW14ebmhurVq7N7XIoRt4KKRMb3ijlI6z0p8mMVD6wUv4eePXsGDw8PmJublwn0kibE+zxhwgSYm5vDxMQEtWrVwvjx4/mCFN9DdB1TUlJgaGgoEHrlPVcmTZr0QwpY/FvevXsnKI8ujrgAHjRoEF/QQtyfu1OnThg6dGi5H3Znz54FUFrd72sBXFhYiIYNG0JWVhY1a9aEtbW1VFXzY/wYfpj4Fb+JRJGkNjY2UFRUhK+vL7/t3Llz8PHxgbq6OhwdHWFsbMwm1i9OdHQ0OI7jAwa+9u0VX+J/8+YNateujcjIyJ/ez59BUFAQzM3N+QwOV69eRfXq1aGsrCxIawaUWtOqV6+O0NBQifX3r3Dy5Eno6OhAW1ubTx8kXpI6OTkZM2fOxOTJk3nhyyy+0sfWrVvLZGp49uwZjI2Ny83lK618+fIFISEh4DiOt+yWJ/JWrVoFTU1NQb55aWX+/PnQ09PD6dOnAQDdu3dHlSpV+KC1v0JCQgKMjIwEIk/EtWvXsGXLlh/b6f+Qrz+g+/Tpg2rVqqFHjx5YunQpQkJCoKKiUsa1o6SkBNeuXQPHcXxVt/IEMFCafjIqKkpgPWf8Ovxwt4d3796hSZMmiI+Px9u3b3HmzBno6OigQ4cO/D4PHjzAxo0bMX36dJbb8xdG9MJJS0tDt27dULlyZd7H9Vvi5/Hjx3B0dMTx48d/Wj9/JkePHkW1atUE47t+/Tq0tbXRtWtXfvk4MzMT1tbWaNGihaS6Wi7fsvRdvHgR6urq8PX1LTepvjhM+EovgYGB0NbWxosXL/D27VtUq1YNgwcPluqVh/L6lp2djaCgIMjJyeHQoUOC/URzWCSCyiuPKy2UlJQgNzcXbdq0wYoVKwCUVhVTV1fn/VkLCgoEAaXfo3nz5rCysirjpjJmzBj06NHjLxeRkCTiluzhw4fzxrPBgweD4zjY2tpi3LhxfPn38mjZsiW6devGp7a7du1auQL46/+T8evwQ8XvnDlz4OHhAV9fX8FNdPnyZejo6KBjx47lvjzZxPo1Ec+ZmZOTg+7du0NFRYUXwOJzoaioCCkpKbC1tUW3bt1+el9/Jq1atYKzs7Og7erVq9DS0kLPnj3x/PlzWFpaCipKScPysngf7t69i7Nnz+LNmze8P++ZM2egqqoKf39/gQCWhr4zvo/4M3js2LGoXLkyqlSpgqCgIKl+PosL34sXLyIqKgrHjx/nxWBgYOA3BfDixYvRsmVLviiLNFJYWIjCwkI4OTnh0aNHOH/+PFRVVXnhm5eXh+XLl+PGjRvYsWMHb838GtE9mJycDFtbW9SuXRs7d+7Ezp07ERwcDDU1Nan+CPiap0+fQl9fH3369BGsHPfo0QONGjX6ZtyEaN/Vq1fD2dlZ4OZz7do1eHh4wMXFhXfLZPy6/FC3hy1btkBHRwd16tQpU/nk8uXLqFq1Kpo0acKsvL8BK1euRKdOndCsWTO+TGZeXh58fX0FAhgAPnz4gM2bN8PW1lawQiDN1qZ/gmjeHzlyBHXq1OGtv+KWKB0dHXAch9atW/PHSYN4FL8W48aNg7GxMbS1tVGtWjX4+vryaYjOnDkDNTU19O3bt0JYkRh/IhKMubm5UFVVhaKiIq5fvy7hXn0b8TkZGhqKmjVrQl1dHTo6OujSpQtycnJQVFRUxgIMlMYgODk5YerUqZLo+jcRz5G8bNkyPitOx44dYWFhAVVVVWzatInf582bN2jcuDGWL18OGRkZNGnSpNzKZeKkp6fD29sblpaWqFmzJtzd3aUmU4c4ouubkpKC5ORk/hnz5csXNG7cGH369OH3Ef9Ae/XqVRlf6MuXLwus41lZWahWrRpCQkIE+126dKlMtTvGr8k/Fr/llR3Oz8/Hvn37oKKigqFDh5Y55uzZs2jdujWbWL84I0eOhK6uLoYNGwYHBwfo6+tjyJAhAEr9WP38/AQCOD09HZs2bcKSJUv4c/wKc2T37t3lLqFlZGTAysoKffv25dtED/ErV65g9OjRfLu0/Q7Lly+Hjo4OTp06hdevX2Pt2rVo1aoVmjZtyludROXLZ86cKeHeMv4qonn25MkTVKtWDaNGjcLQoUOhoaEh9blNR4wYAV1dXZw8eRIPHjzA5MmTYWBggOnTpwMovd+Cg4MhJyfH+y5bWlrC29ubP4c0fGg/ePAAtWrVQkhICEJCQiAnJ8cHnsXGxqJ+/fqoX78+v//Hjx/RqlUruLq6oqioCM+ePYO+vj6aNWv23SV/Ea9fv8bbt2+/G9AoKUTX48CBA7CysoKVlRWqVKmCgQMH4u7du7h69WqZayYSwAEBAfDy8uLn7alTp2BqagozMzNERUXxfsDr16+Hq6srHjx4wJePF0fanr2MH8s/Er87d+5E3759kZiYWMa/r6CgALt27YKSkpIgGf/XsIn1azJu3DhoamryZSjz8vIwcOBA6Ovr8w/kd+/ewc/PD2pqarh8+TK/n4hfYW6kpaWhbt26kJWVRY8ePcrkoYyKioK2trYgNdjXSNvvUFBQAF9fX4wcOVLQfuTIEbi6umLy5Ml8261bt9gKTwXj7du3qFGjBgYOHMi3iUpvS6NlEACWLl0KjuMEFtOcnBzUq1dPkObq06dPGDlyJOTk5KCmpgZPT09+m7TcZ5mZmVi2bBm0tLSgpqYmyLiQk5ODNWvWwMzMDDVr1kSzZs3QoEED2NvbIz8/H/n5+SgqKkJycjI0NTXRrVu3/+kCIe2cPn0aKioqWLt2LTIzM7F3715wHIfo6OjvHhcTEwNTU1P07NkTCQkJKCgowMOHDxEQEABHR0fUqlUL8+fPx5YtW2BmZsavCFSU34XxY/jb4vfTp0+oWbMmdHV1UbduXfTv31+wDAOUChmRAA4ODv5RfWVIOSdPnoSioiICAwMF7ZcuXYK2trbAgvT+/Xv06tULHMfxVXh+NbKysnDy5Em4ubnB2NgYdevWxcaNG5GcnIysrCzUq1ePL+MpjX6VSUlJiIuLE7xEfX19y+TOBEqzWFhYWJQZBxPAFYfk5GRERESgpKREIATGjBnDf8xKEwUFBRgxYgRsbGwwY8YMQYxB69at4efnJ/AH/fjxI4KDg9GzZ0++TVoEj8jquHfvXlSuXBmmpqaCFSCg9L2amJiICRMmYPLkyVizZg1fua2wsBBRUVGYNGkS6tevz7tOSeN1+6uEhoby75InT56gVq1agg+z8hBd78uXL8PU1BR+fn6CPMHx8fHYuHEjatWqhW7duvEBcm/fvv3PxsGQTv62+C0qKkJoaChWr16NmzdvYv78+dDQ0ECPHj0QHh4ueNjs3LkTHMdh0aJFP7TTDOkkNTUVQ4cOhZubG+/nCwCjR49G9erV8eHDB8H+aWlpv0WJ24yMDNy5cwedO3eGpaUlqlatiq1bt6J169YwNjbGu3fvJN3FMmzbtg0uLi5wdXXF9u3bkZ+fDwCYOnUqjI2NyySe37JlC1xdXfk8xYyKRXnL/hXhw+XTp08ICwuDk5MTwsLCAABLliyBsrIynjx5AkA4NnE/dGkQvuIpAYHS1HIPHjxAREQErKysMHz48P95jqKiIpw5cwaKiopYvXo1YmJisHfvXmhra6NFixYVUgCXlJSgRYsWmDlzJvLy8mBoaIhBgwbxv9PSpUtx+PBhwTHi1/PBgwd8IF/37t0FKwNAaT7ro0ePomvXrtDR0SkTf8H49flHbg/Hjh2Dmpoa74Cem5uLSZMmgeM42NvbY+7cubxfzZkzZyrEQ5TxYxCvzb5q1SrMmzePr7IEfPvh8rs8dK5du4apU6fCyMgItWrVAsdx2L17t6S7JWDTpk1QU1PDrl27kJycXGa7i4sL6tSpg4sXLyItLQ1ZWVnw8PBAp06dJNBbxj/hV7jfRGP49OkTxo8fj4YNG6JRo0bQ1NTk3an+SuU6SSF+Dd69e4ecnBy+ANDbt28xb948WFlZCdyMxo0bV26+9LCwMDRt2lRw/sTERGhpaaFNmzZSUbTi77J69Wo0btwYurq6GDJkCP97FRUVoU+fPggODkZ+fn6ZaxkSEgJjY2OMGjUKPXr0gLy8PLp06VLmg11EmzZtBJl1GL8H/zjgbejQoYKgNktLS3To0AGjR49GixYtwHGcwB2CCeDfB5EANjc3h5ycHJ9o/ncuZvL1A/r+/fvYunUrxo8fL6Eelc+NGzdQo0aNMhb54uJiXkjk5eWhSZMmMDY2hqGhIerVqwcbG5syGV4Y0oHoerx//x7v3r0TuAdUdMQFcGhoKKpXry5IlSitIl+8X3PmzEGTJk1gb28PPz8/JCUlASgVwPPnz4eFhQVatGiBVq1awdDQUCDoRdc2MDAQrq6ufLvoGm/evBkcx6FFixZS614mGkNqaipvrQdKK2C6uLjA2tqad5nLyclBWFgYqlWrhsePH5f5uImLi4Ouri7/gQCU+g7r6Oigc+fOvMEO+DPOJDo6Gk5OToLqlIxfn38sfiMjI+Hq6oqMjAzY29vD1dWVjxp99eoVdu7cyQTvb0xaWhqGDx8OGxsb3q8VkE7fVmlA0i9p0QsoMjISzs7OSE1NLXc/8et34sQJREZGYuvWrawKkpQiHjVva2uLWrVqwdDQEAsXLizXql8REd07WVlZCA0NRYMGDTBhwgR+Tkrbx9jXFltdXV1s2rQJGzZsQIMGDWBhYcEHB6enp2PXrl3o1q2bIKft18/RkydPolKlSti6daugfd++ffDw8ICpqakgp620sW/fPtSoUQNGRkZwcnLiVwr37t0LJycnmJmZoXnz5mjRogX09PRw69YtDBw4EDt37hSc58aNGzAyMuIDNEW/04kTJyAjI4O+ffuWyeE7aNAgmJqaSmXWC8Z/x7/K8+vo6AiO4+Du7l7Gn1MEexn+vogswC4uLpgzZ46ku8P4DqIX8uDBg9GgQQNB29ekpKQgISGhTDv7sJFOTp8+DQUFBcybNw9Hjx7FpEmTUKtWLQQFBSElJUXS3fshfG0BdnZ2RmBgoFQJ3699+48ePQobGxte6B05cgSqqqowNzeHkZERn69X/MNYFNyWkJCAQ4cOITo6mr+Gw4cPR82aNfkyxYWFhQgNDUV4eDjvsy9NiK5NfHw8jI2NMWfOHBw/fhyurq4wNTXF0aNHAZTmPl61ahUGDBiAZcuWISkpCdnZ2QgLCyuz2nT79m2oqalh3759AMC7RWRlZcHU1BQcx2HGjBl8HwoLCxEQEICrV6/+zKEzpIB/JH5FE23r1q2wtrbGjRs3BO0Mhog3b94gKCgIpqamOHLkiKS7w/gfTJs2DVpaWvyL+muLdGFhIXr37o1ly5ZJonuMv4Eod2n//v3h5+cn2BYZGQkTExMsX74cgORXHn4E4gJ46NChUlXAonv37mjWrBmePXvGt124cAFjxowBUCqEdXR0sGLFCly5cgV6enqoU6dOmY/MkpIS7N27F9WrV4e9vT0aN24MHR0dXL9+Hc+ePcOoUaNQqVIl2NnZoX79+lBXV/+mr6s0cP36dWzZsgXjxo0TtHt5efHvjK8NaF/P1Q0bNmDevHm8wB85ciSUlZX5jwqgNI3c4MGDcejQIfaRzgDwLy2/r169gr6+PmbPnv2j+sP4BXn16hVvjWBIJ6IP17Nnz6Jq1aoYOHAgvwwo7qv96dMntGvXDjt27JBIPxl/n+7du/PiV9wCOHr0aJiamkqtL/7XIufrFGzfO0bcr1kajDJXr16FqqoqunXrJrC2v337Fvn5+WjRogWfJzsvLw9ubm7Q1NQUFOIASgNmNTQ0eJ/8y5cvg+M4/tjPnz/j8uXLmDRpEubPny+1mR5E18TCwgIcx8Hb27vMdfLy8oKFhQWioqK+abnOz8+Ht7c3HBwcsHz5chQWFiIjIwM9evSArKwspk2bhsWLF6NZs2ZwdnYutyIc4/fkX5c3joiIgLa29jcTajMY4kjDi4jxbQoLC+Hv748qVaogODhYUMTm1atXaNu2Ldzc3NjLowIRFhaGKlWq4OPHjwD+/JjZsmUL7O3tkZ2dLcnufZfU1FTExsaWeW6IB0Z9jfi+0vC8Ef3et27dgrKyMnx8fATld589ewYDAwMcOHAAQGlgYteuXXHq1KkyYn/jxo3o3r07f5yRkZEg8Fwa0yaWh+i6FBYWonHjxtDT08Ply5fLjNfFxQUODg58irryPn4+fvyI3r17w9nZGStWrEBRUREKCgowZ84c2NrawsnJCW3btmUBuQwB/1r8PnnyBL179/4lls0YjN8Z0T2cl5eHLl26QEdHB3Xq1MHUqVPh7+8PNzc31KtX75tBNwzJInqpp6SkICkpCRkZGQCA7Oxs1K9fH7a2tnwbUFqYpFGjRmWqdEoLJSUl6NevH1q3bo1z587x7VOmTIGhoSHev38vuc79Rb4WWjdv3oSysjK6dOnCu0CILL8NGjTArl270LRpU7i7u/P3o/i7dd68eWjbti2SkpJgZGSEQYMG8duPHTuG8ePHC3IZSxPfEp0FBQWwtraGtbU1/vjjjzL7iQL1xH+H+Ph4vjwzUCqAe/bsyQtg0TPqw4cPyMvLE4htBgP4AeIXAFtKYDB+EUT3cEFBASIjI9GpUyfUqVMHbdu2xcyZM/mXB3uJSCd79+6FiYkJtLS00LFjRz4a/vbt23B0dISOjg7atGmD1q1bQ01NTWrLFotIT09H9+7d0b17dzx48ACzZs1ClSpVyhQ4kHamT5/OX4vr16+XEcDHjx9H8+bNUbt2bXh6eqKgoIB383j16hWfluv48eNwdnaGnp4e+vfvD+BP3+5hw4bB399fKsWvSCOcP38eM2bMQP/+/REXF8cHyhcUFMDKygrW1ta4fv36d62z48ePh6GhIapVq4Zu3brxac1EAtjFxQXLli0r4yrBDHQMcX6I+GUwGL8OX3/Efp0CiH3kSicvX76ElZUV1q1bh6ioKHTs2BENGzZEZGQkgFKBMXPmTAwbNgxjxozh02lJK6J5lpmZCX9/f9ja2kJdXR0nTpwAULGWr3v37s2nBgX+dIHo3Lkz3rx5A6BUnL18+ZIXs4WFhTh06BDq1q2LvXv38uKtW7dukJeXx969e/Hx40e8f/8e48ePh66urlS7H+7fvx8aGhpo3749WrVqBW1tbcybN4/3gS4oKICtrS0MDQ35vL6A8DqfO3cOZmZmOHfuHJYuXYpOnTrBzs4OZ8+eBfCnC0StWrWwd+/enzo+RsWCiV8G4zdA3OrxLQvI12KCrehIP+LXLC0tDT169OCDvZKSktC3b1++2mJFo7i4mB/f5MmTUalSJTRp0gRxcXFlygJLO/v374e1tbUg88KtW7egoqKCrl27lvFhLi4uxsGDB6GiooL58+eXKVDRsmVLmJmZQUtLC+7u7jA2NhYIRmnj6tWrMDQ0xIYNGwCUjk9eXh5Vq1bFlClT8OLFCwClLiAuLi58Duqvn1UxMTEYO3Ys/++LFy+iS5cusLW15QVwRkYGpk2bxp5bjO/CAQAxGIxfnvz8fMrJySFNTU0qKioiWVlZ4jiO0tPTSUdHR9LdY/xNABDHcXTixAnasmULKSoqUmpqKp04cYLfJykpiWbPnk1PnjyhDh06UEhIiAR7/M+YOXMmRURE0KpVq2jv3r0kIyNDgwcPJjc3N5KRkZF09wSIrgkRUXFxMcnKyvLbXFxcyMDAgPbt28e33b17l+zt7WnChAk0Y8YMvv39+/fUsmVL6tGjB40ZM4YKCwupqKiITp48SU5OTqSvr09xcXEUHx9PpqamZGFhQdWqVft5A/0bAKCoqCi6desWzZkzh1JSUsjDw4O8vb1JW1ubpk2bRtOnT6du3bpRrVq1yj3HokWLKCEhgT5+/EiGhoa0bNkyftvly5cpIiKCkpOTKTw8nLy8vPhtX18DBoNHotKbwWD8FIqLixEWFgYPDw8+SAQotUh17979mxXdGNLNmTNnICMjg86dO8Pa2hpycnIIDw8X7JOUlAQfHx+0bNkSmZmZkunoP2T//v3Q0tLiCx58+PABXbt2RcuWLaUqjdeaNWsE6dXWrFmDhQsX8i4NQGkuX3t7e1y7dg3An1kgHj9+XMaH/sWLFzA3N8fZs2eRlpaG6dOnw93dHXJycnB0dMShQ4d+wqj+OSKLvMhX+enTp3jw4AFyc3Ph6emJ/v3781ZdIyMjqKmpYe7cuSgsLCyT0m7q1KnQ1tZGhw4dYGNjAzk5OVy8eFHw/12+fBnNmjWDv7+/4P9nML4FE78Mxm/CmTNn0KtXL3Tq1AlAaeWvSpUq8TlDGRWLJ0+eICoqii84kpKSgnHjxsHCwgJz584V7JucnFwhP3CuXLlSplTt+/fv+eIc0sDNmzfBcRwCAwORk5MDAOjYsSNcXFygqamJRYsWIS4uDoWFhbCwsMCsWbMAlAo08aX5rwWws7MzTExMoKuri44dO2LJkiV4/vw5rK2tERYW9vMG+A85ffo0WrduLWh7/vw5bGxs+IDFN2/eoFevXggLC0NSUlKZc6SkpGD69Om4fPkyACAhIQG+vr7Q1tYuI4Dv3r3LgtoYfxk5SVueGQzGz6FJkyYkJydH27ZtIxcXF7p37x5t3LiRevToIemuMf4mz58/J0dHRyIimj9/PhERmZiY0JAhQ4jjONqwYQPJysrSqFGjiIjI1NRUYn0VB2JuAX+l3cXFhf+7rKwsFRcXk46ODgUGBn73uJ9JvXr16OjRo+Tj40OFhYW0Zs0a2r9/P2VlZdHq1avp2LFjtGDBAurXrx81aNCAli1bRl26dKFatWqRrKwsP4YvX76QjIwMycjIkKqqKsXFxdHixYtJQ0ODOnfuTCoqKiQnJ0dWVlb8cUQk8fF/i3fv3tHbt2+JiKikpIRkZGQoIyOD3r9/T2/evKGnT5/S1q1b6cmTJ7R69WpSVlYWXM/Dhw+Tt7c3GRkZUYsWLYiIyMrKiiZPnkwyMjLUuXNnOnDgALm6uhIRkY2NjeD/YjC+iySVN4PB+DmIW5hmzpwJeXl52Nvb84UPmMWkYvHu3TvMnTsXurq6CAwMFGx7/vw5Jk6ciCpVqmDp0qUS6mFZxJei7969i9u3byM+Pp5vq4hzULzPx44dg5ycHMaPH89bgIHS4jBnzpyBi4sL7OzswHEcNm3aBOBPa+/hw4fh6emJGjVqoG/fvuVWUPz8+TPCwsKgpaUlVS4fIr52NTh37hxUVVUFBT2A0vzSqqqqqFmzJqpUqYKbN2+WOVdRUREKCwsRFBQEWVlZ7N69W7D90aNH6N27NziOw927d3/8YBi/PEz8Mhi/AaIX0+HDh6GqqooxY8agV69e6Ny5M18VivnJSS/lXZtPnz5h3rx5UFRUxJQpUwTbRMvF36uE9jMR7//kyZNhbW0NDQ0NWFlZVVi3G/ExTZ8+HWPHjoWmpiY4jsPw4cPLVM7Lzs5GQkICunbtilq1avF5aKOjo6GkpITw8HBs374dPXv2hImJCdatW8cfGx0djdatW8PExESqszpcu3YN58+fx+vXrxEbGwtnZ+dyU+qdOHECx48f5/McixMZGYmWLVuipKQEHz58wMCBA6GgoIAzZ84I9rt37x7L6sD4xzDxy2D8JkRHR4PjOD7d0KVLl9CrVy80adKkwgVC/U6IRNaZM2cwbdo0dOrUCQcPHsSLFy9QUlKCBQsWQENDA1OnThUcJ42FSEaMGAEtLS3ExMRg//79cHd3h5GRkVTnp/1fhIeHQ1tbGydOnMCRI0ewaNEiKCgoYOjQobwFWFwoP3v2DJaWloiJiUFSUhLs7e35D4CPHz+iatWqsLGxQc2aNbF+/XoAwNu3b7F48eJy/WKlhczMTNSqVQs1a9aElpYW7O3twXEc2rRpgx07duDixYt4+vTpd4twFBcXY+XKlahfvz4fmPvu3TsMGDAACgoKfDqzr5HGuc6Qbpj4ZTB+E06dOsULXxGnT5/GtGnTKuSS8+/E/v37oaqqiiFDhqBnz56wtbVFmzZt8PHjR6Snp2PhwoXQ0dHBmDFjJN3VbzJz5kxwHCew9s2ZMwccxyEuLq7M/tK4EhEfHy/oV2FhIVq1aoUJEyYI9tu7dy/k5eUxatSoMuWji4qKYGpqip07d+LDhw8IDg5GamoqXr58CTMzMwwZMgQPHz5EgwYNoK+vL1XBff+LzMxMZGdn4/z58zhz5gx0dXUhIyODZs2aQVVVFXp6enBzc+Ot4uVd4w8fPkBPT0/wm6anp2PAgAFQUVHBsWPHftp4GL8uTPwyGL8h5b10mACWTp4+fQpLS0usXbsWAJCVlQVlZWWEhoby+2RlZWHGjBkwNjbG+/fvpUo4lpSU4Pnz53Bzc0P9+vVx7tw5AKXzzcHBAbKysggKCsLSpUsRFRXFbxMdKy0MGDAAbdu2FbTl5OTAysoKI0aM4NuKiopQUlKCvn37guM49O/fX1Bq9/Dhw5CRkUFiYiKA0msHlFrFu3btyldUDAgIgLGxMVxcXPDhwwep+i2+Tkf2rb6NHTuW/22Sk5ORkJDwl1xx1qxZA2dnZ4Fvc0ZGBnx8fNCkSZN/2XsGA2AhkQxGBaekpKRMG/5H7ZryIsRZhLR0kpeXRzIyMtSrVy9KSkoiKysr6tmzJ82aNYuIiK5evUqVKlWioKAgunXrFuno6Eg8A4D4/OM4jqpXr04zZsyg6tWr06xZs+jIkSPUsGFDUlNTo7Vr15KdnR1dvnyZhg4dSg0aNKCmTZvSx48fJT4OcdatW0f79+8nIqJXr15RUVERKSkpkb+/Px04cIAuXrxIRMQXjzE2NiZPT09KSUkhOTk5/j6VlZWlc+fOkZmZGRERqampEQC6d+8eqaurk7q6Or/fiBEj6MiRI6SlpSXx30LU/8LCQuI4jmRkZOjs2bM0fvx46tSpEx07doxev34tOEZdXZ1OnjxJJSUlZGpqSlZWVlSzZk3BPuHh4dSlSxfauXMn39agQQN68+YNxcfH822ampq0YcMGOnPmzH84SsbvAnvbMRgVGPG0PikpKfTx40fKzc0ljuOouLhYwr1j/FPExWNWVhbJycnRixcvyNPTkzw9PWn16tVERHTjxg3auHEjPX36lCpXrkxaWlqS6jIPxNJVDRgwgE+l16RJEwoODuYFY15eHp09e5b69etH/fr1o507d1JCQgK1adOGXF1dSUNDQ4KjECK6l+Tl5WnDhg1kY2NDcXFxRETk5eVF9vb2NGPGDF4Af/78mW7cuEFGRka0evVqkpGRIQC0f/9+Gjp0KPXs2ZPMzMwoPDycnj59ShzHkb29PcXHx9P8+fNp5MiRFBUVRR07dpSKayp6zty/f5//6Dpw4AB16NCB0tLSSF5enkJCQmjevHn0+PFj/rh69epRQUGB4AP96w/zevXqUVZWFs2bN4/s7Oxo9+7dZGZmRkOHDqVJkyZRZmYmv6+amhrJyMiU+8HPYPwtJGh1ZjAYP4hJkyahZs2asLKygr+/P169egUALBK6AiFaLi8PR0dHcByHoUOHCtrHjh2Lhg0bCqr2SRLx/o8cORJaWlplUllduHABbdu2RePGjXHixAm+XVTx7K8sp0uaevXqwdzcnPdVPnv2LHx8fKCiogIHBwfUrl0blpaWMDY2hqWlJVJSUhAfHw9tbW3MmTMH58+fx6hRo+Do6Ig+ffogLS0NCQkJ6NOnD2rXrg0HBwepyeoguh537twBx3FYtGgR7t69C2NjY0RGRgIoreSmrKwMY2NjDBo0iA/Mu3HjBqpXr460tDQAZZ9HIneQz58/IykpCf369UPDhg1hYmKC3r17w8zMDDExMYJ+MBg/AiZ+GYwKiLgoOHDgAPT09LB3715MmjQJzZs3R/369fH8+XMATABLO19H8IuE0eLFi3Hp0iUAwK1bt1C3bl04OTnh5s2bOHbsGEaNGgV1dXWpyXMqPidHjBiBypUrC/omPg8vXLgAb29veHh4CAKYpE3sfk9wOTo6wtTUlBfAb9++xdGjRzF58mQsXrwYhYWFSEtLg4ODA+rXr4/du3dj5MiRgnOsWbMG9vb2WLBgAYDSbA+fPn1CRkbGfzeov4Fo/Pfv34eSkhKfUi8mJob35X369ClMTEwwdOhQLF26FIqKihgyZAgSEhJQXFyM9+/fl8lLPH/+fHTt2hWdOnVCbGysYFtiYiLWrFkDKysrcBwHb2/v/3ycjN8PJn4ZjApMVFQUZs6cKcgJeurUKTRr1gz16tVjAljK2bt3L+zs7HDw4EEApYUSKlWqhBYtWsDIyAiNGzfG5s2bAQBxcXFwdnaGvr4+6tSpg8aNG/Olf6WJsWPHQktLSyDqi4uL0axZM764A1AqgDt27IimTZti//79kujqdxEX4tu3b8eUKVNw/PhxflUFABwcHGBqaoorV66Um26rsLAQb9++Rb169cBxHJo3b85buEUEBgbC3Nz8vxvIP0QkfO/duwcdHR1YWFjw2968eYOkpCQUFBSgffv26Nu3L/+MsbKygq6uLkJCQlBYWIjFixeD4zi+RPGUKVOgq6uLAQMGwMPDAzIyMmWKWABAWloaduzYgdq1a+PkyZM/YcSM3wkmfhmMCsq9e/dgZ2cHFRUVPh+oiNOnT6N58+ZwdHQsU2GJIT2cO3cO7dq1g4eHB/bs2YPQ0FA+5+vt27cxYMAA2NnZCUTj7du3kZaWJpW5mR88eAB9fX14eHjwbXl5eahXrx48PT3L5Hi9cOEC3NzcMHv27J/d1b/MpEmTULlyZTg5OUFdXR0BAQG4du0av93R0RHm5uY4c+bMNy3XaWlpaNasGapUqYIbN24Ith04cADm5uZ8sRlpQNzVQVlZGU2aNIGBgQGGDx8u2O/t27eoW7cudu7cCaA0TVmPHj0wdepUPqVdcnIyAgICoKqqitjYWEyZMoVf0cjJycG4ceMgJyeHXbt2ASj96BD9jmlpabCzs0NERMRPGTfj94GJXwajgvD1i7WwsBBbtmxB3bp1Ub9+/TJLpWfOnIGtrS369u37M7vJ+JtcuXIFnTp1QsuWLeHk5CQQVvfv38fAgQNhb28vsO5LK1++fMHOnTtRo0YN9OrVCwDg7OwMT09PPqXX164EDx48+On9/B7iadaysrLQoUMHXLlyBQCwY8cO1K9fH71798bVq1f5Y4yNjdG1a9fvnu/t27ewtbWFlZUVrl27xue6HTp0KOrWrcv/PtLC9evXIS8vj6lTp6KoqAhr1qyBjo6OQAA/evQIdevWxbRp03Dnzh1MmTIF9evX58umb9u2DVOnTsWLFy/Qs2dPKCgooGbNmoI5XlBQgHHjxkFeXr5cC3CrVq0QEBAgEMUMxr+FiV8GowIgLhjy8/ORnp4OoPQFvW/fPjg4OKBt27ZlBPCNGzdYoIiUIn5dLl26BG9vbygoKPBuDiIePHiAIUOGoEaNGti6devP7ubfJicnB7t370b16tVRqVIltGnTpkze3vT0dPTu3Vsg+KRB2Ihfk8ePHyMlJQX+/v78/QYAu3btQv369eHv7y8QceW5FolcIUS5e9+9e4f69etDS0sLrq6uGDx4MKpWrSo1wW3iXLhwQSB0P378WK4ADgsLg4mJCapXrw4DAwM+wHHNmjXgOI4Panz79i2CgoLAcRzv5iP6vQsLCxEWFgaO43D69Gn+3CdPnoSRkRHi4+P/8/Eyfi+Y+GUwpBzxF/Ls2bPRpk0bGBoaIjg4GBcvXgQA7Ny5Ew0bNkTbtm3LXQ5nPr/ShUjo3b17F8nJyQBKP1Tatm0LJycnHDp0SLB/fHw8RowYUWFcWHJycrBr1y7UqVMHHTp0EGzLyMiAtbU1HB0dJdS7/82YMWNgZGQEFRUV6Ojo4MKFC4Ltu3fvhrOzM9q1aycozSx+n4n+npKSAmVlZd5vNS0tDV5eXrwwfPny5U8Y0b9DNF8/ffrEC+DAwEB++8WLFxEbG4sXL14AALZs2QJ5eXkcPXpUcJ60tDT4+/tDWVmZD3QTnbugoACrVq0S+E5nZGQIfKwZjB8FE78MRgVhwoQJ0NPTw9q1axETEwM9PT00bdoU7969Q1FREbZv3w43Nzc0aNBA6pZQGX8ietnv378fBgYGmDlzJu/vGRsbi44dO8Ld3R3R0dGC48SrhFUEsrOzsXv3bhgZGaFLly4ASgVOnTp14Onpye8nDRZf8T5cvnwZxsbGOHbsGBYtWgQnJyc0a9aMD9gSsXHjRvTr1w/FxcXfHMPz58+hr6+PgQMHCj5iU1NT0bhxY0Gp54qCuAD+2gcYKP1dOI5DixYt+DZxQfvu3Tv4+flBRUWljAAW318a5gXj14WJXwajAvDgwQNYW1vzpWGvXr2KSpUqYcOGDfw+JSUliIyMxODBg5mrg5Rz+vRpqKioIDIyEm/evBFsu3z5Mjp27IjmzZtj7969Eurhj0HkAmFiYoIOHTrAxsYGLVu25LdL2zzduHEjAgMDER4ezrcdOXIEXl5e8PT0LJOWC/iz1O+NGzewfv16xMXF8asvI0eORHBwcLlCriKvxnz69Anr1q0Dx3EYN24c37527VrIyMhgwIABZQLkxAXw+/fv0atXL6irq/PPNAbjZ8LEL4NRAXj48CHs7OwAlKbHUlVVxapVqwCUBhkdOHAAeXl5AjEhbcKC8SdDhgyBv7+/oE1cHFy9ehVNmzZF27Zty2RIqGiIBLC2tjbatGnDt0vD/BTvw7t379CqVSuoqakhJCREsN+RI0fQqlUrtG7dGmfPni1znkOHDkFZWRmWlpZQUlJCcHAwnj59WuGs9X+Hjx8/YtOmTUhMTAQAPqWZKG/z6tWry1iHvxbAbdq0QbNmzX5uxxkMMPHLYEgd5QnYR48eoWrVqpg+fTo0NDSwYsUKfp+4uDh4eXnhjz/++Ol9Zfx9CgsL4eLigqCgIABll3xfv34NoFQAS7M/6N8Rr1++fBFkR5AG4SvO0aNHkZeXh6tXr6Jjx47Q0tIqI3KPHj0KBwcHgTAuLi5GXl4eunXrhnXr1qGkpATr16+Hvb09evfujdu3b/P7/orL+OJjOn/+PJ/yDPh2gJy4AP748aPUzQXG7wETvwyGFCH+Mtm4cSO2bNmC3NxcAEBISAjk5OT4ykpAaQ7Vtm3bol27duwlImV8T+wEBQXBwcGBF7qifVNSUjBx4kQ+cEiaEPVRPKBSvGCDKHXX/0La5um1a9dgYmLCZym4fPkyfHx8YGtri/Pnzwv2vXLlisDHNz09Hfn5+QgMDBQEvm3fvp3PCCGNhUj+S8Tn/bf8g78u9CFtc4Lx6yNDDAZDKigpKSGO44iI6OXLlzRjxgxasWIFHTt2jEpKSmjQoEHUsWNH2rp1K82cOZMmT55M7dq1o5SUFNq3bx/JyMhQSUmJhEfBEMFxHBUXF5e7rXHjxlRcXEwLFy6k1NRU/rpv2LCBdu/eTbKysj+zq38JjuMoMzOTgoODaf78+UREJC8vT0REERERtGnTJiosLPyf55GRka7XjoODA6mrq9OiRYuIiMjV1ZWCg4PJ3NycgoOD6eLFi/y+Li4uJCMjQwBo//795O7uTmZmZnTgwAFKS0vj9+vRoweNGjWKHj16RNOnT6d79+799HFJCtFcJiJSV1en7t27U3h4OO3cuZNGjhxJRH/OGxHSNicYvz5yku4Ag8EoRfQCGDVqFL148YL09PQoKSmJQkJCSEZGhjp06EBz5syh7du3086dO8nU1JQsLCzo2LFjJCcnR0VFRSQnx25pSbN+/Xo6evQo7du3j2RlZam4uLiMmPXx8aEnT55QdHQ0tWzZkuzs7CgzM5NiY2Pp/PnzZGBgIKHefx8AVKNGDbp27RqtWLGCAgMDadGiRTR+/Hg6efJkGVEjbZSUlPDileM4KiwsJHl5eZo1axaFhobSlStXqGHDhuTm5kYyMjK0bNky6tatGx0/fpzs7Oz441JSUmjQoEE0evRo+vLlC0VHR9O0adNISUmJXFxciIjI19eX8vLyaMuWLaStrS3hkUsOkQDmOI4GDx5MJiYmFBwcLOluMX5zOACQdCcYDEYpGzdupFGjRtG5c+dIX1+fFBQUqG3btpSenk5z5syhNm3akJycHH358oVUVVX548oTWIyfT1FREW8FdXBwoPXr1/MWYNH1EQkwIqKYmBiKi4uj27dvk7m5OfXr14/q1KkjySH8T96+fUubN2+mO3fuUHZ2Nl2+fJm3glYULl++TG5ubvy/k5KSqGPHjtSvXz8KCQnh28+dO0fnzp2jKVOm8Nfv2rVrdPbsWcrKyqLZs2cTEdGRI0doxYoVREQ0ZcoUatCgAX+OrKwsUldX/xnDkmo+fvxIFy5coLZt27JnFUPySNLngsFgCJk8eTLc3d1RWFjIp0IqKCiAo6MjatasiT179iAvL09wzK8YSFOR+fz5M1avXg1nZ2f4+fnx10c8tVVF9XEUD1by8vJCpUqVBMUOKsK4YmNjISsri8aNG2PRokV4//49gNKKZHp6enj48GG5xxUVFeHDhw/o2rUrVFRU0KNHD8H26OhoeHp6ol27dnzxGUb5iM8jBkMSMEcbBkMKEPnq5ufnU2ZmJsnJyZGsrCzl5uaSvLw8zZs3j54/f04RERF04cIFwbHiPnYMyQGAioqKSFVVlVxcXMjT05OOHj1Kw4YNIwC8CwRRxfVxFLnVLF26lK5evUq9evWitLQ03uopcimQJr72g7exsaHk5GSqXbs2HTp0iCwsLCgiIoKUlJTIw8ODrly5QkTE+y+LxiMrK0taWlo0YMAA8vLyoiNHjtDly5f587Zr146CgoLo/fv3tGzZMsrLy/tJI6x4MPcshqRhbg8MhgQQX/oWJzExkezt7WnYsGE0b948vv3UqVO0a9cuun//PnEcR3FxcT+zu4y/wZ49e2j27NlkZmZGN27coI8fP1KHDh3KdYGoiMycOZPmzJlDJ06cIFtbW1q9ejXFxcWRs7MzjRs3TtLdEyDy6SUiunXrFqmrq5OCggIZGRlRYWEhffnyhVasWEFxcXH06NEjSklJIRcXF4qNjRWc5/Tp07RlyxbasmULERFdunSJFi9eTCkpKbRs2TKBC8WJEyfI0tKSqlev/vMGymAw/hYV0/zAYFRgxIXv0aNHafny5bRnzx66e/cumZubU0REBC1fvpyCgoIoKSmJHj9+TEuWLCETExPatWsXXbt2jU6cOCHhUTDKIzExkQIDA2nQoEG0ceNGio+Pp5CQELp58yb179+/jAW4opGdnU25ubm0d+9ecnNzIzU1Nerbty9ZWVmRoqKipLvHM3r0aDp//jwvfMeNG0ft27cnd3d36tevHx0/fpzk5eVJU1OTJk6cSGvXrqUtW7ZQ+/bt6dmzZ7Rhwwb+XADow4cPtG3bNurfvz8RETVq1IiCgoKoVq1aNGzYMIFY9vLyYsKXwZB2JOdxwWD83owePRr6+vqwtbWFhYUFdHV1ceDAAQDArl27oKenB319fRgYGMDe3h55eXl48uQJTE1NBcnzGdLDmTNnYGBggJSUFL4tMzMTU6ZMgbq6OoYPH17hfbTFq5aJxiJehU7S43vw4AGaNGmCevXq4Y8//sCdO3dgYmKCixcvYtOmTfD394exsTEOHz7MHyPyx87MzISPjw/69OkjGEdeXh6ioqKgqqoqqMx39uxZdO/eHdWrV0dcXNxPGyODwfh3MPHLYEiA3bt3Q0dHB3FxcSgsLERiYiJGjx4NWVlZ/qWckZGBc+fOITY2lg8kCg0NhZWVFd68eSPJ7jO+wf3792FqaoqDBw8K2tPT01G9enUoKChg0KBBEurd9ykvWO3vBrBJWvgCpRXyTpw4AR8fHzg4OGDs2LGYOXMmv/3evXvo378/jIyM+HutpKSED8I6dOgQqlevjtjYWMF58/LysHv3bqiqqqJPnz58e0xMDPz9/ZGcnPwTRsdgMH4ETPwyGD+Br0XErFmz0KJFC0Hbhw8fMGTIEDg5OSE1NVWwLSEhAf369YOmpiaz+koJ4kJPvPqZm5sb2rVrJ8gakJ6ejk6dOmHhwoV4/vz5T+/r/0I8E0VGRgYyMjL4f0uDoP2rLF68GMbGxkhPT8f58+fRtWtXaGpqYuzYsYL9EhISMGDAAJiYmCAqKkqwbfTo0TAzM4O6ujrGjBkj2Jabm4uNGzeC4zhBmeO/Wt2OwWBIByzkksH4jwHA+/hGRkaSq6sraWpq0sOHD+nt27ekp6dHRERaWlrUvHlz2rt3L+Xm5vLHl5SUUGZmJuno6NClS5fIyspKIuNg/An+v9jBmTNnKCYmhhISEqhr167Url072rx5M7m6utK4ceOoW7duZGdnR5s3b6bU1FTy8/OjKlWqSLr7AkpKSvgAvODgYLp58ybl5eWRgYEBbdq0ibS0tCTcw7/GmjVraPz48bRhwwbS1tYmd3d34jiOvnz5Qhs3biRvb29q2LAhERFZWVnRyJEjKTMzk3bs2EE+Pj5UUlJCJSUl9PTpU1q5ciXdunWLFixYQAoKCjRjxgwiIlJUVCQvLy+qWbMmLV68mHJycmjVqlWkrKwsyaEzGIy/i6TVN4PxKyNu8V20aBEMDAxw8+ZNXLx4ETY2Npg1axbS0tL4fW7fvg1LS0vcu3dPcJ6SkhKBryVD8uzfvx9qamoYNGgQxo4dCwMDA7Rp0wZFRUW4d+8emjVrhho1aqBatWqoVq0abt68KekufxcfHx9YWVlh3759uHLlCjiOQ4cOHZCTkyPprv1PduzYAY7jeDcG8Xvl8uXL6NChA+zt7XHlyhXBcU+fPkVxcTFKSkpQVFSEoqIi3tL94cMHLF68GBoaGpg4cSJ/TG5uLgYOHIjt27fj8ePHP2F0DAbjR8MsvwzGf4jI4puQkEAPHjygZcuWUb169YiIqG3btrRjxw7KyMigTp06kYaGBo0fP560tbXJ0tJScB6O46hSpUo/vf+M8nnx4gVNnjyZ5s+fT4MHDyYAtGLFCrK2tiYiImtrazp06BClp6fT27dvydjYmLfwSyM3btyglJQUOnDgAJmZmdGSJUtIW1ubBg8eTEpKSvx+30rRJ0nWrVtHgwcPpmrVqtGLFy+IiKhSpUp8mjNXV1e+8t6wYcNoxYoVfAW2GjVqEErd/+jMmTN05MgRyszMpFGjRpGdnR0NGjSIiEqrtmVmZlLPnj3pwIEDdP36dZo1axbp6OhIbNwMBuNfIGHxzWD8cixatAjnz5/n/71//35oaWlBX18fMTExgn1nzJgBd3d3cBwHGxsbNGjQAAUFBQAqRrWs35Xnz5+jXr16yMnJwePHj2FoaIiBAwfy269du4YvX75IsIff5+u5tXfvXtSoUQMAsGDBAmhqavJz9cWLF1ixYsVP7+NfYeXKlVBQUMC6deswevRoODs7Y968efx20b0EABcuXICPjw8MDQ2RkJAgOE9MTAwqVaqEzp07w9raGurq6oiMjEReXh5yc3Oxbds2aGlpoWbNmjA2NsatW7d+2hgZDMaPh4lfBuMHcv36ddSoUQO+vr64evUq3z5o0CDIyspizJgx+Pjxo+CYzMxMXLt2DXfu3OFFCSv/Kd3cunWLzwhQs2ZNDBw4kL92t2/fhq+vL+7evSvhXpbP69ev+b/v378fQKnA9fT0RP/+/aGhoYHTp0/z+5w9exZeXl64f//+T+/r9xC5ZogC1l6+fImhQ4d+VwCfPHkSYWFhAveGjIwMjB07FqtXr+b3Gz58OHR0dLBmzRo+mC0zMxMJCQl8OWQGg1FxYeKXwfjBHD58GM7OzujRo4fAAty3b1+YmpoiMjJSkBf1a5jFV7oQiaQbN24gOjqab/f19QXHcejevbtg/9DQUDg5OUllOrrly5ejc+fOSEpKQsuWLaGnp4fs7Gy8ffsWbdu2hZKSkkA4pqamwtbWFkOHDpVgr8snNTWV940XZat49epVuQJY9DG5e/duPgtHYWEhbt68CS0tLdja2uLQoUOC8w8fPhza2tpYt24d0tPTf8aQGAzGT4KJXwbjByFuYdq8eTOcnJzQrVs3QfJ7Pz8/1K5dG+vXr/+uAGZIByLhu2/fPlStWhVTp05FYmIiAODixYto1qwZLC0tceHCBRw4cAAhISFQU1OTKqtvfn4+8vLyAADnzp2DkZERjIyMYGZmhk+fPvH73b9/H3Xr1kWjRo3Qt29fTJo0CRYWFmjbti2/jzSnPRN9NL5+/ZoXwPPnzwdQ2u87d+7A3NwcL168EBzn4+MDjuOwcOFCwT0MACNHjgTHcdi0aZNUj53BYPw9mPhlMH4A4i/GqVOnYvDgwTAxMeEj5i9fvsxv79WrFywsLBAREVEhIul/d06dOgUVFRWsWrVKkA8XAK5evYqOHTtCXV0d1tbWaNq0qVQJ39zcXLRt2xYHDx7k56iXlxcqVaqELl264NGjR4L9ExISMGXKFDRo0AB9+vTBtGnT+G0VYUVCNMbXr18jMDAQDRs2xOTJk/ntIrF/79493Llzh2/v2rUrNDQ0cPjw4TICePz48fwHD4PB+DXgAEDSQXcMxq/CkiVLaMqUKXTo0CGqUqUK3bhxg2bPnk22trYUHBxMLi4uRFSa6UFNTY127NhBHMdJuNeM8gBAxcXFNGjQIFJQUKBVq1ZRVlYWJSYm0q5duwgATZ06ldTV1enRo0dkYGBARETq6uoS7vmf5Ofn09q1aykoKIhvO3z4MBUWFtLo0aOpYcOGNHr0aLKzsxNkcsD/5zEWIY1ZHr6FqO+pqak0duxYUlJSolWrVpGsrCxxHEcZGRlkbW1NzZo1ozFjxpCNjQ0REXXq1IkuXLhAmzdvJk9PT5KXl5fwSBgMxn8FE78Mxg/Ex8eHtLS0aO3atXzbvn37KDAwkBo2bEhjxozhBbBIUHwtNBjSxYgRI+j69es0d+5cWrduHaWlpVFmZiZ9/vyZVFRU6MaNG1J3DfPy8ujRo0dkZ2fHt02ZMoUUFRUpODiYlJWV6eTJkzR48GBydXWlsWPHko2NDWVnZ1NUVBT16dNHYn3/EeD/05dlZGSQqqoqKSoqEgC6d+8eWVhY0NGjRykkJISaN29OgYGBZGtrS0SlAvjKlSu0YsUKat++PRPADMYvSsX4lGcwpJySkhIiIlJWVqbs7GwiIiouLiYios6dO9OgQYPozJkzNGPGDLp9+zYRleYALikpkSrRxCiLs7MzqampUfPmzamgoIACAwPpypUrNHXqVFJQUKDPnz9L1TUsKSmhkJAQCggIoD/++IOIiAoLCykhIYEOHjxIq1atouzsbGrZsiWtXbuW4uLiaNq0abRq1SpydnamNWvWSHgE/x6O44jjOMrLy6MGDRpQZmYmnThxgjw8POju3bvUoUMHWrx4MR0/fpxWrFhBd+/eJSKi/fv3k7W1NY0dO5by8/MlPAoGg/FfwcQvg/EPEIldEaIl4fr169O+ffvo2rVrfMlYIiJNTU2ytrammjVr8lYm8eMYkke0CPbgwQO6cuUKnTx5koiIfH19adu2bXTt2jXauXMntW/fnuTk5OjKlSukrKwsuM7SgIyMDDVp0oS0tLRo2rRpFBcXR/Ly8rR9+3aysbGhPXv28AK4RYsWFBkZSR8/fqTNmzeTg4MDxcXFEdGfv4ekEH08iiOy6Ir4+j4Uh+M4+vDhA+np6ZG1tTV5e3vT2rVrycHBgQCQt7c3LV++nBfA8fHxRER0+vRpunDhAqmqqv74QTEYDOngZzsZMxgVHfHAn+joaOzZswenTp3i23x8fKCjo4PTp0/j9evXyM7ORvv27bF27Vo+IKciBA/9Toiuy/79+1G9enVYWlpCVVUVnTp1KlPCNiEhASNGjICGhoZUBbcBwsDLQ4cOoWXLlmjdujUfcJmbm4v+/fvDyckJ8+fP5wtxvH//Hm/fvuWPlZb5mZ2djdGjR/P9Ef158uRJxMfH/6VzrFmzBhzHQUdHB6mpqQBKM2CIfquDBw+iRo0a6N69e5niFwwG49eEiV8G428gLi5CQkKgq6sLAwMDWFlZISAgAEBp/lA/Pz+oqKigZs2aqFWrFszNzflcoyxlknRy8uRJaGhoYN26dSgpKcHFixfBcRzat2/PF3i4ceMGBg4cCCcnJ0G2AGlCXLgePHjwmwK4QYMGWLBgQZlKdNI0P7OysiAnJ4euXbvy98/+/fuhoKCAXbt2ffdYUWaOixcvYunSpejQoQOqV6/OZ7jIy8sTfPRYWlry4pjBYPzasIA3BuMfkJycTP3796dly5aRsrIynThxgiIiIsjFxYU2bdpERERHjhyhrKwsys3NJX9/f5KTk6Pi4mKpWyZnEH3+/JnCwsJIR0eHpkyZQikpKdSiRQtydnamM2fOkI2NDUVERFCdOnXo7t27VLVqVdLT05N0twV8a24dOHCAVq1aRfLy8hQWFkaurq6Ul5dHw4YNo7Nnz9LKlSvJy8tLAj3+PqLxZGRkkK2tLXl4eJC3tzf17duXFixYQIMGDSr3OHwj+PD69es0ZcoUun//Pp05c4Zq1apFRESnTp0id3d3KioqImVl5f90TAwGQzpg4pfB+Jts2LCBdu3aRXp6erRx40aSk5Ojz58/0549e2jevHnk5OREW7duLXMcE77SS1FRER05coSsrKxIR0eHWrRoQXZ2dhQZGUmHDx8mb29vcnNzow0bNvCiSZoQn1tRUVGUn59PHMdRz549iaj0QywiIoLk5eVpwoQJ1LBhQ8rNzaUdO3ZQ//79Jdn171JQUECVKlUiIiIdHR3KysqiiIgICggIKHd/kfC9cuUKxcTEEBGRjY0Nde7cmYiIbt68SZMnT6a7d+/S5s2b6ezZs7R+/Xq6efMmGRoa/pxBMRgMicOibRiMv0FOTg49efKEHj9+TElJSSQnJ0dERGpqatStWzcaN24c3bx5k9q3b1/mWCZ8pQN8FTRFRCQnJ0deXl5kZmZGp06dIjk5OZo4cSIRlQrjli1b0rt37/jrLU0A4OeWt7c3hYWF0bRp02jEiBHk6OhIDx8+pLZt21JgYCCVlJRQeHg4nTt3jpSUlHjhK602EFGqsfPnz1NeXh6pqqrSuXPnvhnoxnEc7d+/n7y9ven69ev08OFD6tOnDy1ZsoSISgNSZ8+eTS4uLuTr60v79++nI0eOMOHLYPxmMPHLYHyHr0WBsrIyBQUF0eDBg+nx48c0btw4fpuqqip17dqVhgwZQioqKt+NRGf8fL58+UJEpVZSjuPo+vXrtH79etq7dy89fvyYFBUViYjo2bNnlJGRQSoqKkRUulzetGlTSkhIIBMTE0l1/5uIlvgnTZpEDx8+pEuXLlFsbCzdvHmTSkpKqEuXLpSRkUHe3t40aNAgSktLo1u3bpV7DmmD4zg6cOAAtWnThiIjI+nly5cUFxdHvr6+VFxcTEVFRUT053167do1CgoKopkzZ9KxY8do+vTpBIBCQkJo8uTJRFRqCd65cyedO3eOzp8/Tw4ODhIbH4PBkBAS8TRmMCoA4oFDGRkZyM3NRV5eHgAgNTUVM2bMgKWlJUJDQwXH5eTksKwOUsaWLVvQoUMHvHz5EgCwZ88eKCsrw9zcHDVr1oSysjJ27twJAHj06BFUVVVhb28Pd3d3VK5cWWqD28Tp3bs3goODAfw573JycmBqaooePXrw+926dUsS3ftHPHv2DJaWllizZg3flpGRATk5ObRq1QqrV6/mA/YKCwuxatUqjB07FgDw4sULmJiYYODAgVi4cCE4jsOiRYskMg4GgyFdMMsvg1EO4uVcFyxYQF26dKEmTZpQYGAgpaamkr6+PvXt25d8fX3p0KFD/BI5EZGSkhJxHEcAWB5fKeHdu3eUlpZGEydOpDt37tCOHTto6dKldOvWLTp9+jQFBwdTr169aOfOnWRubk6XL1+mevXqkYODA125ckWQm1nawP9bPV+/fk1PnjwhotJcv/n5+aSkpERBQUGUmJhImZmZRERkb28vOE6aMTY2pv379/PBbUVFRaSpqUmZmZnEcRwtXLiQ9u/fT9nZ2SQnJ0cdOnSgDh06UH5+PvXu3ZuaNm1Ka9eupQ4dOpC2tjaNGjWKZs2aJeFRMRgMSSN9DmwMhoQRF61hYWG0fv16mjFjBhUXF1NkZCS1b9+eDh48SNWqVaO+ffuSjIwMLVq0iIyMjGjw4MH8eaR1Kfl3ZNSoUaSiokK7du2i2bNnU3p6OjVt2pSUlZXJxMSEZs2aRcXFxTR06FBycHAgW1tbWrduHRFJ33UsKioS+B6L+hcQEECjRo2i1atXU0BAACkoKBARkaKiIlWqVKlMqV5pGxe+ytIg+gA1Nzfn2+Tk5KiwsJBUVVXp6NGj5Ovry1+7zp07U9WqValq1aqUnJxMHz9+5O9HFRUVat26NTVq1Ijc3Nx++tgYDIZ0wcQvg/H/pKenk46ODv8CPnz4MB0+fJiio6PJ2dmZDh8+TI8fPyZdXV1q2rQpnTt3jgwNDcnPz4//kyF9iERUQEAAFRYW0tatW+n+/fu8T7YoU4K/vz/t2rWLUlJSyMzMTKrEYXFxMZWUlJC8vDwvfPfs2UNv374lBwcHMjExoTZt2vDZC7Kysqhfv3706tUrWrlyJbm5uUlVxbK4uDiKj48nRUVFatCgAZmbm5f5vb9eNRFdR1lZWcrPzycFBQXauXMn+fn50Zw5c4jjOOrSpQspKytTfn4+3b17l+Lj48ne3p4iIiIoMTGRli5dShoaGj9xpAwGQyqRqNMFgyElNGrUCJMnTxa0xcTE8P6DR44cgba2NpYvX46zZ89CS0sL9erVw7NnzwTHiBLrM6QLcd/rdevWwdTUFK1bt0ZKSgrf/uHDB5iammLPnj0S6OG3ycvLg6urK7Zs2cL7knt7e0NfXx+mpqbQ19dHixYtcO3aNWRmZiI0NBQ6OjrQ1NSEqakpOnXqxJ9LGgpYREZGokqVKnBycgLHcfDw8OALcHwL0fV7/PgxAgIC4OnpiZCQEHz48AEA0KNHD9SpUwebNm3C58+fAQATJkwAx3GoU6cONDU1cfv27f90XAwGo+LAxC+DgdLKXaJgtqysLL79zZs3yM3NhYeHB6ZOnQoA+PLlCxwdHaGiogIfHx8A0iEqGN8nPz+f//v69evRoEEDtGzZEvfu3cOdO3cwYcIEaGlplfmgkQa8vb2hoaGBqKgo7N69Gy4uLnjy5AkA4Pjx4+jatSucnZ35wLwPHz7g1KlT+OOPP/hzSEPw5bp16yAvL4+oqCgUFRXh4MGDkJWVRXh4+DePEfX7zp070NHRQatWreDl5QUVFRU0b96cr/zWrVs3WFhYYNOmTfy1vnDhAnbt2iWV15TBYEgOJn4Zvz2ilycAhIeHo1OnTnjx4gXf9uTJExgYGCAmJgYAkJaWhq5du+LMmTNSISgY/xuRRf7Vq1c4ffo0AGD16tWoUaMGVFVV4e7uDl9fX9y8eVOS3SyD+Pzq06cPtLW1ERAQgFGjRgn2u3jxItzd3fmViu+dR1IcOHAAHMdh2bJlfNuHDx+go6ODzp07lymzDPzZ77t370JNTQ1hYWF8u6j89OLFi/n9fX19YW5uji1btvAWYAaDwfgaForO+O0RDx5ydXWlAwcO0LRp0+j169dERKSvr081atSgOXPm0OHDh6lnz56Unp5OTZo0IRkZGZbPV8opKioiWVlZev78OdWrV49u3LhBRESDBw+mSZMmUbVq1ah27dq0cuVKqlevnoR7K0RGRoaKi4uJiGjjxo3UsWNHWrNmDd25c4fPW0xE1KhRI3JxcaHt27dTdnZ2ueeRNDk5OaSqqkovX76kly9fEhHRgAED6MOHD5SdnU0tWrSgkJAQWrlyJeXn51NeXh7JyMhQbm4uderUibS0tCg8PJyISoPj7O3tydLSkvLy8vjfaMeOHeTo6Ehjxoyhw4cPV4iMFgwGQwJIWn0zGJIiJiaGXxYeO3Ys5syZA6B0qVReXh59+/bF69evAQAHDx6Eq6sratWqhebNm6OgoACAdFjUGH8icj/52vf61atXUFJSQkBAAEpKSgRuKmvWrBFY+qUF8T6Kr04MHToUMjIy2Lx5s8C6uW3bNjg7O/N+sNKCuOvFtm3bYGhoiDFjxsDT0xM2Nja4ffs2Xr58ib1792LkyJHQ09ODnp4epkyZwh938OBBqKqqYtiwYbxb0vPnzyEnJ8f7aItf8wEDBvBuIQwGg/E1TPwyfkvS0tLQpk0b1K1bF35+fpCXlxcUMjh//jzk5eXh7++P9PR0AEBBQQGePn3KC15xQcKQPCKxeOzYMXTp0gX9+vVDVFQUgNJiCeHh4YKPFWkOThTvW05ODjIyMgTbe/fuDWVlZcyZMwdXrlzBzZs3YW5uDj8/v5/d1e+yatUq6OvrIyEhgW/bsmULdHR0oKGhgXPnzpU5Jj09HWvXri1zfaKjo6GgoIDQ0FAkJibC0NAQw4YNE+zD7kkGg/FXYOKX8dty/fp1GBsbQ05ODtu2bQNQKnBFL9ALFy6gUqVK6NOnD54/fy44lll8pZNz585BTU0Nvr6+aNWqFeTl5XmLfkVBXPQNHToUHh4e0NfXx6xZs/Do0SN+W9++fcFxHDQ1NdGrVy8MGDCA3yYNAZhr1qyBjIwM9u/fX2bb7t27YWBggJEjR+Lx48d8u2hFRUR5AlhJSQkcxyEgIIBvZ/cjg8H4OzDxy/jtEAmDBw8eoHHjxnB3d4eDgwPi4uIAlL5wRS9hUVDNjBkzJNZfxl9n9+7dfAnbjIwMLFu2DDIyMpg1axa/jzQIw79C165dYWVlhU2bNmHbtm1QVlbG4MGDcePGDX6f4OBgcByH69ev823SIARXr14NOTk57Nu3T9AeGxvL/33Lli0wNDREcHAwkpKS/vK5T548CTU1NQQGBgoyeDAYDMZfhYlfxm/D16KgqKgIhYWFuHTpEry9vWFvb88LYOBPkXT//n22nCqliK7RnTt3cPbsWXTt2lUQ/Z+bm4vly5dDRkYGc+fOlVAv/z6rVq2CnZ0d73O+detWyMnJQUdHB926dRPkrF25ciX/d2kQ9qKsDtHR0YL29u3bw9/fX+CnvHXrVlSvXh3+/v54+fLlX/4/Dh8+DAUFBQwfPhy5ubk/rO8MBuP3gFV4Y/wWQKxk8e7du+nz58+kqKhIfn5+5ObmRoWFhRQREUFBQUEUERFBLi4u1KVLF2rSpAkNGzaMiMqWlWVIHo7j6ODBg9S1a1eqXbs2JSUlkaKiIuXm5pKSkhIpKirSgAEDSEZGhgIDA0leXp5Gjhwp6W4TkbCcr6jKnAgjIyMaPXo0GRgYUEREBM2YMYOuXLlCWVlZ1LJlS1JTU6M+ffqQq6srDRkyhIj+rIAmSfLz8ykmJoZMTU0pJSWFb/fx8aGkpCQ6duwYqaqq8uP18/Ojz58/U0xMDBkYGPzl/6dt27a0f/9+atu2LSkoKNC8efP+i+EwGIxfFUmrbwbjv0bcGjZmzBioq6vDxsYGioqK8PX15bedO3cOPj4+UFdXh6OjI4yNjcv4IDKkA9E1TUtLg7u7OzZs2IB79+5h3bp1kJOTQ1hYmODa5ebmYt26dXjw4IGkuvxN7t27x/995MiRuH//PjIyMpCZmYmnT5/Czs4O27dvBwC8fv0ahoaGkJWVxdq1ayXV5e+SmpqK4OBgNGjQAEuWLIGPjw9sbGyQnJwM4M9rJ74SU17bX+HEiRN4+PDhD+o5g8H4XWBmLMYvj8i69v79e7p+/TpdvnyZ9PT0KCEhgbp160YdO3akAwcOUJMmTUhPT4/atGlDL1++pNDQUJKTk2MWXymE4ziKiYmhffv2kZ6eHrVv3560tbXJ2tqalJWVqXfv3kRENG3aNJKTk+MtwNLGqVOnyNPTkw4ePEirVq2i58+f05QpU6hy5cpERPT8+XPKycmhatWqERHRly9fqFu3btS5c2dq2LChJLv+TfT19Wn8+PEUHh5OS5cupU+fPlF8fDwZGhpSYWEhycvLExFRu3btqG7dujRnzhwi+nN1BgCVlJSQrKyswDpeHp6enj9lTAwG49eCvdEZvwVz586lmJgYvmCFqqoqNW3alA4ePEgdOnSgTp060d69e8nCwoIsLCz444qLi5nwlVLy8vIoMjKSlJWV6eXLl6StrU1ERD169CCi0gIK2dnZtGDBAqm9hi1atKDx48dT9+7dSUdHh+7evcsLX6JSQfjhwweKioqiBw8e0IoVK8jOzo4XvtLg6lAeVatWpYkTJ5KMjAzFxsbSzp07afTo0SQvL0/FxcXUvn17evLkCR08eJCIiMaNG0eGhoYUHBzMC99Xr17R5s2baeTIkaSsrCzZATEYjF8K6XtqMhg/GABkYGBA9+7do9u3b5OCggLf7urqSgcPHqS4uDhq1qwZFRUVCY4V98NkSAevXr2i7Oxs8vb2plOnTlFubi6tWLGC0tLS+H169OhBK1asoO3bt1NmZqYEe/ttIFZ9LC8vj96+fUsXL14U7GNnZ0dLliyhkydP0urVq8ne3p62bt3KHy+NwleEnp4ehYaGkouLC0VFRdGCBQuIiKhTp06UnJxMCQkJJC8vT7m5uVS9enVaunQprV27VlCN7/Pnz0z4MhiMH4/kPC4YjP8Gkd+guP9gfn4+9u3bBxUVFQwdOrTMMWfPnkXr1q2lIk0U49vcuXMH9vb2WL58ObKzswGU5n6VkZHB0KFDkZaWJtj/06dPkujmdylvjuXn52PMmDGoVKkSdu3aBUCY4zY/Px/v3r377jmklTdv3iAoKAgNGzZElSpVULt2bd4fW5RFJScnB5GRkahZsyZmz54NY2NjBAQEsCwrDAbjP4GJX8Yvxc6dO9G3b18kJibiy5cvgm0FBQXYtWsXlJSUEBQU9M1zVCRh8buRn5+Pdu3aoUGDBli7di0vgA8dOgQZGRkMHz4cqampEu7ltxEXtJcuXcLBgwcFOXqHDx+OSpUq8flxs7Oz4evrKwjqkoZ0Zn+XN2/eoHfv3mjVqlUZ4SvOvHnzICcnB3d3d76N3Y8MBuNHwwFia28MRgUmKyuL6tWrR1lZWVS1alVycnKiRo0akb+/P79Pfn4+HTx4kPr27UuDBg2iJUuWSK7DjP8Jygl4KigooN69e1NycjINGjSIevbsScrKynTkyBFq3749jR49mmbPni11LiviY+nSpQs9ffqU0tLSyNzcnO8/EdHYsWNpwYIFNHjwYIqJiSFzc3M6fvy4JLv+Q8jMzKTKlSuTjIyMIIhUFAT36tUrcnZ2ptq1a9OzZ89owoQJfJBiefOAwWAw/inSGQXCYPwDVFRUqGvXrmRsbEyOjo509uxZGjFiBJ08eZKsrKxozJgxpKCgQN26dSMA1KNHDzI2NpaavK+MsnAcR9euXaP3799T69atSUZGhipVqkRbtmyh3r1709KlS0lWVpa6d+9Obdu2paNHj5KJiYnUCV+iP7OOBAYG0r179+jkyZNkZGREPXv2pOjoaEpISCBra2uaN28e6evr0x9//EFdu3YVZEOoyAJQU1OTiEqD9MQDEOXl5Sk5OZk8PDyoY8eONHfuXNqzZw/Nnj2bcnNzKSgoqEKPm8FgSCEStDozGD+cY8eOQU1NDXfv3gVQmt910qRJ4DgO9vb2mDt3Lp9X9cyZM8ynUMopLCxEw4YNYWNjg6NHj5ZZAq9fvz5sbGywdOlS3gVCmsnMzESLFi1w8uRJAMDChQuhpaWFU6dOAYDAr1d8PL/60v+QIUPQrVs33qUjJycHK1asgK2tLTIzMyukqweDwZBemNsD45cjMDCQiIhWrFhBRERWVlZUu3ZtqlWrFt29e5dOnz5NGzdu5N0hWB5f6ebDhw/UuXNnKiwspNDQUGrVqhVv2Q0JCaFNmzaRs7Mz7dy5kzQ0NCTb2f9BTk4Oubu7U0REBF29epVmzJhBO3fuJE9PT8rOzqbly5eTra0teXl58cegglt8/yl5eXmUn58vSP3GYDAYPwL2xmf8ctSrV482btxImZmZ1KxZM9LU1KTNmzeTuro6vX79mi5dukQ+Pj78/kz4Sg8ioZeamkoqKipUUFBAurq6tG/fPvL29qbZs2cTEfECuFKlShQZGUkNGjSQOuH7dcliotLx6erq0rBhw+jVq1e88CUiSk5OpsOHD5O5ubngmIoofP9O/uFv7auoqEiKioo/umsMBoNBzPLL+CVxcnKiGzduUOPGjWn//v2kpaVVZh9m8ZVODhw4QGFhYQSArKysaNiwYeTh4cFbgPPz80lfX580NTVpz549dP/+fapevbqkuy1AXPjGxsaSpqYmValShXR0dOjq1avUokULcnNzo82bN5OysjKlpqZS586dycbGhrZv3y7h3v87RGL26dOnFBUVRSkpKdS5c2dycXEhVVVVSXePwWAwmPhl/FqILIfbtm2juXPn0qZNm6h+/fq/7dKxtCO6LqI/nzx5Qs7OzjRlyhTKzc2lmzdv0s2bN2nFihXk5eVFmZmZtGDBAnrw4AEVFRXRrFmzqG7dupIexjfp0qULXbx4kZSVlcnExIRWrFhBlpaWFB0dTT169KBatWpRTk4OqaiokImJCR04cICIKq6rg0j43r17l9q0aUNmZmaUnp5Ojx8/pvnz59Pw4cOltiodg8H4fWDil/FL8vr1a3J0dKThw4fT+PHjJd0dxl/gjz/+oLi4OHr37h2Fh4cTEdHdu3dp0aJFdOHCBVq9ejV5eXnxFvu8vDypWxYXF61RUVG0aNEiWr9+Pd28eZP27dtHN2/epBMnTpCVlRUlJibS9evXKTs7m0xMTHj3h4oqDkVjj4+Pp4YNG1JISAiNHz+eOI6j1q1bU1JSEiUkJJCGhkaFHSODwfg1YGu+jF8SQ0NDCg0NpWnTplH79u3J0tJS0l1iiBEaGkpKSko0efJkIiJKT0+n2bNn08mTJ6lbt278fra2thQSEkIAKCgoiJYsWUJt2rQhIpI64fu1j29+fj75+PiQpaUlWVpakrW1NU2ePJk8PT3pxIkTZG1tTWZmZgIRWJFFIcdx9P79e7K3t6eOHTvS9OnT+W0aGhr05csXys7OJiUlJb7EuIiKaulmMBgVk4r5lGUw/gKtW7emNm3aUJ06dSTdFYYYubm5ZGRkRB07duTbdHR0qH///uTh4UHR0dF0584dfputrS2NHj2arK2tKSwsjHJyckjaFqwA8MJ32LBh1KNHD1q0aBFlZmby+9jb29OMGTOofv361KpVK4qPjy8jdCui8C0pKeH/rqurSz4+PnTp0iU6d+4cERHNnz+foqOjSV1dnUJDQ8nU1JQmTpxIBw8epPT0dCKqmEF9DAaj4sLcHhi/NCKLUnmR9wzJIbJwnjp1is6cOcMXcjhz5gwtWrSI3r9/T2vWrCF7e3v+mISEBNLS0iIDAwNJdbtcxOdWv379KDY2llxdXSkxMZHu3btHFy5cEIzjzp07FBgYSI6OjhW+wqDoOiYmJtIff/xBvXr1opKSEurduzedOHGCvL296ejRo3w6Oo7jaPfu3XT+/HnavXs3NWnShA4cOMDSmTEYjJ/Lz0oozGAwfl/EixSI/33BggWQkZHBhAkT+LYTJ06gXbt2cHBwwO3bt39mN/8V9+/fR2BgIFJSUgAAL1++RMeOHaGpqYk7d+4I9n3+/LkEevhjERXeuH37NhQUFBAREcFvKykpwYABA8BxHObMmVPm2KKiIjx9+hTJyck/rb8MBoMhgolfBoPxU3j79i2ePn0KANi1axdOnjyJ3NxcLFu2DJqamggNDeX3PXHiBDp27IiaNWvy1fqkhU+fPiEkJAQfPnzg21atWgWO42BkZMRXEASA1NRUdOzYETo6OuWOo6JWLisqKgIA3LlzByoqKhg/fnyZfQoKCtC3b19oamrizJkzAP4cr+h4BoPBkAQVz8GMwWBUKADQp0+fqGnTprRq1SpauXIl+fr60qtXr0hRUZF69uxJU6ZModWrV1NYWBgREXl6elLfvn3JycmJ1NTUJDwCIQ8ePKBnz54JckcPHjyYL1yRmJjIt+vr69OKFSuocePGZGdnRy9fvhScq6L6usrKytK9e/eoUaNGNHLkSL74CBHR1atXKScnh+Tl5SkyMpLatGlDnTt3pnPnzvHjZS5IDAZDokhafTMYjN+D7du3o0qVKuA4DgsXLhRsy8jIwJIlS6CpqSlwgfjy5cvP7uZ3ES31i1i7di3vwlBSUgI/Pz9UrlyZt3SKePnyJZYuXfrT+vlfU1hYCE9PT3Ach4yMDL59+vTpUFdX510/gNLfzN/fHxzH4cKFCxLoLYPBYAhhll8Gg/Gfgv+PqXVzc6OioiKqXLkyffjwgZKTk/l9NDU1qXfv3jR9+nSaNWsWnyZLRUVFIn0WR9R/AFRcXMy3Jycn0+DBg2nKlCn0+vVr4jiOtm7dKrB0iqhWrRoNHz6ciITZESoqcnJytGLFCqpduza1b9+eSkpKaN68ebR8+XLatWsXmZiY8PvKyMjQhg0baODAgaSnpye5TjMYDMb/w7I9MBiMn0ZSUhL98ccfNHbsWOrevTsNHTqUatasyW8vLCykyMhIatq0KZmbm0uwp2V5+fIlGRkZERHRjh07qEePHnTx4kXy9PSk7t2708yZM8nQ0JCIiHr16kVHjx6l7du3U6tWrSTZ7R+CKKsDSuNE+JRsz549o2bNmtHnz5+ppKSEdu/eTc2aNZNwbxkMBuP7MMsvg8H4TxB9V+fk5PD5XM3MzKhnz540depU2rVrF61Zs4aePHlCRERTpkyh8+fP05AhQ6RO+EZFRZGHhwfdv3+fvLy8aMGCBfT582dq3LgxnThxgrZv304TJ06k169fExHR1q1bqUGDBnTo0CEJ9/zfIxK+KSkpNG/ePOrduzfvu2xiYkJnzpyhGjVqkJaWFtnZ2Um2swwGg/EXYBXeGAzGDwf/n1/5yJEjtGLFCkpKSqImTZqQj48PeXl50cCBA4mIaNasWfT48WNSUlKi3bt30x9//CHhnpdPlSpVyM7Ojtzd3UlDQ4MX7IWFheTu7k6nT5+m5s2bE8dxNH36dKpWrRodO3ZMwr3+94iE771796hbt27k6elJtWrV4i3gBQUFZGJiQrt376bmzZuTt7c37dmzR+pyMTMYDIY4zPLLYDD+NaLlcBEcx9Hhw4fJ19eX6tWrRwsXLqSEhAQKDw+nzZs3ExHRwIEDafbs2aStrU0FBQUUHx9PDg4OkhrCd3F3dydVVVXKyMggFRUVio+PJ6JSf9aioiJq3LgxnT59mrZv305Dhw4VVHarqJ5lIveGR48ekbu7O3Xo0IFmzZpFU6dOJSKiLVu20ObNm+nz589kYmJCp0+fprS0NOrRowe9evVKsp1nMBiM78B8fhkMxr8mIyODtLS0+GpnycnJ1LlzZxowYAANGzaM8vPzycTEhBQUFKhKlSo0fPhw8vPzIyKivLw8kpGRoUqVKkl4FEJEVs+SkhIqKSmh2NhY+vTpE23dupWSk5Np1apV5OzsTIWFhSQvL09ERBcuXKDNmzfThg0bJNz7H0NOTg717NmTNDU1af369XyqsunTp9PUqVNJRkaGVqxYQT179iRVVVV6/vw51atXj5ycnOjIkSMspRmDwZBKmOWXwWD8K/bs2UNGRkb06NEjkpWVpeLiYqpUqRL5+vqSr68vpaamkqWlJfn4+NCVK1coPT2dIiIiaPXq1UREpKioKHXCt7i4mA/qev36NaWnp5O7uzu1b9+eAgICyNjYmIYMGUI3btwgeXl5ysrKopUrV5K7uzsvfH8Fu0JeXh4lJiZSkyZNeOEbGxtLCxYsoOvXr9PEiRMpKCiItm3bRllZWWRsbEy3b9+m5cuXM+HLYDCkFiZ+GQzGv6JGjRrUqFEjat26NSUmJpKsrCzp6upSr169SFtbm8LDw6lBgwY0a9YsMjAwIDc3N3r69CmdOnWKPn36JOnul4tIuPXs2ZOaNm1KLi4uFBgYSEREzZo1o+HDh1ONGjXI19eX1qxZQ05OThQTEyM4R0UsYPG1YH/9+jU9ffqUz2JBRFS3bl26desW1a9fn6ZOnUrjxo2joUOH0q1bt4iIqHr16oIMHgwGgyFtMPHLYDD+NuIiydHRkebPn0+1a9emFi1a0KNHj0hRUZH09fWJiOj58+ekqanJV2pTV1enBQsWUEREBFWuXFki/f8W4nl8J02aRPfu3aPZs2dTUFAQ7dixgzp16kQAyMPDg8aMGUMeHh4UERFBjRo14jM7VFSLb0lJCXEcR2lpaXybsrIycRzHByICIHV1dapVqxb/W/Xq1YucnZ1JWVlZIv1mMBiMvwvz+WUwGH8LkS/sx48fKT09nSpVqkTVq1en5ORkGjp0KD18+JBOnTpF5ubm9PnzZxowYAB9+fKFPD096fnz57R582aKj4+X6owAe/bsodTUVLK1tSUPDw8iIrp8+TJ16tSJ3NzcaN++fbxl98OHD6StrU1Ef/42FQ1Rv+/cuUMdOnSgyMhIat68ORGVBibu3r2bTp06Rc7OzlRUVERycnJ8Ro+xY8fSjRs3KCoqiv8dGAwGQ6r5ecXkGAxGRUdU3vfevXtwc3NDtWrVYGxsjJEjRwIAHj9+DC8vLxgZGeHhw4cAgDt37qBJkyaws7ND3bp1cfv2bUl1/y9x7do1cBwHjuNw7NgxAKWliwHg8uXL0NPTQ6dOnZCfny84TrRPRUN0Te/cuQNFRUWEhoYKtt+8eRP29vaoXLkyTp06hezsbADA8+fPMWbMGKirqyM+Pv6n95vBYDD+Kczyy2Aw/hIi6+Ddu3fJzc2NevfuTW5ubhQTE0MnT56kgQMH0rRp0+j27ds0adIkunv3LsXExJClpSW9f/+e5ORK04prampKeCR/5iEWIcpSQVSau/fw4cMUEBBA7du3p8jISMGxsbGx1KhRI1q6dCkFBQX91H7/aMSvqYuLC40YMYJmzZrFb3/69CmZmprS2bNnaebMmXT+/HlycHAgACQvL09v376lvXv3kr29vQRHwWAwGH8PJn4ZDMZf5smTJ1S3bl0aM2YMTZ8+nYiIcnNzqU2bNpSXl0dXrlwhIqI7d+7QxIkT6cGDBxQdHU3W1taS7PY3uXDhAtWtW5e0tLQE7YWFhXTgwAHq06cPDRgwgCIiIgTbk5KSyMzM7Gd29T9DdE1Hjx5NM2bM4D8MwsPDKTY2lnbs2EEaGhr0/v172rdvH92+fZtyc3PJw8ODmjZtSsbGxpIeAoPBYPwtWIU3BoPxlygpKaENGzaQmpoa6ejo8O1KSkrk4eFBR48epY8fP5KGhgbZ2dlReHg4DRs2jHx9fenWrVskJycnVRkQli1bRsHBwVSjRg0KCwuj2rVrU6NGjYiISF5enry9vWnjxo3Up08fkpGRoSVLlvDHioRvRfXxFSF+TUX+uhzH0ezZs2n+/Pm0e/du0tDQICIiXV1dCggIqPBjZjAYDCZ+GQzGX0JGRoaGDRtGOTk5tGPHDvry5QuFhYVReno6zZs3jyZNmsQLJSIiW1tbWrlyJWloaPBFIKSJ6tWr06BBg6hGjRoUFxdH4eHh1Lp1a+rcuTN5eHiQgoICdenShYiI+vTpQxkZGbRlyxbBOSq6CBS/prt27SJFRUXKysqihQsX0u7du8nT07PcYxgMBqMiw9weGAzG3yItLY3Cw8Pp1q1b5OrqSjt37qSOHTvyrgGiR4o0WXnL4/79+9SxY0datWoVNWvWjGJjY2nlypWUkpJCWlpaFBYWRrVq1aIqVarQpk2b6PLly2X8f38VRNf01KlTlJycTDExMdS0aVM+swMR0ZQpUygtLY3WrFkj4d4yGAzGv4OJXwaD8bd58+YNzZo1i/bt20eGhoZ0/fp1IiKBWKoILFiwgA4ePEjbtm0jExMTunv3LjVo0IAMDAxIVVWVlJWVqVu3bjR06FC+Ct3XwXK/Cm/fvqVZs2bR+fPnqXfv3jRq1Ch+25QpU2jevHl0+fJlql+/vgR7yWAwGP8etn7FYDD+Nvr6+jRx4kTy8fEhWVlZmjt3LhERycnJUUlJiYR799dp3rw575KRlpZGLVq0ID8/P0pOTqb58+dT/fr16caNG4Lyy7+i8CUi0tPTo9DQUGrcuDFFRUXx1zQ8PJwJXwaD8UvBLL+M/2vv3oOirPo4gH8XUECWOwsUhiCRmmAYYzFpYtwWLPGSYmDcnBy8JIwzlpcuQnlJkklEczIb0UC0pZs2liHhSBKmCXiBRgyQQUdlETBASdzz/uHsDo+7CL69yiv7/cww4/Pb33Oec84z4/z27Nlnif5r2o/Ly8rKEBwcjLS0tP7u0n2LiYlBeXk51Go1Xn75ZWRlZUEul+vlDdQV37tp72lFRQU6Oztx6tQpFr5ENKCw+CWif+Xy5ctYsWIFGhoasGfPnkfmV760xWxNTQ2CgoIwbtw45OTkwNzcvMdcY3H58mWsXLkSxcXFUKlU8PPz6+8uERH9z7D4JaJ/7cqVKwDufHT+qLl+/Tpmz54NZ2dn7Ny5E4DxFbuGNDY2QqPRPJL3lIjoXlj8EpHRKy4uRkhICPLz8zFlypT+7g4RET1A/MIbERm9cePGwcfHB9XV1f3dFSIiesC48ktEBKC+vh7u7u793Q0iInrAWPwSEXXD/b5ERAMbtz0QEXXDwpeIaGBj8UtERERERoPFLxEREREZDRa/RERERGQ0WPwSERERkdFg8UtERERERoPFLxERgMOHD0MmkyE/P7+/u0JERA8Qi18iGrBkMlmf/g4fPtzfXf2/19HRgdTU1Ac2VwcOHEBqauoDaZuIqDuz/u4AEdGD8uWXX0qOd+3ahYKCAr34qFGjUFVV9TC79sjp6OhAWloaAGDSpEn/8/YPHDiALVu2sAAmogeOxS8RDVivv/665Li0tBQFBQV6cQAPrfhtb2+HlZXVQ7lWfzKWcRLRo4fbHoiIutFoNFizZg2GDh0KCwsLBAcH4/z583p5x44dQ3h4OGxtbTFkyBAEBgbi6NGjkpzU1FTIZDJUVlYiJiYG9vb2mDBhAgDg1KlTSEhIwPDhw2FhYQFXV1fMnTsXTU1NBtv4888/ERUVBRsbGzg6OiIlJQU3b97U5QUGBuKZZ54xOKYRI0ZAqVTec9wnTpyAUqmEk5MTLC0t4enpiblz5wIA6urqoFAoAABpaWm67SLaVdqEhATI5XL89ddfmDx5MqytrTFnzhwAQHFxMWbNmgV3d3eYm5vjiSeewJIlS3Djxg3dtRMSErBlyxYA0q0q3e/Jxo0bMXr0aFhYWMDFxQVJSUlobm6WjEGj0SA1NRWPP/44hgwZgpdeegmVlZXw8PBAQkICAKCmpgYymQyffPKJ3hyUlJRAJpMhLy/vnnNFRI82rvwSEXXz0UcfwcTEBEuXLkVrayvS09MxZ84cHDt2TJfzyy+/ICIiAv7+/li1ahVMTEywY8cOBAUFobi4GM8995ykzVmzZsHb2xtr166FEAIAUFBQgJqaGiQmJsLV1RVnz57Ftm3bcPbsWZSWlur9zHJUVBQ8PDywbt06lJaWYtOmTWhubsauXbsAALGxsZg3bx7OnDkDHx8f3XnHjx/HuXPn8O677/Y45qtXryIsLAwKhQLLly+HnZ0d6urq8M033wAAFAoFtm7digULFmD69OmYMWMGAGDMmDG6Nrq6uqBUKjFhwgRs2LABQ4YMAQCoVCp0dHRgwYIFcHR0xO+//46srCw0NDRApVIBAJKSknDp0iWDW1K0r2dnZyMxMRHJycmora3F5s2bUVZWhqNHj2LQoEEAgBUrViA9PR1TpkyBUqlERUUFlEql5E3C8OHDMX78eOTm5mLJkiWS6+Tm5sLa2hpTp07tca6IaAAQRERGYtGiRaKn//aKiooEADFq1CjR2dmpi2dmZgoA4vTp00IIITQajfD29hZKpVJoNBpdXkdHh/D09BShoaG62KpVqwQAER0drXe9jo4OvVheXp4AII4cOaLXRmRkpCR34cKFAoCoqKgQQgjR0tIiLCwsxLJlyyR5ycnJwsrKSrS1tfU4L99++60AII4fP95jTmNjowAgVq1apfdafHy8ACCWL1/ep3GuW7dOyGQyceHCBV2sp3tTXFwsAIjc3FxJ/KeffpLEL1++LMzMzMS0adMkeampqQKAiI+P18U+++wzAUBUVVXpYv/8849wcnKS5BHRwMRtD0RE3SQmJmLw4MG64xdffBHAnY/LAaC8vBzV1dWIiYlBU1MT1Go11Go12tvbERwcjCNHjkCj0UjanD9/vt51LC0tdf++efMm1Go1AgICAAAnT57Uy1+0aJHkePHixQDufFEMAGxtbTF16lTk5eXpVpdv376NvXv3Ytq0affcf2tnZwcA+OGHH3Dr1q0e83qzYMECvVj3cba3t0OtVuOFF16AEAJlZWW9tqlSqWBra4vQ0FDdXKvVavj7+0Mul6OoqAgAUFhYiK6uLixcuFByvnaeuouKioKFhQVyc3N1sYMHD0KtVhvcD05EAwuLXyKibtzd3SXH9vb2AKDbX1pdXQ0AiI+Ph0KhkPxt374dnZ2daG1tlbTh6empd51r164hJSUFLi4usLS0hEKh0OXdfT4AeHt7S469vLxgYmKCuro6XSwuLg719fUoLi4GABw6dAhXrlxBbGzsPcccGBiIV199FWlpaXBycsLUqVOxY8cOdHZ23vO87szMzDB06FC9eH19PRISEuDg4AC5XA6FQoHAwMAex3m36upqtLa2wtnZWW++29racPXqVQDAhQsXAABPPvmk5HwHBwfdPdSys7PDlClTsHv3bl0sNzcXbm5uCAoK6vOYiejRxD2/RETdmJqaGoxrV1O1q7off/wx/Pz8DObK5XLJcffVT62oqCiUlJTgrbfegp+fH+RyOTQaDcLDw/VWjg25e08wACiVSri4uCAnJwcTJ05ETk4OXF1dERIS0mtb+fn5KC0txf79+3Hw4EHMnTsXGRkZKC0t1RuPIebm5jAxka6n3L59G6Ghobh27RqWLVuGkSNHwsrKChcvXkRCQkKfxqnRaODs7CxZpe1O+0W8+xUXFweVSoWSkhL4+vpi3759WLhwod4YiGjgYfFLRHQfvLy8AAA2Nja9FpU9aW5uRmFhIdLS0vD+++/r4tpVZUOqq6slK8jnz5+HRqOBh4eHLmZqaoqYmBhkZ2dj/fr1+O677zBv3rweC/q7BQQEICAgAGvWrMHu3bsxZ84c7NmzB2+88YbBYrs3p0+fxrlz57Bz507ExcXp4gUFBXq5PbXv5eWFQ4cOYfz48QbfRGgNGzYMwJ156T5PTU1Nek+FAIDw8HAoFArk5ubi+eefR0dHR68r5EQ0MPAtLhHRffD394eXlxc2bNiAtrY2vdcbGxt7bUNbjGpXk7U2btzY4znaR4FpZWVlAQAiIiIk8djYWDQ3NyMpKQltbW192sPa3Nys1xftqrZ264P26Q0tLS29tqdlaJxCCGRmZurlavck391+VFQUbt++jQ8//FDvnK6uLl1+cHAwzMzMsHXrVknO5s2bDfbNzMwM0dHR+Oqrr5CdnQ1fX1/J0yuIaODiyi8R0X0wMTHB9u3bERERgdGjRyMxMRFubm64ePEiioqKYGNjg/3799+zDRsbG0ycOBHp6em4desW3Nzc8PPPP6O2trbHc2praxEZGYnw8HD89ttvyMnJQUxMjN6zfceOHQsfHx+oVCqMGjUKzz77bK9j2rlzJz799FNMnz4dXl5e+Pvvv/H555/DxsYGkydPBnBn68bTTz+NvXv34qmnnoKDgwN8fHwkj1W728iRI+Hl5YWlS5fi4sWLsLGxwddff21wJdbf3x8AkJycDKVSCVNTU7z22msIDAxEUlIS1q1bh/LycoSFhWHQoEGorq6GSqVCZmYmZs6cCRcXF6SkpCAjI0M3TxUVFfjxxx/h5ORkcGU5Li4OmzZtQlFREdavX9/rPBHRANGPT5ogInqo+vKoM5VKJYnX1tYKAGLHjh2SeFlZmZgxY4ZwdHQU5ubmYtiwYSIqKkoUFhbqcrSPKWtsbNS7XkNDg5g+fbqws7MTtra2YtasWeLSpUt6jxPTtlFZWSlmzpwprK2thb29vXjzzTfFjRs3DI4lPT1dABBr167t07ycPHlSREdHC3d3d2Fubi6cnZ3FK6+8Ik6cOCHJKykpEf7+/mLw4MGSfsbHxwsrKyuDbVdWVoqQkBAhl8uFk5OTmDdvnqioqNCb066uLrF48WKhUCiETCbTu0/btm0T/v7+wtLSUlhbWwtfX1/x9ttvi0uXLknaeO+994Srq6uwtLQUQUFBoqqqSjg6Oor58+cb7N/o0aOFiYmJaGho6NNcEdGjTybEXZ91ERHR/43U1FSkpaWhsbERTk5OfTonMzMTS5YsQV1dnd7TK4xNS0sL7O3tsXr1arzzzjt6r48dOxYODg4oLCzsh94RUX/gnl8iogFECIEvvvgCgYGBRlf4dv/JZC3tPupJkybpvXbixAmUl5dLvoxHRAMf9/wSEQ0A7e3t2LdvH4qKinD69Gl8//33/d2lh27v3r3Izs7G5MmTIZfL8euvvyIvLw9hYWEYP368Lu/MmTP4448/kJGRgcceewyzZ8/ux14T0cPG4peIaABobGxETEwM7OzssHLlSkRGRvZ3lx66MWPGwMzMDOnp6bh+/bruS3CrV6+W5OXn5+ODDz7AiBEjkJeXBwsLi37qMRH1B+75JSIiIiKjwT2/RERERGQ0WPwSERERkdFg8UtERERERoPFLxEREREZDRa/RERERGQ0WPwSERERkdFg8UtERERERoPFLxEREREZjf8A+uREoJTjg8sAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 800x500 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set figure subplots\n",
    "fig, axes = plt.subplots(nrows=2, ncols=1, figsize=(8,5), gridspec_kw=dict(height_ratios=[1, 1]))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# create accuracy dataframe \n",
    "df_all = pd.DataFrame()\n",
    "for col in ['RAGLLM_unstruc_res', 'RAGLLM_struc_res']:\n",
    "    df = pd.crosstab(plot_df['therapy_strategy_2'], plot_df[col])\n",
    "    df['accuracy'] = df[True] / (df[True] + df[False])\n",
    "    df_all = pd.concat([df_all, df.rename(columns = {'accuracy':col})[col]], axis = 1)\n",
    "\n",
    "# add counts (number of relationships)\n",
    "group_cnt_df = pd.DataFrame.from_dict(Counter(plot_df['therapy_strategy_2']), orient=\"index\", columns=[\"Number of relationships\"])\n",
    "df_all = df_all.merge(group_cnt_df, left_index=True, right_index=True)\n",
    "\n",
    "# sort by number of relationships (descending) \n",
    "df_all = df_all.sort_values(by=\"Number of relationships\", ascending=False)\n",
    "\n",
    "# create a mapping of names to colors\n",
    "struc_unstruc_colors = dict(zip(df_all.columns[0:2], [cols[23],cols[6]]))\n",
    "num_rel_color = cols[7]\n",
    "\n",
    "# create bar plot\n",
    "df_all[['RAGLLM_unstruc_res', 'RAGLLM_struc_res']].plot(kind='bar', color=struc_unstruc_colors, width=0.6, legend=False, ax=axes[1])\n",
    "df_all['Number of relationships'].plot(kind='bar', color=num_rel_color, width=0.6, legend=False, ax=axes[0])\n",
    "    \n",
    "# x, y label and ticks\n",
    "axes[0].set_ylabel('Number of entities', fontsize=12)\n",
    "axes[0].set_xticks([])\n",
    "axes[1].set_ylabel('Accuracy', fontsize=12)\n",
    "axes[1].set_xlabel('Therapy strategy', fontsize=12)\n",
    "axes[1].tick_params(axis='x', labelrotation=45, size=5)\n",
    "for label in axes[1].get_xticklabels():\n",
    "    label.set_ha('right') \n",
    "    label.set_rotation_mode('anchor') \n",
    "\n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(axes[0].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "for i, patch in enumerate(axes[1].patches):\n",
    "    patch.set_alpha(0.75)\n",
    "\n",
    "# change background and grid color\n",
    "for ax in axes:\n",
    "    # change background color\n",
    "    ax.set_facecolor('white')\n",
    "    # change grid color\n",
    "    ax.grid(visible=True, axis='y', color='lightgray', linestyle='dotted')\n",
    "\n",
    "# save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure3_therapyAcc_heatmap.jpeg', dpi=600, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_unstruc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "RAGLLM_struc_res",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Number of relationships",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "perc_increase",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "0eb7e6ec-f35e-4a5c-9651-fef3da7c95ff",
       "rows": [
        [
         "Antiandrogen + PARP",
         "0.125",
         "1.0",
         "16",
         "700.0"
        ],
        [
         "B-RAF",
         "0.3333333333333333",
         "1.0",
         "6",
         "200.00000000000006"
        ],
        [
         "B-RAF + MEK",
         "0.42857142857142855",
         "1.0",
         "7",
         "133.33333333333331"
        ],
        [
         "EGFR",
         "0.7",
         "1.0",
         "10",
         "42.85714285714287"
        ],
        [
         "ER",
         "0.75",
         "1.0",
         "8",
         "33.33333333333333"
        ]
       ],
       "shape": {
        "columns": 4,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>RAGLLM_unstruc_res</th>\n",
       "      <th>RAGLLM_struc_res</th>\n",
       "      <th>Number of relationships</th>\n",
       "      <th>perc_increase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Antiandrogen + PARP</th>\n",
       "      <td>0.125000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>16</td>\n",
       "      <td>700.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>B-RAF</th>\n",
       "      <td>0.333333</td>\n",
       "      <td>1.0</td>\n",
       "      <td>6</td>\n",
       "      <td>200.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>B-RAF + MEK</th>\n",
       "      <td>0.428571</td>\n",
       "      <td>1.0</td>\n",
       "      <td>7</td>\n",
       "      <td>133.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EGFR</th>\n",
       "      <td>0.700000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>10</td>\n",
       "      <td>42.857143</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ER</th>\n",
       "      <td>0.750000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>8</td>\n",
       "      <td>33.333333</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     RAGLLM_unstruc_res  RAGLLM_struc_res  \\\n",
       "Antiandrogen + PARP            0.125000               1.0   \n",
       "B-RAF                          0.333333               1.0   \n",
       "B-RAF + MEK                    0.428571               1.0   \n",
       "EGFR                           0.700000               1.0   \n",
       "ER                             0.750000               1.0   \n",
       "\n",
       "                     Number of relationships  perc_increase  \n",
       "Antiandrogen + PARP                       16     700.000000  \n",
       "B-RAF                                      6     200.000000  \n",
       "B-RAF + MEK                                7     133.333333  \n",
       "EGFR                                      10      42.857143  \n",
       "ER                                         8      33.333333  "
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# calculate percentage increase dataframe\n",
    "df_all['perc_increase'] = df_all.apply(lambda row: perc_increase(old=row['RAGLLM_unstruc_res'], \n",
    "                                                                 new=row['RAGLLM_struc_res']), \n",
    "                                       axis=1)\n",
    "\n",
    "df_all_perc=df_all.sort_values(by=\"perc_increase\", ascending=False)\n",
    "\n",
    "# top cancer types with percentage increase >= 30 and number of relationships >= 5\n",
    "df_all_perc.loc[(df_all_perc['perc_increase'] >= 30) & (df_all_perc['Number of relationships'] >= 5), :]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Antiandrogen + PARP', 'B-RAF', 'B-RAF + MEK', 'EGFR', 'ER'], dtype='object')"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_all_perc.loc[(df_all_perc['perc_increase'] >= 30) & (df_all_perc['Number of relationships'] >= 5), :].index"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Accuracy from a subgroup of questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "def avg_acc_over_questions(results_dict, question_ind):\n",
    "    \n",
    "    exact_acc = np.mean([\n",
    "        np.mean([results_dict[run]['exact_match_acc'][q] for q in question_ind])\n",
    "        for run in range(len(results_dict))\n",
    "        ])\n",
    "    \n",
    "    partial_acc = np.mean([\n",
    "        np.mean([results_dict[run]['partial_match_acc'][q] for q in question_ind])\n",
    "        for run in range(len(results_dict))\n",
    "        ])\n",
    "    \n",
    "    return f\"avg exact acc={exact_acc*100:.2f}; avg partial acc={partial_acc*100:.2f}\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "LLM-only: avg exact acc=0.00; avg partial acc=0.00\n",
      "Unstructured: avg exact acc=11.25; avg partial acc=48.75\n",
      "Structured: avg exact acc=100.00; avg partial acc=100.00\n"
     ]
    }
   ],
   "source": [
    "ar_parp_ind = [i for i in range(len(moalmanac_data)) if moalmanac_data.loc[i, 'therapy_strategy'] == 'Antiandrogen + PARP inhibition']\n",
    "\n",
    "print('LLM-only: '+avg_acc_over_questions(all_results_ls['llm'], question_ind=ar_parp_ind))\n",
    "print('Unstructured: '+avg_acc_over_questions(all_results_ls['unstructured'], question_ind=ar_parp_ind))\n",
    "print('Structured: '+avg_acc_over_questions(all_results_ls['structured'], question_ind=ar_parp_ind))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4A-B. RAG-LLM performance on real-world questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "real_questions = pd.read_csv(os.path.join(root_dir, 'data/real_world_queries.csv'), index_col=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load LLM outputs from real-world queries (gpt4o) \n",
    "base_model = 'gpt4o'\n",
    "real_rag_res_dict_4 = load_object(filename=os.path.join(root_dir, f'output/RAG_res_{base_model}/realworld/RAGstra4n5temp0.0_res_dict.pkl'))\n",
    "real_rag_res_dict_5 = load_object(filename=os.path.join(root_dir, f'output/RAG_res_{base_model}/realworld/RAGstra5n5temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Label results from real-world queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load mapping between real-world queries and ground-truth drugs\n",
    "real_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/real_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load results from all runs\n",
    "all_real_results = {\n",
    "    4: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]},\n",
    "    5: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]}\n",
    "}\n",
    "\n",
    "for i in range(len(real_rag_res_dict_4['full output'])):\n",
    "    for strategy, output_dict in zip(\n",
    "        [4, 5],\n",
    "        [real_rag_res_dict_4, real_rag_res_dict_5]\n",
    "    ):\n",
    "        res = calc_eval_metrics(output_dict['full output'][i], real_questions['prompt'], real_prompt_groundtruth_dict)\n",
    "        all_real_results[strategy]['ragllm_input'].append(output_dict['input prompt'][i])\n",
    "        all_real_results[strategy]['ragllm_output'].append(output_dict['full output'][i])\n",
    "        all_real_results[strategy]['full'].append(res)\n",
    "        all_real_results[strategy]['partial'].append(res['partial_match_acc'])\n",
    "        all_real_results[strategy]['exact'].append(res['exact_match_acc'])\n",
    "        all_real_results[strategy]['avg_partial'].append(res['avg_partial_match_acc'])\n",
    "        all_real_results[strategy]['avg_exact'].append(res['avg_exact_match_acc'])\n",
    "\n",
    "def make_eval_df(data, prefix):\n",
    "    return pd.DataFrame(data).T.add_prefix(prefix)\n",
    "\n",
    "real_res_stra4_partial_acc_df = make_eval_df(all_real_results[4]['partial'], 'partial_match_acc_')\n",
    "real_res_stra4_exact_acc_df   = make_eval_df(all_real_results[4]['exact'],   'exact_match_acc_')\n",
    "\n",
    "real_res_stra5_partial_acc_df = make_eval_df(all_real_results[5]['partial'], 'partial_match_acc_')\n",
    "real_res_stra5_exact_acc_df   = make_eval_df(all_real_results[5]['exact'],   'exact_match_acc_')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "def calc_cnt_by_categories(strategy, results_dict, nth_iter, real_questions):\n",
    "\n",
    "    matching_cnt_ls=[]\n",
    "    missing_cnt_ls=[]\n",
    "    hallucinating_cnt_ls=[]\n",
    "    no_output_cnt_ls=[]\n",
    "    \n",
    "    all_true_set_of_subsets=results_dict[strategy]['full'][nth_iter]['true_drugs_generic_set_ls']\n",
    "    all_pred_set_of_subsets=results_dict[strategy]['full'][nth_iter]['pred_drugs_generic_set_ls']\n",
    "\n",
    "    for i in range(len(real_questions)):\n",
    "        true_set_of_subsets = all_true_set_of_subsets[i]\n",
    "        pred_set_of_subsets = all_pred_set_of_subsets[i]\n",
    "\n",
    "        matching_cnt=len(pred_set_of_subsets.intersection(true_set_of_subsets))\n",
    "        missing_cnt=len(true_set_of_subsets - pred_set_of_subsets)\n",
    "        hallucinating_cnt=len(pred_set_of_subsets - true_set_of_subsets)\n",
    "        no_output_cnt=1 if len(pred_set_of_subsets) == 0 else 0\n",
    "\n",
    "        matching_cnt_ls.append(matching_cnt)\n",
    "        missing_cnt_ls.append(missing_cnt)\n",
    "        hallucinating_cnt_ls.append(hallucinating_cnt)\n",
    "        no_output_cnt_ls.append(no_output_cnt)\n",
    "\n",
    "    res_df=pd.DataFrame({\n",
    "        'matching_cnt':matching_cnt_ls,\n",
    "        'missing_cnt':missing_cnt_ls,\n",
    "        'hallucinating_cnt':hallucinating_cnt_ls,\n",
    "        'no_output_cnt':no_output_cnt_ls\n",
    "        })\n",
    "    \n",
    "    res_df=pd.concat([real_questions, res_df], axis=1)\n",
    "\n",
    "    return(res_df)\n",
    "\n",
    "real_rag_res_cnt_df_4 = calc_cnt_by_categories(\n",
    "    strategy=4, \n",
    "    results_dict=all_real_results, \n",
    "    nth_iter=0, \n",
    "    real_questions=real_questions)\n",
    "\n",
    "real_rag_res_cnt_df_5 = calc_cnt_by_categories(\n",
    "    strategy=5, \n",
    "    results_dict=all_real_results, \n",
    "    nth_iter=0, \n",
    "    real_questions=real_questions)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4A. Accuracies of RAG-LLM based on structured data on real-world questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 450x370 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# compute means and standard deviations\n",
    "means = {\n",
    "    'Structured RAG-LLM \\n(without out-of-scope instruction)': \n",
    "        [np.mean(all_real_results[4]['avg_exact']) * 100, np.mean(all_real_results[4]['avg_partial']) * 100],\n",
    "    'Structured RAG-LLM \\n(with out-of-scope instruction)': \n",
    "        [np.mean(all_real_results[5]['avg_exact']) * 100, np.mean(all_real_results[5]['avg_partial']) * 100]\n",
    "}\n",
    "\n",
    "stds = {\n",
    "    'Structured RAG-LLM \\n(without out-of-scope instruction)': \n",
    "        [np.std(all_real_results[4]['avg_exact']) * 100, np.std(all_real_results[4]['avg_partial']) * 100],\n",
    "    'Structured RAG-LLM \\n(with out-of-scope instruction)': \n",
    "        [np.std(all_real_results[5]['avg_exact']) * 100, np.std(all_real_results[5]['avg_partial']) * 100]\n",
    "}\n",
    "\n",
    "# convert to dataframe\n",
    "plot_res = pd.DataFrame(means, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "# Convert stds to DataFrame for error bars\n",
    "error_bars = pd.DataFrame(stds, index=['Exact match accuracy','Partial match accuracy'])\n",
    "\n",
    "# set figure size\n",
    "plt.rcParams[\"figure.figsize\"] = [4.5, 3.7]\n",
    "\n",
    "# set color palette\n",
    "cb_palette = sns.color_palette(\"colorblind\")\n",
    "\n",
    "# create a mapping of rownames to colors\n",
    "row_colors = dict(zip(plot_res.columns, [cb_palette[0], cb_palette[1]]))\n",
    "\n",
    "# create bar plot\n",
    "ax=plot_res.plot(kind='bar', \n",
    "                 yerr=error_bars,\n",
    "                 capsize=4,\n",
    "                 color=[row_colors[name] for name in plot_res.columns], \n",
    "                 width=0.6, \n",
    "                 legend=False\n",
    "                 )\n",
    "\n",
    "# add text\n",
    "for bar in ax.patches:\n",
    "    x = bar.get_x() + bar.get_width() / 2\n",
    "    y = bar.get_height()\n",
    "    ax.text(x, 1, f'{y:.2f}', ha='center', va='bottom', fontsize=10, color='black')\n",
    "    \n",
    "# x, y labels, ticks, grid\n",
    "ax.set_xlabel('')\n",
    "ax.set_ylabel('Accuracy (%)', fontsize=12)\n",
    "ax.tick_params(axis='x', labelsize=10, rotation=0)\n",
    "ax.tick_params(axis='y', labelsize=11)\n",
    "ax.set_facecolor(color='white')\n",
    "\n",
    "# borders\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "    \n",
    "# set alpha for the rest of the bars\n",
    "for i, patch in enumerate(ax.patches):\n",
    "    patch.set_alpha(0.6)\n",
    "\n",
    "# Create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=row_colors[name]) for name in plot_res.columns]\n",
    "legend = ax.legend(handles, plot_res.columns, \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=9,\n",
    "          title_fontsize=9\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure4_realworld_accuracyRAGLLMbar.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4B-C. Stacked bar plot of RAG-LLM drug outputs from real-world questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The result from the first iteration was used for the calculation of matching, missing, hallucinating, and no output counts."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x300 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# convert to DataFrame\n",
    "df = pd.DataFrame(real_rag_res_cnt_df_4\n",
    "[['Question_index','Is_there_an_approval','matching_cnt','missing_cnt','hallucinating_cnt','no_output_cnt']])\n",
    "\n",
    "# add a 'Total' column to sort by\n",
    "df['total'] = df['matching_cnt'] + df['missing_cnt'] + df['hallucinating_cnt'] + df['no_output_cnt']\n",
    "\n",
    "# sort by the 'Total' column\n",
    "df_sorted = df.sort_values(['Is_there_an_approval','total'], ascending=[True, True])\n",
    "\n",
    "# split into groups\n",
    "df_true = df[df['Is_there_an_approval'] == True].sort_values('total', ascending=True)\n",
    "df_false = df[df['Is_there_an_approval'] == False].sort_values('total', ascending=True)\n",
    "\n",
    "# create subplots\n",
    "fig, axes = plt.subplots(nrows=1, ncols=2, figsize=(8, 3), sharex=True)\n",
    "\n",
    "# set colors\n",
    "cb_palette = sns.color_palette(\"colorblind\")\n",
    "colors = [cb_palette[2], cb_palette[5], \"orange\", \"grey\"]\n",
    "\n",
    "# count columns to plot\n",
    "plot_cnt = ['matching_cnt', 'missing_cnt', 'hallucinating_cnt', 'no_output_cnt']\n",
    "\n",
    "# set axes background color\n",
    "ax.set_facecolor('white') \n",
    "\n",
    "# plot each facet\n",
    "for ax, subdf, title in zip(axes, [df_true, df_false], ['FDA-approved', 'Not approved']):\n",
    "    subdf.set_index(\"Question_index\")[plot_cnt]\\\n",
    "        .plot(kind=\"barh\", stacked=True, color=colors, ax=ax, edgecolor=None, legend=False)\n",
    "    \n",
    "    ax.set_title(title)\n",
    "    # ax.set_xlabel(\"Number of Therapies\")\n",
    "    ax.set_ylabel(\"Questions\")\n",
    "    \n",
    "    if title == 'Not approved':\n",
    "        ax.set_ylabel(\"\")\n",
    "\n",
    "# save\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure4_realquestions_stackedbar_1.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x300 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Convert to DataFrame\n",
    "df = pd.DataFrame(real_rag_res_cnt_df_5\n",
    "[['Question_index','Is_there_an_approval','matching_cnt','missing_cnt','hallucinating_cnt','no_output_cnt']])\n",
    "\n",
    "# add a 'Total' column to sort by\n",
    "df['total'] = df['matching_cnt'] + df['missing_cnt'] + df['hallucinating_cnt'] + df['no_output_cnt']\n",
    "\n",
    "# sort by the 'Total' column\n",
    "df_sorted = df.sort_values(['Is_there_an_approval','total'], ascending=[True, True])\n",
    "\n",
    "# split into groups\n",
    "df_true = df[df['Is_there_an_approval'] == True].sort_values('total', ascending=True)\n",
    "df_false = df[df['Is_there_an_approval'] == False].sort_values('total', ascending=True)\n",
    "\n",
    "# create subplots\n",
    "fig, axes = plt.subplots(nrows=1, ncols=2, figsize=(8, 3), sharex=True)\n",
    "\n",
    "# set colors\n",
    "cb_palette = sns.color_palette(\"colorblind\")\n",
    "colors = [cb_palette[2], cb_palette[5], \"orange\", \"grey\"]\n",
    "\n",
    "# count columns to plot\n",
    "plot_cnt = ['matching_cnt', 'missing_cnt', 'hallucinating_cnt', 'no_output_cnt']\n",
    "\n",
    "# set axes background color\n",
    "ax.set_facecolor('white') \n",
    "\n",
    "# change background grid color\n",
    "ax.grid(visible=True, axis='x', color='lightgray', linestyle='--')\n",
    "\n",
    "# plot each facet\n",
    "for ax, subdf, title in zip(axes, [df_true, df_false], ['FDA-approved', 'Not approved']):\n",
    "    subdf.set_index(\"Question_index\")[plot_cnt]\\\n",
    "        .plot(kind=\"barh\", stacked=True, color=colors, ax=ax, edgecolor=None, legend=False)\n",
    "    \n",
    "    # ax.set_title(title)\n",
    "    ax.set_xlabel(\"Number of Therapies\")\n",
    "    ax.set_ylabel(\"Questions\")\n",
    "    \n",
    "    if title == 'Not approved':\n",
    "        ax.set_ylabel(\"\")\n",
    "\n",
    "# create a custom legend\n",
    "handles = [plt.Rectangle((0,0),1,1, color=col) for col in colors]\n",
    "legend = fig.legend(handles, ['Matched', 'Missing', 'Hallucinating', 'No output'], \n",
    "          title=None, \n",
    "          bbox_to_anchor=(0.5, -0.05), ncol=4,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=10,\n",
    "          frameon=False\n",
    "          )\n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure4_realquestions_stackedbar_2.jpeg', dpi=500, bbox_inches='tight')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure 4D. Radar plot comparing all evaluation metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAtUAAAIxCAYAAACCZkT/AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/OQEPoAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzdd3iTZffA8W/SvSfdA0pbaKFQ9hTZSwQHslUE14ui4ut8VcCtP9ziVmQ4wMlSUZQ9LKMtlC4Khe69V9KM5/dHbKC2hY40acv9ua5etMkzTkqf5OTOuc8tkyRJQhAEQRAEQRCEVpObOgBBEARBEARB6OxEUi0IgiAIgiAIbSSSakEQBEEQBEFoI5FUC4IgCIIgCEIbiaRaEARBEARBENpIJNWCIAiCIAiC0EYiqRYEQRAEQRCENhJJtSAIgiAIgiC0kUiqBUEQBEEQBKGNRFItXLMuXryITCZDJpN1qGMJQkdW93d+8eLFDn1MQRAEYxNJtdAqixcv1r8Q1n3J5XKcnZ0ZPHgwK1eupKioyNRhCkKH1BGvn3379rF69Wq2bt1q1PMKgiB0FeamDkDo3CwsLHB1dQVAq9VSUFDAyZMnOXnyJJ9//jl//vkn4eHhJo6ycRYWFvTq1avDHUu4dnSk62ffvn08//zz3Hnnndx0001Nblf3d25hYWGUuARBEDoLMVIttMnIkSPJzc0lNzeX/Px8KioqeP/997G2tiYnJ4f58+cjSZKpw2yUr68vSUlJJCUldahjCdeOznj91P2d+/r6mjoUQRCEDkUk1YJB2dvb8+CDD/Lss88CcPr0aY4ePWriqAShcxDXjyAIQuclkmqhXcybN0//fXR0NFB/MtKZM2dYuHAhvr6+mJub88gjj9TbPzY2ljvvvJPAwECsrKxwcXFh7NixbNy4Ea1W2+R5lUola9eu5frrr8fd3R1ra2t69OjBjTfeyFdffYVKpdJve7XJhT/99BNTp07Fw8MDCwsL3N3dCQ8P56677mLXrl31tm3ORMU//viDmTNn4uHhgaWlJb6+vsyfP5+TJ082uv2+ffuQyWR0794dgP379zN16lRcXV2xtbVlyJAhbNq0qcnzCZ1XY9dPRUUFX375JbNnzyY8PBwHBwfs7Ozo06cPTzzxBAUFBY0e699/Rzt27GDSpEm4u7sjk8nYunUrMpmM559/HoANGzY0qPe+fAJhU5MKlUolW7ZsYdGiRURERODi4oKNjQ0hISEsW7asXSYhJicns3r1asaOHat/rnBzc2P8+PFs3LjxqqP8Fy5c4KGHHiIsLAx7e3ucnJzo27cvDz74ICdOnGjzPmPHjkUmk7F+/fomY2jq91lXd7969Wpqamp4/vnn6dOnD7a2tjg7O+u3y8jI4PXXX2fy5Mn07NkTa2trnJ2dGTlyJO+//z61tbVX/B3k5+fzv//9j/79++Po6Ii9vT1hYWEsXryYPXv26LebNGkSMplM/4avKcOHD0cmk/H6669fcTtB6JIkQWiFO++8UwKk66+/vtH7q6urJUACpJdfflmSJEn/8/r16yUbGxsJkBwdHSVLS0vp4Ycf1u/79ttvS3K5XL+9g4NDvZ9vvvlmSa1WNzhnWlqa1KdPH/12ZmZmkpubm2RhYaG/7cKFC/rtL1y4oL/935588kn9fYDk5OQkWVpa6n8eNmxYve2vdCxJkqQnnnhCf79cLpecnZ0lmUym//njjz9usM/evXslQAoMDJQ+//xzSS6XSzKZTHJycqoX25o1axo9p9Bxteb6ef/99/W3mZubS66urpKZmZn+Nj8/P+n8+fMNjnX539Hrr78uAZJMJpNcXFwkuVwu/fzzz5Knp6dkZ2cnAZK1tbXk6elZ7ys9PV1/vMauJUmSpB07dtT7G3d1da137Tk7O0tRUVGNPt6mjnk1gwYN0u9ra2srOTs717s2FixY0OS+X3/9tWRlZdXk/o3937R0n+uvv14CpC+//LLJOJp67HV/I0888YT+cVpaWkqOjo6Sk5OTfrtbb71Vfwxra2vJxcWl3u9g7NixklKpbPTcf/75Z73nEysrK8nFxUX/3BQYGKjf9ttvv5UAKSAgQNJoNI0eLzExUf/cm5WV1eRjFoSuSiTVQqtcLSlISkrSP1F/8MEHkiRdevGwt7eXxo8fLyUmJkqSJElqtVr/gvLjjz9KgOTi4iK9++67UlFRkSRJklRTUyP98MMPko+PjwRIL7zwQr3z1dTUSBERERIg+fj4SFu2bJFqamokSZKk2tpa6fDhw9KSJUukjIwM/T5NJcKpqamSTCaTzMzMpLffflsqLy+XJEmStFqtlJ2dLa1fv17673//W2+fKyXVX3/9tf6+xx9/XCopKZEkSZKys7Ol+fPn65OQo0eP1tuvLhmytbWVLC0tpUcffVQqKCiQJEmSCgoKpHnz5ulfCOtuFzqH1lw/mzdvlp577jkpOjpaUqlUkiRJkkqlko4cOSKNHDlSAqQJEyY0OFbd35G1tbVkZmYmPfzww/q/l7KyMikvL0+SJElatWqVBEh33nnnFWNvKgnct2+ftGLFCunIkSOSQqGQJEmSNBqNdPr0aWnGjBkSIIWGhjaakLU2qX7ggQek9evXS5mZmfrbKioqpE8++URydHSUAGnTpk0N9tu/f7/+DckNN9wgxcbG6u8rLi6Wvv76a+nRRx9t8z6GSKrt7e0lV1dX6YcfftD/v6ekpOi3e+6556QPPvhAOn/+vKTVaiVJ0r0p++677yRfX18JkF588cUG501KSpLs7e0lQBo+fLh06NAh/f4VFRXS1q1bpSVLlui3VygUkqurqwRIu3fvbvSx1A1GTJs2rcnHKwhdmUiqhVa5WlJw+cjs8ePHJUm69OIRHBysT3gvp1arpYCAAEkmk0n79+9v9LhHjx6VZDKZ5OzsXG/05d1339W/AF3+gnMlTSXCW7ZskQBp6tSpzTrOlY6l1WqloKAgCZDuvvvuBvtpNBpp2LBhEiBNnjy53n11yRAgLVy4sMG+CoVC8vT0vOqLttDxtOb6uZKSkhLJw8NDAqRz587Vu+/yv6NFixY1eYy2JtVXolQq9Z8i/fnnnwY55tXUvZkdPXp0g/sGDhwoAdL06dObHHU1xD6GSKqb+p01x+HDh/WfYvzbzTffLAHSgAEDGn0+bszy5cubfD7SaDT6JP67775rVbyC0NmJmmrBYLRaLefPn+e5557jrbfeAmDYsGEMHjy43nYPPPAA1tbWDfbfu3cv6enpDBkyhDFjxjR6juHDhxMUFERpaWm9WuSvvvoKgP/85z8EBwe36XE4OjoCulrDK9VvN0dMTAypqakAPPPMMw3ul8vlPP300wDs3r2bsrKyRo/TWB2jlZUVkyZNAiA+Pr5NcQqm19zrpzHOzs6MGDECgL///rvJ7f773/8aJtgWsrS0ZOLEicCV4zOk6dOnA3DixAk0Go3+9oSEBH2d+po1a5DLr/4y2Jp9DKV///5MmDChVfuOHDkSZ2dnMjMzycrK0t9eUVHB9u3bAXjppZcafT5uzNKlSwH4+eefKS8vr3ff7t27ycrKwtXVlZkzZ7YqXkHo7ESfaqFN9u/f3+TkvODgYDZv3tzg9uHDhze6fV2Xg7i4OLy8vJo8Z3FxMaCboDNixAhUKhUxMTEATJs2rUXxN2bYsGG4uLgQHR3N2LFjuffee5kwYQLe3t4tPlbdC3GPHj30E8X+bdy4cQBIksSpU6cavKGwsrIiNDS00X3r2pqVlpa2ODbB9Fp6/Vy4cIF3332XPXv2cOHCBaqqqhpMxsvJyWn0eDY2NvTr188wgTchPz+f9957j127dnHu3DkqKioavDFtKr7W2rlzJ+vWrePEiRPk5+ejVCrr3a9QKCgpKcHd3R2AqKgoAAICAprdA7w1+xhKU8+Xlzt06BAff/wxR48eJScnh5qamgbb5OTk6J8v6t5oWFhYtChh79+/PwMHDiQ6OprvvvuOu+++W39f3WTM+fPnY2Vl1exjCkJXIpJqoU0uX7xCJpNhb29PcHAw06dPZ8mSJdjZ2TXYp1u3bo0eq+7FtqamptEXhX+rrq4GdEm2Wq0GdC96beXi4sLGjRtZtGgRBw8e5ODBg4AuMZ46dSr33nsvkZGRzTpWYWEhwBV7+jo6OuLs7ExpaWmjHRy8vLyaHBmrG2G6vKuJ0Hm05Pr566+/mDlzpv7vvm4FRktLSwDKyspQKBRUVVU1ei43N7d2HWGNi4tj/Pjx+r95ACcnJ/3faGVlJVVVVU3G1xr33Xcfn376qf5nKysr3N3dMTMzAyAvLw+AqqoqfVKdn58PtOy5ojX7GEpTz5d1XnnllXqfgtX9TdUtzlNQUIBWq633e697PJ6eni1OgJcuXUp0dDTr16/XJ9VlZWX6lTjvuuuuFh1PELoSUf4htMnli1fk5OSQkpLCb7/9xvLlyxtNqAH9C96/1Y1oLVy4EElX73/Fr8WLF7fXw2LGjBlcuHCBjz76iFtvvRVPT0/9zwMHDmxxu6h/j54JAjT/+qmtreWOO+6gurqasWPHcvToURQKBcXFxfr9Z8+eDdBkG7mmrjtDWbJkCYWFhURERPDXX39RXV1NaWmpPr4VK1ZcMb6W+uWXX/QJ9fPPP8/FixdRKBQUFBSQm5tbr9zBUOc0hSv9v8XFxfHcc88BsGzZMpKTk1EoFBQVFel/7z4+PoDhfgcLFizA2tqaw4cPc+7cOQC2bNmCQqEgIiKCQYMGGeQ8gtAZiaRa6DA8PT0BSE9Pb9F+rq6umJvrPnRJS0szWDwuLi7cf//9/PDDD+Tm5hIdHc3s2bORJIlnnnmGhISEqx6jbpTpSo+poqJCX75xtVEp4dp09OhRsrOzsbOzY8eOHQwfPrzBMuF1o4+mkJaWpu/RvH37dsaPH4+NjU29bQwd3w8//ADAnXfeycqVKwkMDGzW+eqeZ1ryXNGafQD985JCoWj0/qbmUDTXTz/9hFar5frrr+eDDz4gNDS03qcRGo2GoqKiBvvVPZ68vLwWv+F3dnbm1ltvBS6VfNT9254DHYLQGYikWugw6moHjx071ugLQVMsLCz0oyP/XpTFkAYMGMDmzZsJDAxEo9Fw6NChZu0DuhevxMTERrepW2BBJpPRv39/wwUsdBl1o669e/fG3t6+wf01NTX6ut/WqkvGWjOiWRefm5tbk3MH9u3b19rQrnjOpiZy7t27t9Hb655nMjIymvXGuLX7APpFWi4fNb9cUwvMNNfVfgdRUVGNltINGjQIc3NzVCoVf/31V4vPWzdhcdOmTSQlJXH06FHMzc1ZtGhRi48lCF2JSKqFDmPChAn4+/ujVCr1HTGaUlJSUu/n22+/HYCPPvpI/5Fka11pBTIzMzN9DWtTo0+XGzBgAD179gRotGREq9Xy6quvAroVy5ycnFoTstDF1XWkuXjxYqMji2+++WabRz3rztGaSa91+xYXFzc6L+Crr77i7NmzbYqvqXMmJyc3uE+hUOivq3/r3bu3Pgl9/PHHm9XhpzX7AERERAC6VSwbs2bNmmYdpylX+h1otVpWr17d6H4ODg7cdNNNgK4rUXOeyy43duxYgoKCSE9P1yfY06dPx8PDo0XHEYSuRiTVQodhaWnJu+++C8Bnn33G/Pnz67WKUygUHDp0iAceeIBRo0bV23fp0qVERERQWVnJ2LFj+f777/XJh0ql4sCBA8ybN4/MzMyrxvHRRx8xdepUNm/eXO8j5MLCQh577DFSUlKQy+X6FmFXIpPJeOGFFwDd8s//+9//9MlPbm4ut99+O1FRUcjlcv0y0YLwbyNHjsTa2pqioiKWLFmiT1zLysp44YUXWLlypX7CY2v16dMH0HWSSElJadG+4eHheHt7I0kSCxcu1JdJVFdX8+GHH3L33Xe3Ob5/q+ta8emnn/L111/rJyufOXOGqVOnkp2d3eS+b731FmZmZvz666/MmjWL06dP6+8rKSnh888/56GHHmrzPrfeeisymYxTp07x3//+V9+GLjMzk0WLFnHs2DGD/A527tzJW2+9pX/Ou3jxInPmzOHAgQNNzm15+eWXsbOzIzY2lvHjx3PkyBH9pxSVlZX6JecbI5PJ9BMSjxw5AogJioIANLL8myA0w9UWr2gMzVzg4dNPP623vLGtra1+SeW627p3795gv4sXL0phYWH6bczNzVu1TPnbb79db5lfe3t7/epsdV+vvPJKvX1asky5mZlZvaWA5XK59NFHHzXY5/LlpZvS3AU7hI6lNdfPa6+9Vu9v0NnZWX9NLFq0SH/MVatW1duvOX9HkqRbebRnz54S6JYx79atmxQYGCgFBgbWW4m0qev4m2++0f9NA5KTk5Nkbm4ugW6p7P/9739N/q0297nhcjU1NdKAAQP0+1pYWOivUysrK2nnzp1XPO5XX30lWVpa6rexs7Ort8R3Y/83rdmnbsGUut9r3bLm1tbW0q5du666+Mu//z8vp9VqpWnTpumPIZfL9ceXy+XSJ598IgUGBkqAtHfv3gb77969u95zm7W1teTq6qr/u7rS30xGRoZ+u27dukm1tbVNbisI1woxUi10OPfccw+JiYksX76c3r17A7qRE09PTyZNmsTrr7+ub3N3ucDAQKKjo3nrrbcYPnw4dnZ2VFVV4efnx8yZM/nmm2/w8/O76vkXLFjAp59+ym233Ubv3r0xMzOjpqYGPz8/brvtNvbt23fV8pR/e/311/n999+ZMWMGLi4uVFZW4uXlxdy5c4mKiuL+++9v0fGEa8+TTz7JV199xeDBg7GyskKr1TJ48GA++eQTNm7c2ObjW1hY8Ndff3H77bfj6+tLSUkJaWlppKWl6UeBr2T+/Pn8+uuvjBkzBjs7O9RqNeHh4bz++uv88ccfDSZWtpW1tTV79+7l4Ycfxt/fH9D14p49ezZHjhzhhhtuuOL+CxcuJD4+nvvvv5+ePXui0WiQJImIiAiWL1/O22+/bZB93n33Xd577z369u2LpaUlZmZm3HTTTRw9epQpU6a06Xcgk8nYunUrq1atIjg4GDMzM8zNzZk2bRq7d+/m3nvvveL+EydOJCkpiccee4zw8HDkcjkqlYrQ0FCWLFnChg0bmtzXz8+PIUOG6H8vhv7/FYTOSCZJnbjXkCAIgiAIRldaWoq3tzcKhYLY2FgxyVoQEDXVgiAIgiC00MaNG1EoFAwePFgk1ILwD5FUC4IgCILQbOfOneOVV14BaDA5UxCuZaL8QxAEQRCEq5o3bx6HDh0iJycHrVbLoEGDiIqKavfVOgWhsxAj1YIgCIIgXFXd8u8uLi4sWLCAnTt3ioRaEC4jRqoFQRAEQRAEoY3ESLUgCIIgCIIgtJFIqgVBEARBEAShjURSLQiCIAiCIAhtJJJqwWgkSaJ///7Y2dlRUFBg6nA6lNjYWGQyGTfffLOpQxGENhHXedPEdS4IXZtIqgWj+fbbbzl9+jT33HMP3bp1M3U4TcrMzOTrr7/mkUceYdSoUdjZ2SGTyejevXuzj7Fjxw4mTZqEu7s7tra29OnThxdeeIGamppGt4+MjGTatGls3bqV48ePG+iRCILxdZbrPDExkZdffplJkybh5eWFhYUFLi4ujBw5kjfffJPq6uom923tc4S4zgWhi5MEwQhUKpXUs2dPycLCQsrIyDB1OFf08MMPS0CDr8DAwGbt/9RTT+n3MTc3l+zt7fU/R0RESCUlJY3ud+DAAQmQJk6caLgHIwhG1Fmu83379tW7tmUymeTs7CzJZDL9baGhoVJ6enqj+7flOUJc54LQdYmRasEoduzYwfnz55kyZQp+fn6mDueKZDIZQUFBzJ07lzVr1vD44483e9+ff/6Z1157DYBVq1ZRXl5ORUUFe/bswdPTk7i4OO6+++5G973uuusIDg7mzz//JCEhwSCPRRCMqbNc5yqVCgsLCxYuXMiuXbuorKykpKSE8vJyPvroI+zt7Tl79iy33HILUiNdZ9vyHCGuc0Howkyd1QvXhhkzZkiAtGnTJlOHclVqtbrez5s2bWr2KFR4eLgESAsWLGhw3++//64f0Tp58mSj+z/zzDMSID322GOtil0QTKmzXOfp6enShQsXmrx/48aN+mt17969De5vy3OEJInrXBC6KjFSLbS7/Px8du3ahYWFBbNmzWp0m7FjxyKTyVi/fj1VVVU8++yzhISEYG1tjbe3N3fddRdZWVlGibe1K4TFxcXpR55WrFjR4P7JkycTHh4O6OpOGzN79mwANm3ahFarbVUcgmAKnek69/f3v2L987x587C0tAQgOjq6wf1tXUVQXOeC0DWJpFpod3v37kWtVhMREYGDg8MVty0vL2fkyJG8/PLLZGVlIZPJyM3NZf369YwcOZKioiIjRd1y+/btA8DFxYVBgwY1us3EiRMB3e+kMf369cPe3p68vDzi4uLaJU5BaA9d6Tq3sLDQPwaNRmPw44vrXBC6JpFUC+3uyJEjAE0mmpdbtWoVVVVV/PXXX1RVVVFRUcEvv/yCi4sL6enpvPrqq+0dbqslJiYC0Lt3b2QyWaPbhIWFAZCUlNRoraZcLmfgwIEAHD58uJ0iFQTD60rXeXx8vD6x79u3r8GPL65zQeiaRFIttLu61lH9+vW76raVlZXs2LGD8ePHI5PJMDc3Z/r06axcuRKAH374ocE+69evRyaTtepr/fr1BnucOTk5AHh7eze5Td19VVVVVFZWNrpN//79ATh27JjBYhOE9taVrvNVq1YBujKRCRMmtGjf5hLXuSB0PeamDkDo+nJzcwFwd3e/6ra33nqrfjT3cjfeeCMrVqwgLS2Nqqoq7Ozs9PfZ2Njg6enZqthsbGxatV9jqqqqrnpMW1tb/feVlZWNfkxe93uqS9IFoTPoKtf5hg0b+PHHHwF488039bXVhiauc0HoekRSLbS7wsJCQFdrfDVNjXL5+vrqvy8tLa33Yjt37lzmzp3bxig7jrrfU93vTRA6g65wnR89epT//Oc/ANx3333cdttt7XYucZ0LQtcjyj+EdqdUKgGwsrK66rY+Pj6N3m5tba3/XqVSGSYwA6tLAJpaNRGot0qbvb19o9vUPVaFQmHA6AShfXX26zwuLo4bbriBmpoabrzxRtauXduu5xPXuSB0PSKpFtqdq6sroBt56srq6qWv9HFu3Ufk9vb2TSbVJSUlALi5uRk4QkFoP535Ok9JSWHSpEmUlJQwduxYvvvuO8zN2/eDXHGdC0LXI8o/hHbn7u5Obm6u/kXE0LZs2cLDDz/cqn3fffddg32k/O/OHo11AGlOh5C631NzalMFoaPorNd5eno6EyZMIC8vj6FDh7J9+/Z6I+btRVzngtD1iKRaaHe9evXizJkzXLx4sV2OX1NTQ15eXqv3NZSxY8cCuhfL6OjoRluL/fnnnwCMGzeuyePU/Z569eplsNgEob11xus8Ly+PiRMnkpGRQUREBL/99ttVe2wbirjOBaHrEeUfQrsbNWoUACdOnGiX4y9evBhJklr1tXjxYoPFERERQZ8+fQB45513Gtz/559/Eh8fD+hWbGtKXWuyut+bIHQGne06LykpYfLkyaSkpBAaGsru3bv1JSzGIK5zQeh6xEi10O5Gjx4NwMmTJ00cSfOoVCrKysr0P9f1k9ZqtfVm6ltbWzeoi37ppZe4+eab+eqrrwgJCeGJJ57A2tqa/fv3c/vttwO6dmJ1Cz/8W0lJCefPn0culzNy5EhDPzRBaDed6Tqvqqrihhtu4PTp03Tv3p0///yzRe362vIcAeI6F4SuSoxUC+1u8ODB9OjRg7y8PKKjo00dzlUdPnyYbt266b/qWmxlZGTUu/3BBx9ssO9NN93EU089BegWkHBwcMDBwYGxY8eSm5tLREQEn332WZPn/u233wAYP368UUfNBKGtOtN1/uOPP3L06FFA19JuyJAheHl5Nfr1xhtvNNi/Lc8RIK5zQeiqRFIttDuZTKb/+HXLli2mDcYIXn31VbZv387EiRNxdHREo9EQHh7O888/T1RU1BX7+Nb9fgxZliIIxtCZrnOtVqv/vrKykry8vCa/mlr5tC3EdS4IXZNMkiTJ1EEIXV96ejo9e/bE19eX1NRU5HLxfu7fSktL8fLywtbWlqysLIOu9igIxiCu86sT17kgdF3iGU8wioCAAO68807S0tL46aefTB1Oh/Thhx+iVCp54oknxAut0CmJ6/zqxHUuCF2XGKkWjCYjI4OQkBD69OnTKSYzGVNNTQ3du3dHLpdz/vx5bG1tTR1Sh6XVaikqKiI/P5/KykoqKiqoqKho8H15eTmVlZWoVCq0Wi0ajQatVoskScjl8npfVlZW2Nvb4+joiL29vb4W/vLvHRwc8PT0xNnZucke44K4zq9EXOeC0LWJ7h+C0fj7+7N+/XqSkpIoLCwUix5cJj09nf/85z+MHDnymn6hraqq4ty5c2RkZJCTk0NOTg7Z2dlkZWWRnZ1Nbm4u+fn5qNVqbG1tsbOzw9bWVv9V93Pdv3UrV16eQMtkMiRJQqvV6r+USiUFBQWkpaVRVVVFdXU1VVVV1NTU6P+trKxEoVBgaWmJp6cn3t7e+Pr64uPjg4+PD97e3vj4+BAYGEhQUBCWlpam/nWahLjOmyauc0Ho2sRItSAIRqVSqbh48SJnz57l7NmzJCcnk5SUREpKCtnZ2djb2+Pl5UW3bt1wd3fH09MTHx8ffH198fPzIyAggO7duze5zHt7Ki4uJi0tjfT0dDIzM8nKyiInJ4f8/Hzy8/MpKioiJyeH2tpaAgICCA0NpVevXvTq1YvQ0FBCQ0Px9/cXtcaCIAhdkEiqBUFoN6WlpURHR3Py5EmOHz9OTEwMFy9eRCaT4e/vT2BgID169KBXr16Eh4cTERHR6ZNOjUZDamoqp0+fJiEhgbNnz3Lx4kXS0tLIzs7G3Nyc4OBgBg4cyJAhQxg0aBCRkZFi5FIQBKGTE0m1IAgGUbc8e10CfeLECS5evIiXlxfh4eH069ePwYMHExkZSa9evTA3v/aqzxQKBQkJCURHR3PixAni4uJITEykrKyM0NBQBg8eXC/RtrOzM3XIgiAIQjOJpFoQhFbJz89n//797N27lz179pCcnIyPjw9hYWH079+foUOHMmrUKPz8/Ewdaoem1Wo5f/48hw4d4vjx4/pEu6SkhMjISMaPH8+4ceMYPXo0jo6Opg5XEARBaIJIqgVBaJZ/J9Fnz54lJCSEoUOHMm7cOKZMmYKvr6+pw+wS6hLt3377jf3793P8+HGys7Pp37+/SLIFQRA6KJFUC4LQKJVKxaFDh9i+fTu7du0iOTmZ4OBgfRI9ffp0vL29TR3mNSMlJYVff/1Vn2Tn5OTQv39/pk+fzqxZsxg4cGCnrkUXBEHo7ERSLQiCXmlpKbt27WLr1q3s2rULc3NzxowZw7Rp05g+fboYie5AUlJS2LlzJ7t27eLIkSPY29szc+ZMZs6cyfjx48XCIoIgCEYmkmpBuMalpqayY8cOfv75Zw4fPkz37t2ZMGECt9xyCxMmTMDMzMzUIQpXoVAo2LFjB9u2bWPv3r2UlJQwadIkZs2axQ033ICnp6epQxQEQejyRFItCNeg7Oxsvv32WzZu3EhCQgKDBg1iypQpzJs3j7CwMFOHJ7SBVqslKiqK77//nt27d5OYmMioUaO44447uPXWW3F2djZ1iIIgCF2SSKoF4RpRXl7OTz/9xMaNGzl48CCDBg3itttu48477xSr3nVhFy5cYN26dfz000+cO3eOG264gdtvv53p06djZWVl6vAEQRC6DJFUC0IXVltby++//87GjRvZsWMH3bt35+abb2bp0qUEBwebOjzByKKjo/n888/Zvn07lZWVzJkzh0WLFjF69GgxyVEQBKGNRFItCF1QQkICH3/8MZs2bcLGxoYZM2awdOlShg0bZurQhA5Aq9Xyxx9/sH79en7//Xfs7e1ZsmQJ99xzj+grLgiC0EoiqRaELkKpVPLjjz/y4YcfcuLECSZOnMi9997LDTfcICYbCk1SKBR8++23rFu3jqioKKZMmcKyZcuYPHmy+LsRBEFoAZFUC0Inl56ezkcffcSnn36Kvb09ixYt4sEHHxQ9pIUWS0pK4t133+WHH37Azs6OBx98kCVLluDq6mrq0ARBEDo8kVQLQickSRL79u3jvffe45dffmH06NE88MAD3HzzzaI2VmgzpVLJ+vXr+eSTT0hMTGThwoU89NBD9OvXz9ShCYIgdFji1VcQOhGtVsuPP/7IoEGDuPnmm3Fzc+PUqVPs2bOHW2+9VSTUgkFYWVlx3333ER0dze7duykpKWHYsGFMmTKFAwcOIMZiBEEQGhKvwILQCdTW1vLll1/Su3dvHnjgAaZPn05aWhqff/656CsttKvRo0fz448/cvbsWXr06MENN9zAyJEj2blzp0iuBUEQLiPKPwShA6uurubzzz/n//7v/zAzM+PBBx9k+fLlWFtbmzo04RpVVFTEa6+9xpdffomXlxfPPPMMt912G+bm5qYOTRAEwaREUi0IHVBJSQlr167lnXfewcPDgxUrVrBkyRKRuAgdRmVlJW+//TYff/wxlpaWPPXUU9x5553iDZ8gCNcskVQLQgdSXV3NO++8w+uvv05wcDBPPvkks2fPFrXSQodVW1vLxx9/zHvvvYdCoeDFF1/kjjvuEO34BEG45oikWhA6AJVKxbp161i1ahVubm68+OKL3HLLLaYOSxCaTaPR8NFHH/Haa6/h4ODAa6+9xsyZM5HJZKYOTRAEwShEUi0IJiRJEj/88ANPP/00KpWKZ599lqVLl4qRaaHTUigUvP7667z33nuEhITwf//3f4wZM8bUYQmCILQ78cotCCby119/MXjwYB544AGWLl1KSkoK99xzj0iohU7N2tqaVatWcf78eYYPH8706dOZNm0ap0+fNnVogiAI7Uq8eguCkcXHxzNx4kRuvvlmxo8fz7lz53j66aextLQ0dWiCYDDOzs688847JCcn4+HhwdChQ1m0aBHZ2dmmDk0QBKFdiKRaEIykoqKC//73vwwePBhfX19SUlJYs2YNjo6Opg5NENqNr68vGzZsIDY2lsLCQnr16sWbb76JSqUydWiCIAgGJWqqBaGdSZLE5s2befTRR/Hy9kE2ZTmZlt5M7dWNeQN8mRTaDQsz8f5WuDb8/PPP/Pe//8Xa2poPP/yQsWPHmjokQRAEgxBJtSC0o/j4eJYtW0ZCQgKrVq1C6j+Nh7cl1NvGzdaC2/r7MH+AL6O6uyKXi24JQtemVCpZvXo17733HjNnzuTNN9/Ex8fH1GEJgiC0iRgeE4R2UFfqMWjQIHr06EFSUhIPPvgg609kNti2qFrFx0fTuP7DI/R45U+e3JlAbFaZWAJa6LKsrKx49dVXOXXqFKWlpfTq1Ys33nhDlIQIgtCpiZFqQTCwbdu2cd999+Hn58cHH3zAsGHDAIjJKmPQ2wcAGOTnxLMTQ9kcm8X2+FxqVNoGxwnzsGfeAF/mD/Al2N3OqI9BEIzp8pKQ9evXM3ToUFOHJAiC0GIiqRYEAykuLubBBx9k586dPP/88zz88MP12uM9+FMcHx65CMCHt0Rw/8juAFQo1GyLz2VzTBa/ny1Ao214SQ71d2beAF/mRvrg7SiWgRa6HqVSydNPP81HH33Eww8/zPPPP4+VlZWpwxIEQWg2kVQLggFs376de+65h169evHll1/Ss2fPevfXqDT4vrCb0hoVNhZysldOxsnGosFxCiqV/HA6h80xWRy8UNzgfrkMxvZ0Z/4AX26J8MLFVrThE7qWv//+m7vuuguAjRs3MmTIEBNHJAiC0DwiqRaENiguLmb58uXs2LGj0dHpOt/GZLHw62gAbh/kx4b5A6567PSSarbEZvNtTBax2eUN7rc0kzOtdzfmD/BjRrgHtpbmbX9AgtABKJVKnnrqKT7++GMeeeQRVq9eLUatBUHo8MRERUFopR07dhAWFkZ6ejoxMTGsWLGiydUQ1x1L139/1xB/du7cycCBA7GyssLf359Vq1ah0Wjq7ePvbIN0/CdK3l+M+fuzcf/hUTyyovT312q0bIvPY95XJ/F6/g/u+Caa3xLzUGka1mcLQmdiZWXF22+/zZ49e9i6dSuRkZEcP37c1GEJgiBckUiqBaGFysvLuf3221m4cCFPPvkk+/fvb1DucbkLRdX8lVIIQE83W6wKUpg1axbh4eFs376dFStWsGbNGp588sl6+61Zs4ZnnnmGxYsXs3PHDubMmEL+lld4I7ySh6/rgZfDpZG7SqWGr6KzuOGLY/g8/wfLfjzNwdQitI3UZwtCZzFixAhiY2OZMmUKY8aM4ZlnnhEdQgRB6LBE+YcgtEB0dDSzZ8+mW7dufP311wQHB191n5W7knjpzxQAXprWmwNrllNQUMDJkyf127z55ps8/fTTZGRk4OnpSW1tLe7u7txzzz28+eab+u1uvPFG0tPTOXXqFBqtxP7zRXwTk8VPcTmU1jRMNvydrZkXqesg0t/HEZlM9MAWOqfDhw9z55130q1bN7Zs2UJAQICpQxIEQahHjFQLQjNIksR7773H6NGjufnmmzly5EizEmqNVmLDiQxAN8nwzsF+xMTEMHny5HrbTZkyBZVKxe+//w7A+fPnqaioaHS706dPk56ejplcxvgQdz6f05+cVZP4efEQ5kb6YGNx6bLOKFWwZt95Br59gL5r9vHi7rOcK6xq669DEIxu1KhRREdH4+vrS//+/dm+fbupQxIEQahHzGwShKsoKSlh8eLFREVF8f3333PDDTc0e98/UwrIKFUAMLWXB75ONigUigaTrup+TkxMBEChUNS7vbHtLh+pszI3Y1ZfL2b19WqyRV9ifiWrfk9m1e/JXbpFnyRJaDQaJElCq9UiSVKD72UyGXK5HJlM1uB7MzMzMaLfQTk6OvLDDz+wdu1aFixYwN13383//d//YWkpuuAIgmB6IqkWhCv4+++/mTNnDt27dycmJgZvb+8W7b8u6tIExSXDdElwSEgIx44da3Ae0HUTAejZsycymYxjx44xduzYJrdrjIO1OYsG+bFokF+TLfqOZZRyLKOUx3bEd5oWfVqtFoVCof9SKpVNft+YuqRZJpPpk+ymtrOyssLa2lr/1djPVlZWTU5MFdrXgw8+yOjRo5k3bx4HDx7ku+++u+K8BkEQBGMQSbUgNEKr1fLGG2+wevVqVqxYwYsvvtjiBKqwSsnW+FwAutlZMiPME4Bly5axdOlS3n33XW6//XYSEhJ45pln6o2QOjo6smjRIl5//XUiIiIYPnw4O3bs4NtvvwVo9khqN3sr/jOyO/8Z2b3RFn1aCfacK2TPuUIe+CnOpC36JElCoVBQWlpKWVkZ1dXV9RLm2tpagHoJbt33zs7O9X42NzdvMALd2O+sbuT68pFslUrVIFGvrq6muLhYf3tTsdjZ2eHs7Iyzs7MYPW1nkZGRREdHc8899zBgwAA+//xz5syZY+qwBEG4homJioLwL+Xl5SxYsICYmBg2bNjAxIkTW3Wcdw+msmJbPACPXh/EGzf2AXQJ+3//+1/Wrl2LWq3G0tKSVatW8c477/DAAw+watUqAIqKipg/fz67d+8GwN3dnaeeeorHHnuMffv2cf3117f6MSbmVfBtTBbfxmRxvqi6wf32Vmbc1MeL+QN8mRjaDQszw47IXp5A132VlZWhVCpxcHDAyckJOzu7Djs6rNFoGh0pr6yspLS0lOrqamxsbPQJtrOzM05OTp2+17IkadHWFKKuzEJTmYW6Mlv/r7oyC0ldjdPAFdgFzzJqXF988QUrVqxg8eLFvPXWW5ibi/EiQRCMTyTVgnCZ8+fPM2PGDJydndm6dSuenp6tOo4kSUS+tZ+4nAoAzjw2lnAvh3rblJWVkZaWRkBAACqVCg8PD3bt2sWUKVPqbZednU1xcTEhISFs376dRYsWUVhYiIND/eO1Ns4TGWV8E5PJlthscisalk6421kyu5838wf4Mqq7K3J5y+qNJUmipqZGnzjXJdG1tbU4ODjoE866f7tCQlRbW1vv8ZaVlVFVVaVPtOser7Ozc4dJtCW1EnVVNprKbNSVmf/8W5c0Z+l+rsoG7ZVb2sksHQlYmorcytFIkeucOXOGm266icDAQL7//ntcXV2Nen5BEASRVAvCP/766y9mz57NrFmz+PTTT9v08f3x9FKGvXcQgOGBLhxZPvqK269cuZKvvvqKlJQUzMzMGt1Go9EwadIk/Pz82LhxY6tja4qhWvRJkkR5eTm5ubkUFxdTWlqKSqXSj0DXJZOOjo5dIoFurtra2npJdmlpKVVVVfryFXd3d7y8vLCzszPoeSVJQqssvTSyXJWNuiJTnyTXJc3amkKDndP1utdwGvSowY7XXMXFxdxyyy2kp6ezc+dOwsPDjR6DIAjXLpFUC9c8SZJYu3YtTz75JM8//zyPP/54m495/w+n+fTvNAA+va0fdw8L1N937Ngx9u/fT2RkJDU1NWzfvp1Nmzbx22+/MX78eP12X3/9NTU1NQQHB5Odnc0nn3zChQsXiIqKavGEyZZSqjXsSipgc2wW2+NzqVE1nNQX5mHPvAG6BDvI1YbCwkJyc3PJzc2ltraWbt260a1bt2sygW4ulUqlH7nPz8+nqKgIe3t7vLy88PLywsXF5Yr185JWjaY6D3VFFpqqrIYjy//8K6kblvi0lNzaDXN7H8zs/f751wdze1/M7Hwwd/BFUivI3jwKADN7X/zvSkZmZvy6co1Gw4MPPsjXX3/NN998w4wZM4wegyAI1yaRVAvXtNraWh544AF+/vlnvvrqK6ZOndrmY1bXqvF5YTflCjV2lmZkr5yMg/WlhDI2Npb777+f+HhdvfWwYcN48cUXGTFiRL3jfPXVV7z88stcuHABe3t7pk+fziuvvIKfn1+bY2yJplr0XS7UAcZ6mzE7wouIIF/c3d2bHHEXmqZSqcjPzyc3N5f8nDQstSV42GtxsanFVl6BVJ2L+rKkWVOdC1Ibl6WXm+sSY32i/E/SbOeDmb0v5g66xFlufvXWi3nbb6E6dScA7lPW4RC2qG2xtcFHH33Ef//7X1auXMmTTz4p2iQKgtDuRFItXLPy8/O5+eabKS4uZvv27YSEhBjkuJtOZnDnt7EALB7iz7q5kQY5bkdwMa+YjX+f56eEQk4XqRvcL5fRaVr0mUr9yX51dcuZ//ybjboqC01FFtrasjafS2bpoBtNtvfF3O5S0qwfZbb3wczWA5nMMJM/FVmHyPle92mLhXtffBeeNGkyu3//fubOncu4ceNYt24dNjY2JotFEISuTyTVwjUpOTmZyZMn07t3b77//nscHQ03qWrch0fYn1oEwIEHRjK6h5vBjm1skiRRXFysL+uorq7W1/6qrJ3ZllRUr0Xf5SzN5CZt0WcKkqa2fglG1T9Jc0XmpUmAVdmgqW3beZChNXdBZuuFlXMg1s6B9Uaa65JmuWXbJ7O2KC5JImfLdShzdX3YPW/aiW33yVfZq32lpaUxc+ZMrKys+PXXX3F3dzdpPIIgdF0iqRauOceOHWPq1KnMnj2bjz/+2KAt2s4VVhH62h4AenWzI+GJcZ3yY2eFQkFGRgZpaWnU1tbqa3y7deuGhYVFg+1N3aKvvekm+5VdoW5Zd7u2pqDN55KZWetGli+vW6772U5XjqE2cyG/UPdmJz8/HwcHBwIDA/H19W30/8eYqlJ+Iv+XeQBYB0zA+5bfTBoPQHV1NbNmzSItLY3du3cTGBh49Z0EQRBaSCTVwjVl165dzJ49W7+gi6E981sir/51DoDXbgjjiXHBBj9He5EkiYKCAi5evEheXh6urq4EBgbi7e3d7PpoY7ToMzRJq0FTnVtvYp/6snIMTVUW6oosA032c9UnyWb2Ppjb+WDu4HdZTbMvcmvXFr0RU6lUZGZmkpaWRmVlJX5+fgQGBuLs7GySN3SSVkPmhr6oy84D4LMgCiuPAUaP49/UajWLFi1i//797N69m759+5o6JEEQuhiRVAvXjK+++op7772XNWvW8MADDxj8+GqNlu4v/0V2uQIzuYyMZyfi5Xj1yV2mplAoSEtLIy0tDa1WS0BAAAEBAdjb27fpuJe36PvxdDZlioY12M1p0dcWWlX1ZaPKTbSUq8oFSdO2E8nNMbPz1tUtO/hibvdP0vyvbhly8/at6S0tLSUtLY2MjAzs7Ozo3r07/v7+Ru+8Un7qY4r2PgSAXa95eEwzfAvI1tBqtaxYsYINGzawY8cOrrvuOlOHJAhCFyKSauGaULfk+Jdffsltt93WLuf4JSGPG9fpakln9vFk611D2+U8hlJaWkpqaipZWVm4ubnRvXt3vLy82mXFwroWfd/GZLEj4eot+oLdr9yrWZKkS5P9qrL/1VLu0uIlWmVpm2OXWTr8M8nPVz+aXDfJTz/qbMDJfoagVqvJysriwoULVFVVERgYSI8ePQzeA7spWlU1GeuCdb2vZWb435WMuWOAUc7dHK+88govv/wy33zzDbNmGXf1R0EQui6RVAtdmlar5YknnmDdunX88MMP9fpAG9qt64/z85lcALbeNYSZfbza7VytpdVqyc3N5fz585SVleHv709QUJBBVmdsrqu16LNAxSQ/DXNCZYz3qcVBW/CvZbF1HTLaOtkPZJjZel42ovzvZNkHcztfo68MaEiSJFFSUsL58+fJzc3Fw8ODoKAg3N3d2700pOToC5RGvQSA44CHcbt+Tbuer6W++OILli9fzrvvvss999xj6nAEQegCRFItdFlqtZq77rqLPXv28MsvvxAZGdlu58qvUOL34m7UWgkvByvSn52IeQeajKdWq7l48SKpqakABAUFERAQ0KZVI1tKkiSk2vJ6fZbLi9M5l3GO4oKLmCtz8TIrxt3MAK3kzKwaJsn/LFJiZlc36c8bmZlpJ/UZU01NDRcuXODixYvY2NjQs2dP/Pz82uWTCQBNdQEZX/RE0iiQWdjjvzQVM2vndjlXa23fvp2FCxfy9NNP87///c/U4QiC0Ml1/R5XwjVJrVazcOFCjh8/zqFDh+jRo0e7nm/TyUzU/4y43jHYv8Mk1FqtlrS0NJKTk7GxsaFv377tUuKhm+yX969uGJe1lPtn4p+kqmqwb8A/XzQzv1ebO2Pt6IeFg+8/9cuXSjPqyjFaOtnvWmBjY0N4eDihoaFkZmZy9uxZUlJSCAsLw9vb2+C/LzPbbtiH30FF3KdIqkoq4j7DeUjbVys1pJkzZ7Jr1y5uvPFGlEolq1evFn83giC0mhipFroclUrFvHnzOH36NHv27MHf379dzydJEn3X7CMxvxKAxCfG0cujbZP8DBFTdnY2iYmJyGSyNiVOlyb7ZTfRUi4bTVVO2yf7ycz0HTGqLTxIrnTgcL4N8eUO5GlcydO4kqtxRYlVp2/R1xFc/obL1taW8PBwg/dwVpWkkLmhLyBhZueN/11nkZlbGfQchnDs2DGmT5/O/fffz4svvigSa0EQWkUk1UKXUltby5w5c0hMTGTPnj34+vq2+zmPXixm1NrDAIzu4cqBB0a1+zmbUtcWLyEhAaVSSe/evfH39290ZFqSJLSKon/VKzdMmrXKkjbHJbOwb9AJ41L/5X9W9rPxQCav37qvM7bo62zUajWpqamkpKTg6upKeHg4Tk5OBjt+3o7bqD6/DQD3SZ/h0OdOgx3bkE6ePMnUqVNZsmQJr732mkisBUFoMZFUC12GSqXitttuIzk5mb179+LlZZyJgvd8f4ovotIBWDc3ksVD2ndkvCklJSUkJCRQVlZGaHB3/LtZI9Xk6RNkfbJclY2mQleaIWkaJqktI8PM1qNh+7i6uuV/2ssZYrJfR2jR15XV1taSkpLChQsX8PLyIiwszCDdQhTZf5Pz3RgALFzD8L09tsP+v8TExDBlyhSWLFnCq6++2mHjFAShYxJJtdAlqNVq5s6dy5kzZ9i/f7/REupKpRqfF/6gUqnB3sqMnJWTsbMyzlQFjaKY6gu/Ul14nqKseFTlmdibVWGuLkJbk9/m49dN9qsryagbVa7rlKG73RuZmfEmO9YxdIs+4ZKamhqSkpLIzMwkMDCQ0NBQrK3b1m89+7uxKLOPAOA5axu2PaYZItR2ER0dzeTJk/nPf/7TLgtECYLQdYmkWuj06iYlRkdHs2/fPqOUfNT58lg6S787BcDSYQF8dlt/o5xXkrRkbhqMuvhMq/aXW7n8M7rs12RLObm1W6cYqbtaiz6Aof7OzBvgy9xIH7w7wYI8xrBz505WrlxJfHw8Hh4eLFmyhJUrV+pXzywvLycxMZFffvmF7777josXLxIQEMDTTz/NXXfd1aJzVZ3bRv5OXX94a7/r8Z692+CPx5BOnDjBlClTWL58OatXrzZ1OIIgdBIiqRY6Na1Wy5133smRI0fYv38/fn5+Rj3/dWsPcfiirub4yPLRDA90afdzqlQqzh3diHX0fxreKTPTreynr1u+LGm28/2npZwPcgvbdo/TFAoqlfxwOofNMVkcvFDc4H65DMYFuzMv0pdbIrxwsTX+KHtH8PfffzNq1Cjmz5/P7bffTnx8PM8++yzLli3jjTfe0G936NAhxo4dy4wZMxg+fDiZmZl8+OGHfPfdd8yePbvZ55MkLVkbI1CVpADgM/8oVp6DDP64DCkqKoqpU6fy1FNP8eSTT5o6HEEQOgGRVAud2uOPP84333xjlLZ5/5acX0nY/+0FINzTnrjHxrb7yG5+fj4xMTH4576BTcl+AJxHrMY2cLJusp+tZ4PJfteq9JJqtsRm821MFrHZ5Q3utzSTM613N+YP8GNGuAe2ltdOh9GpU6dSUFDAyZMn9be9+eabPP3002RkZODp6QnAlClTqKys5NChQ+Tn5xMfH8/LL79MVlYWSUlJLTpnedznFP21DAC70NvwmP614R5QOzlw4AA33HAD77//PosXLzZ1OIIgdHCiD5XQab3xxht88cUX/PLLL0ZPqAHWHUvXf79kaEC7JtQqlYrY2FiOHz9OaHd3bMp09alyWw+cBz+GlddgzO19REJ9mQAXWx4fF0z0o9cT//hYnp0YQk+3SyP0tRot2+LzmPfVSbye/4M7vonmt8Q8VJqG9dldTUxMDJMnT65325QpU1CpVPz+++8AKJVK9u7dy2233YZMJsPT05OxY8dyyy23kJyczF9//YVW2/zflX3YQuQ23QCoSvkRVdkFwz2gdjJmzBg2bNjAsmXL+OWXX0wdjiAIHZxIqoVO6auvvmL16tX89NNP7bpSYlNUGi0bT2YCYC6Xcfug9is7yc/PZ+/evVRXVzNu3DhcKvaBVgWAQ9jtJpko2NmEeTrwwtTenH1qPFEPXcfD1/XAy+FSv+RKpYavorO44Ytj+L6wm2U/nuZgahHaRuqzuwKFQoGVVf1+0XU/JyYmAnD+/HlUKhW9e/fWbyOXy/XJ+PHjxzlw4ADl5Q0/BWiM3NwGx0jdSDWSlvKY99v6MIzilltu4e2332bu3LkcPXrU1OEIgtCBXTufdwpdxq5du7j33nvZsGEDY8eONUkMvybmk/dPz+SZfTzpZm/4BS1UKhXx8fFkZWXRp08fAgMDASiOX6ffxqHvEoOftyuTyWQMCXBmSIAzb9zYp9EWfYVVtXx8NI2Pj6Z12RZ9ISEhHDt2rN5tf//9NwDFxbpa9JIS3VwBZ2fnetu5uOjmDfj5+eHp6cmBAwcICQkhJCTkqit1Ova7n7Lja5DU1VScWYfz8Gcxs3Y1xENqV/fddx95eXlMnz6dw4cPEx4ebuqQBEHogMRItdCpREVFMXv2bNasWcNtt91msjj+XfphaHWj01VVVYwbN47u3bsjk8lQZB3UT/ay9huLhUuIwc99rTCTyxgf4s7nc/qTu3oyPy8ewpz+PthYXHpazChVsGbfeQa+fYC+a/bx0p9nOV/YcKn1zmbZsmX89ttvvPvuuxQXF3Po0CGeeeYZzMzMmv3GQS6XExYWxqhRo8jKymrWqLWZjRsOfRYD6BLr05+09aEYzcqVK5k/fz6TJk0iIyPD1OEIgtABiaRa6DSSk5OZNm0ajz76KA888IDJ4sgpV/Brkq4PtK+TNVN6eRjs2CqVilOnTnHs2DFCQkIYOXIktraX6oAr4j7Xfy9GqQ3HytyMWX292Hz7IHJXTWHj/AFM7+2B2WWrMybmV7JyVzIhr+1h+LsHeedAKjnlChNG3XqLFy/mkUce4bHHHsPNzY0JEyZw//334+rqire3N3BpRLqsrKzevnUj2K6urvrtrr/+ejw8PDhw4ADJyclXrLV2HPgQyHQvPeWxH6JVd57f4dq1axkxYgSTJ0/Wj+gLgiDUEd0/hE4hPz+fwYMHM3XqVD799FOTxvL6nnM8/auu7vR/E0J4aVrvq+zRPAUFBcTExGBnZ0dkZGSD1ew0NUVkfN4dSaNEbu2G/90XkJuLnsvtqau36CsrKyMtLY2AgABUKhUeHh7s2rWLKVOmoFQqcXBwYM2aNTz88MP6fXbs2MHMmTO5cOEC3bt3r3e8kpISYmJikMvlDBw4EEfHxlfSzP9lPlUpPwLgPvHjTvUGsba2lilTplBbW8uePXsa1KYLgnDtEkm10OHV1tYybtw47O3t+e23365at9meJEki7P/2crZAVwKQ8tR4erZxtT6VSkVCQgIZGRn06dNHX+rxb2XR71F84DEAHAc8jNv1a9p0XqFlunqLvpUrV/LVV1+RkpKiXwBmypQpVFdXc/DgQf12ixYtIjo6moSEhEaPo9FoSE5OJjU1ldDQUIKDgxtcs8rcE2RvHgmAhUsovnecRibrPB+cVlZWMnToUIYPH84XX3zRZWrtBUFoG5FUCx2aJEnce++9HDp0iKioqCZHvozlYGoR13+oa2c3tqcbe/4zsk3HKy8vJyoqCltb20ZHp+tIkkTWpkhUxboRct87TmHpGtamcwutl5hXwbcxWXwbk8X5ouoG99tbmXFTHy/mD/BlYmg3LMw6VsJ47Ngx9u/fT2RkJDU1NWzfvp1Nmzbx22+/MX78eP12dYu/3HvvvcyZM4e9e/fy4osvsmXLlqvOaSgpKSE6OhoLCwuGDh3aYKnznO8noMjSJeseN/6IXc8bDf9A21FKSgojRozgueeeqzeSLwjCtUsk1UKHtnbtWlavXs3Ro0cJCTH9pLwlm2NZf0I3SWnj/AEsakMrvZycHKKjo+nZsye9evW64miXIvsIOd+NBcDKZxQ+c/a2+ryC4UiSxPGMUr6NyWJLbDa5/3SEuZy7nSWz+3kzf4Avo7q7IpebflQzNjaW+++/n/j4eACGDRvGiy++yIgRIxpsu337dp599lmSk5P1y5QvWdK8cg2NRkNsbCyFhYUMHTpUX6cNUJ36C3nbbwbAync0PrftMcAjM67ff/+dm2++mW3btjFp0iRThyMIgomJpFrosPbs2cOMGTP4+eefmTJliqnDoVyhwuf53VSrNDhZm5O9ajI2Fi1fbEWSJM6ePUtKSgoDBw7Ex8fnqvsU/L6UysRNALhPWYdD2KIWn1doXxqt1GiLvst11RZ9VyJJEufPnycpKYnIyEj8/Pz+uV37z6cvupUZvecewtp7qClDbZW33nqLF198UT+5WBCEa5dIqoUO6fz58wwePJj//e9/PP7446YOB4DP/k7jvh9OA3DfiEA+urVfi4+hVquJiYmhpKSEYcOG4eTkdNV9NIpSMj4PRFLXILdyxv+eNOTmNi0+t2A8SrWGXUkFfBuTxY6EXGpUDbthhHnYM3+gL/Mjfdtcl98Z5OXlceLECXr06EFYWBgymYyKM19S+Od9ANgG34znjC0mjrJ1Fi9ezN9//01UVFSzrmlBELomkVQLHU55eTnDhg1j6NChbNiwwdTh6I147yBR6aUAHHv4Ogb7O7do/+rqao4dO4a5uTlDhgxpdteA8lMfUbRXV7Pp2H8ZbuPeadF5BdOqUKjZFp/L5pgsfj9bgKaRVRqH+jszb4AvcyN98Hbsuh1dKioqiIqKwt7enkGDBmEu05KxLgRNdS4gw29xAhbOPU0dZoup1Wquv/56nJyc2LFjh36ipyAI1xaRVAsdilarZdasWRQWFrJ//34sLTtGi7L43Aoi3tgHQD9vR2IeHdOij+6Lioo4fvw4Xl5e9OvXr9kdTCRJIvvrwdQWxgHgu+gklu4RLY5f6Bi6eou+5qitreXEiRPU1NQwbNgw1AkfUHLkOQAc+t2P+/j3TBxh6xQUFDB48GDmzZvH66+/bupwBEEwAZFUCx3KmjVreOedd4iOjsbT09PU4ej9d3s8bx9IBeCdWX146LqgZu+blpZGXFzcFdvlNUWZe5zszaMAsPIais+8Qy0LXOiwunqLvivRarUkJCSQnp7O4H4hVG8biqSqQmZug//S85jZuJs6xFY5efIkY8aM4bvvvuOGG24wdTiCIBhZx+rzJFzT/v77b1atWsWGDRs6VEJdq9ay6WQmoEt0Fg5sXscPrVZLXFwc8fHxDBs2jB49erR4Ylr5mS/03ztE3N3s/bZv386wYcNwcHDA29ubOXPmkJqa2mC7L774gtDQUKytrenfvz87d+5sUXxC6wW42PL4uGCiH72e+MfH8uzEEHq6XVo9s1ajZVt8HvO+OonX839wxzfR/JaYh0rT9GqFnYVcLqdv37706dOHY7HJaP1vBUBS11B+6mMTR9d6gwYN4pVXXuH2228nMzPT1OEIgmBkYqRa6BBKSkro378/ixYt4pVXXjF1OPX8eDqb2zaeBGBOfx823z7oqvvUfcStUCgYNmxYk/2nr0RbW0H6ZwG6ETxLBwLuSUducfXj7Nu3jwkTJnDHHXewcOFCioqKWLlyJRqNhri4OGxsdJMcN2/ezIIFC3jmmWcYP348W7Zs4YsvvuDgwYMMHz68xfGakkqlQqFQoFQqUSgU+u81Gg2SJKHVapEkSf8lk8n0X3K5HJlMhrm5OVZWVlhbW9f7MmZ9bEta9C0Y6MvIwI7Roq8tiouLiT60g6DU+5GhQW7TDf+l5zr1ZNybbrqJwsJC9u3bh7l51/mEQRCEKxNJtWBykiRxyy23UFRUxL59+0y6YmJjZnwexa9J+QDsumcYk3t5XHH7uslYDg4ODBw4EAsLi1adtzzuc4r+WgaAQ8S9uE9Y26z97r//fv744w/Onz+vHxnfu3cv48eP58CBA1x33XUA9OrVi0GDBvHNN9/o9x05ciTOzs78+uuvrYq5vdTW1lJaWkp5eTk1NTX1kmeFQoFGo0Eul+sT4brk2MzMTJ80X/51eYJdl3Cr1ep6x1QqlUiShLm5eYNE28bGBicnJxwdHVv9/3s111KLvpqaGs5vmYVd6T4A3MavxbHfvaYNqg3KysoYMGAACxcu5MUXXzR1OIIgGIl4Cy2Y3AcffMCRI0eIjo7ucAl1VlkNu5J1CXWAsw0TQ7pdcfvS0lKOHj1KYGCgvm1Ya1XEfa7/3iFiabP3U6lUODg41Dt3XZuvuvfQqampnD17tsGEqnnz5vH444+jVCqb3Z3E0JRKJaWlpZSWllJWVkZpaSk1NTXY2tri5OSkT2g9PT3rjSxbWFgYNKmUJIna2toGibZCoSA/P5+UlBQUCgX29vY4Ozvj5OSk/9cQibaZXMb4EHfGh7jzwS19G23Rl1GqYM2+86zZd75Tt+izsbEhaPLL5H2nmz9QevJtHPouRSbvnF00nJyc+Oabbxg/fjxjx45lwoQJpg5JEAQjECPVgknFxMQwatQovvvuO2bMmGHqcBp4+c+zPLcrGYCVk0JZPaVXk9uWlJToV35s6yIQyvwYsr8ZBoClx0B8F/zd7H0PHjzI+PHjeffdd/XlH8uWLSM/P5/jx49jZmbGr7/+yg033EBiYiK9e/fW77t7924mT57c4Pb2olarKSoqqpdE19TUYGdn1yBR7SidYC6nUCjqJf+lpaUoFAp9/HVfrq6uBnvD2JVb9OX8MBlF5j4AnCZtwrXPXNMG1Eavvvoqb7/9NnFxcR1qnoggCO1DJNWCyVRUVBAZGcnMmTN5++23TR1OA1qtROjre0gtqkYmg/NPT6C7q22j2xYVFfH333/Tu3dvevZse5/dwr8epCLuUwDcxn+AY797WrT/zp07WbBgARUVFQBERkaya9cu/Qv7119/zaJFi8jJycHLy0u/34kTJxgyZAiHDx9m5MiRbX4cjampqSE3N5fc3FwKCwuxtrbGxcWlXhLdXiUVxqBQKOol2SUlJWg0Gjw9PfVfhnqD0NVa9FVf2EXetpkA1Nj0JnDR0VbNR+gotFot06dPR6VSsXv37g73SZwgCIYlkmrBZO68804SExM5cuRIh5zMs+9cIeM/PgrAxBB3/rhvRKPbFRQUEBUVRd++fenevXubz6tVVekmKNZWIDO31U1QtHJs9v5HjhzhhhtuYMmSJcyYMYOioiJefPFFLCwsOHjwIDY2NkZNqiVJoqysTJ9Il5eX4+rqipeXF56enjg4OBjkPB2VJEmUlpaSm5tLXl4e5eXluLm54enpiZeXF/b29gY5T3Nb9D0+LpiR3V0Nck5DkySJrK8GoiqKByA98P8YNOlug/2OTKGoqIjIyEiWL1/OE088YepwBEFoRx0vkxGuCb/88gs//fQTMTExHTKhBlh3LF3//ZKhAY1uk5eXx/Hjx+nXrx8BAY1v01JVZ39AqtWNMNv1mtuihBrgoYceYvz48bz55pv624YPH05AQACbNm3i3nvvxcXFBdBNqLo8qS4pKQHA1bVtSZdGo6GwsFCfSKtUKjw9PenZsyceHh4mq9c2BZlMhouLCy4uLoSFhVFdXa1PsBMTE7G1tcXLywsvLy9cXV1bXRde16Lv8XHBJOZV8G1MFt/GZHG+qBq41KJv7/kiMp+bhL1Vx7vuZDIZToNWUPiHrn2kb81vHDrUm5EjR+Lo2LLroKNwc3Pjs88+45ZbbuHGG28kLCzM1CEJgtBOOt6zqtDllZSUsHTpUlavXk1wcLCpw2lUaY2KH07nAOBiY8FNfb0abFNXoxwZGYmfX/N6VzdHvQmKfZs/QbFOQkICs2bNqnebn58f7u7unD9/HkBfL52UlESvXpfqxJOSkrC0tCQoqPmL29SpG5FNS0sjKysLCwsLvLy8GDBgAG5ubmLp5n/Y2toSFBREUFAQKpWKgoICcnNzOXbsGDKZDH9/fwIDA9s0Ohvm6cALU3vz/JRe+hZ938ZkkV9ZS7lCzR9nC7glwtuAj8pw7HvNo+TwSjRV2Zjl76NHrxUcPnyYUaNGddrEeurUqcyZM4c777yTo0ePimtBELooUeAlGN1DDz1ESEgIK1asMHUoTfo2JguFWtdhYcFAX6wt6r8IFhQUcOzYMYMn1LWFcShzowCwdI/AymtIi48RGBhIdHR0vdvS0tIoLCzUl6cEBQURGhrK999/X2+7LVu2MGHChBbV/KpUKi5cuMC+ffs4fPgwoGvNN2nSJPr164eHh4dIIppgYWGBj48PAwcOZOrUqQwcOJDq6mr27t3L4cOHyczMRKPRtPr4MpmMoQEuvD2rLxvmD9Dfvv1MriHCbxcyM0scBzz4z08SbiXb6dGjB0eOHKGystKksbXF2rVryc/P54033jB1KIIgtBMxUi0Y1Y4dO9i2bVuHbJ93uS8vK/1Y+q/Sj6KiIqKioujXr59BE2qAijPr9N879F3aqlKA+++/n0ceeYSHH36YG2+8kaKiIl566SU8PDyYM2eOfrvVq1ezcOFCevbsybhx49iyZQtRUVEcOHCgWecpLy8nNTWVzMxMHB0dCQoKwtfXt8OW83R0MpkMDw8PPDw8UCqVZGRkkJSURFxcHAEBAQQFBekX7mmNsT3dcLAyp0KpZmdiHmqNFnOzjnkNOkbcQ+mxV5FqK6hM3ETwiFVoNBoOHz7M6NGjO+XkRXt7ez755BNuvvlmZs6cKcpABKELEhMVBaMpLi4mLCyMJ598kkcffdTU4TTpdHY5kW/tB2CgrxMnVozR31dSUsKRI0fo06ePQSYlXk6rriHjs0C0ylJkZtb435OOmbVzi48jSRKffPIJH330EefPn8fBwYERI0bwyiuvNGiT98UXX/Daa6+Rnp5Or169eOWVV67Y2lCSJHJzc0lNTaW4uBg/Pz+CgoL0fbAFw5IkicLCQlJTU8nPz8fLy4ugoKBW117P23SS705lA7Dn/hGMDXY3dMgGU3TgScqjdV2BnIf9D+fhqzhz5gy5ubmMHj26TW8wTGnJkiXExcVx9OhR8QZUELoYkVQLRrNw4ULS09PZv39/hx6lfnjrGd4/dAGAtTdHsGxUd0C3sMuRI0fo1auXQdrm/VtF4lcU/r4EAPuwRXSbsu4qexiPVqslLS2Nc+fOodVq6dGjB4GBgdfUhENTq6qq4sKFC6SlpWFnZ0doaCje3t4tSq6/ic5k0TcxADx8XQ/entW3vcJtM3VFBhlf9gKtGrm1K/5LzyMzt+X06dMUFBQwevRorK07Tw/uOpWVlfTt25f777+fp556ytThCIJgQB03sxG6lO3bt7Njxw7Wr1/foRNqpVrD19GZAFiZy5k/wAfQ9dSuW9ilPRJq+FfpR8Td7XKOlpIkiaysLPbs2UNqaiphYWFMmjSJ0NBQkVAbmZ2dHX379mXKlCkEBARw+vRpDhw4QEFBQbOPMT3ME3O5LgnfHp9HRx5TMXfwxy5UV66kVRRTmbARmUxGv379cHV15fDhw9TW1po4yparKwN54YUXSEhIMHU4giAYUMfNboQuo6Kigvvuu4/Vq1e3W0JqKNvO5FFcrQLg1ghvXGwtqa2tJSoqioCAgDavlNiU2uIklFmHALBw7Y2Vd+M9sY1FkiTy8/PZv38/Z86cISQkhHHjxuHn59eh3xRdC8zNzTl48CBPPfUUkydPJjg4mBEjRpCTk6PfRqFQsHLlSnr06IGVlRUBAQE8/vjjONtYMLanGwAXiquJy6kw1cNoFqdBlyYzl0W/i6TVIJPJGDBgAPb29hw/fhytVmvCCFtnypQpzJs3j6VLl3bK+AVBaJx4dRTa3fPPP4+3tzePPPKIqUO5qn/3ptZqtZw4cQIHBwfCw8Pb7bz1Jyje3epexYZQVzd+4sQJ/Pz8mDhxIoGBgSKZ7iBefvllli9fzrx58/jjjz/49NNPCQwM5NChQ5w4cYKKigpmzZrFt99+y6pVq/jjjz946aWX9B1dZva51B5yW3zH7QICYNWtP9YBEwFQl6VSfe5nQDepc9CgQdTW1nLmzBlThthqb7/9NhcuXGDTpk2mDkUQBAMRNdVCu0pISGDgwIHs27eP4cOHmzqcK0orribo1b+QJOjhakvKU+OJjz9DQUEB1113XbstnS2plaR/3h2togjMLAm4Ow0zG7d2OdeVVFZWkpiYSF5eHkFBQYSEhHTq5cK7ouTkZPr27cv27duZNm1avftqampISkpi3bp1bNiwgVOnTtGjR48Gx0gvqab7y38BMMjPieOPjGmwTUdSk/YnuT9PB8DSczA+8w7r33RWVVVx4MABwsLCDD5x2Bg+/fRT/ve//3Hu3DmcnZ1NHY4gCG0khp6EdiNJEsuWLWPOnDkdPqEGWH8ig7q3mHcN9ScjI52MjAyGDRvWrsll1fmtuoQasAu+2egJtUKhIDY2lr1792JpacmECRMIDw8XCXUH9OWXX9KjR48GCTWAjY0NAwYM4O+//2bcuHHEx8eTmJiISqWqt12Aiy0DfXXdWk5mlpFRWmOU2FvLOmAClu79AKjNO4HinzIp0NWZDxkyhDNnzlBUVGSqEFvt7rvvJjg4mOeee87UoQiCYAAiqRbazZYtWzhz5gxvvfWWqUO5Kq1WYv3xDABkMpjZ0564uDiGDBnS7j1x/136YSySJJGens6ePXuora1l3Lhx9O/fv9O2KrsW/P3330REROj7jltaWjJq1CiionQLBqlUKk6dOsWQIUPYtGkTAwcOxMnJiVmzZpGbe6nU4/ISkO0dvASkbunyOmUn36x3v7u7O3369OHYsWNUV1cbO7w2kcvlfPjhh3z22WfExsaaOhxBENpIJNVCu6ioqGDFihU899xzuLt33F64dfacKyStRDdiN7GnG9nJpwkPD6dbt27tel5V6TkUGXsBMHcOxtrPOB/F19TUEBUVRUJCAgMGDGDo0KFtWhZbMI7c3Fz++OMPNm7cyIcffsjWrVuRyWRMnjyZ/Px8ioqKUKlUvP7661RWVrJ161ZefvllDh06xJQpU/Sj1rP6euqP2dGTagC70DmYOfgDUHPhV2qLE+vd36NHD3x8fIiKikKtVpsixFYbOHAgt99+O8uWLROTFgWhkxNJtdAu6iYnLl++3NShNMvlExRHOlbh7e3daD2qoRliBcWWkCSJjIwM9u7di4WFBePHj8fb27tdzykYjlarpbKykh9++IHZs2czffp0tm/fjiRJrF27Vp+UOTg48NNPPzFlyhRWrFjBhg0bOH36NG+//TYFBQX083Yk0EX3icS+80WU1aiudFqTk5lZ4DTg0nNJ2cl3GmwTERGBpaUl0dHRHbpVYGPeeOMNUlNTxaRFQejkRFItGFxCQgJr167lgw8+6BQdI4qra/n5jG60ztlKxhg/ayIiIto/wdXUUpGwUfeD3AKH8Nvb9XwKhYJjx44RHx/PgAEDGDRokL4jhNA5uLi44ObmRr9+/fS3ubq6MmDAAOLj43F2dkYmkzFy5Mh6fcSnTp2KmZkZVVVVREVFcfr0aWaGewCg0kj8lpRv9MfSUg59liCzdASgMulr1FU59e6Xy+UMHjyYsrIyzp49a4oQW83JyYkXXniBxx57jNLSUlOHIwhCK3X8jEfodB555BFuu+02Rowwba/l5vomOgulWjfCN85TzshhQ43yZqA6dSfaal0yY9dzJma2Hu1ynrrR6T179mBubi5GpzuxPn36NHmfQqHA1tb2il0w7O3tGTduHBUVFfgps/W3d/TWegByK0ccI+7R/aCppTz2wwbbWFlZMWzYMM6dO0d2dnaD+zuyu+++m6CgIF544QVThyIIQiuJpFowqD179nD06FHWrFlj6lCa7fLSj8emRRptpcB/l360BzE63bXMmDGDoqKiepPaioqKiI6OZtCgQfptDh8+jEKh0G+zZ88eNBoNgwYNws7OjlGjRjFrcAj25rr7f0vMp1bd8et5HQcsB7muK03F6U/R1lY23MbRkYEDBxIdHU1ZWZmxQ2w1uVzOm2++yYcffkh6evrVdxAEocMRSbVgMJIk8cQTT3DPPffg5eV19R06gOjMUmKzywGI9LJlRIiPUc6rKrtITdpuAMwde2AdMN7g5ygoKGDv3r2YmZmJ0eku4qabbmLIkCHMnj2bLVu2sH37dmbMmIGVlRXLli0D4PHHH0ehUDBr1ix+/fVXNmzYwJ133sno0aMZN24coOuoERrckxnhugmL5Uo1v57JMNnjai5zex/se88HQKssoSL+y0a38/b2JiQkhKioKJRKpTFDbJPRo0czfvx40WJPEDopkVQLBvPTTz9x8eJFVq1aZepQmu3zv9P0398/Otho562M/xLQTaZy6HsXMpnhLkVJkkhNTSUqKorw8HAGDx4sRqe7CLlczq+//sqIESO47777mDdvHo6Ojhw4cED/Rtbf35+9e/eiVCq59dZbefTRR5k+fTo7duxoME/g1kg//fef7z1NXl6eUR9PazgNfET/fXn0e0jaxrt9hIaG4uLiwokTJzrVxMX/+7//Y8uWLcTHx5s6FEEQWkisqCgYhFqtJjw8nDvuuINnn33W1OE0S41Kg9eq36iolbCxkJO9cjJONu2/4ImkVZPxRTCaqmyQmeF/dyrmdoYZRdZqtZw+fZrc3FyGDBmCm5vxV2YUOo9KpZpuq35HqdbiZW/BJ4NU9O7dm+Dg4HafqNsWuVtnUnNxFwDdpm3CvtfcRrdTqVTs3buXkJAQo3TzMZQFCxZQUVHBjh07TB2KIAgtIEaqBYP48ssvUSqVPP7446YOpdk2HDlLRa3uPeVt/XyMklADVF/4TZdQA7ZBNxgsoVYqlRw5coTS0lLGjBkjEmrhquytzJkQrOsjn1upwr5nJKmpqURHR6PRaEwcXdOcBj2q/77s5FtNjkRbWFjoO6NUVVUZK7w2e/XVV9mzZw+HDx82dSiCILSASKqFNquurmblypU8/fTTRpvk11YqlYpPD5/X/7xkaIDRzl1x5gv994aaoFhWVsb+/fuxsrJi9OjR2NraGuS4Qtc3q++l+Q970qu4/vrrqaqq4tChQ9TUdMwlzK39rsfSYwAAtfkxKDL3Nbltt27d8Pf3JzY2ttOUgQQGBrJ48WKeeOKJThOzIAgiqRYM4P3338fFxYV77rnH1KE02x9Rp4kt1r1YBbvbcV2Qq1HOq67I0H9sbebgj03g5DYfMzs7m4MHDxIYGMjgwYMxNzdv8zGFa8eN4Z7UVXpsj8/F2tqaUaNG4eDgwIEDBygpKTFtgI3QLV1++Wj121fcPjw8nKqqKi5cuNDeoRnMCy+8QEJCAr/++qupQxEEoZlEUi20SWlpKa+++irPP/88ZmZmpg6nWQoKCtgUc6mH7V1D/I1WP1oRvx6kf1a967MYmbz1vzNJkkhOTiYmJoZBgwbRq1evDl0HK3RMXo7WDAtwASAup4LUoirMzMwYMGAAwcHBHD58mIyMjtcZxC7kVswdAgGoubiL2sIzTW5bVwaSkJDQacpA3NzceOCBB3jyySfF8uWC0EmIpFpokw8++ICgoCBuu+02U4fSLCqVihPR0Rwo0o3mymVw52B/o5xb0mp0STWATI5Dn8WtPpZWq+XkyZOkp6dz3XXXiXZ5QpvM7OOp/75uIRiZTEbPnj0ZOnQocXFxJCUldahSBJncHMeBD+l/vtpodV0ZSExMTId6HFfy9NNPk5eXJyYsCkInIZJqodWqq6t5++23eeyxx0wdSrMlJCSQWGVJbqWuDdf03p74OFkb5dw1abvRVOhG/Gy6T8XcoXXJvEaj4fjx41RWVjJmzBgcHR0NGaZwDbrpsrrq7Wfqt9Xz8PDguuuu4+LFi8THx3eohNShz13IrXSj7JXJm1FXZl1x+z59+lBTU9NpykDs7OxYsmQJL7/8cpO/97Vr1zJ48GCsrKy46aab6t1XXl7OggULcHR0xNPTkxdffLFF9wuC0DIiqRZabd26dbi5uTFv3jxTh9Is+fn5ZGRkcKjURn/bkmHGGaUGqDjzuf771k5QVKvVHDt2DKVSyciRIzvNxFChY+vt4UBoNzsADl4oorCq/oIpDg4OjB49muzsbOLi4jpMYi23tMeh3726H7QqymPWXnF7c3NzIiMjO1UZyJNPPklSUhL79u1r9H4fHx+effbZRue0LF++nOLiYtLT0zl48CCfffYZGzdubPb9giC0jEiqhVZRqVS8/vrrrFixArm84/8ZqVQqYmNj8QrqxS/JhQB42FtyQ5jnVfY0DHVVDtWpvwBgZueDbY9pLT+GWk1UVBRqtZoRI0aIBV0Eg5rZRzdarZXgl4T8Bvfb29szevRo8vLyOlQnDcfIZWCmuxbK4z5Dqyy/4vadrQzE1dWVRYsW8fLLLzd6/y233MJNN92Eu7t7vdurq6vZvHkzL730Es7OzoSGhrJ8+XK++OKLZt0vCELLdfxsSOiQvv32W+RyOXfffbepQ2mW+Ph47OzsOFQoR6XRvZDePsgfCzPjXAKV8RtA0vX9te9zBzJ5yzp0qNVqjh49CsCIESOwsDBOT23h2jGrz2UlIP/UVf+bra0to0ePpqioqMMkpeZ23tj3XgiAVFtORfy6q+7T2cpAnnnmGY4cOcLJkyebvU9ycjK1tbVERkbqb4uMjOT06dPNul8QhJYTSbXQYlqtlldeeYVly5Z1ivZt+fn5ZGVlERkZybpjl7oYLDVS6Yckaak48+U/P8lw6HNXi/bXaDRERUUhl8sZPnx4p/idC53P8EAXPOx1I76/JxdQo2p88RcbGxtGjx5NcXExp06d6hCJtdOgR/Tfl8W8j6RRXXF7c3PzTtUNxNfXl1tvvbXJ0erGVFZWYmdnV+/5wtnZmYqKimbdLwhCy4mkWmixbdu2UVxczPLly00dylXVlX2Eh4cTX1TLmVzdC8bI7i709nAwSgyK9D2oy3UjYjYBE7Fwav5yyRqNhmPHjqHVahk2bFinaVsodD5mchkzwnWj1dUqDX+eLWhy27pe1gUFBR2ixtrSNQybHtMB0FRkUHX2u6vu4+7uTkBAQIcZcb+alStX8ssvv5CUlNSs7e3t7amurkatVutvKysrw8HBoVn3C4LQciKpFlpEkiRefvll7r777k6xal9KSgq2trZ0796dL46l62832QqKEc2foKjVajlx4gS1tbVihFowiln1WuvlXWFL3Yj1qFGjyM3NJSEhweSJqdOg/+q/Lzv5drPiCQ8Pp7q6mqysK3cN6QhCQkKYNm0ar732WrO279WrFxYWFpw6dUp/W2xsLBEREc26XxCElhNJtdAiBw8eJCUlhSeeeMLUoVyVQqEgNTVVVz+p0rD5nwVf7CzNuK2fj1Fi0FTnU3V+OwByWw9sg2Y0az9JkoiOjqampkbUULeBJEkolUpqamqoqqqisrKSiooKKisrqa6upqamhtraWpMnhB3FxNBu2FroPg3ZmZCLRnvl34utrS0jR44kIyODs2fPGiPEJln7jsbKcwgAtYWnUaT/ddV9zM3N6d27N4mJiZ1igZWVK1fyzTffkJOTo79NrVajUChQq9VotVoUCgW1tbXY2toyd+5cnnvuOcrKykhJSeH999/Xz4O52v2CILScGPoSWuTdd9/llltuwdnZ2dShXFVycjIeHh64uLiw8UQGFUrdx5xzIn1wsDbOn35FwibQ6uo7HcLvQGbWvI4dZ8+epaSkhDFjxoguH1egUqkoKyujsrISpVKJQqGo96VUKvUJs0wm039JklQviZLL5VhZWWFtbd3gy8HBAUdHx2ui9MbGwowpvbrx85lc8itriUovYWR31yvuY29vz8iRIzl48CAODg74+BjnDeu/yWQynAY/Sv4v8wEoPfkWNoETr7qfv78/586d4+LFiwQFBbV3mG0ycOBAhgwZwieffMLq1asBeOmll3j++ef129jY2HD99dezb98+1q5dy3333Yefnx82NjY8+OCD3HHHHfptr3a/IAgtI5PEEI3QTBkZGfTs2ZOYmBj69Olj6nCuqLKykr179zJ27FgcHBwY++FhDqQWA3DowVFXTRQMQZIkMjf0QV16DgC/xQlYOAdfdb/s7GxiYmK47rrrxMIul6lLoEtLS/VfVVVV+sT338nw5UmyXC5vdAl3SZJQq9X1EvJ/J+dlZWWo1WocHBxwdnbG2dkZJycnnJycumSiveF4BndtiQXgsbE9+b8Z4c3aLycnh5MnT3Ldddfh5OTUjhE2TdJqdNdcWSoAPguPY9Wt/1X3y8nJ4dSpU0ycOLHDl1l9/fXXPProo2RkZIg33ILQwYikWmi2Z555hkOHDrF//35Th3JVx48fx8LCgsjISFIKKun1+l4AenvYE//42EYTLEOrydhP7o+TALD2H4f3rb9fdZ+ysjIOHjzIoEGDrvmlx7VaLSUlJeTm5pKbm0tlZSU2NjY4OTnVS26trdt3RUxJkqipqdEn8nWJvUqlwsnJCS8vL7y8vHB0dDTK31V7K6xS4rX6D7QShHazI+nJ8c3e9+zZs1y8eJHrr7/eZAsTlZ/6iKK9DwNg13sBHlPXX3UfSZI4dOgQHh4e9OrVq50jbBuNRkP37t1Zs2ZNp1l4SxCuFR37LbnQYSiVSj755BM+/PBDU4dyVaWlpeTl5TFhwgQAvjx+qY3eXUP8jZb41Jug2HfJVbdXKpVERUUREhJyzSbUKpWKgoICcnJyyM/XLUDi6elJWFgYbm5uJknUZDIZtra22Nra6ksb6hLtwsJCcnNzSUlJwdLSEk9PT7y9vXFzc+u0o9judlaM7uHKgdRizhZUkZRf0exOOSEhIZSXl3Ps2DFGjRplkoWh7MPvpOToC2gVRVSd/Q71qBcxd7hy+0yZTEZ4eDh///033bt379ArlZqZmXHHHXfw3nvviaRaEDoYMVFRaJaff/4ZOzs7br31VlOHclUJCQn06NEDGxsb1BotG07okmpzuYw7BhunN7Wmpoiqcz8BILd2w67nTVfcXqvVcvz4cVxcXAgNDTVChB2HRqMhMzOTo0ePsmvXLpKSkrC2tmbYsGFMnTqVgQMH4uPj06ESnbpEOyAggKFDhzJt2jT9IhoxMTH89ttvHD9+nLy8vE45CXJW30sLwWw7c+UuIJeTyWRERkai0Wg4ffq0SR673MIWx/736X7Qqim7ytLlddzc3HBzczP5hMvmeOihh4iJiSEuLs7UoQiCcBmRVAvN8uGHHzJ//vwOP/qWn59PaWkpISEhAOxKLiCnXAnAjHBPPB2Mk5hVJn4NmloA7MNvR2be9HklSSIuLg61Ws2AAQO6RAlBc1RUVBAXF8fvv/9OUlIS7u7ujBs3jvHjx9OnTx9cXV07ze/CzMwMDw8P+vfvz+TJk7nuuuuws7MjJiaG3bt3k5ycTE1NjanDbLbLV1fc1sTqik0xNzdn2LBh5ObmmmzFQsf+y5CZ6cqCKs58jlZZ1qz9wsPDuXjxItXV1e0ZXpt5enoyadIkPv74Y1OHIgjCZURSLVxVUlISUVFRHX6xF0mSSEhIICQkRD+BZ50JelNLkkTFmc/1Pzv0vfIKihcvXiQnJ4ehQ4d2+ElSbSVJEnl5eRw9epR9+/ZRW1vL0KFDmTBhAiEhIdjb25s6xDaTyWQ4OTkRHh7O5MmTiYiIoLi4mD///JMTJ05QUlJi6hCvKsjNjr5eupKPqPQScssVLdrfxsaGoUOHkpCQoC/jMSYzWw/sw28HQKqtoDzus2bt5+joiI+PT7MXWDGlBx54gE2bNnWKFSEF4Vohkmrhqj7++GMmTJiAr6+vqUO5ouzsbJRKJT166FYszKtQsjNB99G1t6MVU3t1M0ocypyjqIp1L8pWvqOxdA1rctuCggLi4+MZMmRIp1hMp7UkSSIzM5M9e/YQExODi4sLkyZNYtCgQbi7u3eaEemWksvleHt7M2LECMaNG4eVlRWHDx/m4MGDFBQ0vWJhRzDzn9FqSYIdCc0vAanj6upKREQEJ06coLKy0tDhXZXTwIcB3d9VecxapH8+ObqasLAwsrKyKC8vb3KbrKwsbrrpJtzc3HB3d2fOnDn6/0+VSsWDDz6Ii4sLrq6uLF++vN6qhYYyadIkvLy82Lx5s8GPLQhC64ikWrgilUrFpk2buOeee0wdyhVptVoSExPp1auXfrR308lM1P8sXnHHYH/MzYzz514Rd/koddMTFBUKBSdOnCAiIgI3NzdjhGZ0kiSRn5/P/v37iY+PJzg4mEmTJtG7d+9279rR0djb2xMREcGUKVPw9PTk2LFjHD16lNLSUlOH1qibLqur3t7CEpA6gYGBBAQEcPz4caMvrmLhEoptzxsB0FRlU5ncvOSzbgXWxMTEJrd54IEHAEhLS+PChQsoFAoeeughQNc3+tChQyQkJBAfH8/Bgwd55ZVX2vhoGpLL5SxYsIAvvvji6hsLgmAUIqkWruiPP/7AwsKCmTNnmjqUK0pP15V5BAToSjwkSapf+jHESBMUFaVUpfwIgNzKGbuQxid2SpLEqVOn6NatG4GBgUaJzdhKSko4cuQIJ06cwM/Pj4kTJxIYGNjh6/Lbm4WFBaGhoUyaNAlHR0cOHTrEiRMnOtzH+IP8nPB10r3x+TOlkEpl60Zbw8PDkclkJCcnGzK8ZmnN0uUAoaGhFBYWUlRU1Oj9qampzJkzB3t7exwcHJg7d65+0uC6det49tln8fb2xtvbm2eeeabdEt+7776b48ePc/HixXY5viAILSOSauGKNm3axIwZMzp0IqRWq0lKSiI8PFzfwutoWglJ+bqPnMcEuRLSzTi1ulXJ3yKpdRPS7MMWIje3aXS7zMxMSkpKiIiIMEpcxlRZWcmxY8c4fPiwvswjODi4Q/8NmYKlpSV9+vRhwoQJmJmZsWfPHk6dOoVC0bL65fYik8m4MdwTAKVay+/JrauNlsvlDBgwgPPnzxu9ntzaZwRW3sMBUBXFU3Px6r3iAaysrOjZsycJCQmNJuKPPvoo33//vb5n+bfffsuNN95ISUkJmZmZ+k4wAJGRkaSnp1NW1rzJki3h5+fH8OHD+frrrw1+bEEQWk4k1UKTKioq2LZtG0uXLjV1KFd08eJFbGxs6vV2XnfsUm9qo05QbEbph0KhIC4ujn79+nWoNnFtpdVqSUlJYd++fVhZWTFhwgTCw8OxsLAwdWgdmo2NDQMGDOD6669HoVCwZ88eMjMzO0Qrvln1SkBaXlddx8nJiZCQEGJiYtBoNIYIrfnnHvSo/vuy6LebvV/Pnj2prKxstPZ91KhR5Ofn6+umS0pKePrpp/W1487Ozvpt676vqKho3QO4irlz57Jhw4YO8fciCNc6kVQLTfr555/x9/dnxIgRpg6lSZIkceHCBYKDg/WT3SqVar47lQWAg5U5t0YYZyGV2rwT1BbqPgK28hqGpXvDUei6sg8PDw/9QiJdQUVFBQcPHiQ9PZ2RI0fSv39/bGwaH6UXGufo6MiwYcOIjIzkzJkzHDt2zOSj1uN6uuNorZujsDMhD7Wm9XXRISEhyOVyo5eB2AbdiLlzMACKjL0o82OatZ+FhQU9evTg/Pnz9W7XarVMmjSJUaNGUVlZSWVlJaNGjWLy5Mn67jWXj0rXfe/g0LwFdFrqjjvuICsri5iY5j0uQRDaj0iqhSZt2rSJm2++2dRhXFFOTg6SJNUbpf7uVDaVSt1o2LwBPthZGadNXfnlo9QRdze6TVcr+5AkiZSUFPbv34+7uztjx47F1dXV1GF1aj4+PowbN05fEmLKUWtLcznTensAUFKj4uCF4lYfSy6XM3DgQFJTU41aBiKTm+E08BH9z2Un3mz2vt27d6ewsLDeKHNxcTFpaWk89NBD+pU2ly9fTlRUFBqNBj8/P2JjY/Xbx8bG4u/vj5OTkyEeTgOOjo6MHz+er776ql2OLwhC84mkWmhUbm4u+/bt4+67G08OO4rU1FR69OhRbznkyycoLjVS6YdWWU7V2e8AkFk6Yhc6u8E2Xa3so250Oi0tjZEjR9KnTx9RN20gVlZWDB48mMjISOLi4jh+/LjJRq1ntmEhmH9zdHQ0SRmIffjtyG10LTWrUn5EVXaxWftZW1vj4+NTbxEbd3d3goOD+eCDD1AoFCgUCj744AP8/Pxwd3fnrrvu4uWXXyY3N5fc3FxeeeWVdn8evf322/nmm2+MXlojCEJ9IqkWGrV582YiIyP1KxN2RHWThC7vnpGUX8GRi7pRsL5eDgzxdzZKLJXJW5BUuu4N9r3mIbewq3d/Vyv7yMzMZP/+/bi6ujJu3DgxOt1OfHx8GD9+PDKZjL179zbZjaI9TevtgblcV1q1/Uxum0fNTVEGIje3wbH/f3Q/SBrKY95v9r5BQUGkp6ejUqn0t23bto3o6Gh8fX3x9vbm2LFjbN++HYDnnnuOESNGEBYWRlhYGKNGjeJ///ufQR/Pv910001oNBr27t3brucRBOHKRFItNGrDhg3MmTPH1GFcUWpqKn5+fvrVE6H+BMW7hvobbVGRijOXWmY5RDSc2FlX9tGvXz+jxNNe6latPHXqFEOGDKFv375idLqdWVlZMWTIEHr37s3Ro0dJS0sz6vmdbSwYF6zro36xpIa4nLZNuDNVGYhj//uR/dONpyJ+HRpF887t4uKCk5NTvd97eHg4v//+O0VFRZSUlLBnzx4GDBgA6GqxP/jgA0pKSigpKeH9999v95VSLS0tmT59Ohs3bmzX8wiCcGUiqRYaSEtL48yZM9xxxx2mDqVJSqWSzMxMgoKC9LepNFo2ntAl1RZmMm4f5GecWPJjqM2PBsDSYyBWHgPq3V9X9tG/f/96bwA6G5VKRVRUFNnZ2YwZMwZPT09Th3RN6dGjB8OGDSMhIYHTp08bdTGVy0tAtp5pWwkI1C8DMdbjMLNxxz78TgAkVRUVpz9t9r5BQUFcuHChQ3fYWLhwIdu3b683oi4IgnGJpFpoYMeOHQwYMKBDJ01paWm4urri6Oiov+2XxDzyK3VLEc/q44W7nXHqliviLh+lblg7mZycjLu7e73JlJ1NZWUlBw4cQKvVMmbMmHbrZCBcWbdu3RgzZgyFhYUcPXqU2trmLb3dVpcn1a1dXfHf6krLjLlwidPAh0Gme9krj/0ASa1s1n7e3t5otVpycw3z2NvDhAkTMDc35/Dhw6YORRCuWSKpFhrYunUrkydPNnUYTZIkibS0NHr06FHv9i9N0Jtaq6qiMvlbAGQWdtj3mlvv/srKStLT0wkLCzNKPO2hoKCAAwcO4OnpyfDhwzv1aHtXYGdnx3XXXYe5uTkHDhygvLy83c/p72zDQF9d94rorDIySmvafEy5XE5YWBhnz55FrW7dao0tZeHcE9vgmwDQVOdSmfRNs/aTy+UEBgYavfSmJczMzBgzZgzbtm0zdSiCcM0SSbVQT3l5OQcOHGDu3LlX39hECgoKUKvVeHldGj3LKVfwa5JuxTc/J2smhXYzSixVZ79HqtXVmNr1movcsv4IbmJiIv7+/p12ZDc7O5uoqCj69OlD375963VZEUzHwsKCoUOH4uPjw6FDh4xSm1x/IRjDjNh6eXlhZ2fXoBd0e3IaWH8xGElqXvlJQEAA+fn51NS0/Q1Fe5k5cyZbt27t0GUqgtCViVdIoZ7ff/8df3//Dt1HOS0tjYCAgHoJ3oYTGWi0uheSO4f4YyY30gTFy0o/HPvWn6BYUlJCXl4evXr1MkoshpaZmUl0dDSDBw+u12FF6BhkMhnh4eH06tWLI0eOUFzc+h7SzTHr8tZ6BqirhkuP4dy5cyiVVy7F2L59O5GRkdjZ2eHj48PHH38M6AYCFixYgKOjI56enrz44otXPI6191CsfEcDoCpOoubCb82K1dbWlm7dupGenn71jU3klltuIScnh6SkJFOHIgjXJJFUC/Vs27aN8ePHmzqMJimVSnJzc+sleZIk1Sv9uGuIv1FiqS2MQ5kbBYClez8sPQfXuz8xMZEePXp0ypUF09PTiY2NZejQofU+ERA6np49exIeHs7Ro0cpLCxst/NEeDvQ3UX3t7zvfBGlNYaZEOfm5oabmxtnz55tcptdu3axbNky3nnnHcrLy4mPj2fs2LEALF++nOLiYtLT0zl48CCfffbZVbtgOF++dPnJt5oda10JSEcdCXZ0dGTo0KH69n6CIBiXSKoFPbVazS+//MKtt95q6lCalJGRgaurq345YIBDF4pJKdT1iB4f7E6Qm11TuxtUxZl1+u8dIpbWa9+Xn59PaWlph+7z3ZTMzExOnz7NsGHD8PDwMHU4QjP06NGDvn37EhUV1W4j1jKZTF8CotZK/PZPuZUhhIeHc/HiRaqrqxu9/7nnnmPlypWMHTsWMzMzXFxc6N27N9XV1WzevJmXXnoJZ2dnQkNDWb58OV988UWjx6lj02M6Fi66T5AUWQdR5h5vVpxeXl5otVry8w332A1t2rRp/Pzzz6YOQxCuSSKpFvSOHj2KTCZj4sSJpg6lUXUTFP9dinD5Cop3DTXOKLVWXUNl4tcAyMxtsOs1v16cCQkJhISEdLpJfdnZ2foR6m7djFOXLhhGYGAgYWFhHD16lNLS0nY5R3uUgIBuhNXHx6fRsoWqqipOnjxJVlYWoaGheHl5cdttt5GTk0NycjK1tbVERkbqt4+MjOT06dNXPJ9MJsdp0Ar9z80drZbL5QQEBHToCYvz5s3jxIkTFBQUmDoUQbjmiKRa0Nu2bRtjxoxp94UKWqukpASlUlmvNV25QsX3p3IAcLI255YI47Stq0r5Ea2yFAC7kNmYWTvr78vOzkapVDboTtLRFRQU6GuoxQh15xQUFKSvsa6srDT48Uf3cMXV1gKA35LyUaoNtyx2WFgYWVlZDbqZlJSUIEkSW7duZffu3Zw7dw4rKysWLVpEZWUldnZ29Z6znJ2dqai4+gI1dr0XYGaraxtade5nVGWpzYozMDCQ3Nxco7UzbKkePXrQu3dvdu7caepQBOGaI5JqQW/Xrl1MmzbN1GE0KTc3F09Pz3or+G2OzaZapXthXzDQDxsL46zu9+/SjzparZbExER69erVYd+cNKaqqorjx48TEREhaqg7ueDgYAICAoiKijL4QiDmZnJuCNMlohVKNfvOG27ZdFtbW7p3705CQkK92+tKvR566CECAwOxt7fn+eefZ+/evcjlcqqrq+u15CsrK2tWtx25uTWOkct0P0hayqLfbVacdnZ2ODo6kpeX18xHZnxjx47l999/N3UYgnDNEUm1AEBRUREJCQlMnz7d1KE0KTc3t0HC9+VlpR9LjVT6UVuciDLrEAAWrmFYeY/Q35eeno5MJiMgwDh9sg2hbqXEgIAA0eWji+jTpw+2tracPHnS4JPqLm+tZ8gSEIDQ0FAKCwspKrqUrDs7Ozd5PUVERGBhYcGpU6f0t8XGxja7e5FDv/uQWejmYFTGr0dT07w3CV5eXh16IZhJkyaxb9++DjuhUhC6KpFUCwAcOHCAoKAg/P2Nk5i2VFVVFZWVlfXKEuJzK4hKLwUg0seRgX7ORoml4syX+u8d+l6aoChJEufOnSM0NLTT9HOWJImTJ09ibW1NeHi4qcMRDEQmkzF48GAqKysbjPy21eTQbliZ6/6+t8fnodUaLnGzsrIiKCiIc+fO1bv93nvv5f333ycrK4uamhpeeOEFJkyYgKOjI3PnzuW5556jrKyMlJQU3n//fe6+u+HKpo0xs3bFoc9dAEjqGspPf9ys/by8vMjPzzfqUvEtMXHiREpKSkhJSTF1KIJwTekcr/xCu9u7dy9DhgwxdRhNys3Nxd3dHQsLC/1tX9SboGickWFJraQyYRMAMjMr7MMW6u/Ly8tDrVbj6+trlFgMITExkcrKSgYPHtxp3ggIzWNhYcGwYcNIS0sjIyPj6js0k72VORND3AHILldwMrPMYMcGXU1wfn4+VVVV+tueeuopJkyYQP/+/fH396e6uppNm3TX4dq1a3FycsLPz49Ro0axdOlS7rjjjmafz3HA8suWLv8Qrfrqi7s4OTlhbm7eri0M28LOzo5+/fqxb98+U4ciCNcU8SoqALBnzx7GjRtn6jCa9O/Sj1q1lq9OZgJgZS5n4UDjJLJV57eiVeg+IrYNvhkzGzf9fampqfTo0aPTJKeZmZlcuHCBYcOGdbouJULzODg4MHjwYE6dOmXQVRdnXt4FxECrK9axsbHB29ub1NRLEwfNzMx48803KSwspLCwkO+//17/fODo6Mi3335LRUUF+fn5rFy5skXns3DqgV2Iro2otqZA39XnSmQyWYcvARk+fDh79uwxdRiCcE3pHK/+Qruqq6fuqJMUa2trKSoqqpdUb4/PpbBKN/v+5r5euNoaJym8fAVFh4hLHzGXl5dTVFRE9+7djRJHW1VUVBAbG8vgwYM77RLqQvN4eHjQu3dvjh07ZrCJizeGe1LXlt1QS5ZfLigoiPT0dINPtGyK02WLwZQ3c+lyLy8v8vLyOmzd8sSJE0VdtSAYmUiqhQ5fT52fn4+DgwO2trb62748funj7CVGKv1QlaSgyNwHgIVLCNa+1+nvS01Nxc/PDysrK6PE0haSJBETE0P37t3x9PQ0dTiCEfTs2RNHR0fOnDljkON5OVozPMAFgDO5FZwvrLrKHi3j4uKCvb29QctWrsTKcxDWftcDuuu8+vyOq+7j7u6OUqlsVvs+UxB11YJgfCKpFtizZ0+Hr6e+fJQ6s7SG35N1K5oFutgwPtjdKHHUa6N32QRFlUpFZmZmp+lLfe7cOWprawkLCzN1KIKRyGQyIiMjyc7ONlgruPYsAZHJZAQFBXHhwgWjjbRePlpdFv32Vbc3MzOjW7du5OTktGdYrSbqqgXB+ERSLXToemqtVkteXl69pHr9iQzqGg4sHuKPXC5rYm/DkTS1VCTqJkYht8A+7Hb9fZmZmTg4OODs7NzucbRVRUUFycnJDBw4sF6/b6Hrs7GxoW/fvsTGxhqkrGJW30ufcrRHCYiPjw9KpbLdll3/N5vuU7Fw03XAUWYfQZH991X3qSsB6ahEXbUgGJdIqq9xZWVlJCQkMGXKFFOH0qiioiLMzMz0CatWK/HlMd1HwjIZ3DXEOCUr1ak70VbrRsftes7EzPbSEt6NLZ3eEV1e9uHq6mrqcAQTCAgIwNHRkbi4uDYfq7eHA7266Xo8H7pQTGGVss3HvJyZmRn+/v5GWxJcJpPhNPCy0eqTb151Hy8vL0pLS1EoFO0ZWquNGzeOw4cPmzoMQbhmiKT6GhcTE4Onp2eHTQrrSj/qSi32pxZxobgagEkh3Qhwsb3S7gbT1ATF0tJSKisrO0UbvXPnzqFSqUTZxzWsrgwkJyenWZ0rampqCA4OrvcpTHl5OQsWLMDR0ZH0vT8AoJVgZ0K+weMNDAwkOzvbaBMW7XvNxczOG4Dq89tRlVy5HtnKygpnZ+cOO1p93XXXkZmZ2WFb/wlCVyOS6mvcyZMnO2ySJUlSg3rqdfV6UxtnlFpVdoGa9D8BMHfsgbX/pVKZtLQ0/Pz86vXP7ogqKytJTk5mwIABouzjGldXBnLq1KmrJqsrV65s8IZ7+fLlFBcXk56ezhf/u09/e3uUgDg6OuLo6Gi0CYsycyscIx/85yepWUuXd+TWet26dcPPz4+TJ0+aOhRBuCaIpPoad/z4cfr162fqMBpVUVGBUqnE3V03EbG0RsWPp3WTglxtLbipr9eVdjdcHPFfAroiboe+S5D9s1CEVqslMzOzUyxJnpiYiJ+f3zVT9iFJEtXV1WRnZ5OUlERcXByxsbFER0dz4sQJoqOjOXXqFHFxcZw9e5a8vDyUSsOWL3RkAQEB2Nra1usF/W8nT55k165dPPnkk/rbqqur2bx5My+99BLOzs7cNrof9nI1AH8kF1Cj0hg81sDAQNLT06++oYE4RNyDzMIegMqEjWiqrzwC7+XlRUFBARqN4R+7IYSHh4ukWhCMxNzUAQimdeLECZ5//nlTh9Go3NxcunXrhrm57s/0m+gsFGpd/9iFA/2wMm//EVdJq6YyfoPuB5kZ9n0urdRWWFiIubk5Li4u7R5HW5SUlJCXl8eECRNMHUq7kCSJmpoaSktL9V9lZWWoVCocHBxwcnLC0tISS0tLzMzMkMvlaLVaNBoNWq2W8vJy0tPTqaqqwtraGmdnZ5ydnXFycsLZ2Rlra2tTP0SDk8lkhIeH8/fff9O9e/cGrSDVajX33HMPH3zwQb2luJOTk6mtrSUyMhIAM7mM0d5W7MrSUK3S8OfZAm7sY9g3u15eXpw6dYqamhpsbGwMeuzGmFk749B3KeUx7yJpFJSf+hiXEU0vKOPg4ICVlRUFBQX1PlXrKPr378/x48dNHYYgXBNEUn0NKy8v5/z584waNcrUoTSquLiYbt0uTQj88vil0aolRir9qL7wK5oq3ei4bdAMzP+pt4SG9d4dVWJiIj169DBKQmJMCoWCzMxM0tPTqaysxNHREScnJ7y9vQkLC8PR0bFFpS4qlYqysjJ9Up6ZmUllZSWurq4EBATg4+PT4ct8WsLNzQ03NzfOnj1LREREvfvWrFnDgAEDGDNmTL2WbJWVldjZ2enf6AJMCnJgV1YpAFvjcw2eVFtZWeHi4kJeXp7RFldyGrCc8ti1IGkoP/URToMfQ27R+PwNmUxGt27dGixQ1VEMGzaMzZs3mzoMQbgmiKT6GhYbG0u3bt067CqApaWlhISEAHAqu4yTmWUADPJzor+Pk1Fi+Hdv6jp19d79+/c3ShytlZ+fT2lpKYMHDzZ1KAYhSRJFRUWcP3+evLw83NzcCAkJwdvbu16i1xoWFha4u7vry40AlEolWVlZXLhwgbi4OHx8fAgODsbR0bGtD6VDCA8PZ//+/fTs2VO/uNK5c+f4+OOPiYmJabC9vb091dXVqNVq/e871FoBKiVYWLEzPg+NVsLMwG0u6+qWjfVcZe4YgF2vOVQlfYtWUURlwkYc+9/f5PbOzs5kZWUZJbaWGj16NBkZGRQVFeHm5mbqcAShSxM11dewjjxJsaamBqVSiZOTLnn+4pjxV1BUV2RQc3EXAGYOAdgETtLfV15eTm1tbb0ErKORJImEhARCQkKwtDTOMu7tRZIksrKyOHDgAMeOHcPBwYGJEycyatQo/P3925xQN8XKyoqgoCDGjh3Lddddh1wuZ//+/Rw9epSCgoJOvwS0o6MjPj4+JCUl6W87dOgQeXl5hIaG4u7uzqxZsygvL8fd3Z3y8nIsLCw4deqUfvvEuFO4Veja3hVU1fJ3WonB46yrW1ar1QY/dlOcBq7Qf18W/S6StumaaScnJ8rKyjrk34Onp6eYrCgIRiKS6mtYR56kWFZWhr29Pebm5ihUGr4+mQmAtbmc+QOM076uIn49SLp6Uoc+i5HJL5US5Obm4uHh0aE7aWRnZ6NUKgkKCjJ1KG1SUVHBwYMHiY+Px8/Pj8mTJxMeHl5v2XpjcHJyIjIyksmTJ+Pi4sLx48c5fvx4p5/gGBYWRlZWFuXl5QDMmTOHc+fOERsbS2xsLJ9//jkODg7ExsYyYsQI5s6dy3PPPUdZWRkpKSm8//773NL/0jVp6NUVQVe3bGNjQ0FBgcGP3RQrj0isA3TzENRl56k+v63JbR0dHVGr1VRXVxsrvBbp3bu3SKoFwQhEUn0Ni4mJ6bDLk5eWlup7426Lz6WkRtf6a3Y/b5xt2r+uVdJqdEk1gEyOQ5/F/8/eecc3Va9//HOSNKtJk+496C4d7NGytyAO1Cu4cY+f26sXQQUV19V7ndc9cCEoKgICAmW3pVBmoXTQ3dLdJm32+v7+iAkNHXQkOadw3q9XX+TkjO8nIcn5nOc83+dxWH9xqT+mQQhBYWEhEhISGG38e4MQgnPnzmHfvn3w8fHBzJkzERMT47KodF8RCARITEzErFmzQFEUdu/ezdhb/31BLBYjKioKRUVF9uWwsDD7n7+/PyiKQlhYGPh8Pj766CPIZDKEhYVh0qRJuPfee/H6fTfYUz7+OF3vkogtHaXrHFqXH/1vj6+Ly+XCy8sLCoXCTcr6R1paGmuqWVjcAGuqr1DMZjPKysoYmxPc2VR3rk3trtQPbeUOmDusKSeiqKvAk4bZ1+l0OiiVSgQGBva0O+00NTXBaDQiPNw9EzqdjS06XVFRgfT0dKSkpNBupi9GIBBg3LhxSEtLw6lTp4Z01DomJgb19fXdRlqnT5/uYBa9vLzw008/oaOjA42NjXjppZfg68nH5ChrucaSZjUKG1VO12gz1e5MsRBFzAbfzzqJU19/GPrzPXcnlMlkjDXVycnJ9osmFhYW18Ga6iuUqqoqWCwWxuZU20x1ZasGu0qs3cCifcWYGu2eiTYdpzt1UOw0QREAGhoa4O3t3aUMGZMoKytDVFTUkItSXxydnj59OuMnV4WGhmLmzJkghAzZqLVYLEZgYCDKy8sHfIxrUy5cZLoiBcTHxweEELS1OT9nuycoioLXmE651Uf/2+O2crkcSqXSHbL6TUpKCkpLSx3KI7KwsDgf1lRfoRQXF9tv5zINnU5nn6T4zZFq2AJTd48LB8fJVQW6w6Sug6bsTwAA1zME4mHzHdYzPfVDpVKhqamJsVVdesJkMuHQoUOMjk73xMVR65MnTzJy0lpvREdHo7KycsCTAa/rVEpv0xnnt+3mcDgIDAx0ewqIJH4xuBJrzrimbAsMrYXdbieXy6FQKBj5/56SkgKdTofz58/TLYWF5bKGNdVXKMXFxYztBKhQKCCRSMDhcLHmiDUFg0MBS8e5J5VBdeZbgFhn+kuT7wLFuWDsTCYTGhsbGZ36UVFRgeDg4CHVtMRoNCInJwcWiwXTpk1jfHS6OyiKQmhoKKZNm4ampiYcO3ZsSEUGfX19IRKJBhxpj/b1RGqwFABwqLINde06Z8oDQE9eNcX1gGzUY/Zl5bH3ut3ONllRq9W6SVnfEYvFCAkJQXFxMd1SWFgua1hTfYVSVFSEYcOG0S2jW5RKJeRyOTLPNaNKYT1BXZUQgFCZ65uXEGJBx+lv/l6iIEm+22F9a2srBAIBpFKpy7UMBLPZjOrqakRGRtItpc/o9XocPHgQfD4fEydOHPINVsRiMSZPnoz29nYcPnyYse2rL4aiKERGRqKysnLAx7i2U7R6c4Hzo9UBAQHo6Ohwu3GVptwHim+tTa46+wNM6q7GnsvlQiqVMjavOiIigjXVLCwuhjXVVyiFhYWIj4+nW0a32PKpO09QvNtNHRR1VbtharfmlYoi58BDFtVFm7e3N2O7KNbX19ubmAwFjEYjsrOzIZVKMW7cuCGXA94TQqEQkydPhsFgQF5e3pCJWIeFhUGpVNrL6/UXhxSQ086PKHt4eEAikbg9d5kj8IJX6n3WBbMB7Sc/7nY7WwoIExk2bBg7WZGFxcWwpvoKpbi4GMnJyXTL6BaFQgEzX4zf860nZX9PPq4Z7p4c5vbTX9ofS1Pv7bK+c1USJlJVVYWIiAjGmv7O2HKoxWIxRo8eDQ7n8vo58vDwwMSJE6HRaHD8+PFec231ej3uv/9+DBs2DFKpFImJifj66wvdPNvb23HrrbfCy8sLgYGBePXVV12imc/nIyQkBNXV1ZfeuBvGhMkQKrOmHWWea0aHzvnNWugyrl4jHwX+TgXrOPkZLIauFU6YbKrj4uIcmvywsLA4n8vrLMZg1qxZA4qiMH369C7rpk+fDoqisGbNGrdo0el0qKmpQUpKilvG6w86nQ46nQ5by9QwmK3RvdvHhIHPc/1H1axphKZ0MwCAKw6EeNjCLtsolUp7l0emYTKZ0NzcjJCQELqlXBJCCI4cOQIOh4OxY8dedobaBp/PR3p6Otra2nDmzJketzOZTAgODsauXbvQ3t6ONWvW4JlnnsGOHTsAAI899hhaW1tRVVWFAwcO4IsvvsB3333nEs3BwcEDzlumKMqeAqI3WfBXUaMzpQGgz7jypGGQJCwBAFj0bego+LbLNkzurDh8+HA2/YOFxcUw5ky2dOlSUBTl8MfhcODl5YW0tDQ8/fTTg8r1Y7lAaWkphEIhI3OqlUolPD098e3RC5Ol3FWbuqPge8BibTIjGX4HKK5jbq/BYIBGo2FspLqxsREikQgSiYRuKZekrKwMarUa48ePv2xSPnpCKBQiPT0dlZWVaGzs3mR6enrilVdeQUxMDCiKwsSJEzFjxgwcPHgQGo0G69atw+rVqyGXyxEfH4/HHnsMX331VbfHGiwBAQHQaDRQqQZWa/q65AuTeDe5oLSezbjSgaxTeb32Y++DWBwj8TKZDEajkZGTFVNTU1FZWQmj0ej2sbs7v/f0t3fvXrfrGyx79+7FqlWrsHHjRrqlsNAMY0y1DQ8PDwQGBiIwMBB+fn5QqVTIz8/Hu+++i9TUVOzbt49uiUOe6upqBAUFMTI6qFAoUGfxxMnz1pzOCRFyJAe5flIgIeSi2tT3dKtNLBYzsgwhYM2nDg4OplvGJVGpVDh79ixGjRo15Ccl9hVPT08kJyfjxIkTfTI1Op0Ohw8fRlpaGoqKimAwGDBy5Ej7+pEjR+LUqVMu0crj8eDn5zfgaPX0GD94Ca1pEn+ebYTR7Nx8cplMZr+j5W74fqkQRc4DAJjaK6Au+c1hPZMnK0ZHR8Nisbi9ekpnOp/fe/pj6u9rb+zduxcvv/wya6pZmGeqMzIyUF9fj/r6ejQ2NkKr1WLDhg32Wd+33XbbkO1axhTq6uoYO5FNq9Via5XBvuyuKLWuZj9MinMAAGH4DHjIY7tsw+TUD0IIGhoaGF0/G7DqPH78OCIjI4dk2bzBEBkZCYlE0msaCGB9j+677z7ExcXhhhtugEqlgqenp0PNbrlcjo6ODpdpHUzpOj6PgwWJAQCANq0RB8tbnSnNPlmRLuMqu6gZzMWpHmKxmJGRaoFAAG9vb9TV1dGmofP5vae/jIwM2vSxsAwWxpnqixEIBLjxxhvx4YcfAgBqa2uxZ88emlUNberq6uDv70+3jG5RqrXYWma97Sz24GLxSPfkB3d0nqCY0nWCIsDsSYptbW0ghMDb25tuKb1SWloKvV7P2E6eroSiKIwcORK1tbU9poEQQvDII4+gqKgIGzduBIfDgUQigUajcWjKolQqXVrWMSgoCK2trTAYDJfeuBs6l9bb6IIqIHR2LxSGzwDffyQAwNB4DLqa/Y7rhUJaouh9wc/Pj1ZTzcJyucN4U21j1qxZ9scFBQVd1re3t+OVV17B6NGj4eXlBZFIhKSkJDz33HM9nsBsHDhwALfeeisiIiIgEAgQEBCA8ePH45VXXukyC766uhpvvfUW5s6di5iYGAiFQsjlcmRkZODDDz8c8EnIndTW1iIgIIBuGd2ys1yFDoP1dvHNI0LgJXR9eoBZ2wL1ud8BAByhLzxjrut2Oyab6rq6OgQGBjIypcdGR0cHCgsLMWrUqCHTKdHZiMViJCcn4/jx413SQAgh+L//+z/k5uZix44d9rsiCQkJ8PDwwMmTJ+3bnjhxAqmpqS7TKRKJ4OXlhYaGgdWanp8YAA+utQLNpjP1Tp+4J5PJaItUUxQF2Zin7csXty5nsqn29/cfUl0V//nPf4KiKISHh3d7EaXVapGUlASKorB06VKHdYM9Vzc2NmL58uUYMWIEvLy8IJFIkJSUhKVLl2L37t327SiKwssvvwwA+Pbbb7vkiFdUVPTptXZ0dOCbb77BTTfdhOHDh0MqldrTxp577jk0NTX1ur9er8dHH32EadOmwc/Pzz5v6pprrsEPP/zQbdpZf/bprdiCDVvu/KpVqxye37t3LyiKsnf53bx5M+bMmQM/Pz9QFGVPm9Hr9Vi/fj1uv/12pKamwtvbGyKRCHFxcXjkkUcu+V5aLBZ8//33uOqqqxAQEACBQICIiAjMnj0bn332GdRqNQDgxx9/tNfl763c6aeffgqKovoXBCIM4a677iIAyLRp07pd39jYSAAQAOTf//63w7rTp0+TsLAw+3o+n09EIpF9OTg4mJw+fbrLMc1mM3n88cft2wEgMpmMeHp62pdXrlzpsM+NN95oXycUCom3t7fD/tOnTyd6vb7LWN98802Pr2/atGkEAPnmm2/6+nYNiuuvv548//zzbhmrv4xYvZlQz2wi1DObyP7SZreMqTj6Hil714OUvetBmvc91+02er2ebNy4sdv/WyaQmZlJampq6JbRIxaLhezbt4+cOnWKbim0Y7FYSFZWFjl27JjD84888ghJS0sjzc1dP/d33HEHmT9/PlEoFKS4uJhERESQb7/91qU6z549S44cOTLg/ed9lmP/Lp+oVThRGSFNTU1k+/btTj1mf7CYDKTyyxj774a++cL5paKighw8eJA2bb1x/fXXkxdffNHt417q/N4TOp2OJCcnEwDk9ttv77Ledv6OiIggSqXSYd1Az9WEELJr1y4ik8ns2woEAuLt7U0oiiIASGRkpH3bwMBAu2cQCoUkMDDQ4a+qqqpPr/XDDz+0j8fj8YiPjw/hcrn258LCwkhpaWm3+1ZWVtrfJwCEy+USX19f4uHhYX+uvLx8UPv05mFs2P6fL/ZNe/bssb9vb731FgFAKIoi3t7ehMPhkN9//50QQsjmzZvtY3M4HOLj4+OgRy6Xk9zc3G7Hbm1tJVOnTu2yv0AgsD+3Z88eQgghWq2WyOVyAoDs3Lmzx9czYcIEAoC89dZbPW5zMcwNa11EZmam/XF0dLT9sUKhwIIFC1BTU4M77rgDBQUF0Gq1UKvVOHPmDObPn4+6ujrceOONDrdPAeCNN97ABx98AIqi8Oyzz6K2thYKhQIqlQrl5eV45513upQnGz58OP73v/+htLQUGo0Gra2t0Gg0+PnnnxEaGoq9e/fi3//+t2vfjEFy/vx5hIaG0i2jCyVNHTjVZo1oxft7YvIwH5ePSbpMULy72+2USiVEIhEjJ9EYjUZ0dHTAx8f179dAqaurg06nuyLTPi7GlgZSU1Njb7JSWVmJjz/+GEVFRfbca4lEgoceeggA8NFHH0EmkyEsLAyTJk3CvffeizvvvNOlOn18fNDW1jbg/V2ZAkLnZEXA1rr8cfuy8uh79sdCoZCx834CAwOHVKRaIBDg+++/h4eHB3744Qf89tuFiaGZmZn48MMPQVEUvvnmG3h5eTnsO9BzdVFREa6//noolUpMnDgRBw8ehFarRWtrK9rb27Fx40aHO+f19fX45z//CQBYvHhxlxzx8PC+NS7z9/fHiy++iGPHjkGr1aKlpQU6nQ7Z2dnIyMhATU0NHnjggS776XQ6LFy4EGfOnEFISAjWr18PlUqF5uZmqNVqZGVl4Z577nG4OziQfZxBQ0MDli9fjieeeAKNjY1obW1FW1ubPY9eKpXiqaeeQnZ2NjQajf09OHXqFBYuXAiFQoE77rijS3SZEIIlS5Zg//798PLywueffw6FQoGWlhZoNBocO3YMTz75JEQia1dmoVCIW2+9FQB6LGVcWFiI3NxccLlc3HHHHX1/kX223y6mpytZnU5Hfv31VxIQEEAAEF9fX6JWq+3rly9fTgCQe++9t9vj6vV6MmLECAKArF+/3v58Q0MDEQqFBAB58803nfIasrKy7FeUF8OkSHV4eDjZuHGjW8bqD8s25dsjW29mlrhlTG1tlj3adP7nmT1ud+7cOXLo0CG3aOovzc3NZNu2bXTL6BGLxUL27t1Lzp07R7cURnHs2LEu0WomMdi7M9VtGvv3efR/9zpZHSE7d+4kDQ0NTj9uXzHr20nFx/7W34/3xcTYUUsIIUShUJA///yTNl29sWrVKnLVVVe5fVzb+d3Dw6NLJLfzX3x8fLf7r169mgAgfn5+pL6+nigUChIeHk4AkMcff7zfeno7Vy9atIgAIKNGjSJarbZPx1u5ciUBQO66665+a+kLbW1tdg908e/o+++/TwAQiURCSkr6dt4cyD7OiFSjhzsOfUGv19sj67t27XJY98cff9ij7X29S3T06FECgIjF4i53OQghZNmyZQQAWbBgQb90Mi5SnZ2djaCgIAQFBSEgIABisRg33ngjGhsb7VetYrHYvv2331oL8D/zzDPdHo/P5+Omm24C4Bjt3rBhA3Q6HUJCQnrct79kZGRALpejpqYGtbW1l96BBsjfVSIiItxTVaOvmC0E3x+zvmdcDoW7xoa5ZdyO/M4TFLuW0bOh0+nsV7lMg8m53gDQ2toKlUrFuM8c3cTExKCmpoax+bd8Ph9isXjAucthchHGhFnzwo/XtqOqTeNEdda8bzrfOw5fCmnq/dYFixHtJz4CYI2uGo1GmM1m2rT1RFhYGK2RaqPRiIaGhl7/umPZsmWYOHEimpub8cADD+DRRx9FdXU1EhIS8Oabb/ZbR0/n6o6ODmzatAkAsHr1agiFwoG9UCcjl8uRnp4OADh06JDDuh9++AEA8PDDDyM2tmvVqu4YyD7OYqB+i8/nY/bs2QB6fg9uuOEGTJo0qU/HGz16NEaOHGm/e9EZW242gC65+peCcaa685euqanJHuYPDQ3FyZMnMX/+fPu21dXV9i/EjBkz7Gb84r+3337bvr2N3NxcAMDs2bP7fYvj4MGDuP322xETEwOxWOwwKcF2AmLqDOu2tjYYDAZERkbSLcWBHUWNON9hnThydVIAgrxc/2Nm1rVBXbwBAMAReEMcd0OP2+p0Osb8wF4M0011aWkpoqKirpia1H3Fy8sL/v7+KC8vp1tKjwy20cp1KRdSQDadGdikx54QCAS0X5B4jXoU4FpTwjpOfQGLoQMCgQAURdGurTvCwsJorVM9bdo0EEJ6/OvpAo7L5eK7776DWCzGpk2b8MMPP4DH4+G7777rNdjR33N1Xl4ezGYzPDw8HFI83EV5eTmefPJJpKWlQSqVgsPh2PX+8ccfXfQajUYcP34cABy8UW8MZB9nIRKJkJaW1us2jY2NeOGFFzB27FjI5XJwuVz7e/D+++8D6OqvbH6uv6/nnnusgbSLU0B27tyJ2tpa+Pj44Nprr+3XMRlnqjt/6bRaLfLy8rBgwQLU1tbigQcecMhV6/zG9nbla8tb1GguREpsFUH6Gz17/fXXMWXKFPz4448oKyuDyWSCj4+PvXC9rfqCbZYp02hqagKfz2dc/u3Xhy9c8Nw9zj0RTXXhTyBm64lPknQbOLyef5x1Oh0EAoFbdPUXpVLJWFOt1+tRX19vn/XN4khUVBSqqqoY2dYaGHxL8Os65VX/4eTuikyossHzDIYk0ZqbaTEo0XH6a1AUBYFAwMi86tDQULS0tDD289YbcXFxWLZsmX35mWeewfjx43vcfiDnapsvCAwMdPvvfWZmJlJSUvD+++8jPz/f3r3XptcW1Omst7W11T5XrK9eZiD7OAtfX99eK1Tl5+cjOTkZr732Go4ePWovHWp7Dzw9PQF09VcD9XO33XYbBAIBsrKycO7cOfvzNpN966239vtzwDhT3RmhUIgxY8bgjz/+wPjx47F//34sX77cvr5zsrrRaOz1CpgQMuj2p/n5+XjxxRcBwF5LVqfToaWlxT4pwTaxkak/Wh0dHfYPJlNoUumxqcB6wvUVcrAgyfXl/gghaD/dt9QPgLmRapPJhI6ODsY2pampqYGPjw/jPnNMISAgAISQS5bLoovB1oNOCZJimI81XW9faQsUWue1yGaCqQYA2egn7Y+Vxz8AMRsZo+1i5HI5zGYzIw3/pdDr9Vi3bp19OScnp8dyaEPtXG0wGHDnnXdCo9Fg+vTpyMnJgU6nQ2trq12vLY2VCXoHCpfL7XX9Pffcg+bmZqSmpiIzMxMajQYKhcL+Hjz1lLXxkrPeAx8fHyxatAjABSOtVCrtJf76m/oBMNxU2+DxeHjvvfcAAB988AFKSkoAWK8mbVRVVfXrmLZ9Kysr+7zPb7/9BovFgmnTpuF///sf4uPjHa66zGYzWlpa+qXD3di6szGJH47VwGi2fkmui/OCB9f1H0t9/REYm08DAATBE8H3S+l1e6aaaqVSCYFAwMh8b0IIqqqq2FzqXuBwOAgPD+9SD58pyOVyqNXqAdffpygK1yZbf2tNFoKtZ52XAsKUKht83+EQDVsAADB3VENdsoGxptrWHMqV3ThdxYoVK1BQUIDQ0FDI5XLs37/f7gsuZqDnapsvaGhocOtnKycnB+fPn4enpyc2b96MiRMndkmX667fho+Pjz19ta9eZiD7ALDv09vnejAX4JWVlcjLywMAbNq0CTNnzuxyXuup58hA/JyNe++1Nnv7/vvvYbFYsH79euh0OqSmpmLMmDH9Pt6QMNUAkJ6ejhkzZsBkMuGVV14BAAwbNsz+Zm7btq1fx5s4cSIAYNeuXV1K7fWELX977Nix3a7Pzc1lZHvaznR0dDDKgBFC8HXuBUOxJMU97dMdy+h130HRhslkgslkYqSpVqlULu2sNxh0Oh3a29sRHBxMtxRGExISgvp65zdIcQZ8Ph8CgWBQ6WzXuyivmgk51TYubgYj4PMZo60zIpEIXC53yJnq/fv3491337WXz7Pl1q5YsQJnz57tsv1Az9VjxowBj8eD0Wh0KGxwKWyGfaDfYZvexMRESCSSLuu1Wq09b7gzHh4eduO3ffv2Po01kH0A2FMMeyrCQAjBsWPH+ny8i7Ed19fXt8d0wZ6yDWx+rj+vx8asWbPsaXi7d++2R6wHEqUGhpCpBi7MGv3pp5/sk3vuuusuANb8qd46J5pMJqhUKvvyTTfdBJFIhLq6OvznP//p0/i2OphFRUVd1lksli5dhJgI09I/DlcpcKbB+gOf4s3F8GDXpzFY9O1QF60HAFB8L3jG39Tr9nq9HhRFMbJGNVMj6IB1AqVUKmUnKF4CmUwGi8XC2HkYg426TorygY/Y+hnYWtgAvck5VTFsuphwMSIMnQJ+oNWoGJpOQqQ+yUhTzeFwIBaLHc6FTEelUmHp0qWwWCx4+OGHMWfOHNx55524/vrrodPpcOedd3YJjA30XC2VSnH99dcDsBr2vv4f2sYb6PwD2/4VFRXdRsj/85//9BgFttVQ/uSTTxzygntjIPvYOrjW1NTYJzp2Zt26df3OGOiM7T1obW3tNh3uhx9+QHFxcbf72l7Pb7/9huzs7H6N27kb58qVK5GTkwMej4fbb7+9X8exMaRM9YIFCzB8+HCYzWa89dZbAKyldoYNG4bz588jIyMDf/zxh8OH8ty5c3jvvfeQlJRkv7UAAH5+fnjhhRcAAM8//zz+9a9/OZQaqqiowMsvv4xPP/3U/pxtNvCWLVvw3//+1z5ORUUFbr75Zuzfv59RhrU7VCqVQ0lCuvn6yIUv4ZxguGVyiKpoPYjJOmlVkngLOB69/5/ZJilSFOVybf1Fr9cz2lQzdQIlk+BwOPDy8hrUrVNXMtiIMI/LwcIk6x1Fld6MPeeckyInFAphsVi6bb/sbi5uXc6v+p4RqSndIRaLh1Sk+umnn0Z5eTliY2PtlbwA4LPPPoO/vz/y8vLw+uuvO+wzmHP1a6+9Bk9PT5w4cQIzZ85Edna2/cJNpVLZ22h3Jjk5GYC12ogtPbU/ZGRkQCgUoqWlBffcc4/dVCqVSrzyyit46aWXeiwucO+99yI1NRUqlQrTp0/HL7/8Yn+9RqMR+/fvx5IlS1BTUzOofSIjI+2R/7vvvhsFBQUArOfHr776Cvfdd589vWggDB8+HMHBwSCE4LbbbrOncmg0Gnz88ce47777enwPFixYgLlz58JsNmPBggX48ssv7ReOFosFR48exQMPPNBttN/2ejgcjt2QX3311QgIGODcrn5VtXYhfW1j+uWXX9rbhtbWWovtFxUVkfj4eIcWn76+vg7tKQGQvXsdGxCYzWby6KOPOmwjl8uJRCLptk25xWIh8+fPd2iDaWt1yeFwyGeffUYiIyMd2mHaYErzl3feeYfMnj3b5eP0BZXOSLyWbyXUM5uIdPmfZN1vfxCVSuXycWt+nGBv+KJrOH7p7Wtqunx2mEJubi5jm6pkZ2f32FaXxZETJ06Q06dPX3pDGjh27BgpKCgY1DF+PXXe3gjmoQ0nnaLLYrGQzZs3d9u4gQ4sZiOp+ire/tty4M8v6ZbULcOGDXN7i/e+Nn8JDAwkb7/9tn2/rVu32pt6ZGdndznur7/+aj/u0aNH7c8P5lxNiLWxkJeXl0Obcx8fH8LhcLq0KSeEEIPBQGJiYuztt/39/UlkZCSJjIwk1dXVfXqP3nzzzS5exDbe7bff3mNjFUIIqaioIElJSV08UG9tygeyT1ZWlr1pHgAilUrt29999919alPeG2vXrrW3ggdAZDIZ4fF49rbytmZ/3TXZaWlpIZMnT+5Tm/LumDt3rn07W9v0gTCkItUAcPvttyMoKAh6vR7vvPMOACA+Ph4nT57EBx98gKlTp8LLywsKhQJCoRCjR4/GY489hr1792LatGkOx+JwOPjwww+xe/du3HjjjQgODoZarYanpycmTJiA1atX4/7777dvT1EUNm7ciJUrVyI2NhZcLhc8Hg/z58/Hzp07u20hyjSYlP6x4VQdOvTW23Y3p4VAyCH2yRCbNm3ChAkTIJVKERwcjJtvvhllZWUO+//zn/9EcnIypFIpvLy8MG7cOIfZ4d2hbzwOQ6M174sfOAaCgJGX1NlbisW3336LUaNGQSgUws/PD/Pnz7fn6nWuiXrxn7PqmDO11B8hhNGl/piGTCYbVOk6V7BmzRpQFIXRo0dj+PDh9s9u57JmAPDVV18hPj4eQqEQI0aMwJYtW7oca168P4Q86+lm85kGWCyDT9mgKKrXyYp9+Q1Zv349brzxRoSFhYGiKPs5ZUB6ODzIRj9hX/Zq/GXAx3Ilnp6etEWq+9L8xRZhbG1ttU8ie/bZZ+3NTzpzww034Pbbb4fRaMSdd95p/ywM9lw9e/ZsFBYW4p///CeGDx8ODocDo9GI+Ph43HPPPfamczY8PDyQmZmJO+64A6GhoWhra0NlZSUqKyv7PGfrX//6F3744QeMHTsWAoEAFosFY8eOxWeffYbvvvuu130jIyNx7Ngx/Pe//8XEiRPh6ekJtVqNsLAwXHvttVi7di3CwsIGvU9GRgb279+P+fPnQyaTwWw2IyUlBZ9//jm+/vrrPr3O3rjllluwdetWTJ06FZ6enjCZTBg+fDjeeust7Nixo9dUQh8fH+zduxdfffUVZsyYAblcDpVKhcDAQMyZMwdffPFFryUYbVVA/P39cfXVVw/8RQzYjrMMSZ555hly66230i2DEELI1I8O2qNXB8412lsi79mzh3A4HLJ06VKyc+dOsm7dOhIfH09iYmKIRqOx7//ggw+Sd999l2zbto1s376d3HfffQQA+fHHH3scs2nX/9kjScpTfYsknTlzhpw4caLL86tXryZSqZS88cYbZO/evWTDhg3k4YcfJh0dHYQQQnJycrr8xcXFkZEjR/bzneqZv/76izQ1NTnteM5Co9GQjRs3EqPRSLeUIUFbWxv5888/icVioVuKHdvdtTVr1pAvvvjC/hmuqqqyb/PTTz8RiqLICy+8QHbv3k0efPBBwuPxSE5OTpfjXfNlrv37nlvZ6hSNBw4ccNBjo6+/ITfddBMZOXIkefDBBwkAhyjpQDAbVKTik0BS9q4HKX1XSIztfYtSupNx48a55a4oC8tQYvHixQQAefLJJwd1nP61EmQZ8jAlUl3cpMKB8lYAQFKABOPDZdh22hphWLduHSIjI/H111/b85gDAgIwc+ZM5OXlYcqUKQDgkO8OAPPmzUNBQQHWrFmDW2+9tcuYFoMKqqKfAACUhyckCTf3SavZbO5SX7OoqAirVq3Cpk2bHLo43XjjjfbHthnJNioqKlBSUoJ///vffRr3UhBCGJtTbZuk2N9upVcqUqkUJpMJGo2GEd/PzowZMwbNzc1dPs+AdWLPkiVL8OqrrwKwdrY9deoUXnnlFWzdutVh22tTArHl75J6f5ypx/iIgedf2uByud3WKu7rb8j69evtlRs+++yzQevheHjCK+1BKA6/AQpmtJ/4CD5T+t9G25UMtZxqFhZX09jYaK9Nbbs7MlCGXPoHy+AwmUyMqMbwzZELZfTuGR9hnwhiu80mlUodJgbampuQS8z09/X17bGmrrpkA4jBejLxTFgMDr9vpegIIV0mKX7zzTcYNmxYv9qirl27FhRF4ZZbbunzPr1hNBphsVgYmf7R3t7O2IY0TITL5TJ2smJP3QHLyspQXFyMm292vDhdsmQJMjMzu+xzzfAg2L5Gm047p7QeRVHdmuq+/ob01t1toHiNeATgWL+T7flfwKJn1v+ph4cHzGbnVGBhYRnq6PV6PPXUU9Dr9Zg5cyZSUnrvWXEpWFN9hWE2m11yIukPJrMF3+VZTTWPQ+GOMWH2E52tvE1BQQE+/vhjKJVKlJWVYfny5Rg1ahQmTZrkcCxCCEwmExQKBb7//nvs2LEDjz76aLfjduRf6KDolXJfn/V2Z6oPHTqE1NRUrF69GgEBAeDz+Zg0aVKPs4sBaynIqVOndslTGyg2M3GpLlV0YDQaGVmCkMl4eHj0Of/SnUyaNAkLFixAdHQ03njjDbshKywsBGCtrduZpKQkGAwGe9lTG4FSAdIjrdHpMw0dONc8+BKCFEV1e6Hdn98QZ8P1DIQg1nqhQQwdDjXxmUBPFyIsLFcSGzZsQFRUFHx8fLB27VrweDx7VbnBwJrqKwwmmOpthY2oa7dGsa4ZHogAqcDBVE+ZMgW///47li1bBrlcjpiYGDQ0NGDbtm1dDGRmZiY8PDzg7e2Ne+65B++//769nWtnDE2noK8/DADg+6XZa8r2BYvF0uU9q6+vx44dO/Ddd9/h448/xsaNG0FRFObOndttvfRTp07h9OnT3aalDJTO7xnTYMLnbKjB5XIZFUEMDg62lxVdtWoVFixYgBdeeAFPPGGdjNfW1gYAXSaj2spqtba2djnmtckXGsH8cbp+0Bp7MtX9+Q1xBaLUR0Bg/V4qjvwbxDywjpSugMPhsKaa5YpHpVKhsrLSPiH0zz//7LFZUH9gz3pXGBaLhfbI5sWpH4BVl626QHZ2Nu644w7cf//92L17N3755RdYLBZcffXVXbpgTZgwAUeOHMGuXbvw5JNP4rHHHsNXX3WNDHWc+cb+WJp6X7+MaHeRaovFApVKhQ0bNuCmm27CggULsGnTJhBC8NFHH3U5xo8//ggPD49uDf9A6fyeMQ0mfM6GGgaDgVENQ+bNm4eXXnoJs2bNQlpaGj766CM8/fTT+PTTTwdcvea6Tqb62S0Fg9ZoMBi6TU3pz2+IK+B4xaJDNBoAYNG1ouJjH0Y0qQGs+aO9NUpjYbkSWLp0KQgh0Gq1OHLkCObOneuU47KziK4wmPDDfrz2Qo7h8EBrXnNnXY8//jhmzpzp0Oly4sSJiIiIwPfff+9QDkkqldqvLmfNmgWTyYSnn34aS5cudTB1+sYLHaA8fJP7pbc7U+3t7Q1fX1+kpaXZn/Px8cGoUaNw5syZLvuvW7cO8+fP77F4/UBgwv9lT9gMP0vfaWtrg1qtRlJSEt1SHOhsWm+++Wa88847OHHihD0irVQqERR0wSzbItjdfdYTAhxbMDer9fDzHPicgJaWFnR0dGD48OEOz/fnN8QV6PV6aAQx8NIetT7BoEj18ePHUVVV5bQJ0ywsLBdgI9VXGBwOh3YzdvOIEPvj1zKt3ac66yooKMDIkSMd9gkLC4Ofnx9KS0t7PfaYMWPQ3t7epc2pJP7CZCrF4dcv3q1XurvFbOug1R0XRxsPHjyIqqoqp6Z+AMz4v+yJnqoysPRMcHAw4uPj6ZbRBZFI1O1dB1sutS232kZhYSH4fD6io6MveWyDaXCf35CQEMTFxXV5fjC/Ic5AJBJBYL7wGySOuRbWvhL0c9VVV+G5556jWwYLy2UJa6qvMJiQT/evmbGQCa03SdYcqUJhY4c9qkkIsRel70xlZSWam5sRFRXV67EPHjwILy8v+Pn5OTwvTb0PPJn1JK+ryoS2KrPPerub2LNw4UK0tLTgxIkT9udaWlpw7NgxjBnjmK+9du1aSCQSXHvttX0es6+6AGZGrJnwORtqdFe6kQl0vlOzbt06cLlcjBo1CtHR0YiPj8cvvzg2OVm/fj1mzZrV40TVOD9ryUCRBwchssGVg+zuLhKAQf2GOAOLUQMv9SEAAMX3gv/8H0BRzDjdEkLY+Q4sLC6Ctm8WIQQjRoyAp6dnl6jilc6JEydAUZS9w48zYYLZ8RHz8eyMWACAhQAvbS9yMIgPPfQQNm7ciCeeeAK7du3C+vXrsXDhQgQEBNjLd506dQrz58/H119/jd27d2PTpk144IEH8Pnnn2P58uVd6iNTXD6801fal1sPrgAhfXsfuosIX3/99Rg3bhxuuukmrF+/Hps2bcLChQshEAjwyCOP2LczmUzYsGEDrr/+eohEov6/Wb3AZFPNtEl3Q4HuJsTSybx58/DWW29h+/btOHr0KB566CG8++67eOyxx+zpHqtWrcLatWuxcuVK7N27Fw8//DByc3Px4osv9nhcwd+dFTlOSA/qyVT35TcEsEa0N2zYgA0bNgAA8vPzsWHDBmzbtm1QuvSV28G1WHO3PeNuAIfHnFryTPucDSVY39IzrvQtQ4pBtY4ZBD/++CMBQJ544gm6JPSJ6upq8sMPP5AnnniCZGRkELFY3Kce9p3ZtGkTmT17NvH19SUikYgMHz6cvPzyyw6dvS5m/vz5BAA5fPiwE17FBe655x7yyCOPOPWYA0GlM5KgVX/ZO6xllzbaO/BZLBbyySefkLS0NOLp6UmCgoLIokWLyNmzZ+3719fXkyVLlpDIyEgiEAhIQEAAmTp1Ktm4cWOPY1osZlLzw1h7R8WOop/7pPXkyZPk9OnTXZ5vamoit99+O5HJZEQkEpG5c+eSM2fOOGyzZcsWAoBs3bq1j+9M3zEYDPYulEyjuLiY5Obm0i1jSLFr1y5SX19Ptww7jz/+OImLiyMikYh4eHiQ1NRU8v7773fp+vjll1+S2NhYwufzSWpqKtm8eXOvx03+925CPbOJSJf/OWiNOTk5pLy8vMvzffkNIYSQlStXEljzMhz++vP73h1VGxbaf2c0VbsHdSxnM3v2bPLuu+/SLWNIMlR8S0FBAVm9ejWZPXs2CQwMJDwej8jlcpKenk7eeecdolare9x3MJ7HVb5lKEGLqTYajSQmJoZ4eHiQ6mrmtXHtzBNPPDGoH91ly5bZ9+HxeEQikdiXU1NTSVtbW7f77d+/nwAgs2fPdt6LIYQ89NBD5N5773XqMQfKRwfL7KZ69idZZOPGjcRgMLh0THX5dvvJruqbJGIxXXq8U6dOkfz8fJfqGggWi4Vs3ryZKJVKuqV0oaGhgezYsYNuGUMG2wWSVqulW0oXampqyL59+5x2vOFvWU21bMXgLzSzsrJIRUWFE1Q5D5OmmZS9JyJl73qQyi+iiMVsoluSA1OnTiUfffQR3TKGHEPFt+zdu9fBq1AUReRyOaEoyv5cfHw8qaqq6nb/wXgeV/mWoQQt94A2b96M0tJSzJs3z2mNMFwFRVGIjo7G4sWL8fbbb+PZZ5/t876///473nzT2qJ25cqVaG9vR0dHB3bv3o3AwEDk5+fjvvu6b0IyZcoUxMbGYteuXSgoGHzpKRtSqRRq9eCbLjiD+ydEYpiPGACQea4FpxSuT2UQRc6FMGwaAMCkOOdQaq8neDwejEajS3UNBIqiIBQKGVWGzYZcLodGo+mxuyWLI+3t7RAIBIxsOa/T6ZzatdNiq6/uhGOZTKYuqV50oy75FSDWJj6ShMWgOMzKk9doNJBK+9ZNluUCQ8W3GI1GeHh44LbbbsP27duhUqnQ1taG9vZ2fPLJJ5BIJCguLsYNN9zQ7fl2MJ7HVb5lKEGLqf76668BAIsXL6Zj+H7xzjvvoLS0FOvWrcM///lPhxJql+KFF14AANx6661YtWqVPad2xowZ+O677wAAv/76a5cJNTZs788331za+PUVqVQKlUrltOMNBj6Pg5fnJdiXf6igXJ6HS1EUvCe9Zl9WHFoNi7H3iwyhUNhtLVwmwFRtfD4fYrEYCoWCbilDAoVC0aWJClPQ6XRONfu207gzcqqdbfidgapwrf2xZ+ItNCrpHrVazZrqATBUfEtCQgKKi4vxww8/YN68eRCLrYEriUSChx56CB9//DEAIC8vD/v27euy/2A8D+Aa3zKUcLupbmxsxPbt2+Hh4YHrrruu222mT58OiqKwZs0aqNVqvPDCC4iLi4NQKERwcDDuvvtu1NbWukXvQGfj5+fn26/UnnrqqS7r586da6+t+tNPP3V7DFujkO+//95pkwulUik0Go1TjuUMbhkVipQg6w98SQeF3/MH1lSiPwiDx0Mcez0AwKypR/vxD3vfnqHRYIDZ2mQyGZRK5aU3ZLmiTLXlb1c9WE9NCIFer2dUdN+oLIf+fDYAwCCMBN+vf4bEHWi1WkgkkktvyGJnKPmW8PDwXivcLFmyxF6Zp7uA3mArELnCtwwl3G6q9+zZA5PJhNTU1EteLbe3tyMjIwOvvfYaamtrQVEU6uvrsWbNGmRkZKClpcVNqvvP3r17AVibhFxcYs3G7NmzAVjfk+5IS0uDRCJBQ0MD8vPznaJLIpEwylRzORRem59oX34lswxmi2tTQADAO+MV4O8SV4q8d2DW9vxZEggEjDWuTNYml8vZSHUfYbKpdrZxJU5K/zAajbBYLIwy1eqidfbHev95jGyAxEaq+8/l5Fs8PDzsr8EVd4Zd4VuGEm431dnZ1qv4noxmZ1auXAm1Wo3MzEyo1Wp0dHTgzz//hLe3N6qqqvDGG2+4Wu6AOXv2LABrg4SeflhtndMKCwu7zW3icDgYPdra6jYrK8spupiUU21j4fBApEdau7MVt2jx/dEal4/J90mEJHkpAIAY2qE40nN3MVuKBROvupkcqWZNdd8wmUxQqVSQyWR0S+kWpqZ/6HQ68Hg8xuRUE0KgOnsh9YOEXk2jmp7RaDRspLqfXE6+5cyZM3Zjn5KS4vTju8K3DCXcbqqPHDkCAH3K01GpVNi8eTNmzpwJiqLA4/GwYMECvPTSSwBgry3amTVr1oCiqAH9rVmzxmmvs67OmsYQHBzc4za2dWq1usc85xEjRgAADh8+7BRdUqkUWq3WKcdyFhRF4Y0FF1ozr/qrCHqT62sce098ERTXahY6Tn4MU3tVt9vZDAUTc5eZbqo1Gg1j9TGFtrY2CAQCp9cxdwaEEOenf/x9J2qwQVym5VMbmk7A2FYEADDJRkEgH0azoq5YLBZ2ouIAuJx8y8qV1n4N4eHhmDVrVr/27SvO9i1DCbdf4tfX1wNAl4533XHjjTfao7mdueaaa/DUU0+hsrISarUanp6e9nUikQiBgYED0ubMk5otGtzbMW0TCADrF7G7Hzrb+2Qz6YNFIpEwLlINAFNjfDEpRIis8zpUKbT4LKcSj0+5dJvjwcCThMJr5P9BefQ/IGY92g69Cv+5X3TZjsPhgM/nQ6/XM874SKVStLe399gEg074fD78/PxQU1OD2NhYuuUwlpqaGoSEhNAto1t0Oh1MJpNTI5vOjFQzKfVDVXhhbozaZyZkDDL8Njo6OkAIYU11P7lcfMu3336LX3/9FQDwn//8p8eup4PF2b5lKOF2U93c3AzAmmt8KXq6KgwNDbU/VigUDh/OxYsXM352bn+wvU+2922wMG2iYmeemRiIrN8qAQCv7SrB3eMiIBW69iMqG/ccOk5/BYteAdXZ7yEb8xT4vsO7bMfUiLCXlxcsFgvUajUjb+mGh4fj3LlziImJYZzpZwImkwm1tbWYPHky3VK6RaFQQCqVOrV9ur2knhMi1Uwx1cRihrpovXWBy4dSnI5AhmjrTFtbGwAw8reCyVwOviUnJwcPP/wwAODBBx/EP/7xD5eN5WzfMpRwe/qH7RZ6X27b9RS96fxDysT6wQDsX5jeUi06m9uefuRsr9VZhs7LywtqtZqR+cGjQmWYGWq9cm5SG/DegTKXj8kVekM29u86nMSCtqzu2yszdUIgh8OBl5cXY3OXQ0JCoNFoGKuPbs6fPw9PT0/G5lMrFAqna7NNH7mcItW6mr0wq61ROXHUVdCYPBijrTNtbW3g8/kui1Bergx135Kfn4+rr74aWq0W11xzDT766COXjuds3zKUcLup9vHxAYDL/iRry5fu7faH7ZaSRCLp0VTbIgu+vr5O0RUQEACTyYTGxkanHM+ZiEQi3BHDAZdjPdm+s7cUzWrX5zF7jfw/cD2tP4Sass3Qnc/psg1TI9WANXeZqaXreDwewsLCUF5eTrcUxkEIQVlZGSIjIxkbxXdFVRJ7Sb1BHodJ5fQ6T1AUJ9wCg8HAGG2dqa2thb+/P90yhhxD2beUlJRgzpw5aGtrw/Tp0/Hzzz+7fHKvs33LUMLtptqWa2N7053N+vXrERQUNKC/9evXO03HpSp7AH2rEGJ7n/qSy9UXpFIpxGIxKisrnXI8ZyIQCODHNeCe8eEAgA69CW/uPufycTkeYsgnXohQt2at6PJ/xtQmK4C1HjSTf+xjYmJQW1vLuAmydNPS0gKNRoOIiAi6pXQLIQRKpdLpppr8nVXtjEg1EyYqWowaqEs3AgA4fBm4wTMB9C2q6W5qamoQFBREt4whx1D1LVVVVZg1axYaGhowfvx4bNq0yS0Xe872LUMJt+dUJyQk4PTp06ioqHDJ8bVaLRoaGga8r7OYPn06AOuH69ixY92W4tm1axcAa4fFnrC9TwkJCT1u01+CgoJQVVWFCRMmOO2YzkAoFMJkMmH5jBh8n1cDncmC/2VV4Ikp0QiXu3aCoDT5LrQfexfGtmLoaw9CW7EN4mEL7OtFIhFjo8FyuRxnzpxh5GRFwHohFxAQgPLycnvDIxbg3LlziIqKYkxJuIvR6XTQ6/Xw8vJy6nGd1fxFo9EwYuKwpmwLiKEDACCOuwF6k9VQczi0NCzulZqaGofcXpa+MRR9S0NDA2bPno3q6mqkpqZi27Ztbpug6grfMlRw+7d+0qRJAKwtMl3B0qVLQQgZ0N/SpUudpiM1NRXJyckAgPfee6/L+l27duHMmTMArB2OesJWysf2vjmD4OBgt3Wk7A98Ph8URcFPSOHRydZyVHqTBa/sLHb52BSHZ20I8zetWS+AWC6U9bNFg3u660AnUqkUZrOZkVVdbMTGxqK8vJyxKTTupq2tDU1NTYiOdm2Fm8Fgm6TobNNv+w4NJlKt1+uh0+kYkYuuLrpQ9UOSeAtjIujdUVdXx9hKM0xmqPmWtrY2zJ07FyUlJYiPj8fOnTvtKSzuwBW+ZajgdlNtm+V+9OhRdw89IIxGI5qbm+1/tnrSFoul2+c7s3r1agDADz/8gFdeecVuKPbt24c77rgDgLX8jq1Q+sW0tbWhtLQUHA4HGRkZTntNISEhjDTVFEXZc5eXzYyF7O/KH98crkJRY/d1vJ2JOHYRBIHjAADG5tNQdTpZenl5wWAwMNIUcrlceHt7096pqzd8fX0RGBiIkydPMvLCxJ2YzWYcO3YMCQkJjMy7tdHc3OySEzFxQqTaVj3Bw8PDOaIGiFnbDE3FXwAAriQMwrCpjJpAeTGNjY2sqR4AQ8m3qNVqXH311Th16hSioqKwa9eufpXrG4znAVznW4YKbjfVY8eOxbBhw9DQ0NBt33mmkZWVBX9/f/ufrSRNdXW1w/OPPvpol32vv/56LFu2DIC14LpUKoVUKsX06dNRX1+P1NRUfPFF17rINrZt2wYAmDlzplNPbiEhIfZJkkzDVmXDR8zHP6fHALDeLn5pe6HLx6YoCt6TX7MvK7JfBjFZ86h5PB6kUiljc5cDAwMZ+39qIy0tDW1tbaipcX3HTCZTWFgIHo/H6NrdhBDU19e7JP/WXlJvEMdgSlt3dfGvgMUEAJAk3AyK4jBqAuXFNDU19dqQjKV7hpJv+fXXX5GTY51s39zcjHHjxvWYj/3OO+902X8wngdwnW8ZKrjdVFMUZb9d4cyJgUzljTfewKZNmzB79mx4eXnBbDZj+PDhePnll5Gbm9tr3Uvb++PMtBTAWi+TidU/AMcqG09MiUag1Hob9ZdTdThao3D5+KLw6RBFzgUAmDoq0Z7/uX0dk9tuBwUFoampCSaTiW4pPcLn8zFixAjk5+czMuLvDlpbW1FeXo5Ro0YxMufWRkdHB/R6vUsqRTij+QtTTLWq8ELVD0nirQCYM4GyO5qamthI9QAYSr6lc7lclUqFhoaGHv96ijYPBlf5lqECRWi4F1tVVYWYmBiEhoairKyM0ScXulAoFAgKCoJYLEZtba1TJ+T88MMP+O9//8vIK+6TJ0+Cx+PZ89E/OliOxzeeBgDMjffH9gcmulyDvvE4zq+1TuLkiPwQvrQQHIEXysrK0NDQgPT0dJdr6C+EEOzatQupqamMn91/9OhRmEwmjB8/npETK12F2WzG3r17ER4ejvj4eLrl9EpxcTHa2tpcMpnZ58XtUGiNiPf3ROG/Zg7oGDt27MCoUaNoLQ9nVJah5ptEAICHbzLC7jgOADh06BACAgIYmS8vk8mwd+9ejBo1im4pQw7Wt1waV/qWoQItn4qIiAjcddddqKysxG+//UaHBMbz8ccfQ6/X47nnnnP6BzM4OJixnY48PT0drp4fmBiJKG/r699R3IQ951yvWxAwCp4J1u5WFm0zlMfeBXChHjQTc4IpikJQUBDjU0AA6yTeKzENZCikfdhwVeoHMPiJinq9HlqtlvZItapwnf2xLUoNWKODnbvlMQW1Wo329nY2/WOAsL7l0rjStwwVaLvUWrlyJQQCAd544w26JDAWrVaL999/H0FBQXj88cedfvzIyEjU1dUxMlXg4hQLPo+Dl6+6UJZn+dazbjG13umrAI51oqTy2Hswqxvg5eVlrzrARGymmommvzOd00CYXLHEmTQ3Nw+JtA/AaloVCkW/Jjf1h8E2f2HCJEVCCNSFnap+/H0RbjQaoVaraTf83VFYWAg+n4+AgAC6pQxZWN/SM672LUMF2n7dw8PDsWbNGlxzzTWMjZrSRVVVFR5++GF8++23EIvFTj9+VFQUAOuPLNOQyWT2+rg2bh0VhpQga33N3CoF/jjj+mishzwG0tT7AQDEqIbi8BuMn6zo6+sLs9nMWH2dCQ4ORkREBLKzsy/7pjAKhQK5ublITU11es1nV1BfXw+5XO6yyXaDbf7ChHxqQ+NxGNuKAADC0KngeVkb+CgUCohEIkbmVOfn5yMmJobxF3VMhvUtPeNq3zJUoLXrQG/1ma9kEhISsGrVKpcdn8fjISoqCvn5+UhJSXHZOAPBw8MDnp6eDpEyLofC6vmJuP4ba+3LF7YV4prhQfZ25q7Ce/xyqAq+AzGq0Z7/BbxGP26vV83EW6gcDgdBQUGora3tdQIsU0hOTobRaEROTg4mT54MPp9PtySn09HRgZycHCQkJCAyMpJuOX3i/PnzLs3Lt82jGmg6vVKppP3zreoUpfZMvMX+WKlUMqJ2dncUFhZekc04nA3rW7rH1b5lqMBesl6hJCYm2tukM43uqmxcMzwQ6ZHWE2lBgwo/HHV9Pi7XMxCy0U9YFyxGtGWvsudVM5WIiAhUV1fDbDZfemOaoSgKI0aMgEQiQXZ2NmPbwA+Ujo4OZGdnIyoqakjkUQPWLoVNTU0IDw932RhDPVJNLGaoi/6uAMHlwzPuBvs6urX1xrlz55CYmEi3DBaWyxrWVF+hJCQkoKSkhG4Z3dKdcaUoCq8vuHBCWLWjCHqT642jbPTT4Ij8AADqonXwIrVoa2tjbN6yn58fPDw8hsSERcAaXR87diw8PT1x8ODByyYVRKFQ4ODBg4iIiBhSRqaqqgqBgYEunWQ0mOYvWq0WWq2W1miwrnoPzBrr90scNR9c4YWoOZNNdUVFBRupZmFxMaypvkJJSEhARUUF3TK6xZZicTHTYvxwVYK1hFZlmxaf5VS6XAtH4AX5uGX2ZVP+v0EIQVtbm8vHHggURSEyMpKx/7fdYTPWvr6+OHjwoEtqp7qT5uZmZGVlIS4uDklJSUOmbKDFYkFlZaXL01QGM1GxoaEBPj4+tKYKOdSmTrpQ9YPJkxQBoLKykvGlHFlYhjqsqb5CiY+PR2Wl603pQJDL5dBqtd2mA7y2IOnC410l6NC5voKJV9qD4EmtRkNXuQOhglpGR4IjIiLQ2tqK9vZ2uqX0GVsqSGhoKPbu3YuysjLG3g3oCbPZjDNnzuDQoUNISUkZMikfNurr60FRlMurQwwm/cOVpf76gsWogfrcRgAAhy+DKGq+fZ1SqYRQKGTkJMXW1lY0NzezppqFxcWwpvoKJT4+HvX19YyMCtomK3aXuzwqVIbFI60dwZrUBrx3oMzleiieAPL0l+zLstrPUV9X5/JxB4pAIEBoaCjKy8vpltIvKIrC8OHDMWHCBJSWliIrK2vIlNxrbW3F3r170dzcjKlTpw6ZSYmdKS0tRXR0tMurQ1gGmP5hMpnQ1NTkslJ/fUFTthnEaP3NFMffCA7vQoUUJqd+5OfnQyaTwdfXl24pLCyXNaypvkKxdT06ffo03VK6pbeW4K/MS7BX/vjPvlI0q10/wU2SeCs8fK1dHknrSXAaMxlt+GJiYlBdXQ2DwUC3lH7j7++PGTNmQCqVYs+ePYyOWtui09nZ2QgPD8eUKVOGRNm8i1EoFFAqlYiIiHD5WANt/tLU1ASRSASpVOoKWX1C5VCb+haHdUw21adPn0ZcXNyQSUViYRmqsKb6CoWiKMTHx+P48eN0S+mWnvKqASDOX4J7xlurE7TrTHhz9zmX66E4XPhMWm1fDlWuR/155nYElMlk8Pb2RlmZ6yP5roDH42HEiBGMjlpfHJ2Oj48fsjWAS0pKEBER4ZZc5YHmVNtSP+gyhmZtM7SVOwAAXEkYhGFTHNYrFArGltM7c+bMkJowy8IyVBmaZwAWpzBmzBjk5eXRLaNbeotUA8BLc+Ih5Fk/vv/LqkCNwvVVI0TDFkAQMgkAwNNVo/3Mty4fczAkJibi3LlzQ7pUXeeo9e7du3H06FFaSxoSQtDU1IScnBxkZWUN6ei0jba2NjQ0NCAuLs7lY3W+48DpR515QggaGhpoTf1QF28ALNY5HJKExaCoC6dPpk9SzM/Px9ixY+mWwcJy2cOa6iuYsWPHMjb9QyaTQavV9pi+ECoT4dHJwwAAepMFL+8sdrkmiqLgM/l1+7Jn9dfQa5hbs9rX1xf+/v4oLnb9e+NKbFHrGTNmgMfj4cCBA8jOzsb58+dhsXUScTFGoxGVlZXYt28fjhw5Arlcjjlz5gzp6DRgNasFBQWIjo52aRm9C+NdeNyfeHNbWxssFgutOcE9Vf0ALkxSdFUXysFSWFiIMWPG0C2DheWyZ+ieDVgGzZgxY1BYWOg2Y9If+Hw+xGJxr9Hqf82IhZfQ2hR0zZFqFDW6ftKlMCQd4uiFAAAPcyvqc95x+ZiDISkpCRUVFYxLnRgIEokEI0aMwJw5c+Dr64szZ87gr7/+Qn5+PlpbW53e8MZoNKKxsRHHjh3DX3/9hfLyckRERGDu3LlISkpirIHqD01NTVAqlW6JUgNA58z4/jREra+vR2BgIG0XMEZlGfR1hwAAHn4p4PulOqxXKpWMjVKXlpaipaUFI0eOpFsKC8tlD61tylnoJTU1FVqtFgUFBYxrVw5cSAHpqcSXrycfz06PwYvbi2C2ELy0vRDr73T9LU7vSa9CU74VIBaYCj6GedLTDg0gmISXlxdCQ0Mvq0iVQCBAQkIC4uPj0dLSgqqqKuTm5sJoNEIqlUIul0Mmk9n/5XK5lzym0Wi0T9ZTKBRQKBRQq9UQCoUICQnBlClTGJsvO1BsUeq4uDh4eHi4ZUxLp1B1f3Kj3ZWe0hMOExQTb+2ynsn51Laa6RKJhG4pLCyXPaypvoIRCARISkpCVlYWI021n58famtre62t+sSUaHx4sByNKgN+OVWH52oUGBMmd6kuvm8yJEm3Q1XwHTjmDiiOvA3fKa9fekeaSExMRGZmJmJjYxl74h8IFEXBz88Pfn5+IIRAq9XaDXFDQwOKiopgNBohkUjA5/PB4XDA5XLB4XBgsVhgNpthsVig0+nsBloul0MulyM8PBwymeyyiEb3RG1tLfR6PaKjo902Zuf0j75GqjUaDTo6OmjLpyaEQG031RQkCYu7rG9sbMT48ePdL64PHD58mM2nZmFxE6ypvsIZN24cjhw5ggcffJBuKV0ICgpCfn4+DAZDj1UJJAIeVsyOxxMbrbnhK7YWYvsDE12uzXviS1AVrQfMerSf+BCyUf8HniTU5eMOBLFYjGHDhqGgoAATJ068LMtqURQFsVgMsViMkBBrHXOb0W5vb4fRaLSbaIvF4mCwBQIBZDIZI5t2uAqz2YzCwkIkJib2KZLvLEinBBCqj1nVtbW18PPzc1s0/WIMjcdgbLPOSxCGTQVPGu6w3tZd1dubmXerTp06hRtuuIFuGSwsVwRsTvUVzpgxY3DmzBm6ZXSLSCSCl5cXGhoaet3ugYkRiPK2TrLaUdyEPeeaXa6N5xUBrxEPWxfMeigOre59B5qJj4+HQqFAbW0t3VLchs1oBwUFITw8HFFRUYiOjkZsbCyio6MRGRmJ8PBwBAQEXFGGGgCKi4vB4/EQHh5+6Y2diKXzRMU+eGpCiFtap/eGY+rHLV3W19XV0ZrvfSnOnj172aR+sbAwHWb+CrC4jTFjxuDs2bOMnKwIWKPVl2oJLuBxsWpegn15+dazbmkWIh/3L1Ae1lJqHWfWwNBa5PIxBwqfz8eIESOQn58PnU5HtxwWGmlra0NpaSlGjRrldiPoUFKvD666paUFRqORttbkxGKCumi9dYHLhzi2a8SX7tbpvVFeXo6WlhaMGjWKbiksLFcErKm+wklLS4NarWZstDooKAiNjY2XNP23jQ5DcqC101pulQKbzvQe3XYGXJEv5OOesS4QM9qyX+p9B5oJCQmBn58fTp06xdgOhSyuxWw24/jx44iLi6Mlv76/kerKykqEh4e7NUWlM9rqPTBrrL8l4mELwBXKHdarVCpoNBr4+/vToO7SHDhwALGxsewkRRYWN8Ga6iscoVCIMWPGYPv27XRL6RaZTAYej4fm5t5TOrgcCqvnX+gY9sK2QpgtrjeOXqMeB4TWE6rm3O/Q1x9x+ZiDIS0tDa2trVdUGgjLBYqKisDhcGirpNGfiYoGgwHnz5+nNfVD3bk2dTdVPxoaGuDr60tbvvel2L17N6ZPn063DBaWKwbWVLNg5syZ2L9/P90yuoWiqD6lgADAtcmBmBhpnSx0pqEDPx5zfRtxjocnfCa+aF9uPbiC0VFggUCAtLQ0nDp1ik0DucJoa2tDWVkZRo8eTVv+r0NJvUtMVKyuroZcLodUKnW1rG6xGNVQn/sDAMARyCGOmt9lGyanfgDWyh8zZsygWwYLyxUDa6pZMGPGDOTl5TE+r/pSZpWiKLzeKVq96q8i6E3ObQjSHV6p98IijgAA6Gr2Qlu50+VjDoaQkBAEBATg5MmTjL4AYHEendM+6Gyp3tfmL4QQlJWVubXc38VoSjeDGK0NpTzjbgTFc5zMajAY0NLSwlhT3dTUhKKiIkybNo1uKSwsVwysqWZBRkYGWlpacPbsWbqldIufnx8MBgPa29svue30WD/MS7CmY1S0afH5oSpXywPF9YB3+ir7clvWChDCzAsUG6mpqfbIJcvlDSEEp06dApfLpbWBCtD35i/19fWwWCwIDg52h6xuURWtsz/27KbqR2NjI6RSKcRisTtl9Znt27dj2LBh9hKTLCwsroc11Szw9PTEmDFjsHXrVrqldAuXy0VAQECfUkAA4LVO0erXdhVDpTe5Spod75RbYZJYK5AYmk5CXfSzy8ccDAKBAOPHj8fZs2fR2NhItxwWF1JWVoaGhgaMHz+e9rJvfc2pLisrw7Bhw2jTa9Y0QVvxFwCAKw2HMHRyl22YnvqRmZmJmTNn0i2DheWKgjXVLACYnVcNAIGBgX021aPD5Lh5hDU606gy4L0Dro/GUhQHsvRX7cttOatAzAaXjzsYfHx8MGLECOTl5UGlUtEth8UFNDY24uzZsxg/fjxEIhHdcvrU/EWpVKKtrQ1RUVFuUtUVdckGgFhTxyQJi0FRjqdKi8WChoYGRptqNp+ahcX9sKaaBcDQyKtWKpV9nlz3ylUJ4P4dCntnbyla1K43uAHJ10MntdaDNSnL0HH6K5ePOVjCw8MRGRmJ3NxcGI1GuuWwOBGVSoW8vDykpaXBx8eHbjkAgM4/Lz0FocvKyhAWFtZjF1V3oDrbe9WPlpYWcLlcyOVyN6rqO2w+NQsLPbCmmgUAkJ6ezui8aoFAAG9v70t2V7QR7y/B3eOs3eLadSa8ufucK+XZkaW/Yn/clvsaLAbmR4CHDx8OsViMvLw8duLiZYLRaERubi4iIiIQERFBtxw7nT9d3cWpOzo6UFNTg9jYWHdJ6oJRUQp9fS4AgO+XCr5fSpdtbKkfveWF0wmbT83CQg+sqWYBcCGv+s8//6RbSo/0JwUEAF6aEw8Bz/oR/19WOWoUWldJsxOcNBcab2t0yKJphPL4+y4fc7BQFIWxY8dCo9EwtgkQS9+xWCw4evQoxGIxkpOT6ZbjwKUmKp49exYRERG0Nivp3Jbcs5soNSGE8fnUu3btYvOpWVhogDXVLHauvvpqxjaBAYDg4GA0NjbCYOhbKkeYXIRHJw0DAOhMFryys9iV8gBYjULAtNdB/v5qKY/+F2ZNk8vHHSweHh6YMGECqqurUVzs+veJxTUQQnD8+HFoNBqMHTuWcZHU3iYqtrW1obGxEQkJCe4V1QlCCNRFNlNNQZKwuMs2CoUCer2esV0UAWDfvn1YsGAB3TJYWK44WFPNYufaa6/FoUOHoFar6ZbSLVKpFHK5HNXV1X3eZ9nMWHgJeQCAb45Uo7jJ9ekY/lHjoAu8BgBADB1QHHnL5WM6A4lEgoyMDJw7dw6lpaV0y2HpJ4QQnDx5Em1tbcjIyGBkl7+emr8QQlBQUIDo6GgIhUI6pAEADA1HYWwrAQAIw6aBJw3rsk1lZSXCwsJoa51+KY4dO4a6ujrMmTOHbiksLFccrKlmsZOamgo/Pz/88ccfdEvpkcjISFRWVvY599fXk49/To8BAJgtBC9tL3KlPDshM1bDQlknWrWf+hTG9kq3jDtYZDIZ0tPTUVhYyNawHkLYalE3NTVh0qRJtBrT3uip+UtTUxOUSiXtdbQ7p35IuqlNbTQaUVNTQ2tlkkvx888/Y+bMmfD09KRbCgvLFQdrqlnsUBSFa6+9Fhs3bqRbSo+EhIRAq9Wira2tz/s8OSUaARKrwf355Hkcq1G4SN0F5EEJ0If9fVI2G6DIednlYzoLb29vu7E+d849EzxZBo4tQt3Y2IhJkyYxonReT1gsXXOqbVHq+Ph4WqPrxGKCqni9VRtXAHHsoi7b1NbWQiKRMLbqBwDs2LED119/Pd0yWFiuSFhTzeLAddddh3379jG2tB6Px0NYWBgqK/se+ZUIeFgxO96+vGJboSukdSFi5sswcawTrlRnf4ShOd8t4zoDHx8fZGRkoLi4GEVF7onus/Qfi8WCY8eOobm5GZMnT2Zsdz8b3UWqa2trodfrMWzYMFo02dBW7YZFY22EJBq2AFyhvMs2lZWViIyMdLOyvlNXV4dTp05h4cKFdEthYbkiYU01iwPTpk2DRqPBgQMH6JbSI1FRUaitre1XXeUHJkYg0tsawfurqAl7zzW7Sp4diXcIzDH3/b1E0Jr1osvHdCZyuRyTJk1CeXk5Tp06xdgLrSsVo9GIw4cPQ6lUYvLkyYyOUNvonLVFURQsFgsKCwuRmJhIe46yqrD32tRKpRIdHR0IC+uaZ80U1q9fj9TUVISGhtIthYXlioQ11SwO8Pl8zJs3Dxs2bKBbSo/IZDJIpVLU1NT0eR8Bj4uX512oKrB8W6FbajJHTV8BI88XAKAt3wpdbZbLx3QmMpkMU6ZMQUtLC3JycvpceYXFtahUKuzfvx+EEEyZMoWxOdQX03miIoeyRn4pikJ4eDiNqgCLUQ1NqXUuCUcghzjqqi7bVFZWIiQkhJETQG38+eefbOoHCwuNsKaapQvXX389du3aRbeMXomKikJFRUW/jPFto8OQHCgFAByqbMPmgr41khkMQk8ZqMQn7MutB5cPuQYrnp6emDJlCjw8PLBv3z60t7fTLemKprGxEfv370dgYCAmTpzIaJN3MZ0/+cRCUFRUhOHDh4PTU3tFN6Ep3QRitFY98oy7CRRP4LDeaDSiurqa0RMUNRoNsrOzce2119IthYXlioU11SxdmD9/Ps6dO4eSkhK6pfRIaGgotFotWlpa+rwPl0Nh9fxE+/KKrYUwW9wQrZ76JAwCayROX5cDTdkWl4/pbHg8HsaNG4fw8HAcOHCgX014WJwDIQSlpaU4fPgwUlJSkJKSwrg61Jeic6RaqVTAy8uLEU1UVIXr7I89u6n6UV1dDYlEAm9vb3fK6hd//PEH5HI5Ro4cSbcUFpYrFtZUs3TB19cX06ZNw5dffkm3lB7h8XiIjIzsdz3la5MDMTHSemI809CBtcf7nkIyUDz4QsgmXqj+0Zb9IojF7PJxnQ1FUUhMTMSoUaOQl5eH4uLiIRd1H6qYzWacOHECJSUlyMjIYFTr8f7Q+eOi1WowcuRI2i8MzJpGaCt3AAC40ggIQyc5rCeEoKysDNHR0bRr7Y21a9fi5ptvZrRGFpbLHdZUs3TLnXfeyejSegAQHR2NxsbGfjWroSgKr3eKVq/cXgSDyfUT8AJH3gazLA0AYGwpgOrsjy4f01WEhIRgypQpqKysRHZ2NmObBV0utLW12dNupk2bBh8fH7olDZjOkWofb29GVCtRF28AiPUiV5KwGBTleFpsbGyEyWRi9OS/9vZ27N69G3fccQfdUlhYrmhYU83SLYsWLUJVVRVycnLoltIjIpEIQUFBKC8v79d+02P9MDfe2mK4ok2Lzw+5vjELRVEImvmOfbnt0MuwmHQuH9dVyGQyTJ8+HRKJBHv27EF5eTkbtXYyZrMZBQUFyMrKQlhYGKZMmTIkKnz0RuePiFQioU9IJxyqfiR1rfpRWlqKYcOG0Z733Rvff/89wsLCMGrUKLqlsLBc0TD3V4KFVqRSKa699lp89dVXdEvplejoaFRWVvarvB4AvLbgQrR69a5iqPQmZ0vrgiRyOnihswAA5o5qdJz61OVjuhIPDw+MGDECEyZMQElJCbKzs6HRaOiWdVlgi043NjZi6tSpiI+PZ7Sp6yuNTU32x0xIUzAqzkFffxgAwPdLA9832WF9R0cHWlpaGF2bGgDWrVuHO+64gxHvKQvLlczQ/5VmcRl33nkntmzZArOZufm/Pj4+8PT0RHV1db/2GxMmxz/SggEAjSoD3j/gnpbcgdPfAoH1xKc4/CYseqVbxnUl/v7+mDFjBiQSCXbv3s1GrQdB5+h0aGgopk6dCi8vL7plOQWDwYDCTo2EOAzwfw5tybuJUpeVlSE0NJTRJQtrampw6NAh3HbbbXRLYWG54mFNNUuPzJ07F0ajEVu2MLdaBUVRiI2Nxblz5/pt/l+5KhHcv8/sb+8tRYva9TWY+f5p8ExYAgCw6FqhOPofl4/pDmxR6/Hjx6OkpAT79+9HU6eoJEvvEEJQU1OD3bt326PTCQkJl0V02sbp06fh2Snlg+6gKiGkk6mm4Jmw2GG9VqtFdXU1YmJi3C+uH3z11VcYN24c7R0pWVhYWFPN0gseHh5YsmQJvvvuO7ql9EpoaCh4PB4qKir6tV9CgARLx1lL3bXrTHhrzzkXqOuKT8YqgGOtLaw89gFM6jq3jOsOAgICMHPmTAQHB+Pw4cPIzs6GQqGgWxZjIYSgoaEB+/btQ0FBARISEjBt2rTLJjpto76+HnV1dYiLv9CAiUOzqzY05MGksH7nheHTwZM4TkQsKipCYGAgZDIZHfL6zK+//oo777yTbhksLCxgTTXLJbjjjjuwY8cORld4oCgKw4cPR3Fxcb9zq1fOiYeAZ/0afHSwHLVKrSskOuAhGwavtAetCyYN2g695vIx3QmPx0N8fDzmzJkDmUyGgwcPIi8vDyqVim5pjKK1tRXZ2dk4evQowsLCMGvWLERERFx2ebEGgwEnT55ESkoKBIILTVXofpUOqR8X1abu6OhAdXU1kpKS3C2rX+Tn56OwsBD/+Mc/6JbCwsIC1lSzXIIJEybA398fP/7I7BJwgYGBkEgk/a5bHSYX4f8mRQEAdCYLXtlZ7AJ1XZGPXwbKw3orvOP01zAq3BMldyd8Ph/JycmYNWsWeDwe9uzZg5MnT17x5rqtrc0exffx8cGcOXMQGxsLLpdLtzSnQwjB0aNHIZfLERERcVGbcvpsNbGYoCr+GQBAcQXwjF3ksP7s2bOIiIiAhCEVSnris88+w7x58+Dr60u3FBYWFrCmmuUSUBSFe++9F19//TXdUnqFoigkJyfj3Llz0On6V6pu2cxYSAU8AMDXh6tR3OR608cVB0A25ikAAEVMqN31rMvHpAuRSISRI0di+vTpMBqN2LNnDw4dOoTGxsYrZkKjxWJBbW0t9u/fj6ysLIhEIsyePRtJSUlDqs14fykoKIBGo8Ho0aNBUZRDST06A/LaqkxYNI0AAFH01eAILqR4tLW1obGxEQkJCT3tzggMBgM2bNiA+++/n24pLCwsf8OaapZLcu+99+LYsWPIz8+nW0qv+Pj4wN/fH8XF/Ys2+3kK8M/p1slIZgvByr+KLrGHc5CNfhIckbVeNqn5E00le9wyLl1IpVKMHTsWs2fPhkwmw9GjR7F7926cO3cOer2ebnkuQa1W4+zZs9ixYwcKCgoQGhqKefPmITU1ldEVJZxBdXU1KisrMWHCBPuFQ+dINZ1pLg61qRMvVP0ghKCgoADR0dGM//9Zt24duFwuFixYQLcUFhaWv2FNNcslCQoKwjXXXIP33nuPbimXJCkpCZWVlf3OAX9ySjT8PfkAgPUnzuN4retL3XH4UsgnLLcvN+z5F7Ra1+d0041IJEJSUhLmzp2LhIQENDQ0YMeOHThy5Ahqa2v7nRfPNHQ6nb3bZGZmJtrb2zFq1CjMnj0bMTExl3Vk2kZraytOnjyJsWPHOqRQdI5U01VSz2JQQXPuD6sGgTfEUVfZ1zU1NUGpVCIuLo4ecf3g888/x/333w8ej0e3FBYWlr9hTTVLn3jkkUfw+++/M765h5eXF0JDQ1FYWNiv/aRCHlbMvnAiXbH1rLOldYtX6v3geVlLYXlqTuDkrk8ZXRfcmXC5XISFhWHSpEn2OtfFxcXYtm0bsrKyUFpayugJsjYIIVAqlSgqKsK+ffuwY8cOVFZWwt/fH3PnzsWECRMQGBh42U1A7AmtVovDhw8jKSkJAQEBDuscItXuFvY3mrJNICbr75hn/E2guNaLaVuUOj4+nvEXPoWFhTh8+DCb+sHCwjDYS1yWPjFjxgz4+vriyy+/xOOPP063nF5JTExEZmYmYmNj+1UO68H0SLy7vwyVbVpsL2rCvtJmTIvxc6FSgOLy4Z2xEk3blwIAvOu+xvFjkzFm7NgrxoQBgEQiQVJSEpKSkqBWq1FfX4+GhgacOXMGEokEQUFB8PX1hVwud6ggQQeEEGi1WigUCjQ3N6O+vh4GgwEBAQGIiopCUFAQ7Rrpwmw24/DhwwgMDER0dHSX9Z0z6OmaqKgqXGd/3LnqR21tLfR6/ZCo9/yf//wH8+fPR2ho6KU3ZmFhcRusqWbpExwOB4899tiQMNVisRjDhg1DQUEB0tPT+7yfgMfFqrkJuHv9CQDA8q2FOPjoJJebW8+EJVDm/ReG5lPga4pgqNyMEpkM8fHxLh2XqXh6eiImJgYxMTEwGo1obGxEfX098vPzoVarIRQKIZfLIZfLIZPJIJfLXZb/SgiBRqOBUqmEQqGAQqGAUqmE0WiEVCqFj48PRowYAT8/v8uyekd/IITgxIkToCgKaWlp3X5vHHOq3anOilnTCG3lTgAATxoJQUiGVZfFgsLCQiQmJjL+/1GtVmPDhg349ddf6ZbCwsJyEaypZukzd911F55//nns3r0bM2fOpFtOr8TFxWHXrl1obm6Gn1/fo823jwnD23vPoaBBhZzKNmwpaMA1yUEuVApQFAfek1aj4Y9rAQCh7T8jv2g0vLy8EBTk2rGZjoeHB0JDQ+0ROaPRaDe4SqUSNTU1UKlU8PDwgFAohFAohEAgsD+2LXO5XFAU5dCh0GKxgBACk8kEvV4PnU5n/+u8bDab4eXlBZlMhuDgYCQlJcHLy4vx5svdnDt3Ds3NzZg2bVqP741jTrX7XbWq+BeAWNOrPBMXg6Ksn4fKykpQFIXw8HC3a+ovn376KYKCgjBjxgy6pbCwsFwEa6pZ+oxMJsNdd92F9957j/GmWiAQIDY2FgUFBZgyZUqfo81cDoXV8xNxw5o8AMCKbYVYkBRob2fuKkRR8yAMnQpd7X5Y2suQFluCo0c9MHnyZMZ3dHMnHh4e8PPzc7hQMhqNUKvVXYxxc3Oz3SBbLBa7iSaE2A02RVHgcrkOZtzLy8vBlHt6erIG+hLU1dWhqKgIkydP7vWugUNJPTfouhj12a5VP0wmE4qKijBixAjGt4W3WCz2u4VXUnoYC8tQgTXVLP3isccew6hRo1BeXs743MOYmBiUl5ejrq4OISEhfd7vuuQgTIiQI7dKgdP1HfjpeC1uHxPmQqXW8mLek19D3fop1ieKPkLc5E3IycnBpEmTIJVKXTr+UMbDwwNyuZxuGVcsjY2NOHr0KEaPHn3J/weH5i9uLv9hbCuBvuEIAIDvPwJ83+EAgNLSUojF4iFxV2jr1q2ora3FHXfcQbcUFhaWbmD2ZTkL40hKSsLs2bPx6quv0i3lkvB4PCQkJKCgoKBfFTUoisLrCy60J175VxEMJosrJDogDJ4Accx1AACzug4BHdsRERGB7OzsIVEFg+XKo7m5GYcPH8aIESP6dOHaeaKiu+Osjm3JrVFqrVaLc+fOYfjw4UMi8vvmm2/i//7v/xjf6ZGF5UqFNdUs/eaFF17A+vXr0dDQQLeUSxIZGQkPD49+l9ibEeuHOfHWFIPyVg2+yK10hbwueE96Bfg7z1OZ9w7ihwUiNDQUWVlZjC9nyHJl0draitzcXKSmpvY5F5muNuWEEKiKbFU/KHgm3AxCCE6ePIng4OB+zbugiwMHDuDo0aN46qmn6JbCwsLSA6ypZuk3EydOxNixY/HGG2/QLeWScDgce7pKa2trv/Z9bf6FaPXqXSVQ603OltcFvk8SJMPvAgBYDEq0572N5ORkBAYGIisr64poDsPCfBQKBQ4dOoSkpCRERkb2eT+62pTr64/ApDgHABCGzwBPEoqqqioolUqkpKS4T8ggWL16Ne65554utb9ZWFiYA2uqWQbEihUr8O2330KpdH3nwcHi5eWFhIQEHDt2rF9pIGPD5bgpLRgA0NChx/sHy10l0QHviS+C4lone7Wf+B/MqhqkpaXB398fBw8eZCPWLLTS2tqKrKwsJCQkdFuLujfoav6iLuqc+nELtFotTp8+jREjRoDP57tRycA4ceIE9uzZg2effZZuKSwsLL3AmmqWATFnzhxERUXhnXfeoVtKn7C1hz57tn+dEl+9KtFe+ePtPefQqjG4Qp4DPGkYvEY+AgAgZj3aDr0KiqIwYsQIBAYG4uDBg1CpVC7XwcJyMc3NzcjJycHw4cMRExPT7/3paP5CzEaoin4GAFBcAcQx1+HEiRMIDg4eEpMTAeDVV1/FzTffjKioKLqlsLCw9AJrqlkGBEVRWLFiBb744gvodDq65VwSDoeD0aNHo6Kiol9pIAkBEtw11povqtSZ8Nbuc66S6IBs3HPgCOQAAFXBdzC0FICiKKSmpiI0NBQHDx5ER0eHW7SwsADWKh+HDh1CSkrKgCv/WCzub/6ircqERdsEABBHL0RNgxLt7e1ITU11j4BBcu7cOWzZsgXPP/883VJYWFguAWuqWQbMokWLIJVK8eGHH9ItpU9IpdIBpYGsnBsPAc/6VfnwYDlqla7Pa+YKfSAb+0/rArGgLfslANaLmeHDhyMyMhIHDx6EQqFwuRYWlrq6OnuVj/7kUF8MHZFqVeGF2tQe0Tfi9OnTGDlyJDw8PNwy/mBZvXo1rrrqKiQnJ9MthYWF5RKwppplwHC5XCxfvhz/+9//YDK5fhKfM4iNjQWfz+9XGki4XIRHMqIAADqTBa/uLHGROke8Rj4Krqe1TJmmdBN05w8BsBrrpKQkxMbG4uDBg6itrXWLHpYrD0IISkpK7HWoB9tx0N0TFS0GFTSlmwAAHKEPClsDEBwcjMDAQNcP7gTq6urw888/Y8WKFXRLYWFh6QOsqWYZFLfddhsA4IMPPqBZSd+gKAqjRo1CRUUFWlpa+rzf87NiIRVYeyV9dbgKJU2uz2nmeIghn/iCfbktawVIJ1cSFxeHsWPH4sSJEygsLHRY1xemT58OiqK6/Vu3bp19u6+++grx8fEQCoUYMWIEtmzZMvgXx8J4zGYzjh07hvLyckyePLlfDZR6wt0l9TSlf4CYrBN7LUFz0a7SDpm0D8A6IXzSpEkYP3483VJYWFj6AGuqWQYFn8/Ha6+9hrfffnvINCixpYEcP368zxF2P08BnplmnZhlthCs/KvIlRLtSJOXwsM7DgCgqz0AbcV2h/VBQUGYMmUKqqurceTIkX7dMfj444+Rk5Pj8Ld48WLweDzMnj0bALBu3Trcf//9WLx4MbZt24b09HQsWrQIhw4dct6LZGEcWq3WXmlm6tSpTutY6e7mL6rCCxeH5abUIZX2UVJSgp9++gn//ve/6ZbCwsLSRyjS3/AWC8tFWCwWjBw5Etdccw1ee+01uuX0CUIIDhw4AB8fnz7Xqe3QmRD7Riaa1NYKIEefmopRoTJXygQAqEt+ReOftwAA+H6pCLntCCjK8XrYYDDgyJEjMBgMmDBhAsRi8YDGio6ORlJSEv78808AQEJCAsaMGYO1ay/kpWZkZEAul2Pr1q0DfEUsTKa1tRWHDx9GYGAg0tLSwOVynXbsjafrcMOaPADAGwuS8K+ZsU479sWY1Q2o+jISIBaY+IFQTdyIUaPHuGw8Z7No0SLw+XysX7+ebiksLCx9hI1UswwaDoeDt956Cx9//DGam5vpltMnBpIGIhXysHx2nH35hW3969I4UMSxN4AfOBYAYGjOh7pTu2UbfD4f6enp8PX1xb59+wb0/5CdnY3y8nJ7Sk9ZWRmKi4tx8803O2y3ZMkSZGZmQq/XD+DVsDCZqqoqZGdnIy4uDiNHjnSqoQbcm1OtKv4FIBYAgFI6FSmpaa4d0IkcPnwY27ZtGzJBChYWFiusqWZxCldddRVSUlLw4osv0i2lz0ilUiQmJvYrDeSh9EhEyEUAgG2Fjdhf2ve87IFCURR8Jl84ubblvAxi6mpoORwO0tLSkJSUhEOHDqGioqJf46xduxaenp647rrrAMDe2j0xMdFhu6SkJBgMBpSXu6cZDovrIYTgzJkzOH36NMaPH4+YmBhQLnC97syp7lz1I2ziw0Mm7QMAli1bhnvuuQexsa6L5LOwsDgf1lSzOAWKovD222/j22+/7beZo5OYmBgIhUIcP368TxP9BDwuVs1LsC8v33a23xMEB4IofAZEEXMAAKb2CrTnf9HjtlFRUUhPT8fZs2dx8uTJPpUPNJlM+Pnnn3HttdfC09MTANDW1gYAXfJpvb29AaDfbd9ZmInBYMChQ4dQX1+PqVOnurQNtkOk2mWjAMa2YhgarGkmZkkCguImu3A05/LXX38hNzcXL730Et1SWFhY+glrqlmcxsSJEzFnzhwsW7aMbil9hqIojBs3Dm1tbSguLu7TPneMCcPwQAkAILuiDVsKGlwp0Y735NX2x4rDb8Bi6Ln5i6+vL6ZNm4a2tjbs27fvkvWsd+7ciaamJtx6663OkssyBKivr8fu3bvB4XAwdepUSCQSl45ncVP6R8fZCylSviOWum4gJ2OxWLB8+XI89dRTQ6bbIwsLywVYU83iVN588038/vvvOHnyJN1S+oxAIMCECRNQUlKCurq6S27P5VB49aoLKRErthXCbHF9tFoQMAqe8db8Zou2Ccqj7/a6vVgsxtSpU+0dGM+ePdtj1Hrt2rXw9fXFvHnz7M/ZItJKpdJhW1sE28fHZ8CvhYVeDAYDjh07hqNHj2L48OEYP368W9IjCFyf/kEIgeL0d38vUZAm3eKScVzBunXrUF5ejueee45uKSwsLAOANdUsTiUpKQl33HEHnnzySbql9AuZTIbRo0fj2LFjaG9vv+T216cEYXy4HABwur4DPx13TwMW74xVAMdaL1t57D2YNY29bs/hcJCQkIApU6agoaGh26i1VqvFxo0b8Y9//MPBWNlyqW251TYKCwvB5/MRHR09+BfE4nbq6+uxZ88e6PV6zJw5ExERES7Jn+4Od0xUPH96KyhNNQBAGD4DPMng62u7A71ejxdeeAEvvvgivLy86JbDwsIyAFhTzeJ0Xn/9dRw/fhw//dS1SgWTCQkJQUxMDHJzcy9Z2YKiKLy+IMm+vPKvIhhMFldLhIc8FtKU+wAAxKiC4vAbfdpPJpN1iVpbLFa9mzZtgkql6pL6ER0djfj4ePzyyy8Oz69fvx6zZs0Cn893witicRdGo9EenU5MTMTEiRMhEoncqsHVExXb29tRn3dhvoEkceikM61atQpCoRCPPvoo3VJYWFgGCGuqWZxOQEAAVq9ejX/961/QaDR0y+kXCQkJkMlkyMvLs5vOnpgZ54c58X4AgPJWDb7IrXSHRMgnLAfFs9ahbj/1OYzKsj7t11PUeu3atYiIiMDkyV0nc61atQpr167FypUrsXfvXjz88MPIzc0dUlVeWICGhgbs3r3bHp2OjIx0W3S6M65s/mIwGJB7KAvemhzr8blCeMZe7+RRXENpaSk+/PBDfPzxx0OqSgkLC4sjrKlmcQkPP/wwvL298cILL1x6YwZBURRGjx4Ng8GA/Pz8S27/2vwL0erVu0qg1ve9o+FA4XkGQTb6CeuCxYi2nJf7tb8tah0cHIzt27dj27ZtWLx4cbcm65ZbbsEXX3yBtWvXYt68ecjKysLvv/+O9PR0Z7wUFhdji07n5eXRFp3ujKsi1RaLBUeOHIGfpQiU0ZrzL45eCI5gaKRRPProo7jmmmswffp0uqWwsLAMAtZUs7gELpeLTz75BJ9++mmXnFymw+PxMGHCBJw/f/6StZjHhstxY2owAKChQ4/3D7qndrNszDPgCH0BAOrCddA39W9iKIfDQWJiIubPn4+//voLc+fOxfnz57stD3jvvfeipKQEer0ep06dwsKFC53yGlhch8ViQVlZGTIzM6HT6WiNTnfGVTnVp0+fhsFgQIg5z/6cZ+LQmKD4xx9/4ODBg/jPf/5DtxQWFpZBwppqFpeRkZGBf/zjH/i///s/uqX0G7FYjPHjx+PMmTOX7E746vwEcP42CG/vOYdWjcHl+jgCL8jH20oXErRlDSwdQyaTYdq0aYiNjUV+fj7279+PpqYm5wllcSuEENTU1CAzMxMVFRUYMWIE0tPTaY1Od6ZzkRyOk0x1RUUFamtrMXZkErTlm63HFvpAHDXvEnvSj16vx1NPPYWVK1ciJGRoTKhkYWHpGdZUs7iUt99+G3l5eVi/fj3dUvqNr68vUlJScOTIEajV6h63SwyQ4q5x4QAApc6Ef+8pdYs+adqD4EojAADaiu3Q1uwf0HE4HA6ioqIwa9YshISE4MiRI8jOzr5kbWsW5kAIQUNDA/bu3YuCggIkJCRgxowZCA4Opj063ZnOd0KcoaulpQWnT5/GuHHjgPpdICYtAMAz7iZQXOZPpH355ZchEAjwxBNP0C2FhYXFCbCmmsWl2CYtPvfcc0Nu0iJg7U4YGhqKw4cP99rKfOWceAh41q/TBwfKcF6pc7k2Dk8I7/QLXdfaDi4fVHdHHo+HuLg4zJ49GzKZDAcPHkReXh5UKpUz5LK4iNbWVmRlZeHo0aMIDw/HrFmz3Fomrz9YnNhRUaPR4PDhw0hOToafnx/Uhevs6yRJzK/6UVpaig8++ACffPIJOzmRheUygTXVLC7HNmnx2WefpVvKgEhJSQGfz8fRo0d7rAgS4S3GwxlRAACdyYJXd/WtO+NgkSTeBg/fZACAvv4wNKV/DPqYfD4fycnJmDVrFng8Hvbs2YOTJ09Cp3P9hQJL3+no6MDhw4eRnZ0NX19fzJkzB7GxseByuXRL6xFnNX8xGo3Izc1FSEgIhg0bBpO6HtqqXQAAnlcUBMHMnkhrsVjw4IMPYuHChezkRBaWywjWVLO4HB6PhzVr1uDrr7/GgQMH6JbTbzgcDsaNGweNRoNjx471GA1+fmYspAJrY5avcqtwrrnnlBFnQXG48Jn0qn25LetFEItzKpCIRCKMHDkS06dPh16vx65du3D69OkhecfhckKpVOLYsWPYu3cvBAIBZs+ejaSkpCER7XTGREWj0YicnByIRCKkpqYCANTFvwDEesHrmbiEkVH6znz22Wc4ceIEPvzwQ7qlsLCwOBHWVLO4hZEjR+K5557DPffcMyQjnnw+H+np6VAqlTh+/Hi3xtpfIsDT06xdBk0WgpV/FblFm2jY1RCEZAAAjG1FUBV879TjS6VSjB8/HpMmTYJWq0VmZiYOHz6M5ubmQaWbsPQdQgjOnz+PgwcP4sCBA+ByuZgxYwZGjBgBoVBIt7w+M9iSeiaTCbm5ueDxeBg3bhw4HOspTFW41r6NhOFVPyorK7F8+XJ8+umn8Pf3p1sOCwuLE6EIe1ZkcRMGgwFjx47FlClT8L///Y9uOQNCq9UiKysL/v7+SEtL6xIR69CZEPNGJprV1gogx56aipGhMpfr0p3PRt3P0wEAXEkowpYWgMNzTcUHjUaD8vJyVFZWQiwWY9iwYQgNDQWPx3PJeFcyer0e1dXVKCuzNvgZNmwYIiMjh2w3y0+zK/DIb9b6798sHmmf4NsXzGYzcnNzYbFYMHHiRPvnzdBahNrvrBFrfsAohN6a63zhTsJisWDOnDnw8fHp0qmUhYVl6MNGqlncBp/Px3fffYevv/4a+/bto1vOgBCJRMjIyEBDQwNOnz7dJVIrFfKwfFacffmFbe6p0S0MyYA4+moAgFlVi/YTH7tsLLFYjOTkZMydOxdRUVEoKyvDX3/9hZMnT7IVQ5wAIQRNTU3Iy8vDjh07UF9fj5SUFMyePRtxcXFD1lADF5XU68fZx9bcxWQyORhqAFAX/WR/zPQo9SeffIKTJ0/i449d9/1kYWGhD9ZUs7iVkSNH4l//+hfuu+++IZkGAlhN5aRJk3D+/HmcPXu2i7F+KD0SEXJrlHhrYSMOlLW4RZd3xquw1VRQHvk3zDqFS8fj8XiIiorC9OnTkZGRAYvFgoMHD2Lv3r0oLy8fsv+/dKFWq1FcXIxdu3YhLy8PIpEIM2bMwOTJkxESEmJPdRjKdJ6oSPWx/ofFYkFeXh70ej3S09MdDDUhBCpb1Q+KA8/4m52q15lUVFRgxYoV+Oyzz9i0DxaWy5Sh/yvNMuRYsWIFxGIxnnrqKbqlDBhPT09kZGSgqqoKBQUFDsZa6MHFyrnx9uXlW7sab1fA90uBJOl2AIBF3wZl3tsuHxOw1hv29vbGqFGjMG/ePERFRaG6uho7duzA/v37UVxcjPb2djb/+iIIIWhtbUVBQQF2796NzMxMtLS0YPjw4Zg3bx6Sk5MhkUjolulU+tv8xWw2Iy8vD2q1Gunp6V0mY+rrcmFSWlNjhOEzwJMws4GKxWLB3Xffjblz5+LGG2+kWw4LC4uLYJMgWdyOh4cHvv/+e0yYMAGLFy8esiWlpFIpJk+ejKysLFgsFqSkpNhzrO8YE4Z39pbibKMKWRVt+PNsIxYOD3S5Jnn6S1AVrwfMBrSf+AheI//PrUbDw8MDUVFRiIqKgk6nQ0NDA+rr61FcXAyBQICgoCAEBgbCz8/vsoi89heTyYTGxkbU19ejoaEBhBAEBgYiISEBAQEBQ6KCx2DoT/MXs9mMI0eOQK/XY9KkSd2mvaiGSOrH//73P5w+fRpnz56lWwoLC4sLYU01Cy2kpaVhxYoVWLp0KU6cOAG5XE63pAEhkUgwefJkZGdnw2Kx2Ccv8rgcvDo/ETd9mwcAWLHtLBYkBoDjrN7MPeDhFQmvtIfRfvx9EJMWikOr4TebnvxNoVCIyMhIREZGwmw2o6mpCQ0NDTh+/DhMJhMCAgLsJnso5wlfCq1Wi/r6etTXwG2ZngAAZlJJREFU16O5uRkikQjBwcEYP348vL29r6iLi75Gqk0mk73hUkZGRrcXG8RstJbSA0BxhfCMud7Jap3DmTNnsGLFCnz77bfw8/OjWw4LC4sLYat/sNCG2WzGrFmzIJVKsXnzZrrlDApbVRAfHx+MGjUKFEWBEIKJHxzEkWoFAOD7W0fhttFhLtdi1jaj+ptEEEM7QHERescJ8H0SXD5uXyGEQKFQ2KPYSqUSnp6ekMvlkMlkkMvlkMvlQzJqq9PpoFAooFQqoVAooFAooNPp4Ovra7+AkEqldMukjXf3l+KZTQUAgHW3j8HNI7veRbE1dgGACRMm9Pg50JRvRcMf1wMAPOP/gYAFP7pG9CDQ6XT2ikeffPIJ3XJYWFhcDBupZqENLpeLtWvXIi0tDf/973/x9NNP0y1pwIhEInsqyNGjRzF69GhwOBy8viARcz47BABY+VcR/pEWAj7PtZFJrsgPsjFPQ5GzCiBmtOWsRODV6y65n7uw5WB7e3sjMTERer3ebkDb2tpQXl4OrVYLT09Pu8m2/cukiLbNQHc20TqdDhKJBHK5HL6+voiJiYFMJhuSFwiuoHND0u6yP2yNXXg8HsaPH99rmUbVWebXpn7kkUdAURTeffdduqWwsLC4AdZUs9BKSEgIfvzxR9xwww2YNm0axowZQ7ekASMUCu2pILm5uRg7dixmxfljdpwfdpU0o6xFgy9zq/DIpCiXa5GNfgIdJz+BWdMATclv0NfnQRA01uXjDgSBQIDAwEAEBl7IOdfr9Xaj2tbWhoqKCmg0GohEIohEIgiFQgiFQggEAvtj25+Hh8egOuoRQqDX66HT6ez/dv7T6/XQaDTQ6/V2A+3n58ca6D7Q+bboxekfGo0Gubm5EIlEGDduXK/t1i2GDmjKrHe3OEJfiCLnukDt4Pjxxx/x888/4+jRo0OqQQ8LC8vAYU01C+3MmzcPjz32GJYsWYLjx48P6YoHAoEAkydPRl5eHvbv348JEybgtflJ2FVibc++elcx7hobBk+Ba796HA9PyCesQMuexwEArVkrEHTDdsa3b7YhEAgQEBCAgIAA+3MGgwHt7e3QarV2s9ve3o7Gxka74TWbzeBwOHazzeVyQVEUOBwOKIqy/xFCQAiBxWKxPzYajdDr9dDr9SCEwMPDo4tx9/Pzg1AohEgkgpeXF9vwpp/0NFGxpaUFhw8fRmhoKFJSUi6ZZ64+txHEpAUAeMbfBIrLnDsYAFBSUoJHH30Un376KRISmJN6xcLC4lrYnGoWRmA0GjFlyhRERETg559/plvOoCGEoKCgAJWVlRg7diz+b1sVfs2vAwC8Nj8Rz3dqEOMyDWYjar5Lg0lZCgDgSsIgjl4IcfRCiMKmgeIJXK7B3ZhMJoeIstls7mKeCSEOBttmuHk8noOJ7i1SyjIw3tp9Ds9vtVbA+G3pWFyfEoyKigqcPn0aKSkpiIqK6tNx6n+7GtqqnQCA4Jv3QRiS7irJ/cZgMGDixIlIS0vDmjVr6JbDwsLiRlhTzcIYKisrMXLkSLz++ut4+OGH6ZbjFKqrq3Hy5El4BEXj6vWlsBBALvJA6fMz4S12fXRNXfIrGv/smm9K8aUQR861Guxh88EV+rhcCwvLm7tLsHyrtcvob3eNQTRpRm1tLcaNG9fnyhgmdT2qv4wCiAU8r2EIu7uQUXdgHnnkEWRmZuLYsWPw9PSkWw4LC4sbuXJqObEwnsjISKxZswbPPfccjh8/TrccpxAeHo6MjAyQ5ipcEy0GACi0Rry1p9Qt43vG3YiAhb9AFHUV0OkWOTF0QF3yK5r+uhtVn4Wi7pfZUB57H0aFe3SxXJl0LqlXXFSElpYWTJ06tV+l5tRFPwPEOuNRkriEUYb6l19+wbfffosNGzawhpqF5QqENdUsjOK6667DQw89hEWLFqG5uZluOU7Bx8cH06ZNwy1RHHj8/Y378GAZzivd08bbM/Y6BF2/CZEP1iHg6nWQJN0OTufINDFDV7sfrfufRc2aJNR8NwKtB1dAd/4QCLH0fGAWln7S+cYoj8fDlClT+m0+VYUXqn54Mqjqx4kTJ3Dffffh448/RmpqKt1yWFhYaIBN/2BhHGazGQsXLkR7ezv27dt32UwGM5vNuOvrfVhbpAYAPJgeiU9uTKNFC7GYoK87BHXpZmjKNsOkONftdhxxAMTDrramiUTMAsdD7GalLJcT//r9GN7OqgUAbL5nHK4eHtSv/Q2thaj9zvqd4QeMRuith5yucSA0Nzdj/PjxWLRoEf7zn//QLYeFhYUmWFPNwkiUSiXGjx+PSZMm4euvv6ZbjtNo7NAh+vVMaIwW8DhAwXMzEetH721iQgiMbUXQlG2BpmwL9Odz4Fj8zArFE0EUMQvi6GsgHrYAXE/Xt11nuTwghKCkpASv7CjC2grrc3/eOx7zk/r3GWrLXgnF4TcAAD5T34Zs9BNOVtp/TCYTZsyYAbFYjK1bt7ITXFlYrmAujxAgy2WHTCbDli1bMG7cOKSlpeHJJ5+kW5JTCJAK8eyMWLy8oxgmC/Dkz4ex+eHptOaFUhQFvk8i+D6JkI/9J8yaRmjKt0FTthnayl0gJg0AgJi0duMNUBAEjbdWE4m5Bh4+SYzKbWVhDiaTCSdOnEBrayvCwiOAiioAAKe3PuXdQAiBqvDvJkYUB54JNztb6oB4+OGHUV9fjyNHjrCGmoXlCofNqWZhLHFxcfjll1+wfPly7Nixg245TuPpqTHw87ROGtxapsIPO7JgNBp73WfTpk2YMGECpFIpgoODcfPNN6OsrKzLdgqFAo8//jhCQkIgFAoRExPT79vRXHEApMl3IfCaDYh4qA6B122ENOVecMWdb9UT6Otz0Zb9Imq/H4maNcPRsu9ZaKv3gVhM/RqP5fJFo9Hg4MGD0Gq1mDp1KgSdmqD09xJMX3cIpvZyAIAwfCZ4nsFOVDowPvjgA/zyyy/YsmUL5HI53XJYWFhoho1UszCaOXPm4PXXX8dtt92GnJwcxMbG0i1p0EiFPCyfFYenN50BAHyar0IAdmPkyJEOXQVt7N27F4sWLcKdd96J1157DS0tLXjppZcwd+5c5OfnQyQSAQDUajWmT58OHo+Hd999F4GBgSguLkZ7e/uAtXJ4IoiHLYB42AIQYoGh4SjUZZuhKdsCY/Np+3YmZSnaj7+P9uPvgyPwhmjYfHhGL4Qoci44Aq8Bj88yNCGEoLKyEmfOnEFYWBhSUlLA5XJ7bP7SF1SFP9kfM6EteWZmJpYtW4bff/+dbfDCwsICgM2pZhkCEEJw77334tChQzh8+PCQ7rhoQ2c0I+Gt3ahWWCuArL8hBuK2coSEhCAlJcWh1fVDDz2EHTt2oLS01G5E9uzZg5kzZ2L//v2YMmUKAODFF1/E2rVrcerUKbeU8zIqy6Ap+xOasi3Q1ewHiLnrRhwPiMKmQxxjbTrDk4a7XBcLvWg0Gpw4cQIdHR0YNWqUQ1fMF7YV4vXMEgDAzgcnYlacf5+OScxGVH0RAYuuBRRPhIgHasDhS12ivy+UlpYiPT0dy5Ytw9NPP02bDhYWFmbBpn+wMB6KovDJJ5/Ax8cHCxcuhMFgoFvSoBF6cLFq7oXo1gfHWjFjxgxotVrs3r0bDQ0N9nVGoxFSqdQhsieTyQA4lij78ssvcc8997itPq6HLBqyUY8h+Ma/EPHgefhf9R084/8Bit8pMm0xQlu1Ey17nkD1VzGo/XE82nJegb7xONjr+csLQggqKiqwZ88eiEQizJw508FQAwDpNAGW6kcCiLZyByy6FgCAOPoaWg11U1MTrrrqKixcuBBPPfUUbTpYWFiYB2uqWYYEAoEAmzdvRlNTE5YsWQKLZejXT75jTBgSA6xR96yKNuyp6EB6ejoSExORl5eH48ePw2g0YunSpSgoKMDHH38MpVKJsrIyLF++HKNGjcKkSZMAABUVFaivr4efnx+uvfZaCAQC+Pj44P7774dKpXL5a+EKvSFJXIKABT8i8sHzCLphG7xG/h+40giH7QxNJ6DIXY3zayeg+qsYNO9+HJqKHSAmvcs1srgOjUaDnJwcFBUVYezYsRg1apTD3RYbnZu/9GeeIlNSP9RqNebNm4f4+Hh8/vnn7ORcFhYWB9j0D5YhRW1tLSZOnIirr74an376Kd1yBs1v+XW46ds8AEBasBeOPTUVHA7V5Rb64cOHceutt6KjowMAMHLkSGzfvt2eg33o0CGkp6dDIpHghhtuwJ133omSkhIsW7YM8+fPx08//dSjBldCCIGh+ZS9aoih4Wi321EeEoiirG3TxcMWsG3ThwiEEFRVVeH06dPdpi5dzLI/z+Lfe6w10fc8nI5pMZfupGgxdKDq8zAQkxYcoS8i7q8Cxe15DFdhMpkwd+5caDQa7N69G2IxW7OdhYXFEXaiIsuQIjQ0FDt37kRGRgYCAwPx8ssv0y1pUCxKCcK4cDmOVCtwqq4d607U4tbRYRCLxUhPT0dlZSW+++47vPLKK7j33ntx7bXXoqWlBa+++iquvvpqHDhwACKRyB65j4+Px7fffgsAmDVrFng8Hu6//3689tpriI6OdvvroygKAv8REPiPgPeEFTCpaqEp22ot11e9GzBbU3mIUQVNyW/QlPwGUFwIQybZ87A95EN/curliFarxYkTJ9De3o6xY8d2O8n2YiydYjicPkZ51ec2gpi0AGBNL6LBUFssFixZsgTnz59HdnY2a6hZWFi6hTXVLEOOxMREbNu2DbNmzUJQUBAefvhhuiUNGIqi8Nr8RMz93NoZ7qW/inBTWgj4PA4oikJUVBTWrl2L0aNH46qrrkJycjICAgIwceJERERE4Pvvv8cDDzwAb29vAMCMGTMcjj9r1iwAwJkzZ2gx1RfDk4TCK+1+eKXdD4tBBW3VTmhKt0BTvtWeM2trm25tnf4cPHwSrQ1noq+BIGgcKA5bC5hOLo5Ojx07ttfotOO+Fx73NXPCMfXj1v5IdRqPPfYYcnJycOjQIfj4sHdRWFhYuoc11SxDkgkTJuCXX37BjTfeCD8/P/zjH/+gW9KAmR3vj1lxfsgsaUZZiwZfHa7CwxlR9vWFhYVYtmwZEhIScOTIEYSGhiI5ORl+fn4oLS0FAMTExEAgEPQ4hk6nc/XL6DccvgSesYvgGbsIxGKGvi4HmrItUJducmibbmwthLK1EMq8t/9um77g77bps9m26W5mINHpzvQ3Um1S10FXvRsAwJNFQxA8oX+CncArr7yCtWvXIisrC+HhbPUaFhaWnmEnKrIMWebPn49PP/0Ud999N3bv3k23nEHx2vxE++NXdxZDY7jQQCUyMhLHjx9HVFQUZsyYAbVajbVr16K5uRkREdaJgHw+H3PnzkVmZqbDcXfu3AkAGD16tBtexcChOFwIQyfDZ8qbCF9agNA78+E9+XUIQjLQuU2IRdMI1Zk1aNx8E6o+DULDpkXoOP01TOp6+sRfARiNRhQVFWH37t0QCASYMWNGvw01AHSewNOXQLW66GeAWFObJIlL3D4x8PPPP8dbb72FP//8E8OHD3fr2CwsLEMPNlLNMqS588470dTUhBtuuAFbtmzB5MmT6ZY0IMZHeOOG1CD8ll+P+g49PjhYjmUz4wBY61Q/+eSTeOKJJ3DNNdegubkZb775JuRyOYKDg1FbW4uQkBCsXLkSGRkZuO2223DXXXehpKQEzz//PG677TbExMTQ/Ar7B98nAXyfhL/bpjd1apu+80LbdLPu7zrZf8KxbfpCePgMZyszOAGLxYKKigoUFRVBIpFg4sSJ8PX1HfDx+tv8pXPqh2eCe6t+rFmzBk8++SR+/vlnZGRkuHVsFhaWoQlb/YPlsuCNN97Av//9b2zduhXp6el0yxkQZxs6kPrOXlgIIBd5oPT5mfAW80EIwWeffYZPPvkEpaWlkEqlSE9Px+rVqyEWi1FUVASBQIDhw4cjPz8fy5YtQ35+Pry9vXHbbbfhtdde6zU1ZChhMWmhq97zdx72nzCr67rdjieLthrs6GsgDJ0EisPGD/oDIQQ1NTUoLCwEl8tFUlISgoKCBn2h8sTG0/jwoLXV+KHHJ2N8hHeP2xpaC1H7XRoAgB84BqG35Axq7P7www8/4IEHHsCPP/6IRYsWuW1cFhaWoQ1rqlkuG1599VW8++672L59O8aPH0+3nAFxz/oTWHOkGgDwr5mxeGNB0iX3MZlMKC8vR0lJCeRyOYYPHw65XO5ipfRjbZt+DOqyTV3apnfG2jb9KqvJjpzHtk3vBUIIGhsbUVBQAKPRiMTERISHhzst6v/4xtP46G9Tnfv4FIyLkPe4bVv2SigOvwEA8Jn6DmSjH3eKhkuxfv163H333fj222+H9FwNFhYW98PmVLNcNrz44ot47LHHMH/+fOTm5tItZ0CsmhsPPtf6tfzgQBnq2i89wZDH4yEuLg6zZ8+GTCbDwYMHceTIEbc0faETiuJAEDQWPhmvIOz2Ywi7uwg+0/4LYfgMgLpQIcSib4O68Cc0bb0NlZ8Fo/63q9F+8hOY2qtoVM888vLysGjRImRkZGDOnDl4+umnERER0cVQf/XVV4iPj4dQKMSIESOwZcuWLsdSKpW499574ePjA6lUiptuugl1dXWwdOr+wunl7EMIgapwnXWB4sAz4WanvMZLYTPUX3/9NWuoWVhY+g1rqlkuK15++WW7sc7Jcd/tYmcR4S3GwxmRAACt0YJXdxb3eV8+n4/k5GTMmjULHh4e2LNnD06ePMnIyh+uwEM2DLJRj17UNv3mntumfx2L2h/HXfFt0zs6OpCbm4uNGzciNzcXI0aM6HFS3rp163D//fdj8eLF2LZtG9LT07Fo0SIcOnTIYbvFixdjx44d+PTTT/Hjjz+iqKgI8+fPh9l8YQJub7Fvfd0hmNqtEW1R+CzwPIMG/TovxY8//oi7774b33zzDZYsWeLy8VhYWC4/2PQPlsuSV199Ff/973+xadMmTJkyhW45/aJJpUfMG5lQ6c3gcSicfW4GYvw8+32cjo4OnD17Fo2NjYiOjkZcXFyf6wlfThCzAbraA9aujqVbYOqo7HY7riQM4uirIY6+BqKwaaB4l0ceek9otVoUFhaipqYGERERiIuLszc1Wbp0KfLy8nD6tGNKTUJCAsaMGYO1a9fan8vIyIBcLsfWrVsBADk5OcjIyMBff/2FuXPnAgCKioqQlJSEWU+9hUzKWunm2FNTMTJU1q225t2PoePUZwAAv3lfQ5p0u3Nf/EV89913eOihh/Ddd9/hpptuculYLCwsly9spJrlsuTFF1/Ec889h4ULF2LXrl10y+kX/hIBnp5qrdZhshCs/KtoQMeRSqUYP348Jk2ahLa2NuzcuRMFBQXQarXOlMt4KC4foohZ8J3+LsLuKUbobXmQp68EP3CMw3ZmVQ06Tn2Gho0LUflZMBr+XIKOsz/ArG2hSblraG9vx4kTJ5CZmQmz2YwZM2ZgxIgRl+wSWFZWhuLiYtx8s2MqxpIlS5CZmQm9Xg8A2LZtG+RyOebMmWPfJiEhASNHjkTV0YP253pK0yZmA9TFG6zb8ETwjLluIC+zz3z++ed46KGH8OOPP7KGmoWFZVCwU+JZLluef/55iEQiXHfddfj666+xePFiuiX1maenReN/WeVo0Rjx04laPDsjBiNCuo/qXQpvb29kZGSgubkZZWVl2LVrF4KCghATEwNvb+8rqvQcRVHg+6eB7592Udv0LdBV7wYxW43h5dY2nRCChoYGlJaWorW1FWFhYZgyZQpksr5/pgoLCwFYO5p2JikpCQaDAeXl5UhMTERhYSESEhK6fK6SkpKw60i+fbmn5i/ayh327primGvB4Uv7rLG/vPrqq3jrrbfw888/Y+HChS4bh4WF5cqANdUslzVPPvkkAgMDcffdd6OhoQGPP+6eCgKDxUvogeWz4/DMpgIQArywrRCb7x14NzmKouDv7w9/f3+o1WqUlZUhJycHEokE0dHRCA0NBae3mWOXKQNvm74Q4uhrGd823Wg0oqqqCuXl5TCZTBg2bBjGjh07oBKLbW1tANClsoy3t7UsXmtrq3277qrPeHt7Q6dS2pd7upRzbEvumtrUFosFjz32GNauXYsdO3awdahZWFicAmuqWS57brnlFvj6+uLGG29EfX09Xn/9dbol9YmH06Pw3v4yVCt0+PNsI9Ydr8W0GF8ESQWDii57enoiNTUViYmJqK6uRlFREc6cOYOIiAhERkbC07P/+duXA13bph+CpmxzL23T32Fs23SFQoHKykrU1NRAIpEgMTERISEhjLpw6i5SbdG3Q1O62bpe5AdRxJwu2wwWk8mEJUuWICcnB1lZWWynRBYWFqfBmmqWK4K5c+diz549uOqqq1BfX48vv/ySUQajO4QeXKycm4D7fj4JALj1x2PW53kcRPmIMcxHbP93mI/I/thb5NEn0+3h4YHo6GgMGzYMjY2NqKysRGZmJvz8/BAZGYng4GDGv0euwto2fRKEoZPgM+VNGFqLrBMdy7ZAfz4btobbtrbpqjNrQHGFEEXOsk50HLbALRUrOmM0GlFbW4uKigqoVCqEhoYiPT0dPj4+Tjm+LSKtVCoRFHThtdki2LZxvL29/7+9+45r6ur/AP5JQkIGe8heKuDCSdG6cFD3QKul2qpYx9OnT7Vaq7Z1gNba+rO17lHbilurVat1KzjaoqJWUdzIlr0kbMj5/UFzJSbMAEH5vl+vvDR3nHvuTc65X27OQFxcnNr+mZmZ0JcZI+ff95q+ormRR8BKy0arkbmNBU9Qtx1rc3NzMXz4cDx79gxXrlyBg4NDnaZPCGnaKKgmTYanpydCQ0Ph4+ODkSNH4uDBg41+psGJXeyx+tJT3E3K4ZYVlCjwIEWOBymax6E2Euv9G2iXD7r/fW8qgUxftdjzeDxYWVnBysoKBQUFiI2Nxf379xEeHg4HBwc4OTnB0LD+2rW+Cl5Mmz6nmtOmo9y06cPrbdp0xhgyMzMRExODhIQEGBgYwNnZGXZ2dnU+0ouyLbWyzbTSgwcPIBKJ0Lx5c267c+fOgTGmcs4PHjyAsa0z0v59r+lyqDb9GF+n+U9NTcXAgQMhEonw999/19kfG4QQokRD6pEmJzExEQMHDoShoSGOHz/e6GcfTHpegL23EhCZlofojDxEZeQhOjMP+cWKWqVnKROVBdnm6kG3o4kEIj0+GGNIS0tDTEwMEhMTIZPJYG1tDWtr6ybXubEyipKCf6dNP1bNadOHQWzbQ6snsAqFAmlpaUhKSkJSUhKKi4thb28PJyenOvsuVzak3htvvIFdu3Zxy3r27AkjIyO1IfXOnj0LHx8fAMCjR4/QqlUr9J7xDS4Jy5pbPJjfF26WBlw6JfJniPu5OcAU0DNuAXv/e3X2PYuMjMSgQYPg6uqKgwcPVjnSCSGE1AYF1aRJys7Ohq+vL+Lj43H06FG0bl31dOCNCWMMyTmFiOKC7Pyyf/99H5uZjxJFzYs2jwfYGYlVnnQ7GuvDmFcAceFzKHJSIRQIYGVlBWtra1haWkJPj37wAl5Mm5739Bjynv6BorQ7GrerzbTpRUVFSE5ORlJSElJSUqCnp8f9kWNhYQGBQPvOknl5eVxgvGHDBkRGRmLVqlVITEzE9evXcfv2bYSHh4MxhsWLF6Nv377Yv38/fvrpJ1y6dAn37t3DihUrEBsbC6FQCLFYjI0bN0IsFmPBggXg8/lw/2gVfl33DfDkCmQCYNCggVi3bh1sbGyQfXM1Mi7NAwCYdF0A0zcDtD4nADh37hzGjRuH4cOHY8uWLU1yrHZCSMOgoJo0WcXFxZg1axb27NmDnTt3vlZDapWUKpCQXcAF3cqAWxl8P3tegNqUfKGABztDEawlPJgKimEhLEXLZobwcGiGTi3s4GhhRE+x/1WcHfVvc5A/UJBwCVCUqG/EF0Js7w3Zv0+x9YwcuVVyuZx7Gp2RkQEjIyMukDY2Nq7z6xwdHQ0XFxeN6ywsLODt7Y1Hjx4hPT0dUqkUsbGxcHd3x/LlyyGXyzF+/HgsWLAA/fr1w44dO7B9+3YYGBiAMYYBAwZg3bp18Bw8BolPHwN9PsBmvy5Yv+IrCAQCXL9+Hcm/9kBRyj8AAPtJdyE0ddP6nNasWYMvvvgCy5Ytw+zZs+m7SQipVxRUkyZv8+bN+PTTT7Fo0SJ88cUXus5OgygsKUXMvwF2VHqeylPu6Mx8pOUW1SpdsQCwNxKhuYUBXJsZqTQtcTGTwljSNJ8SlhZkIT/6VFlnx+hTYEXPNW7HN22HQtPuSOK1RTazg4WlJRdISySSBs51GYVCwXVYrYuZFvH2EvCcO+HJF/1QnBaP1q1bY9dP3+HN558DAERWnrAb97dWeS4pKcF//vMf/Pbbb9i/fz8GDhyoVXqEEFId9LstafI+/PBDtGnTBqNGjUJ4eDiCgoIafQdGbenrCeBmaaDSprW8nIISRGfmqT3pVv5fXliqcb+CUuBJZhGeZGbgzOMMtfWmEuG/zUok6p0ozaSQCBvvmM/aEIhNYNDqXRi0evffadP/hPzJ78iNPAaWG89tp8i8C2HmXTgAcJbZQmowHFLeMIiFtjrLe1UjwChnWlyxYoXK8nfffRdz585FYWEh9PX1cfLkSQilhih26liWLo/HzbR47OB2vFk2o7nWY1OnpaXB19cXKSkpuHbtGtzctH/iTQgh1UFBNSEAevfujRs3bmD48OHo2bMnjh49ChsbG11nS2cMxXrwsDGCh416e1/GGDLyilUCbpUn3Rn5KCrV3IkyM78YmQnZuJmQrXG9taE+F2Q7mUlUgm4HEwmEgldziL+ioiJkZ2cjKysLWVlZyM5WIDe3HySOQ2AuSodR3nXoZ/yJ0vRb3D6luc+QE74FOeFbwBMaQOL0FqQthkPqPBgCibnuTuYlNZlp0cjGCRn/NsHgldvu/pVDwAAAPAEM3FSnQa+JW7duYdSoUXBzc8O1a9cafSdkQsjrhYJqQv7l7OyM0NBQvP/++/D09MTBgwfx5ptv6jpbjQ6Px4O5TARzmQieDiZq6xUKhqRynSiVr6dpcjxNz8WznCJU1IcyKacQSTmFCI3JVFvH5wEOJhKVoQKdywXeNoZi8Pm6bzNbVFRULnguC6Tz8vIglUphbGwMExMTODk5wdjYuNwvImXDx5XIn71oh/3ytOlPDiPvyWGAxy+bNv3fdthCU1cdnWmZmsy0KJS++GVE+VkZigqQmVMAQAiJY38IZFa1ysevv/6KadOmYfr06fj222/rpPMmIYTUBAXVhJRjYGCAQ4cOYcmSJejfvz8CAwPx2WefNdlJUGqDz+fB1lgMW2MxeriojwVcXKpAXFZZe+7Hydl4kJiFyDQ5YjLzkSAvQWYFzbkVDIjJzEdMZj4Qma62Xl+PDydTidr43M6mUriYS2AuFWndUa20tBSFhYUoKChQeSmXyeVyLoA2MTGBsbExN9SdSCSqMn09A9uXpk0/V9YOO+oEFPn/jvDMFChIuIyChMvIuDy/3LTpw6Fv7dWop00v/7eU8pMoznzMLatN04+ioiJ88skn2LFjBzZt2oSJEydql0lCCKklCqoJeQmfz8eSJUvQq1cvjB8/HhcuXMCuXbtosog6IhTw0dxchubmMvR3tVRbn5mTi7uxKXic8hzRGfmIycpH3PMiJOSUIDFPAbmGQTQAoLBEgUepuXiUmqtxvYFIAEcTMZxMxHAyFcPRWB+OxvpwMNaHg6EIMlHZ+NzFxcUaA+aCggIUFxeDx+NBX18f+vr6EIvFEIvFkEgkMDU15YLp6gTQVSmbNt0Xspa+KtOm5z39A8WZj7jtVKZNl1iWTZveYjgkjv3BF9b/lPM1mWmxOCr5xfnxeGClRUh/9hgmUh54elJIW4ys0bEfP34MPz8/5Ofn4+rVq2jXrp22p0MIIbVGQTUhFfDx8UF4eDjGjx+Pjh07YteuXejdu7eus/XaMzWUoVdbF/Rqq3l9Zm4hHiZn43FyNp6myxGVnofYrELEPS9EgrwEBZr7UEJeVIp7Kbm4l6I56DYSAtZSPmykfDgYieBoog8XUymaW1ighZMhjGUSiMVi6OvrN/jQbJVOm54YCrCyNuyK/FTI722H/N528ARiiB37QdZiRL1Om16TmRaPnDjNzbTI4wF50acRmVgAdxsepC1GgC/S3HFWk127dmHGjBkYPXo01q1bRxO6EEJ0jobUI6QKpaWl+Oabb7B8+XLMnz8fixYtouYgjRRjDKnyItUOlJnKTpT5iMnMQ3Fp7ao8WyMxXMzUm5e4mElhZyyGno46UZbmpSIv+iTyIlWnTX8ZN21682EQmret1R8GdTHTIsYsBc+pI54tfgtR+8agx4fHsXaCAB8EHoPUZXCVeSgoKMCHH36I3377DZs3b8Z7771X4/MghJD6QEE1IdV0+fJl+Pn5oXXr1ti3bx8sLdWbLpDGrVTB8Ox5ATc294tJccr+H59du0lx9Pi8lzpRqo5cYmXYME+3uWnT/32KXRfTplc00yIAeHt7w9LSEnv37sV7772HRYsWqc20WL6zr5XHm0iJeQJ4f4Ad73rg63mTwIcCxxbYoPl/Yqqcvj0iIgJ+fn4QCAQ4cOAADZdHCGlUKKgmpAbS0tIwceJE3Lp1C5s2bcLIkTVrA0oat6ISBWL/7USpMlRgelngnSKv5aQ4evxyI5Yog+0XgbepVPs22C+r/rTpJpA4Dyobrs9pAPj6xirrK5tpMSQkBH369AEA/Pzzz/j2229VZlp8eZbSIeuDcXLLN8DjUMgEJejZsgiBowVw7f0/mPddXeG5KBQKrF+/HgsWLMDEiRPx/fffQywWV/9iEEJIA6CgmpAaYoxh3bp1+OKLLzBy5Ehs2rQJxsbGVe9IXnm5hSXcVO+aJsV5XlBBL8oqGIv1uIBbbVIcUwlk+tp3fynOjuaeYFdn2nRJ86EQGjlpfdzyhv98FcfvpwAAor3WofTZBQCAjd+fENt4adwnOjoa/v7+iIiIwNatW+Hr61uneSKEkLpCQTUhtRQZGYlJkyYhOjoaGzduxIgRI3SdJaJDjDFk5ZefFCf/pUlx8lBQonlSnKo0MxBVGHQ7mkgg0qtZe+7Sgizkx5xG3tM/kB91CooizZPxiCw7cMP1iZp10roJy7CfruLEgxQ042cg1HY6AAY94xaw97+nlrZCocCGDRuwaNEiDBo0CBs2bIC5eeOZ9IYQQl5GQTUhWlAoFFi3bh2+/PJLjBo1Chs2bKCn1kQjxhiS1SbFyeeC7tisfJRWNCtOJfg8wM5Y/GImStNyQbe5FLZGYggqmRRHOW163tM/kBd5DCU5MRq3ExjYQeoytGy4Pvs+4Onpa9yuMkO2XsGph6mYYnAUX5psBwCYdF0I0zcXq2wXHR2NyZMn4+7du9iyZQtGjx5d42MRQkhDo6CakDrw5MkTTJo0CbGxsdiwYQM9tSY1VlKqQHx2gdrTbWXw/ex5Qa3SFQp4/wbakhftussF3pYGLybFYYyhOP0uciP/bYedfF1jmty06c2HQeoyGAKJRbXyMnjrFZx+mIrfm32GdqIoAID9pAhuVkiFQoGNGzdi4cKFGDBgADZu3AgLi+qlTQghukZBNSF1RKFQYM2aNVi4cCF8fX2xdu1a+rma1JmC4lLEZKo3KVE+9U7PK65VujKRgAuync1fdKB0NpXCST8bgsQzZe2wY89z06arqMG06YN+vIKnT2/itPUsAIC+1RuwHfcXgLI/TKdPn47w8HBs2bIFb7/9dq3OhxBCdIWCakLq2OPHjzF16lTcu3cPixcvxv/+9z8a15rUu5yCkgrG5y57yQsrmBWnCqYSIVzMpHA3BXroh8Oj9E9YZ1+AXnGGxu2Fpu5lAXaLEWrTpg/YEooOyWvwkdEhAICZ9yqI20xDQEAA1q1bhxEjRmDt2rU0XCUh5JVEQTUh9YAxhv3792PWrFmws7PDhg0b0K1bN11nizRRjDGk5xUhKl115JKYTOUT73wUlVa/EyUfpegkegwfyTUMlN6AkyBe83bKadObD4PEyQeDfr6FRfJ3YK+XCvAEuNlsA+YuWAaxWIyNGzdyw/MRQsiriIJqQupRTk4OlixZgvXr18PPzw+rVq2iJiGk0VEoGBJzCl4E3OkvOlBGZ+YhLisflfWhdNFLQH/xdfhIwtBZ9BACnnqAXgx93Ct1RQfBXSRlMXx1ygKXI+QIDAzEzJkzIRRWPvELIYQ0dhRUE9IA7t27h48++gh3797F4sWL8fHHH1OTEPLKKC5VIE5tUpwX75NzXrS1NuNno4/4JvqLw9BLfBsy/osOlkUlDD9fZFh3lgdf39H4ftUPsLW11cUpEUJInaOgmpAGomwSMnv2bNjY2GDlypXo37+/rrNFiNbyikq4TpTlJ8WJz8iCZc5VdOWFQhz9F9b+kQ89Axts+2U7vL29dZ1tQgipUxRUE9LAcnJysHz5cqxZswY9evTAihUr0LlzZ11ni5B6cerUKcz7/HPEx8Vh0cKF+Pjjj6mpByHktUS/PxPSwAwNDfHNN9/gyZMnaN68Od58802MGTMGT5480XXWCKkzV69eRZ8+fTBmzBj4jhiB6KgozJ49mwJqQshri4JqQnTE1tYWW7ZswZ07dwAA7du3x9SpU5GcnKzjnBFSew8fPsTIkSPh7e2Ndu3aITIyEkuXLoWRkZGus0YIIfWKgmpCdMzNzQ0HDx7EpUuX8PTpU7i5uWHevHl4/vy5rrNGSLUlJCTA398fHTt2hFQqxb1797B+/XpYWVnpOmuEENIgKKgmpJHw9PREcHAwfvvtN5w7dw7Ozs6YPXs2UlNTdZ01Qir0+PFjTJw4ES1btkRSUhJCQ0Oxd+9eNG/eXNdZI4SQBkVBNSGNjI+PD27cuIE9e/bg+vXrcHFxwdSpUxEdHa3rrBHC+eeffzBq1Ci0a9cOcrkcly9fxqlTp9CxY0ddZ40QQnSCgmpCGiEej4dBgwbh8uXLOHPmDBITE9GqVSv4+fkhIiJC19kjTdjFixfx1ltvoVu3bjA2Nsbt27dx6NAheHp66jprhBCiUxRUE9LIde/eHcePH8e1a9fA4/HQqVMnDB06FFeuXNF11kgToVAo8Pvvv6N79+4YPHgwWrdujcePHyMoKAitWrXSdfYIIaRRoKCakFdE+/btsW/fPty/fx/29vbw9vZG165d8csvv6CkpETX2SOvIblcjpUrV6J169aYNGkS+vbti5iYGKxduxaOjo66zh4hhDQqNPkLIa+o1NRUbN26FRs2bABjDO+99x5mzZoFOzs7XWeNvOIiIiKwatUq/Pbbb7Czs8PMmTPx/vvvQyaT6TprhBDSaNGTakJeUZaWlvjyyy8RExOD9evXIywsDM2bN8eQIUNw9OhRKBQKXWeRvEKKiorwyy+/oEePHujUqRMyMjJw5MgR3L17F//5z38ooCaEkCrQk2pCXiMPHjzAli1bsG3bNpiZmeHdd9/FtGnT4OLiouuskUbq1q1b+PHHH/Hbb79BKBRi+vTpmDp1KmxtbXWdNUIIeaVQUE3Iayg/Px8HDx7Ezz//jL/++guenp545513MGnSJJiZmek6e0TH4uLisHXrVhw6dAiPHj3C4MGDMX36dAwaNAgCgUDX2SOEkFcSBdWEvObi4+Oxd+9ebN++HZGRkfD29sb777+PsWPHQl9fX9fZIw0kOzsb27dvx6+//oqrV6+iW7dumDhxIsaMGQNTU1NdZ48QQl55FFQT0oTcuXMHu3btwu7du5Gbm4tBgwbhvffew6BBg6Cnp6fr7JE6lpubiyNHjmDv3r0IDg6Gk5MTJk6ciPHjx8PJyUnX2SOEkNcKBdWENEEKhQKXL1/Gzp07cfjwYSgUCvTs2RMjRozA22+/TU1EXmFxcXHYt28fTp48iStXrsDCwgLvvPMOJkyYgPbt24PH4+k6i4QQ8lqioJqQJq60tBRXrlzB0aNHceTIEURFRcHT0xMDBw7Eu+++C3d3d11nkVRCoVAgLCwMBw4cwNmzZxEREYGOHTvC19cXI0eORLt27SiQJoSQBkBBNSFExZMnT3Ds2DEcOXIEf//9N5o3bw5vb2/4+Phg4MCBMDY21nUWm7ykpCScOHEC58+fx8WLF5Geno7+/fvD19cXQ4cOhY2Nja6zSAghTQ4F1YSQCmVmZuLkyZM4deoUQkJCkJSUhLZt26Jr167w8fHBgAEDKMhuAMogOiQkBNeuXcPjx4/h5uaGvn37YsiQIejfvz+kUqmus0kIIU0aBdWEkGqLjo7GhQsXEBwcrBZk9+nTB71796YZHbWkUCgQGRmJS5cu4cKFCypBdL9+/dC3b1/07t0bVlZWus4qIYSQciioJoTUWnR0NEJCQhAcHIw///wT0dHRsLa2Rps2bdC+fXt4eXmhV69esLe313VWGyWFQoHHjx/jzz//RFhYGO7cuYP79+8jOzsbbm5u6NOnD/r27Qtvb28KogkhpJGjoJoQUmcyMzPxzz//4MaNGwgLC8P169cRFRUFa2trtG7dGu3atUPbtm3Rtm1beHh4NKmmI6mpqQgPD0dERAQiIiK4APr58+dwd3eHp6cn3njjDXTp0gUdOnSgacEJIeQVQ0E1IaReZWVlcYH2jRs38PDhQzx+/BhyuRxWVlZwdHSEs7MzXF1ducDbzc3tlWwjnJ2djQcPHuDu3bt48OABnjx5gujoaMTGxiIjIwNmZmbceXbp0oULoF/FcyWEEKKKgmpCSINjjCElJQWPHj3Co0eP8PDhQ+4VFRWFoqIiGBkZwdLSEhYWFrC0tESzZs1gY2MDOzs7ODg4wNbWFsbGxjAxMYGJiUm9TK9dVFSE7OxsZGVlITMzE/Hx8YiPj8ezZ8+QmJiIlJQUpKWlITU1FWlpacjNzYVUKkXLli3h7u6OVq1awdXVFW5ubnB1daXxvxvYhQsX0LdvXzg5OSE6OlptfU5ODgICAvD7778jLi4OxcXF3LZV7VtT/v7+2L59OwICAhAYGKh1eoSQxoemUCO1prxJVCUkJAR9+vTh3oeHh+Pvv/9GWFgYwsLCcO/ePZSWlmLSpEkICgrSKk9yuRxbtmzBkSNHcO/ePeTk5MDU1BQ2NjZo27Yt+vXrh4EDB1IbXx3j8XiwsrKClZUVevXqpbKutLQUqampSExMVHklJCTgzp07OH36NBITE5GWlobCwkJuP4lEAqlUqvbS09MDn88Hj8cDn88Hn8+HQqGAQqEAYwwKhQLFxcXIy8tDbm4u8vPzkZubi7y8PJX0pVIpLC0tYWNjA1tbW9ja2qJ169awsbHhXra2tjAzM3ulxoVuymVm9OjROHfuHADAyMgIZmZmsLS0bNA8ZGVlYfXq1QBAwTYhrzgKqonWhEJhpU/gRCKRyvuJEyfi9u3bdZ6Phw8fYuDAgYiJieGWGRoaIi8vD7dv38bt27exZ88eTJkyBT/99FOdH5/UDYFAAGtra1hbW6NTp06VbltSUgK5XI6cnBzu35f/X1paCoVCwf2rUCggEAi4AJvP50MoFMLQ0BCGhoYwMDBQ+79MJquXJ+G69rqXGalUCnd3d40j0kRERODcuXMQCoW4dOkSunXrVu19a8PGxgbu7u6wsLBQWZ6VlYUlS5YAoKCakFcdBdVEa927d8eFCxeqvb1QKESHDh3wxhtvwNPTE0ePHsWJEye0ykNxcTF8fX0RExMDGxsbLF26FGPHjuU6wiUlJSEkJAR79+59LYOjpkpPT49r/kFqpimUGS8vLzx48EDjuoiICABA+/bt1QLqqvatjW+++QbffPNNnaVHCGl8KKgmDe7KlSsqN+mwsDCt0zx37hx3Azx27Bi6dOmist7a2hrjxo3DuHHjUFBQoPXxCHnVNfUyk5+fDwAwMDDQcU4IIa8Lvq4zQJqe+njqdffuXQCAlZWVWnDwMrFYXOG6y5cvY/z48XB0dIS+vj6aNWsGLy8vLF26FHFxcWrbl5aWYsuWLejZsydMTU0hkUjg5uaGWbNmITExUeMxAgMDwePx4O/vj9LSUqxevRqdO3eGoaEheDwesrKyuG0LCwuxevVqdO/eHaamphCLxWjRogX++9//1knnKdJ0aVNmnJ2dwePxcOHCBcTExOCDDz6AnZ0dxGIx3NzcEBgYWGUgfuHCBYwdOxZ2dnYQiUSwsLDA4MGDcezYsUr3e/78OZYvX46uXbtyZc7V1RXvvPMODh8+rHYMHo8HZ2dnbllQUBBX/gDg4sWL4PF43Ev5q5umfV8WHh6OKVOmoEWLFpBIJDA3N0enTp0wf/58tafc/v7+4PF4Kk08/P394eLiwr0vnw/ltvn5+TA2NgaPx+Paf2uSlZUFiUQCHo+Hq1evVnoNCSH1g55Uk9dKRkYGCgoKKg2cNVEoFJg9ezbWrl3LLTM2NkZeXh7XoVKhUKjcEHNzczFixAgEBwcDKGs7LhaL8fjxY6xZswY7duzAqVOn4OXlVeExR44ciePHj0NPT09tXOKEhAQMGjSIC34EAgEkEgmePn2KzZs3Y8+ePfj9999VOoESUlO1LTMA8PjxY4wZMwbp6ekwNDTkli1ZsgQnT57E+fPn1Z4EM8bw2WefYdWqVdwyIyMjpKen49SpUzh16hRmzJihUhaVbt++jWHDhiE+Ph4AuLbwUVFRePLkCQ4cOICqBrSSSCSwsrJCfn4+nj9/rtYn5OU+IBVZuXIlPv/8cygUCgBlbdFLSkpw69Yt3Lp1C8nJyVV2vDY2NoaFhQXS0tIAQG2CHwMDA0gkEowbNw5btmxBUFAQfHx8NKa1b98+FBQUoHXr1ujatWu1zoEQUscYIbU0adIkBoB5e3trlc6UKVMYADZp0qRap3H+/HkGgAFgH3zwAZPL5TXaf9myZQwA4/F4bO7cuSwhIYFbFxUVxb777ju2ZcsWlX2mTZvGADCpVMqCgoJYUVERY4yxf/75h3Xq1IkBYLa2tiwzM1Nlv4CAAAaAGRgYMLFYzH788UeWn5/PGGMsOjqaFRUVsaKiItalSxcGgA0ZMoSFhYWx4uJibpsJEyYwAMzCwoKlp6fX9HIRolWZcXJyYgCYsbExc3d3Z6GhoYwxxoqLi9nu3buZgYEBA8CmT5+utu/333/PADB7e3u2Y8cO9vz5c8YYYzk5OezHH39kRkZGDADbsWOHyn4pKSnM1taWAWCtWrViJ0+e5MpEfn4+O3v2LHv77bdV9gkJCWEAmJOTk1o+tm3bVmn9Vdm+u3bt4q7dpEmT2JMnT7h1iYmJbPPmzezrr79W2UdZXwYEBKgsj4qK4tKqyLVr17i6Jjs7W+M2Xbt2ZQDYihUrKkyHEFK/KKgmtaa8SQiFQmZlZaXxtWjRoirTqYugWqFQsJ49e3I3JwMDAzZixAi2fPlydv78eZabm1vhvsnJyUwsFjMA7Ntvv63W8Z4+fcr4fD4DwHbt2qUxTZlMxgCw5cuXq6xTBtUA2E8//aQx/R9//JEBYAMGDGAlJSUatxk8eDDdREmtaVNmlEG1RCJhT58+VVu/Z88eBoDx+XwWFxfHLc/MzGQymYzJZDJ2//59jWnv37+fAWCtW7dWWT579mwGgNnZ2bG0tLRqnWN9BNWFhYXM2tqaAWAffvhhtfLBmHZBNWOMeXh4MABs69atausePHjAADCBQMCePXtW7TwRQuoWtakmWisuLkZycrLG1/PnzxskDzweD8eOHcP48ePB4/Egl8tx9OhRfPnll+jfvz9MTEwwevRo/PPPP2r7Hjx4EAUFBbC1tcWcOXOqdbzDhw9DoVDAxcUF7733ntr6Zs2aYdq0aVz6mpibm2PSpEka1ynH/541a1aFbdDHjx8PADh//ny18kxIedqUGSU/Pz+VNsFK48aNg7OzMxQKhUo754MHDyI3NxdDhw5Fq1atNKY5evRo6Ovr4/79+yr9Enbv3g0A+PLLL2Fubl7b09bauXPnkJSUBLFYjK+//rrBjjtlyhQA0NikRLls4MCBsLGxabA8EUJUUVBNtObt7Q1W9quH2ks5qUFDMDExwe7duxEZGYmVK1di5MiR3BizxcXFOHz4MLy8vLibs5KyU4+Pjw/09KrXzeDmzZsAUGl75r59+wIo68xUWlqqtt7T01Pj8UpKSrgRUSZNmsSN2fzya+bMmQCgsQMlIdVR2zKj5O3tXWHavXv3BgCVoDw0NBQAcOLEiQq/1/b29iguLgbw4rsdFRWFlJQUAMDgwYO1PGvtKOsLLy+vBp0h8/3334dIJMJff/2FJ0+ecMsVCgV27twJAJg8eXKD5YcQoo6CavLacXFxwWeffYYjR44gPj4e0dHR+Pbbb2FsbIySkhJMnTqV6+gEgLtZOzo6VvsYyo5FlU0M4eTkBKAsSC4/oodSRTO3ZWRkoKioCACQmppa4a8AmZmZAIC8vLxq55sQTWpaZpRsbW0rTFO5LjU1lVumfPIsl8sr/F4nJydznf+U321lGQUABwcH7U9YC7WpL+qCubk5Ro4cCUD1afXZs2eRkJAAc3NzjBgxokHzRAhRRUE1ee05OTlh/vz5OH78OPh8PgoKCvDrr7/WSdrlp7GuqYqadSgDCqBsJIWKfgVQvmhoPVLX6qvMKL/bCxYsqPJ7zRijkW1eomwCsnPnTu5aKpuKjRs3rtojlxBC6gcF1aTJ6NGjB1xdXQGUBatKymGsyk/VXBXlU+bY2NgKt1Gmp5z1r7rMzc25gLuy9AmpbxWVGaVnz55VuK9yXflfZJRlrabf6/JDzem6TNSmvqgrb731FhwcHBAbG4vg4GBkZ2fjyJEjAKjpByGNAQXVpEmRSqUAVMeiVU5RfO7cOZSUlFQrnU6dOgEA/vrrrwr3CQkJAVA2DXJNJrwRCoXcZBwnT56s9n6E1AdNZUbp0qVLFe53+fJlAC/KClC7sgaUTTajDGZPnTpV7f3qg/Icrl27hoyMDK3T4/Nf3IZZFWNs8/l8LngOCgrC/v37kZ+fDw8PD3Tu3FnrvBBCtENBNXkt3L17F8nJyZVuc+/ePYSHhwMAOnTowC0fM2YMJBIJEhMT8f3331freKNHjwafz0d8fDx27dqltj4lJQVbt27l0q8p5WxvmzdvxsOHDyvcjjGG7OzsGqdPiDZlRmn//v0an9j++uuviIqKgkAgwKhRo7jlY8eOhUwmQ2JiIlasWFHpsZV9BpQmTJgAAFi+fDnS09Mr3bc+9e/fH7a2tigsLMSCBQu0Ts/IyIj7v6a+Fy+bPHkyeDweDh06hE2bNnHLCCG6R0E1aXB5eXlIS0vjXsp2yYWFhRqXV8eFCxfg4uICf39/nDhxQuXmlJGRgS1btsDHxwelpaWwtrZWCXQtLCywcOFCAMAXX3yB+fPnq/ysHR0djSVLlmDz5s3cMmdnZ65944wZM7Br1y5uxIJbt25h0KBByM3Nha2tLf773//W+BpNmTIFb7zxBuRyOXr37o2dO3dCLpdz6+Pi4rB161Z06dJFbWpmQqpDmzKjJBQKMWjQIFy7dg1AWafcffv2YerUqQDKvsf29vbc9hYWFli2bBkAYOHChZg5cyaioqK49XK5HGfPnsWECRMwduxYlWPNnz8ftra2SEhIQK9evXD69GnuaXdBQQFOnDiBoUOH1s3FqYRQKMTKlSsBlP3RO3nyZERGRnLrk5KSsGrVKixdurRa6ZmYmHCdOrdt21bl9s7OzujXrx/y8/Nx69YtCIVCvP/++7U4E0JInWuwEbHJa6e2MyqWn/ykste2bduqnebmzZvV9jc0NOQmYFG+rKys2LVr19T2Ly0tZR9//LHKtiYmJtzMcNAwaYNcLmd9+/bl1uvr63OzwQFgpqam7MqVKxWef1WT3SQlJXGzpOHfiTTMzc2ZRCJRyWdQUFC1rxMhStqUGeXkLz/++CMzNzfn9lVOogSAeXl5sZycHI3HXrx4MePxeCrHNTExUVnWp08ftf1u3brFzaoIgIlEImZubs4EAoHGCVTqa0ZFxhj79ttv1c6hfPl/uXxXNPmL8noo95PJZMzJyYk5OTmxH374QeOxlZPrAGAjR47UuA0hpOHRk2ryWvjPf/6D69evY+nSpRgwYAAcHBxQWFiIoqIiNGvWDH379sXKlSvx8OFDvPHGG2r78/l8rFu3DsHBwXj77bdhY2OD3NxcyGQydO3aFcuWLeMmc1GSyWQ4c+YMNm3ahDfffBP6+vooLCxEy5YtMXPmTERERKBr1661PicrKyv89ddfCAoKwsCBA2Fubo7s7GwIBAK0a9cOU6dOxR9//EFPqUitaFtmAMDV1RU3btyAv78/DAwMoFAo0LJlSyxevBgXL16EgYGBxv2WLFmCmzdv4oMPPkDz5s1RUlKCvLw82NvbY9iwYVi3bh0OHDigtl+HDh1w7949BAYGolOnThCJRMjPz0fz5s3h5+eH33//vU6vUWXmz5+P69evY8KECXB0dERhYSGEQiE6deqEzz//vEZNQxYvXowVK1agffv2YIwhJiYGMTExFTYHGTFiBNcWm5p+ENJ48BiromcEIYQQUo6zszNiYmIQEhJCw97pwKlTpzB48GBYWloiISEBQqFQ11kihIDaVBNCCCGvlB9//BFA2YyrFFAT0nhQUE0IIYS8Io4ePYojR45AT08PH330ka6zQwgpR0/XGSCEEEJI5ZydnZGXl8dN+/7xxx/DxcVFx7kihJRHQTUhhBDSyMXExIDH48HBwQETJ05EQECArrNECHkJdVQkhBBCCCFES9SmmhBCCCGEEC1RUE0IIYQQQoiWKKgmhBBCCCFESxRUE0IIIYQQoiUKqkmDYYyhQ4cOkMlk3LBQpMytW7fA4/EwatQoXWeFEK1QOa8YlXNCXm8UVJMGs3fvXoSHh2PatGmwtLTUdXYqFB8fj927d2PWrFno0aMHZDIZeDwenJ2dq53GsWPH8NZbb8HCwgJSqRRt27bF0qVLkZ+fr3H7jh07YvDgwThy5AjCwsLq6EwIaXhUzqmcE9JkMUIaQHFxMWvRogUTCoUsLi5O19mp1CeffMIAqL2cnJyqtf/nn3/O7aOnp8cMDAy49x4eHiwzM1PjfpcuXWIAmI+PT92dDCENiMo5lXNCmjJ6Uk0axLFjxxAZGYmBAwfC3t5e19mpFI/HQ/PmzeHn54eVK1di7ty51d738OHD+PbbbwEAAQEBeP78OXJychAcHAwrKyvcuXMHU6dO1bhvr1690LJlS5w7dw737t2rk3MhpCFROadyTkiTpuuonjQNw4YNYwDYzp07dZ2VKpWUlKi837lzZ7WfYLVp04YBYOPHj1dbd/r0ae5J1o0bNzTuv2DBAgaAffbZZ7XKOyG6ROWcyjkhTRk9qSb1LiUlBadOnYJQKMTIkSM1btOnTx/weDwEBQUhNzcXCxcuhKurK8RiMWxsbDB58mQkJCQ0SH4FAkGt9rtz5w735Gn27Nlq6wcMGIA2bdoAKGt3qsmYMWMAADt37oRCoahVPgjRBSrnZaicE9J0UVBN6l1ISAhKSkrg4eEBQ0PDSrd9/vw5unfvjq+//hoJCQng8XhISkpCUFAQunfvjvT09AbKdc1duHABAGBqaoouXbpo3MbHxwdA2TXRpH379jAwMEBycjLu3LlTL/kkpD5QOX+ByjkhTRMF1aTe/f333wBQ4Q2ovICAAOTm5uL8+fPIzc1FTk4Ojh8/DlNTU8TGxuKbb76p7+zW2v379wEArVq1Ao/H07hN69atAQAPHjwAY0xtPZ/PR+fOnQEAf/31Vz3llJC6R+X8BSrnhDRNFFSTeqccOqp9+/ZVbiuXy3Hs2DH069cPPB4Penp6GDJkCBYvXgwAOHjwoNo+QUFB4PF4tXoFBQXV2XkmJiYCAGxsbCrcRrkuNzcXcrlc4zYdOnQAAFy7dq3O8kZIfaNy/gKVc0KaJj1dZ4C8/pKSkgAAFhYWVW779ttvc095yhs+fDhmz56NmJgY5ObmQiaTceskEgmsrKxqlTeJRFKr/TTJzc2tMk2pVMr9Xy6Xa/yZXHmdlDdvQl4FVM5foHJOSNNEQTWpd2lpaQDK2iBWpaKnXHZ2dtz/s7KyVG62fn5+8PPz0zKXjYfyOimvGyGvAirnNUPlnJDXDzX/IPWusLAQAKCvr1/ltra2thqXi8Vi7v/FxcV1k7E6pgwAKppNDQDy8vK4/xsYGGjcRnmuBQUFdZg7QuoXlfMXqJwT0jRRUE3qnZmZGYCyJ0+vM2U7ysp+zlX+RG5gYFDhzTYzMxMAYG5uXsc5JKT+UDl/gco5IU0TNf8g9c7CwgJJSUncTaSu7d+/H5988kmt9l2zZk2d/aT8co9/TSMDVGfkAOV1qk7bVEIaCyrnL1A5J6RpoqCa1Dt3d3fcvXsX0dHR9ZJ+fn4+kpOTa71vXenTpw+AspvlzZs3NQ4tdu7cOQBA3759K0xHeZ3c3d3rLG+E1Dcq5y9QOSekaaLmH6Te9ejRAwBw/fr1eknf398fjLFavfz9/essHx4eHmjbti0AYPXq1Wrrz507h4iICADAu+++W2E6yqHJlNeNkFcBlfMyVM4JabooqCb1rmfPngCAGzdu6Dgn1VNcXIy0tDTupRxnVqFQaFxe3rJlywAAu3btwtKlS7lOSBcvXsSECRMAlA0nppz44WWZmZmIjIwEn89H9+7d6+P0CKkXVM6pnBPS5DFC6plCoWAuLi4MALtx44bGbby9vRkAtm3btgrTAcAAsKioqPrJ6L9CQkK4Y1X2mjRpksb9P//8c24bPT09ZmBgwL338PBgGRkZFR579+7dDADz8fGpp7MjpH5QOadyTkhTR0+qSb3j8Xjcz6/79+/XbWYawDfffIOjR4/Cx8cHRkZGKC0tRZs2bbBkyRJcvXq10nF8ldenLn+uJqQhUDmnck5IU8djjDFdZ4K8/mJjY9GiRQvY2dnh6dOn4PPp77mXZWVlwdraGlKpFAkJCXU6CxwhDYHKedWonBPy+qIajzQIR0dHTJo0CTExMTh06JCus9Mobdy4EYWFhZg3bx7daMkricp51aicE/L6oifVpMHExcXB1dUVbdu2fWU6MzWU/Px8ODs7g8/nIzIyElKpVNdZIqRWqJxXjMo5Ia83GqeaNBgHBwcEBQXhwYMHSEtLo0kPyomNjcV///tfdO/enW605JVG5bxiVM4Jeb3Rk2pCCCGEEEK0RG2qCSGEEEII0RIF1YQQQgghhGiJgmpCCCGEEEK0REE1IYQQQgghWqKgmhBCCCGEEC1RUE0IIYQQQoiWKKgmhBBCCCFESxRUE0IIIYQQoiUKqgkhhBBCCNESBdWEEEIIIYRoiYJqQgghhBBCtERBNSGEEEIIIVqioJoQQgghhBAtUVBNCCGEEEKIliioJoQQQgghREsUVBNCCCGEEKIlCqoJIYQQQgjRUpMMqnfv3g0vLy8YGxvDyMgIrVu3xtSpU5GSksJts3r1apw4caLB83br1i0EBgYiLy+vwY9dEV9fX/Tp06fSbQIDA8Hj8biXubk5evbsWek17NChA3g8Hi5fvlzhNqGhoRgzZgxsbGwgEolgbm6Ofv36YcuWLSgqKqoy7zweD999912l+TYwMKgyDR6Ph82bN6utO3v2LLc+Ojq6yvwQ8iqgOrJmqI6kOpIQoAkG1f/3f/+HCRMmoFevXti/fz/279+PDz74ANevX8ezZ8+47XR5w1iyZEmjumFUl0QiQWhoKEJDQ7F161YUFBRg+PDh+Pvvv9W2jYiIQHh4OABgz549GtPbtGkTevbsifT0dKxYsQLnzp3Dzz//DDc3N3zyySfYtm1bvZ5PeQYGBti3b5/a8r1791Z5wyHkVUJ1ZP2hOpKQ15uerjPQ0NauXQt/f398//333LLBgwdj7ty5UCgUNU6vsLAQQqEQfH7j/PuktLQUCoUCQqGw3o/F5/PRrVs37n3Xrl3h4OCA7du3o3v37irb7t69G3w+H97e3jhw4ADWrl2rksfbt29j5syZmDhxIn755RfweDxuna+vL+bMmYO4uLh6PyelkSNHYu/evUhISICdnR2Ass/+0KFD8PX1xa5duxosL4TUJ6oj6w/VkYS83hpnLVePMjMzYWNjo3GdstJ3dnZGTEwMNmzYwP1sFRQUxK37+OOP8X//939wcnKCRCJBRkYG/P390a5dO5X0srKyVPZV2rFjBzp16gSxWAwLCwsMGTIEMTExCAoKwuTJkwEAlpaW4PF4cHZ2BlDxT3AmJiYIDAzk3vfp0wfDhg3D9u3b4e7uDn19fdy+fRsAcPz4cXTt2hUSiQSWlpb473//i9zcXJX07t+/D29vb4jFYrRo0QLbt2+v1nXVxM7ODpaWloiNjVVZzhjD3r170a9fP3z66adIT0/HqVOnVLZZu3YtBAIBvv/+e5WbhZKrqyv69etX67zVVMeOHeHm5ob9+/dzy06cOAHGGIYOHdpg+SCkvlEdSXVkbVAdSUgTfFLdpUsXbN68GS4uLhg2bBisra3Vtjl8+DCGDBmCnj17Ys6cOQCAFi1acOt/++03uLq6Ys2aNRAIBJDJZNU+/sqVKzFv3jxMmTIFX3/9NYqLixEcHIzU1FQMHToUCxcuxLJly3Dq1CkYGxtDX1+/xud4/fp1REdHY+nSpTA1NYWDgwMOHjwIPz8/TJ48GUuWLEFiYiI+//xzZGZmcj/ZFRQUYMCAAZDJZNi5cycAYPHixXj+/DlcXV1rnA+5XI6MjAy4uLioLP/7778RHR2NxYsXY+DAgTA3N8eePXswfPhwbpsLFy7A09MTZmZmNT5ufRk3bhz27t2LTz/9FEDZz5qjRo2CWCzWcc4IqTtUR1IdWVtUR5KmrskF1Rs3bsSoUaMwbdo0AICLiwuGDx+O2bNnc088OnXqBH19fVhZWan8VKdUXFyMkydP1uhGAQDZ2dkIDAzE9OnTsWXLFm75yJEjuf8rb0xdunSBhYVFTU8PAJCRkYGwsDA4ODgAKHvq8dlnn8HPzw8//fQTt52NjQ2GDBmCRYsWoW3btggKCsKzZ8/w4MED7gbRqVMnuLu7V/uGUVJSAgB49uwZ5s2bB0NDQ3zyyScq2+zZswdisRijR4+GUCjEmDFjsHPnTsjlcu5J07Nnz+Dl5VVh+kDZU7OG/El53LhxCAgIQGRkJKysrPDHH3/gyJEjr2TbTkIqQnUk1ZG1RXUkaeqaXPOPdu3aISIiAsePH8cnn3wCY2NjrF27Fu3bt8etW7eqlUafPn1qfLMAynpp5+XlYcqUKTXetybat2/P3SwA4NGjR4iJicE777yDkpIS7uXt7Q0+n4/r168DAK5evYp27dqp3BxatmyJDh06VOu4ubm5EAqFEAqFcHJywsGDB7Fz5064u7tz25SUlODAgQMYMmQIjI2NAQDjx49HXl4eDh8+rJLeyz9pXr9+nUtfKBRixIgRAMpuiOXPq7S0tAZXq/pcXV3RpUsX7N27F0eOHIGhoSH69+9fL8ciRFeojqQ6sraojiRNXZMLqgFAJBJhyJAhWL16Nf755x+cOnUKeXl5WLp0abX2t7KyqtVx09PTAQC2tra12r+6Xs5fWloaAGDUqFEqFa5UKkVpaSnXmSUxMRHNmjWrMr2KSCQShIWF4erVq9i1axdsbGwwceJEJCYmctucOXMGqampGD58OLKyspCVlQUPDw/Y2Nio9HC3tbVFfHy8Svpt2rRBWFgYwsLC0LlzZ275xYsXVc6rPitx5c+be/bswTvvvAOBQFBvxyJEV6iOpDqytqiOJE1Zk2v+ocnAgQPRoUMH3L9/v1rba+oUIhaL1cYEzczMVHlvbm4OoOxnO3t7+xrlUSwWo7i4WGVZcXEx5HJ5lflTtrlbv349unbtqra98gZmY2ODmzdvqq1PTk6GkZFRlXnk8/nw9PQEAHh5ecHd3R1du3bF0qVLsWnTJgAvhoaaPHky1+FIKTU1FSkpKWjWrBn69OmDPXv2IDMzE6ampgAAqVTKpW9oaMjt16VLF4SFhXHvy6+ra35+fpg7dy4ePHhQ6dixhLxOqI6kOrK6qI4kTVmTe1KdnJystiw/Px9xcXEqHXJEIhEKCgqqna69vT3i4+NVKvAzZ86obPPmm29CKpVWOnaoSCQCALVj29vbo6ioCJGRkdyy4ODgav2M16pVK9jb2+Pp06fw9PRUeylvGF5eXrh79y6ePHnC7fvkyROuZ3xNeXp6Yty4cdi2bRuSkpKQl5eH33//Hb6+vggJCVF57d27FyUlJVzP8ZkzZ6KkpARz586t8jiGhoYq51P+p9S6Zm9vj1mzZmH8+PFqQ2AR8jqgOpLqSG1QHUmasib3pNrDwwPDhw/HwIEDYWNjg4SEBKxfvx5paWkqnUVat26N4OBgnD17FqampnBxceGeomgyevRoLF68GB988AGmTZuGiIgIlQ4vAGBsbIyAgADMnz8fCoUCI0eOhEKhQEhICMaNGwdPT0+0bt0aALBhwwb4+vpCKpXCw8MDgwcPhkwmw7Rp0zB//nzEx8djzZo11epVzePxsGrVKowfPx65ubkYOnQoZDIZYmJicPz4cSxfvhxubm7w9/fHsmXLMGzYMHz11VcAynq2a+r9X12LFi3Cvn37sHr1anTo0AFyuRwzZ87UOPvY//3f/2HPnj2YMWMGOnTogLVr1+Ljjz/G06dPMXnyZDg7O0Mul+P69esIDw/HwIEDq5WHO3fu4ODBgyrLDAwMMGjQIABl49S+vB4ou4E6OjqqLV+1alW1jkvIq4jqSKojAaojCakV1sRs2LCBDRo0iNnZ2TGRSMRsbW3ZoEGDWHBwsMp2d+/eZb169WKGhoYMANu2bRtjjDEnJyf2v//9T2PaO3bsYC1btmQSiYS99dZb7NatWyr7Kv3yyy/Mw8ODiUQiZm5uzoYNG8ZiYmK49YGBgcze3p7x+Xzm5OTELT916hRr27YtE4vFrFu3buyff/5hxsbGLCAggNvG29ubDR06VGP+zpw5w7y9vZlMJmMymYy1bduWzZkzh2VlZamdt0gkYi4uLuyXX35hI0eOZN7e3pVe14CAACaTyTSue++995iRkRHr06cPc3R0ZAqFQuN2q1evZgDYkydPuGV//fUXGz16NLOysmJ6enrM1NSU9e3bl23atIkVFhZWmifGGAOg8dWiRQsu3xVts3PnTi6NlStXVniMw4cPMwAsKiqqyvwQ0thRHUl1JNWRhNQOjzHG6jtwJ4QQQggh5HXW5NpUE0IIIYQQUtcoqCaEEEIIIURLWnVUfGP1JSTlFNZVXmrF2lAfYbN66zQPhBCiScKebijNUx9NoyEJpFawG39Fp3kghJCmQKugOimnEAnZ1R9SiRBCmpLSvGSUyhN0nQ1CCCENQKvmH9aG+rAzFuv0ZW2oX6u8e3l5YcOGDbU+9wsXLoDH43HT1wJAYGAg/v77b7VteTwevvvuu1ofq6Zu3bqFwMBA5OXlNdgxgbJrsnz58jpP9+zZs/Dw8IC+vj5MTEzqPP3GJCgoCDwej5vhra7U12dTHbooF2+99Ra+/vrrekm7JgRSKwgM7HT7ktZudsPXuY7UhOov7VH9VTcaS/1FakHXw4/owqFDh5ilpSXLy8urdRrZ2dksNDSUyeVybhkqGFaoouX1Zdu2bQwAS01NbbBjMlb5kFHasLOzY4MHD2aXLl1iYWFhdZ5+Y5KSksJCQ0NZcXFxnaZbX59NdVT0/Q8NDWXPnj2rl2MGBwczExMTlpGRUS/pv+5e9zpSE6q/tEf1V92g+uvV1SQ7Kq5evRrjxo2DRCKpdRpGRkbo1q0bZDJZHeaMvEwulyMhIQFjxoxBr169uCl4X1eWlpbo1q0b9PR0Ny9Tfn5+gxynW7dusLGxqZe0+/btC1NTU2zfvr1e0n/dUR1ZN6j+anhUfxGd0nVU39CePn3KeDweu3TpErdsx44dTCQSqTyVadeuHRMIBCw7O5tb1q1bN/bRRx8xxhgLCQlhALgnD9AwMH5ISAi3bsWKFSwgIIA1a9aMmZubM39/f5UnOIwxFh4ezgYMGMCkUikzMjJib7/9tsqEB1FRUQwAO3DggMp+n3zyCTcBgvIpdflX+ckRNLl48SJ78803mVgsZubm5mzy5MksPT2dW//yuSqVn/BA0wQBVU2GwBhjmzdvZm5ubkwkEjEnJyf21VdfsdLS0grPZdKkSRrTyczMZFOnTmW2trZMX1+f2dvbMz8/P5Vt4uPj2YQJE1izZs2YWCxm7u7ubPXq1dz60tJS9tVXXzEnJycmEomYu7s727x5s0oayicm165dY2+88QbT19dnrVq1YseOHVPL0x9//MG8vLyYWCxmFhYW7MMPP1T7zF/28q8Mys98586d7H//+x8zMTFh1tbWbM6cOSpPg+Li4tjYsWNZs2bNmL6+PnN2dmazZs3i8lzRZ6M8n6tXr7Ju3boxfX19tnLlymp95kr37t1jo0aNYqampkwikbD27duzPXv2MMaqLhcvPwGq7PtQ/vrcvHmTDRo0iEmlUtayZUu2fft2tWs5b9481rFjx0qvN1HXmOtITaj+KkP1F9VfRPeaXFC9detWJhQKWUFBAbcsOjqaAeBmDEtLS2M8Ho+JxWJ24sQJxhhjubm5TCgUsn379jHG1Cvq0NBQBoDNmDGDhYaGstDQUO5mA4A5ODiw8ePHs5MnT7I1a9YwkUjE5s+fz+UhNjaWmZiYsC5durBDhw6xPXv2MBcXF+bs7MyeP3/OGKteUJ2SksIWLlzIALBTp06x0NBQdvPmzQqvx/Xr15lIJGIDBgxgx44dYz/99BOzsLBgXl5erKSkROO5KpWvoOLi4tiUKVOYRCLhzj8iIqLSz2Lt2rXcNTt9+jQLCAhgAoGAzZkzhzuXs2fPMgBs4cKFLDQ0VGUmsfImT57MrK2tWVBQELtw4QLbu3cvmzhxIrc+LS2NOTg4MAcHB7Z161Z2/vx5tnnzZjZ37lxum08//ZQJBAIWEBDATp8+zWbMmMEAsHXr1nHbBAQEcDOprV+/nh0/fpwNGzaM6enpsfDwcG67AwcOMD6fz6ZMmcJOnjzJfvnlF9asWTO1G+XLKropOTo6shkzZrAzZ86wwMBABoBt2rSJ269v377M3d2d7du3j4WEhLDt27ezGTNmVPnZBAQEMKFQyFq0aMHWr1/PgoOD2e3bt6t9U3r06BEzNjZm7dq1Yzt37mRnz55lP/zwA/v2228ZY1WXi/I3paq+D+WvT+vWrdmqVavYmTNn2NixYxmPx2P37t1TyeuRI0cYAJaSklLpNSeqGmsdqQnVX1R/Uf1FGpMmF1RPnz6dtW3bVm25o6MjCwwMZIyVTalqZ2fHRo0axVXqyspR2YZKU6HV9JercrmXl5fKskmTJnHTwDLG2OzZs5lMJlN5wnL//n3G4/HY2rVrGWPVC6oZq1mb6lGjRjFHR0dWVFTELTt9+jQDwI4ePVrhuTKmXkHVpN1bSUkJs7CwYO+++67K8i+++IKJRCKWlpbGGCt7ggOoT2P8srZt27JPP/20wvVffvkl09fXr3Ca3NTUVCYUCtnnn3+usnzcuHHM0tKSu0Ern5r8/PPPKufi4uLCnYtCoWBOTk5s3LhxKmmdPHmS8Xg8dvfu3QrzWdFNaezYsSrbeXt7s/79+3PvZTIZ9z3RpKLPRnk+ykBIqbqf+fjx45mlpaXK08qXVVYulMur+31QXp8NGzZw28jlciaVStlXX32lsq/y2v3xxx8V5o2oa6x1pCZUf5Wh+ovqL9I4NLk21YmJibC0tFRb3rt3b1y6dAkAcOnSJfTu3Rve3t64ePEit6xly5a1bkP11ltvqbxv06YN4uPjufeXL19Gv379YGZmxi1r1aoVOnTogD///LNWx6yOy5cvY+TIkRAKhdyyAQMGwMTEpM6OW1JSwr1KS0sBAA8ePEBaWhrGjh2rsq2fnx+Kiopw7do1jWkpFAqV9BQKBQCgc+fOCAoKwnfffYe7d++q7Xf+/Hn069cPzs7OGtO9evUqiouLNeYnNTUVjx49Ulk+atQo7v8CgQC+vr64evUqAODRo0eIiYnBO++8o5JXb29v8Pl8ldEQqmvAgAEq71/+/nTu3BnfffcdNm3ahCdPntQ4/aFDh9Z4H6Dsuo4ZMwZGRka12l+ppt+H8tdDJpPByclJ5XoAgIWFBYCyMk+qr7HWkZpQ/VWG6i+qv0jj0OSC6oKCAujrqw/D5+3tjStXrqC4uJi7YfTu3Rs3btxAXl4et6y2Xh5KSSQSobDwxcQ5mZmZsLJSH/rKysoKGRkZtT5uVer7uNHR0RAKhdyrRYsW3HGVx3n5uAAqPPbSpUtV0lu6dCkAYN26dZgwYQK+//57eHh4wNHREZs2beL2S09Ph62tbYX5rEl+hEIhTE1N1bZTVn7K4aRGjRqlklepVIrS0lLExcVVmI+KaPr+FBS8GCN+//796N+/PxYsWABXV1e0atUKhw4dqlbaUqkUBgYGNc4TUPV1ra6afh+quh4AuHLeUB2XXheNtY7UhOov1Dg/VH+9QPUXqWu666KrI2ZmZoiOjlZb3rt3b+Tl5SEkJAS3bt1C79690apVK0ilUoSEhODq1avw9/ev13ylpKSoLU9OToabmxsAQCwWAwCKiopUtlEW6Lo+rvKpeWXH5fF4laZva2uLsLAw7r2yolCm/fKxk5OTVda/bPr06Rg2bJhK+gBgbGyM1atXY/Xq1bhz5w7WrFmDjz76CO3atUOvXr1gbm6OZ8+eVZjP8vmxs7OrND/FxcXIzMxUuTElJydzT+iU265fvx5du3bVeE3qmo2NDX755Rf89NNPuHHjBpYtWwY/Pz88fPgQzZs3r3RfTZ9hdT/zqq5rddX2+1CZrKwsAGV5JNXXWOvIivJK9RfVXy+j+ovoSpN7Uu3u7o6oqCi15W5ubrC2tsby5cthZmaGNm3agM/no2fPnli5ciUKCgqqfAojFArV/tqsrp49e+L8+fMqAfLDhw8RHh6Onj17AgCaNWsGoVCI+/fvc9sUFRVxP78qiUQiAKhWXnr27IkjR46gpKSEW3b27FlkZWVxx7W3twcAleOmpaXh5s2basd9+cmSSCSCp6cn9/Lw8ABQ9jlYWlriwIEDKtv/+uuvEIlE8PLy0phfW1tblfQ0VfAeHh744YcfVPLs4+OD4OBgxMbGakzXy8sLQqFQY36aNWvG/WGjdPjwYe7/paWlOHLkCHcDatWqFezt7fH06VOVvFaW57rC5/PxxhtvYNmyZSgpKeF+Sq3OU7/yqvuZ+/j44ODBg8jJyakwreqUi9p+HyqjDAzd3d1rvG9T1ljrSE2o/ipD9Zcqqr+IrjS5J9U9evTA0qVLER8fzxU8pV69euHAgQMYPXo0t6x3796YP38+7O3tq/yLuXXr1vj999/Rq1cvyGQyuLu7w9DQsFr5mj17NrZt24YBAwZgwYIFKCgowMKFC+Ho6Mg9/eHz+Rg9ejTWr1+Pli1bwsLCAuvXrwdjTOWv79atWwMANmzYAF9fX0ilUu5m8LIFCxage/fuGDZsGGbMmIHk5GR8/vnn8PLywpAhQwCUVVBdu3bFkiVLYGxsDD09PaxYsQLGxsZq519SUoI1a9age/fuMDIyqrBCEAgEWLRoEWbOnIlmzZphyJAhuHLlClasWIFZs2bV+K/zHj16YNSoUWjXrh0EAgF27NgBkUiEXr16cdd3x44d6N27NxYtWoTmzZvj6dOnePToEVasWAELCwvMmDEDK1euhFgsRrdu3XDixAns2bMH69atg0Ag4I4lEomwbNkyFBQUwMXFBRs3bkRcXByOHDkCoOzJyapVqzB+/Hjk5uZi6NChkMlkiImJwfHjx7F8+XK1m5w2srOzMXDgQEyYMAHu7u4oKirCunXrYGJigs6dOwOo2WcDVP8zDwgIwB9//IGePXti3rx5sLGxwb1795CXl4d58+Zxx66qXNT19wEArl+/DgMDA3Ts2LHG+zZljbWO1ITqL6q/NKH6i+iMrntKNrTCwkJmbm7OfvzxR7V169evZwBUxv68cuUKA6DWE1pT7+LLly+zzp07M4lEUuV4lj/88AN7+fLfvn2bvfXWW0wqlTJDQ0M2evRoFh0drbJNSkoK8/X1ZUZGRszOzo6tXr1abfQPxhgLDAxk9vb2jM/nVzlO9YULF9ibb77J9PX1mZmZGfP391cZhYQxxp48ecL69u3LZDIZa9GiBdu7d69aT+ri4mL20UcfMSsrK8bj8ao1zuumTZuYq6srEwqFzNHRUW1cz+r2np87dy7z8PBgBgYGzMjIiPXo0YOdPn1aZZvY2Fj23nvvMTMzMyYWi1mrVq1UepyXlpaypUuXMkdHRyYUCpmrq2uF47xeuXKFdenShRsP9vfff1fL05kzZ5i3tzeTyWRMJpOxtm3bsjlz5rCsrKwKz6Oi3vOVjfhSUFDApk6dytzd3ZlEImFmZmZswIAB7Nq1a9z2FX02lY14UJ3PnDHGIiIi2IgRI5iRkRGTSqWsY8eOKr3xa1Iuqvo+VDSyTYcOHdTGAB4+fDibMGGCxnMjFWvMdaQmVH+VofpLFdVfRBd4jDHWcCF84zBnzhz8888/CA4O1nVWyCsmMDAQ3333HeRyua6zQiqRmZkJa2trnD17VqvOc00V1ZGvJ6q/Xg1Uf726mlybagD47LPPcPXqVdy+fVvXWSGE1IN169ahR48edEOqJaojCdEdqr9eXU0yqLaxsUFQUBBSU1N1nRVCSD0wMzPD2rVrdZ2NVxbVkYToDtVfr64m2fyDEEIIIYSQutQkn1QTQgghhBBSlyioJoQQQgghREsUVBNCCCGEEKIlCqoJIYQQQgjREgXVhBBCCCGEaImCakIIIYQQQrREQTUhhBBCCCFaoqCaEEIIIYQQLVFQTQghhBBCiJYoqCaEEEIIIURLFFQTQgghhBCiJQqqCSGEEEII0RIF1YQQQgghhGiJgmpCCCGEEEK0REE1IYQQQgghWvp/Wwa5ydooV98AAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 500x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from math import pi\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# Metrics\n",
    "metrics = ['Exact accuracy\\n(n=21)', 'Partial accuracy\\n(n=21)', 'Precision\\n(n=10)', 'Recall\\n(n=10)', 'F1 Score\\n(n=10)', 'Specificity\\n(n=10)']\n",
    "\n",
    "# strategy 4: without out-of-scope JSON schema instruction (averaged across five runs)\n",
    "strategy=4\n",
    "values_without_schema = [\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_exact_match_acc'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_partial_match_acc'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_precision'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_recall'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_f1'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_specificity'] for run in range(5)])\n",
    "    ]\n",
    "values_without_schema = [value*100 for value in values_without_schema] \n",
    "values_without_schema += values_without_schema[:1] \n",
    "\n",
    "# strategy 5: with out-of-scope JSON schema instruction \n",
    "strategy=5\n",
    "values_with_schema = [\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_exact_match_acc'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_partial_match_acc'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_precision'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_recall'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_f1'] for run in range(5)]),\n",
    "    np.mean([all_real_results[strategy]['full'][run]['avg_specificity'] for run in range(5)])\n",
    "    ]\n",
    "values_with_schema = [value*100 for value in values_with_schema] \n",
    "values_with_schema += values_with_schema[:1] \n",
    "\n",
    "# radar angles\n",
    "angles = [n / float(len(metrics)) * 2 * pi for n in range(len(metrics))]\n",
    "angles += angles[:1]\n",
    "\n",
    "# set color palette\n",
    "cb_palette = sns.color_palette(\"colorblind\")\n",
    "\n",
    "# Set up the plot\n",
    "plt.figure(figsize=(5, 5))\n",
    "ax = plt.subplot(111, polar=True)\n",
    "\n",
    "# Plot the models\n",
    "ax.plot(angles, values_without_schema, color=cb_palette[0], linewidth=2, linestyle='solid', \n",
    "        label='RAG-LLM without out-of-scope instruction')\n",
    "ax.plot(angles, values_with_schema, color=cb_palette[1], linewidth=2, linestyle='solid',\n",
    "        label='RAG-LLM with out-of-scope instruction')\n",
    "\n",
    "# annotate each metric value\n",
    "for i in range(len(metrics)):\n",
    "    ax.text(angles[i], values_without_schema[i] - 8, \n",
    "            f\"{values_without_schema[i]:.0f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "    ax.text(angles[i], values_with_schema[i] - 14, \n",
    "            f\"{values_with_schema[i]:.0f}\",\n",
    "            color='black', fontsize=11, ha='center', va='center')\n",
    "\n",
    "# labels and ticks\n",
    "ax.set_ylim(0, 100)\n",
    "ax.tick_params(axis='y', labelsize=9)\n",
    "ax.set_xticks([])\n",
    "for i, metric in enumerate(metrics): # Manually set the position of the labels outside the chart\n",
    "    angle = angles[i]  \n",
    "    if angle == 0:  \n",
    "        ax.text(angle, 160, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "    else:\n",
    "        ax.text(angle, 130, metric, horizontalalignment='center', verticalalignment='center', fontsize=17)       \n",
    "\n",
    "# create a custom legend\n",
    "from matplotlib.lines import Line2D\n",
    "handles = [Line2D([0], [0], color=col, linewidth=2) for col in [cb_palette[0], cb_palette[1]]]\n",
    "legend = ax.legend(handles, ['Structured RAG-LLM\\n(without out-of-scope instruction)', 'Structured RAG-LLM\\n(with out-of-scope instruction)'], \n",
    "          title=False, \n",
    "          bbox_to_anchor=(0.5, -0.12), ncol=2,\n",
    "          frameon=False,\n",
    "          borderaxespad=1,\n",
    "          loc='upper center',\n",
    "          fontsize=11\n",
    "          ) \n",
    "legend.get_frame().set_facecolor('white')\n",
    "\n",
    "# save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig(f'./figures/{base_model}/Figure4_ragllmRealworldPerformance_radar.jpeg', dpi=600, bbox_inches='tight')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Run McNemar's test on accuracies from real-world assessment"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create contingency table\n",
    "exact_table_ls=[]\n",
    "partial_table_ls=[]\n",
    "\n",
    "for i in range(5):\n",
    "    exact_table_ls.append(create_mcnemar_table(\n",
    "        all_real_results[4]['exact'][i], \n",
    "        all_real_results[5]['exact'][i]\n",
    "        )\n",
    "                          )\n",
    "    \n",
    "    partial_table_ls.append(create_mcnemar_table(\n",
    "        all_real_results[4]['partial'][i], \n",
    "        all_real_results[5]['partial'][i]\n",
    "        )\n",
    "                            )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Exact: Significance: True; Test Statistic: 24.025; P-value: 9.509294351575039e-07\n",
      "Partial: Significance: True; Test Statistic: 13.58695652173913; P-value: 0.00022776260245036984\n"
     ]
    }
   ],
   "source": [
    "exact_result_ls=[]\n",
    "partial_result_ls=[]\n",
    "exact_result_pval=[]\n",
    "partial_result_pval=[]\n",
    "exact_result_bc=[]\n",
    "partial_result_bc=[]\n",
    "pooled_exact = np.array([[0, 0], [0, 0]])\n",
    "pooled_partial = np.array([[0, 0], [0, 0]])\n",
    "\n",
    "for i in range(5):\n",
    "    # run mcnemar's test separately\n",
    "    exact_result, exact_bc = conduct_mcnemar_test(exact_table_ls[i])\n",
    "    partial_result, partial_bc = conduct_mcnemar_test(partial_table_ls[i])\n",
    "    exact_result_ls.append(exact_result)\n",
    "    partial_result_ls.append(partial_result)\n",
    "    \n",
    "    # pool matrix\n",
    "    pooled_exact += np.array(exact_table_ls[i])\n",
    "    pooled_partial += np.array(partial_table_ls[i])\n",
    "\n",
    "    # mcnemar's p-values\n",
    "    exact_result_pval.append(exact_result.pvalue)\n",
    "    partial_result_pval.append(partial_result.pvalue)\n",
    "    \n",
    "    # get discordant (b,c) values (if b > c, model A is better)\n",
    "    exact_result_bc.append(exact_bc)\n",
    "    partial_result_bc.append(partial_bc)\n",
    "\n",
    "# run mcnemar's test on pooled matrix\n",
    "pooled_exact_result, pooled_exact_bc = conduct_mcnemar_test(pooled_exact) \n",
    "pooled_partial_result, pooled_partial_bc = conduct_mcnemar_test(pooled_partial)\n",
    "\n",
    "print(f'Exact: {print_mcnemar_res(pooled_exact_result, alpha=0.05)}')\n",
    "print(f'Partial: {print_mcnemar_res(pooled_partial_result, alpha=0.05)}')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([1.90185887e-06, 2.27762602e-04])"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# multiple test correction\n",
    "_, p_corrected, _, _ = multipletests([pooled_exact_result.pvalue, pooled_partial_result.pvalue], alpha=0.05, method='fdr_bh')\n",
    "p_corrected"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Calculate mean precision, recall, F1 score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "def compute_metric_mean(metric_name, results_dict, strategy, idx_list, n_runs: int=5) -> float:\n",
    "    \"\"\"Compute the mean of a metric over selected questions (e.g. with on-label FDA-approved drugs) across multiple runs\"\"\"\n",
    "    means = []\n",
    "    for x in range(n_runs):\n",
    "        values = [\n",
    "            val for i, val in enumerate(results_dict[strategy]['full'][x][metric_name])\n",
    "            if i in idx_list\n",
    "        ]\n",
    "        means.append(np.mean(values))\n",
    "    return np.mean(means)\n",
    "\n",
    "fda_questions_idx = real_questions[real_questions['Is_there_an_approval'] == True].index\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Avg Precision: 99.0000\n",
      "Avg Recall: 82.5758\n",
      "Avg F1: 86.1667\n",
      "Exact acc: 70.0\n",
      "Partial acc: 100.0\n"
     ]
    }
   ],
   "source": [
    "# Strategy 4 - without out-of-scope JSON schema instruction\n",
    "for metric in ['precision_ls','recall_ls','f1_ls']:\n",
    "    avg = compute_metric_mean(\n",
    "        metric_name=metric,\n",
    "        results_dict=all_real_results,\n",
    "        strategy=4,\n",
    "        idx_list=fda_questions_idx\n",
    "        )\n",
    "    print(f\"Avg {metric.replace('_ls','').capitalize()}: {avg*100:.4f}\")\n",
    "print(f\"Exact acc: {np.sum([all_real_results[4]['full'][0]['exact_match_acc'][ind] for ind in fda_questions_idx])/len(fda_questions_idx) * 100}\")\n",
    "print(f\"Partial acc: {np.sum([all_real_results[4]['full'][0]['partial_match_acc'][ind] for ind in fda_questions_idx])/len(fda_questions_idx) * 100}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Avg Precision: 80.0000\n",
      "Avg Recall: 67.4545\n",
      "Avg F1: 70.0128\n",
      "Exact acc: 60.0\n",
      "Partial acc: 80.0\n"
     ]
    }
   ],
   "source": [
    "# Strategy 5 - with out-of-scope schema instruction\n",
    "for metric in ['precision_ls','recall_ls','f1_ls']:\n",
    "    avg = compute_metric_mean(\n",
    "        metric_name=metric,\n",
    "        results_dict=all_real_results,\n",
    "        strategy=5,\n",
    "        idx_list=fda_questions_idx\n",
    "        )\n",
    "    print(f\"Avg {metric.replace('_ls','').capitalize()}: {avg*100:.4f}\")\n",
    "print(f\"Exact acc: {np.sum([all_real_results[5]['full'][0]['exact_match_acc'][ind] for ind in fda_questions_idx])/len(fda_questions_idx) * 100}\")\n",
    "print(f\"Partial acc: {np.sum([all_real_results[5]['full'][0]['partial_match_acc'][ind] for ind in fda_questions_idx])/len(fda_questions_idx) * 100}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Figure S1. Distribution of structured/unstructured context length"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "# function to calculate IQR (interquartile range)\n",
    "def calc_iqr(chunk_size_list):\n",
    "    q1 = np.percentile(chunk_size_list, 25)\n",
    "    q3 = np.percentile(chunk_size_list, 75)\n",
    "    iqr = f'{q1}-{q3}'\n",
    "    return(iqr)\n",
    "\n",
    "# import tiktoken\n",
    "import tiktoken\n",
    "encoding = tiktoken.encoding_for_model(\"gpt-4o\")  # or \"gpt-4\", \"gpt-3.5-turbo\", etc."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Unstructured dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "56"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# load unstructured context derived from FDA drug label indication and usage sections (deduplicated, full)\n",
    "with open(os.path.join(root_dir,\"data/unstructured_context_chunks.json\"), \"r\") as f:\n",
    "    unstructured_dataset = json.load(f)\n",
    "    \n",
    "len(unstructured_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 56\n",
      "Min: 47\n",
      "Max: 2476\n",
      "Mean: 238.16071428571428\n",
      "Median: 162.0\n",
      "IQR: 126.75-239.5\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# get chunk size in tokens\n",
    "unstruc_chunk_size=[len(encoding.encode(chunk)) for chunk in unstructured_dataset]\n",
    "print(\"# chunks: \"+str(len(unstruc_chunk_size)))\n",
    "print(\"Min: \"+str(np.min(unstruc_chunk_size)))\n",
    "print(\"Max: \"+str(np.max(unstruc_chunk_size)))\n",
    "print(\"Mean: \"+str(np.mean(unstruc_chunk_size)))\n",
    "print(\"Median: \"+str(np.median(unstruc_chunk_size)))\n",
    "print(\"IQR: \"+str(calc_iqr(unstruc_chunk_size)))\n",
    "\n",
    "# set figure size and subplot\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "fig, ax = plt.subplots(tight_layout=True, figsize=(4,3))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# histogram with KDE\n",
    "n_bins=35\n",
    "sns.histplot(unstruc_chunk_size, bins=n_bins, kde=True, stat='count',\n",
    "             color='royalblue', alpha=0.5, edgecolor='white', ax=ax)\n",
    "\n",
    "# median line\n",
    "plt.axvline(np.median(unstruc_chunk_size), color='black', \n",
    "            linestyle='--', linewidth=1.5, label='Median', alpha=1)\n",
    "\n",
    "# x, y labels and ticks\n",
    "ax.set_xlabel('Length of unstructured indication section', fontsize=11)\n",
    "ax.set_ylabel('Frequency', fontsize=11) # raw counts\n",
    "\n",
    "# remove top and right border\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# add the legend\n",
    "# plt.legend()\n",
    "ax.legend(ncol=1, frameon=False)\n",
    "\n",
    "# save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig('./figures/FigureS1_unstructuredlength_dist.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Structured dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "234"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# load structured context derived from moalmanac data fields\n",
    "with open(os.path.join(root_dir,\"data/structured_context_chunks.json\"), \"r\") as f:\n",
    "    structured_dataset = json.load(f)\n",
    "\n",
    "len(structured_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 234\n",
      "Min: 130\n",
      "Max: 284\n",
      "Mean: 187.10683760683762\n",
      "Median: 181.0\n",
      "IQR: 165.0-203.5\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# get chunk size\n",
    "struc_chunk_size=[len(encoding.encode(chunk)) for chunk in structured_dataset]\n",
    "print(\"# chunks: \"+str(len(struc_chunk_size)))\n",
    "print(\"Min: \"+str(np.min(struc_chunk_size)))\n",
    "print(\"Max: \"+str(np.max(struc_chunk_size)))\n",
    "print(\"Mean: \"+str(np.mean(struc_chunk_size)))\n",
    "print(\"Median: \"+str(np.median(struc_chunk_size)))\n",
    "print(\"IQR: \"+str(calc_iqr(struc_chunk_size)))\n",
    "\n",
    "# set figure size and subplot\n",
    "plt.rcParams[\"figure.figsize\"] = [3.5, 3]\n",
    "fig, ax = plt.subplots(tight_layout=True, figsize=(4,3))\n",
    "\n",
    "# set color palette\n",
    "cols=sns.color_palette(cc.glasbey, n_colors=40)\n",
    "\n",
    "# histogram with KDE\n",
    "n_bins=35\n",
    "sns.histplot(struc_chunk_size, bins=n_bins, kde=True, stat='count',\n",
    "             color='royalblue', alpha=0.5, edgecolor='white', ax=ax)\n",
    "\n",
    "# median line\n",
    "plt.axvline(np.median(struc_chunk_size), color='black', \n",
    "            linestyle='--', linewidth=1.5, label='Median', alpha=1)\n",
    "\n",
    "# x, y labels and ticks\n",
    "ax.set_xlabel('Length of structured indication section', fontsize=11)\n",
    "ax.set_ylabel('Frequency', fontsize=11) # raw counts\n",
    "\n",
    "# remove top and right border\n",
    "ax.spines['top'].set_visible(False)\n",
    "ax.spines['right'].set_visible(False)\n",
    "\n",
    "# add legend\n",
    "ax.legend(ncol=1, frameon=False)\n",
    "\n",
    "# save plot\n",
    "save = False\n",
    "if save == True:\n",
    "    plt.savefig('./figures/FigureS1_structuredlength_dist.jpeg', dpi=500, bbox_inches='tight')\n",
    "\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Supplementary Note 1-2. Example of synthetic prompt and output from RAG-LLM "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Unstructured version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['INDICATIONS AND USAGE  --------------------------  \\nLynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \\nOvarian cancer \\n for the maintenance treatment of adult patients with deleterious or \\nsuspected deleterious germline or somatic BRCA-mutated advanced \\nepithelial ovarian, fallopian tube or primary peritoneal cancer who are in \\ncomplete or partial response to first-line platinum-based chemotherapy. \\nSelect patients for therapy based on an FDA-approved companion \\ndiagnostic for Lynparza. (1.1, 2.1) \\n in combination with bevacizumab for the maintenance treatment of adult \\npatients with advanced epithelial ovarian, fallopian tube or primary \\nperitoneal cancer who are in complete or partial response to first-line \\nplatinum-based chemotherapy and whose cancer is associated with \\nhomologous recombination deficiency (HRD)-positive status defined by \\neither: \\n a deleterious or suspected deleterious BRCA mutation, and/or  \\n genomic instability.  \\nSelect patients for therapy based on an FDA-approved companion \\ndiagnostic for Lynparza (1.2, 2.1). \\n for the maintenance treatment of adult patients with recurrent epithelial \\novarian, fallopian tube or primary peritoneal cancer, who are in \\ncomplete or partial response to platinum-based chemotherapy. (1.3) \\nBreast cancer \\n for the adjuvant treatment of adult patients with deleterious or suspected \\ndeleterious gBRCAm human epidermal growth factor receptor 2 \\n(HER2)-negative high risk early breast cancer who have been treated \\nwith neoadjuvant or adjuvant chemotherapy. Select patients for therapy \\nbased on an FDA-approved companion diagnostic for Lynparza. (1.4, \\n2.1). \\n for the treatment of adult patients with deleterious or suspected \\ndeleterious gBRCAm, HER2-negative metastatic breast cancer who have \\nbeen treated with chemotherapy in the neoadjuvant, adjuvant or \\nmetastatic setting. Patients with hormone receptor (HR)-positive breast \\ncancer should have been treated with a prior endocrine therapy or be \\nconsidered inappropriate for endocrine therapy. Select patients for \\ntherapy based on an FDA-approved companion diagnostic for Lynparza. \\n(1.5, 2.1) \\nPancreatic cancer \\n for the maintenance treatment of adult patients with deleterious or \\nsuspected deleterious gBRCAm metastatic pancreatic adenocarcinoma \\nwhose disease has not progressed on at least 16 weeks of a first-line \\nplatinum-based chemotherapy regimen. Select patients for therapy based \\non an FDA-approved companion diagnostic for Lynparza. (1.6, 2.1) \\nProstate cancer \\n for the treatment of adult patients with deleterious or suspected \\ndeleterious germline or somatic homologous recombination repair \\n(HRR) gene-mutated metastatic castration-resistant prostate cancer \\n(mCRPC) who have progressed following prior treatment with \\nenzalutamide or abiraterone. Select patients for therapy based on an \\nFDA-approved companion diagnostic for Lynparza. (1.7, 2.1) \\n in combination with abiraterone and prednisone or prednisolone for the \\ntreatment of adult patients with deleterious or suspected deleterious \\nBRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer \\n(mCRPC). Select patients for therapy based on an FDA-approved \\ncompanion diagnostic for Lynparza. (1.8, 2.1) \\n ----------------------', 'INDICATIONS AND USAGE---------------------------\\xad\\nRUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \\nOvarian cancer \\n\\t for the maintenance treatment of adult patients with recurrent epithelial \\novarian, fallopian tube, or primary peritoneal cancer who are in a complete \\nor partial response to platinum-based chemotherapy. (1.1) \\n\\t for the treatment of adult patients with a deleterious BRCA mutation \\n(germline and/or somatic)-associated epithelial ovarian, fallopian tube, or \\nprimary peritoneal cancer who have been treated with two or more \\nchemotherapies. Select patients for therapy based on an FDA-approved \\ncompanion diagnostic for RUBRACA. (1.1, 2.1) \\nProstate cancer \\n\\t for the treatment of adult patients with a deleterious BRCA mutation \\n(germline and/or somatic)-associated metastatic castration-resistant prostate \\ncancer (mCRPC) who have been treated with androgen receptor-directed \\ntherapy and a taxane-based chemotherapy. Select patients for therapy based \\non an FDA-approved companion diagnostic for RUBRACA. (1.2, 2.1) \\nThis indication is approved under accelerated approval based on objective \\nresponse rate and duration of response. Continued approval for this \\nindication may be contingent upon verification and description of clinical \\nbenefit in confirmatory trials. (1.2) \\n-----------------------', 'INDICATIONS AND USAGE----------------------------\\nKEYTRUDA is a programmed death receptor-1 (PD-1)-blocking \\nantibody indicated: \\nMelanoma \\n for the treatment of patients with unresectable or metastatic \\nmelanoma. (1.1) \\n for the adjuvant treatment of adult and pediatric (12 years and \\nolder) patients with Stage IIB, IIC, or III melanoma following \\ncomplete resection. (1.1) \\nNon-Small Cell Lung Cancer (NSCLC) \\n in combination with pemetrexed and platinum chemotherapy, \\nas first-line treatment of patients with metastatic nonsquamous \\nNSCLC, with no EGFR or ALK genomic tumor aberrations. \\n(1.2) \\n in combination with carboplatin and either paclitaxel or \\npaclitaxel protein-bound, as first-line treatment of patients with \\nmetastatic squamous NSCLC. (1.2) \\n as a single agent for the first-line treatment of patients with \\nNSCLC expressing PD-L1 [Tumor Proportion Score (TPS) \\n1%] as determined by an FDA-approved test, with no EGFR \\nor ALK genomic tumor aberrations, and is: \\no Stage III where patients are not candidates for surgical \\nresection or definitive chemoradiation, or \\no metastatic. (1.2, 2.1) \\n as a single agent for the treatment of patients with metastatic \\nNSCLC whose tumors express PD-L1 (TPS 1%) as \\ndetermined by an FDA-approved test, with disease \\nprogression on or after platinum-containing chemotherapy. \\nPatients with EGFR or ALK genomic tumor aberrations should \\nhave disease progression on FDA-approved therapy for these \\naberrations prior to receiving KEYTRUDA. (1.2, 2.1) \\n for the treatment of patients with resectable (tumors 4 cm or \\nnode positive) NSCLC in combination with platinum-containing \\nchemotherapy as neoadjuvant treatment, and then continued \\nas a single agent as adjuvant treatment after surgery. (1.2) \\n as a single agent, for adjuvant treatment following resection \\nand platinum-based chemotherapy for adult patients with \\nStage IB (T2a 4 cm), II, or IIIA NSCLC. (1.2) \\nHead and Neck Squamous Cell Cancer (HNSCC) \\n in combination with platinum and FU for the first-line treatment \\nof patients with metastatic or with unresectable, recurrent \\nHNSCC. (1.3) \\n as a single agent for the first-line treatment of patients with \\nmetastatic or with unresectable, recurrent HNSCC whose \\ntumors express PD-L1 [Combined Positive Score (CPS) 1] as \\ndetermined by an FDA-approved test. (1.3, 2.1) \\n as a single agent for the treatment of patients with recurrent or \\nmetastatic HNSCC with disease progression on or after \\nplatinum-containing chemotherapy. (1.3) \\nClassical Hodgkin Lymphoma (cHL) \\n for the treatment of adult patients with relapsed or refractory \\ncHL. (1.4) \\n for the treatment of pediatric patients with refractory cHL, or \\ncHL that has relapsed after 2 or more lines of therapy. (1.4) \\nPrimary Mediastinal Large B-Cell Lymphoma (PMBCL) \\n for the treatment of adult and pediatric patients with refractory \\nPMBCL, or who have relapsed after 2 or more prior lines of \\ntherapy. (1.5) \\n Limitations of Use: KEYTRUDA is not recommended for \\ntreatment of patients with PMBCL who require urgent \\ncytoreductive therapy. \\nUrothelial Carcinoma \\n in combination with enfortumab vedotin, for the treatment of \\nadult patients with locally advanced or metastatic urothelial \\ncarcinoma who are not eligible for cisplatin-containing \\nchemotherapy.1 (1.6) \\n as a single agent for the treatment of patients with locally \\nadvanced or metastatic urothelial carcinoma who: \\no are not eligible for any platinum-containing \\nchemotherapy, or \\no who have disease progression during or following \\nplatinum-containing chemotherapy or within 12 months of \\nneoadjuvant or adjuvant treatment with platinum-\\ncontaining chemotherapy. (1.6) \\n as a single agent for the treatment of patients with Bacillus \\nCalmette-Guerin (BCG)-unresponsive, high-risk, non-muscle \\ninvasive bladder cancer (NMIBC) with carcinoma in situ (CIS) \\nwith or without papillary tumors who are ineligible for or have \\nelected not to undergo cystectomy. (1.6) \\nMicrosatellite Instability-High or Mismatch Repair Deficient Cancer \\n for the treatment of adult and pediatric patients with \\nunresectable or metastatic microsatellite instability-high \\n(MSI-H) or mismatch repair deficient (dMMR) solid tumors, as \\ndetermined by an FDA-approved test, that have progressed \\nfollowing prior treatment and who have no satisfactory \\nalternative treatment options. (1.7, 2.1) \\nMicrosatellite Instability-High or Mismatch Repair Deficient \\nColorectal Cancer (CRC) \\n for the treatment of patients with unresectable or metastatic \\nMSI-H or dMMR colorectal cancer (CRC) as determined by an \\nFDA-approved test. (1.8, 2.1) \\nGastric Cancer \\n in combination with trastuzumab, fluoropyrimidine- and \\nplatinum-containing chemotherapy, for the first-line treatment \\nof patients with locally advanced unresectable or metastatic \\nHER2-positive gastric or gastroesophageal junction (GEJ) \\nadenocarcinoma whose tumors express PD-L1 (CPS 1) as \\ndetermined by an FDA-approved test.1 (1.9) \\nEsophageal Cancer \\n for the treatment of patients with locally advanced or metastatic \\nesophageal or gastroesophageal junction (GEJ) (tumors with \\nepicenter 1 to 5 centimeters above the GEJ) carcinoma that is \\nnot amenable to surgical resection or definitive chemoradiation \\neither: \\no in combination with platinum- and fluoropyrimidine-based \\nchemotherapy, or \\no as a single agent after one or more prior lines of systemic \\ntherapy for patients with tumors of squamous cell \\nhistology that express PD-L1 (CPS 10) as determined \\nby an FDA-approved test. (1.10, 2.1) \\nCervical Cancer \\n in combination with chemotherapy, with or without \\nbevacizumab, for the treatment of patients with persistent, \\nrecurrent, or metastatic cervical cancer whose tumors express \\nPD-L1 (CPS 1) as determined by an FDA-approved test. \\n(1.11, 2.1) \\n as a single agent for the treatment of patients with recurrent or \\nmetastatic cervical cancer with disease progression on or after \\nchemotherapy whose tumors express PD-L1 (CPS 1) as \\ndetermined by an FDA-approved test. (1.11, 2.1) \\nHepatocellular Carcinoma (HCC) \\n for the treatment of patients with HCC who have been \\npreviously treated with sorafenib.1 (1.12) \\nBiliary Tract Cancer (BTC) \\n in combination with gemcitabine and cisplatin, for the \\ntreatment of patients with locally advanced unresectable or \\nmetastatic biliary tract cancer. (1.13) \\nMerkel Cell Carcinoma (MCC) \\n for the treatment of adult and pediatric patients with recurrent \\nlocally advanced or metastatic Merkel cell carcinoma. (1.14) \\nRenal Cell Carcinoma (RCC) \\n in combination with axitinib, for the first-line treatment of adult \\npatients with advanced RCC. (1.15) \\n in combination with lenvatinib, for the first-line treatment of \\nadult patients with advanced RCC. (1.15) \\n for the adjuvant treatment of patients with RCC at \\nintermediate-high or high risk of recurrence following \\nReference ID: 5274826 \\nThis label may not be the latest approved by FDA.  \\nFor current labeling information, please visit https://www.fda.gov/drugsatfda  \\nnephrectomy, or following nephrectomy and resection of \\nmetastatic lesions. (1.15) \\nEndometrial Carcinoma \\n in combination with lenvatinib, for the treatment of patients with \\nadvanced endometrial carcinoma that is mismatch repair \\nproficient (pMMR) as determined by an FDA-approved test or \\nnot MSI-H, who have disease progression following prior \\nsystemic therapy in any setting and are not candidates for \\ncurative surgery or radiation. (1.16, 2.1) \\n as a single agent, for the treatment of patients with advanced \\nendometrial carcinoma that is MSI-H or dMMR, as determined \\nby an FDA-approved test, who have disease progression \\nfollowing prior systemic therapy in any setting and are not \\ncandidates for curative surgery or radiation. (1.16, 2.1) \\nTumor Mutational Burden-High (TMB-H) Cancer \\n for the treatment of adult and pediatric patients with \\nunresectable or metastatic tumor mutational burden-high \\n(TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as \\ndetermined by an FDA-approved test, that have progressed \\nfollowing prior treatment and who have no satisfactory \\nalternative treatment options.1 (1.17, 2.1) \\n Limitations of Use: The safety and effectiveness of \\nKEYTRUDA in pediatric patients with TMB-H central nervous \\nsystem cancers have not been established. \\nCutaneous Squamous Cell Carcinoma (cSCC) \\n for the treatment of patients with recurrent or metastatic cSCC \\nor locally advanced cSCC that is not curable by surgery or \\nradiation. (1.18) \\nTriple-Negative Breast Cancer (TNBC) \\n for the treatment of patients with high-risk early-stage TNBC in \\ncombination with chemotherapy as neoadjuvant treatment, and \\nthen continued as a single agent as adjuvant treatment after \\nsurgery. (1.19) \\n in combination with chemotherapy, for the treatment of \\npatients with locally recurrent unresectable or metastatic \\nTNBC whose tumors express PD-L1 (CPS 10) as determined \\nby an FDA approved test. (1.19, 2.1) \\nAdult Classical Hodgkin Lymphoma and Adult Primary Mediastinal \\nLarge B-Cell Lymphoma: Additional Dosing Regimen of 400 mg \\nEvery 6 Weeks \\n for use at an additional recommended dosage of 400 mg every \\n6 weeks for Classical Hodgkin Lymphoma and Primary \\nMediastinal Large B-Cell Lymphoma in adults.2 (1.20, 2.2) \\n1 This indication is approved under accelerated approval based on \\ntumor response rate and durability of response. Continued \\napproval for this indication may be contingent upon verification \\nand description of clinical benefit in the confirmatory trials. \\n2 This indication is approved under accelerated approval based on \\npharmacokinetic data, the relationship of exposure to efficacy, \\nand the relationship of exposure to safety. Continued approval for \\nthis dosing may be contingent upon verification and description of \\nclinical benefit in the confirmatory trials. \\n-----------------------', 'INDICATIONS AND USAGE---------------------------\\nAKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase \\n(PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with \\nprednisone for the treatment of adult patients with deleterious or suspected \\ndeleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate \\ncancer (mCRPC). Select patients for therapy based on an FDA-approved test \\nfor AKEEGA. (1, 2.1) \\n------------------------', 'INDICATIONS AND USAGE----------------------------\\nTALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated \\nfor: \\nBreast Cancer \\n As a single agent, for the treatment of adult patients with deleterious or \\nsuspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative \\nlocally advanced or metastatic breast cancer. Select patients for therapy \\nbased on an FDA-approved companion diagnostic for TALZENNA. (1.1) \\nHRR Gene-mutated mCRPC \\n In combination with enzalutamide for the treatment of adult patients with \\nHRR gene-mutated metastatic castration-resistant prostate cancer \\n(mCRPC). (1.2) \\n----------------------', 'INDICATIONS AND USAGE---------------------------\\nBALVERSA is a kinase inhibitor indicated for the treatment of adult patients \\nwith locally advanced or metastatic urothelial carcinoma (mUC) with \\nsusceptible FGFR3 genetic alterations whose disease has progressed on or \\nafter at least one line of prior systemic therapy. \\nSelect patients for therapy based on an FDA-approved companion diagnostic \\nfor BALVERSA. (1, 2.1) \\nLimitations of Use \\nBALVERSA is not recommended for the treatment of patients who are \\neligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (1, \\n14.1) \\n------------------------', 'INDICATIONS AND USAGE-------------------------\\nBRAFTOVI is a kinase inhibitor indicated: \\n\\uf0b7 in combination with binimetinib, for the treatment of patients with \\nunresectable or metastatic melanoma with a BRAF V600E or V600K \\nmutation, as detected by an FDA-approved test. (1.1, 2.1)\\n\\uf0b7 in combination with cetuximab, for the treatment of adult patients \\nwith metastatic colorectal cancer (CRC) with a BRAF V600E \\nmutation, as detected by an FDA-approved test, after prior therapy. \\n(1.2, 2.1)\\n\\uf0b7 in combination with binimetinib, for the treatment of adult patients \\nwith metastatic non-small cell lung cancer (NSCLC) with a BRAF \\nV600E mutation, as detected by an FDA-approved test. (1.3, 2.1)\\nLimitations of Use\\nBRAFTOVI is not indicated for treatment of patients with wild-type BRAF \\nmelanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. (1.4, 5.2)\\n---------------------', 'INDICATIONS AND USAGE------------------------------ \\nTYKERB is a kinase inhibitor indicated in combination with: (1) \\n\\uf0b7 capecitabine for the treatment of patients with advanced or metastatic breast \\ncancer whose tumors overexpress human epidermal growth factor receptor 2 \\n(HER2) and who have received prior therapy including an anthracycline, a \\ntaxane, and trastuzumab. \\nLimitations of Use: Patients should have disease progression on trastuzumab \\nprior to initiation of treatment with TYKERB in combination with capecitabine. \\n\\uf0b7 letrozole for the treatment of postmenopausal women with hormone receptor-\\npositive metastatic breast cancer that overexpresses the HER2 receptor for \\nwhom hormonal therapy is indicated. \\nTYKERB in combination with an aromatase inhibitor has not been compared to a \\ntrastuzumab-containing chemotherapy regimen for the treatment of metastatic \\nbreast cancer. \\n----------------------------', 'INDICATIONS AND USAGE---------------------------\\nRYBREVANT is a bispecific EGF receptor-directed and MET receptor-\\ndirected antibody indicated: \\n in combination with carboplatin and pemetrexed for the first-line treatment \\nof adult patients with locally advanced or metastatic non-small cell lung cancer \\n(NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion \\nmutations, as detected by an FDA-approved test. (1, 2.2) \\n as a single agent for the treatment of adult patients with locally advanced or \\nmetastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an \\nFDA-approved test, whose disease has progressed on or after platinum-based \\nchemotherapy. (1, 2.2) \\n------------------------', 'INDICATIONS AND USAGE -------------------------\\xad\\nSTIVARGA is a kinase inhibitor indicated for the treatment of patients with: \\n Metastatic colorectal cancer (CRC) who have been previously treated with \\nfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-\\nVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. (1.1) \\n Locally advanced, unresectable or metastatic gastrointestinal stromal tumor \\n(GIST) who have been previously treated with imatinib mesylate and \\nsunitinib malate. (1.2) \\n Hepatocellular carcinoma (HCC) who have been previously treated with \\nsorafenib (1.3) \\n----------------------']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# Input prompt\n",
    "print(rag_unstruc_res_dict_0['input prompt'][0][180])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Lynparza\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"Deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.fda.gov/drugsatfda\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Lynparza in combination with abiraterone and prednisone or prednisolone\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Deleterious or suspected deleterious BRCA-mutated (BRCAm)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.fda.gov/drugsatfda\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"RUBRACA\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Treated with androgen receptor-directed therapy and a taxane-based chemotherapy\",\n",
      "        \"Genomic Features\": \"Deleterious BRCA mutation (germline and/or somatic)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.fda.gov/drugsatfda\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"AKEEGA (niraparib and abiraterone acetate) with prednisone\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Deleterious or suspected deleterious BRCA-mutated (BRCAm)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.fda.gov/drugsatfda\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"TALZENNA in combination with enzalutamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"HRR gene-mutated\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.fda.gov/drugsatfda\"\n",
      "    }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# RAG-LLM response\n",
    "print(rag_unstruc_res_dict_0['full output'][0][180])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Structured version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# Input prompt\n",
    "print(rag_struc_res_dict_0['input prompt'][0][180])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Enzalutamide + Talazoparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# RAG-LLM response \n",
    "print(rag_struc_res_dict_0['full output'][0][180])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Quick error analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"epithelial ovarian cancer\",\n",
      "        \"Disease Phase or Condition\": \"advanced\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"treated with three or more prior lines of chemotherapy\",\n",
      "        \"Genomic Features\": \"somatic variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'niraparib'})}\n",
      "Predicted drugs: {frozenset({'olaparib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"epithelial ovarian cancer\",\n",
      "        \"Disease Phase or Condition\": \"advanced\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"treated with three or more prior lines of chemotherapy\",\n",
      "        \"Genomic Features\": \"somatic variant in gene BRCA2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'niraparib'})}\n",
      "Predicted drugs: {frozenset({'olaparib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Alpelisib + Fulvestrant\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Following progression on or after an endocrine-based regimen\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene PIK3CA\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Locally Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Capivasertib + Fulvestrant\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene PIK3CA\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'alpelisib'})}\n",
      "Predicted drugs: {frozenset({'fulvestrant', 'capivasertib'}), frozenset({'fulvestrant', 'alpelisib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"epithelial ovarian cancer\",\n",
      "        \"Disease Phase or Condition\": \"advanced\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"treated with three or more prior lines of chemotherapy\",\n",
      "        \"Genomic Features\": \"germline variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'niraparib'})}\n",
      "Predicted drugs: {frozenset({'olaparib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"epithelial ovarian cancer\",\n",
      "        \"Disease Phase or Condition\": \"advanced\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"treated with three or more prior lines of chemotherapy\",\n",
      "        \"Genomic Features\": \"germline variant in gene BRCA1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'niraparib'})}\n",
      "Predicted drugs: {frozenset({'olaparib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"epithelial ovarian cancer\",\n",
      "        \"Disease Phase or Condition\": \"advanced\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"treated with three or more prior lines of chemotherapy\",\n",
      "        \"Genomic Features\": \"germline variant in gene BRCA2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'niraparib'})}\n",
      "Predicted drugs: {frozenset({'olaparib'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Margetuximab-cmkb + Chemotherapy\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Lapatinib + Capecitabine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received prior therapy including an anthracycline, a taxane, and trastuzumab; disease progression on trastuzumab\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Neratinib + Capecitabine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received two or more prior anti-HER2 based regimens in the metastatic setting\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Previously received trastuzumab and a taxane, separately or in combination; received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not received prior anti-HER2 therapy or chemotherapy for metastatic disease\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'chemotherapy', 'margetuximab-cmkb'}), frozenset({'hyaluronidase-zzxf', 'docetaxel', 'pertuzumab', 'trastuzumab'})}\n",
      "Predicted drugs: {frozenset({'capecitabine', 'lapatinib'}), frozenset({'chemotherapy', 'margetuximab-cmkb'}), frozenset({'capecitabine', 'neratinib'}), frozenset({'ado-trastuzumab emtansine'}), frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Margetuximab-cmkb + Chemotherapy\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Lapatinib + Capecitabine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received prior therapy including an anthracycline, a taxane, and trastuzumab; disease progression on trastuzumab\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Neratinib + Capecitabine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received two or more prior anti-HER2 based regimens in the metastatic setting\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Previously received trastuzumab and a taxane, separately or in combination; received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Breast Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab + Docetaxel\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not received prior anti-HER2 therapy or chemotherapy for metastatic disease\",\n",
      "        \"Genomic Features\": \"Copy number in gene ERBB2\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'chemotherapy', 'margetuximab-cmkb'}), frozenset({'hyaluronidase-zzxf', 'docetaxel', 'pertuzumab', 'trastuzumab'})}\n",
      "Predicted drugs: {frozenset({'capecitabine', 'lapatinib'}), frozenset({'chemotherapy', 'margetuximab-cmkb'}), frozenset({'capecitabine', 'neratinib'}), frozenset({'ado-trastuzumab emtansine'}), frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed or relapsed/refractory\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'olutasidenib'})}\n",
      "Predicted drugs: {frozenset({'ivosidenib'}), frozenset({'ivosidenib', 'azacitidine'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene IDH1 (c.395G>A or p.R132H)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene IDH1 (c.395G>A or p.R132H)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'olutasidenib'})}\n",
      "Predicted drugs: {frozenset({'ivosidenib'}), frozenset({'ivosidenib', 'azacitidine'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.395G>A or p.R132H)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.395G>A or p.R132H)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'olutasidenib'})}\n",
      "Predicted drugs: {frozenset({'ivosidenib'}), frozenset({'ivosidenib', 'azacitidine'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>A or p.R132S)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"IDH1 (c.394C>A or p.R132S)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'olutasidenib'})}\n",
      "Predicted drugs: {frozenset({'ivosidenib'}), frozenset({'ivosidenib', 'azacitidine'})}\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene IDH1 (c.395G>T or p.R132L)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene IDH1 (c.395G>T or p.R132L)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Relapsed or refractory AML\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Relapsed or refractory\",\n",
      "        \"Genomic Features\": \"Somatic variant in gene IDH1 (c.395G>T or p.R132L)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "True drugs: {frozenset({'olutasidenib'})}\n",
      "Predicted drugs: {frozenset({'ivosidenib'}), frozenset({'ivosidenib', 'azacitidine'})}\n"
     ]
    }
   ],
   "source": [
    "exact_failed=[i for i, e in enumerate(struc_results['exact_match_acc']) if e == False]\n",
    "for i in exact_failed:\n",
    "    print(f\"Input prompt: {rag_struc_res_dict_0['input prompt'][0][i]}\")\n",
    "    print(f\"RAG-LLM output: {rag_struc_res_dict_0['full output'][0][i]}\")\n",
    "    print(f\"True drugs: {struc_results['true_drugs_generic_set_ls'][i]}\")\n",
    "    print(f\"Predicted drugs: {struc_results['pred_drugs_generic_set_ls'][i]}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "disease",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "proportion",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "9ccde4f0-a7a5-4009-93c4-030ca3a5b564",
       "rows": [
        [
         "Ovarian Cancer",
         "5",
         "0.38461538461538464"
        ],
        [
         "Acute Myeloid Leukemia",
         "5",
         "0.38461538461538464"
        ],
        [
         "Breast Cancer",
         "3",
         "0.23076923076923078"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 3
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>count</th>\n",
       "      <th>proportion</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>disease</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Ovarian Cancer</th>\n",
       "      <td>5</td>\n",
       "      <td>0.384615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Acute Myeloid Leukemia</th>\n",
       "      <td>5</td>\n",
       "      <td>0.384615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Breast Cancer</th>\n",
       "      <td>3</td>\n",
       "      <td>0.230769</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        count  proportion\n",
       "disease                                  \n",
       "Ovarian Cancer              5    0.384615\n",
       "Acute Myeloid Leukemia      5    0.384615\n",
       "Breast Cancer               3    0.230769"
      ]
     },
     "execution_count": 121,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "counts = moalmanac_data.iloc[exact_failed]['disease'].value_counts()\n",
    "proportions = moalmanac_data.iloc[exact_failed]['disease'].value_counts(normalize=True)\n",
    "pd.DataFrame({'count': counts, 'proportion': proportions})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "therapy_strategy",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "proportion",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "cb0b6d71-1e87-43f4-a882-f98a87278d3f",
       "rows": [
        [
         "PARP inhibition",
         "5",
         "0.38461538461538464"
        ],
        [
         "IDH1 inhibition",
         "5",
         "0.38461538461538464"
        ],
        [
         "PI3K/AKT/mTOR inhibition",
         "1",
         "0.07692307692307693"
        ],
        [
         "Taxane-based chemotherapy + ER signaling inhibition",
         "1",
         "0.07692307692307693"
        ],
        [
         "ER signaling inhibition + Chemotherapy",
         "1",
         "0.07692307692307693"
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>count</th>\n",
       "      <th>proportion</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>therapy_strategy</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>PARP inhibition</th>\n",
       "      <td>5</td>\n",
       "      <td>0.384615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>IDH1 inhibition</th>\n",
       "      <td>5</td>\n",
       "      <td>0.384615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PI3K/AKT/mTOR inhibition</th>\n",
       "      <td>1</td>\n",
       "      <td>0.076923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Taxane-based chemotherapy + ER signaling inhibition</th>\n",
       "      <td>1</td>\n",
       "      <td>0.076923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ER signaling inhibition + Chemotherapy</th>\n",
       "      <td>1</td>\n",
       "      <td>0.076923</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    count  proportion\n",
       "therapy_strategy                                                     \n",
       "PARP inhibition                                         5    0.384615\n",
       "IDH1 inhibition                                         5    0.384615\n",
       "PI3K/AKT/mTOR inhibition                                1    0.076923\n",
       "Taxane-based chemotherapy + ER signaling inhibi...      1    0.076923\n",
       "ER signaling inhibition + Chemotherapy                  1    0.076923"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "counts = moalmanac_data.iloc[exact_failed]['therapy_strategy'].value_counts()\n",
    "proportions = moalmanac_data.iloc[exact_failed]['therapy_strategy'].value_counts(normalize=True)\n",
    "pd.DataFrame({'count': counts, 'proportion': proportions})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Supplementary Note 3. Example real-world query without FDA-approved drugs available"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n",
      "Input prompt: \n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n",
      "     \n",
      "    \n",
      "RAG-LLM output: {\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "True drugs: []\n",
      "Predicted drugs: set()\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(real_questions)):\n",
    "    if real_questions.loc[i, 'Is_there_an_approval'] == False:\n",
    "        print(f\"Input prompt: {all_real_results[5]['ragllm_input'][0][i]}\")\n",
    "        print(f\"RAG-LLM output: {all_real_results[5]['ragllm_output'][0][i]}\")\n",
    "        print(f\"True drugs: {real_prompt_groundtruth_dict[real_questions.loc[i, 'prompt']]}\")\n",
    "        print(f\"Predicted drugs: {all_real_results[5]['full'][0]['pred_drugs_generic_set_ls'][i]}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n",
      "     \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "# An example of real-world expert query without FDA-approved drugs available\n",
    "i=2\n",
    "print(real_rag_res_dict_4['input prompt'][0][i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n",
      "        \"Disease Phase or Condition\": \"Relapsed or refractory, systemic\",\n",
      "        \"Drug Name\": \"Crizotinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Relapsed or refractory\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable, recurrent, or refractory\",\n",
      "        \"Drug Name\": \"Crizotinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Unresectable, recurrent, or refractory\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Ceritinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Crizotinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Lorlatinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Second- or third-line treatment\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 6\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Alectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"ALK-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n",
      "    }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# Full RAG-LLM's response from the corresponding real-world query\n",
    "i=2\n",
    "print(real_rag_res_dict_4['full output'][0][i])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After specifying a JSON schema for no approvals"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "# An example of real-world expert query without FDA-approved drugs available\n",
    "i=2\n",
    "print(real_rag_res_dict_5['input prompt'][0][i])\n",
    "print(real_rag_res_dict_5['full output'][0][i])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Merge real-world results for supplementary table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_selected_output_df(all_results_dict, selected_output, column_prefix):\n",
    "    df = pd.DataFrame.from_dict(all_results_dict[selected_output]).T\n",
    "    df = df.add_prefix(column_prefix)\n",
    "    return(df)\n",
    "\n",
    "strategy=5\n",
    "input_df=create_selected_output_df(all_real_results[strategy], 'ragllm_input', 'RAGLLM_input_prompt_')\n",
    "full_output_df=create_selected_output_df(all_real_results[strategy], 'ragllm_output', 'RAGLLM_full_output_')\n",
    "\n",
    "pred_drug_output_ls = list()\n",
    "for i in range(len(all_real_results[strategy]['full'])):\n",
    "    pred_drug_output_ls.append(all_real_results[strategy]['full'][i]['pred_drugs_generic_set_ls'])\n",
    "\n",
    "drug_output_df=pd.DataFrame(pred_drug_output_ls).T.add_prefix('RAGLLM_drug_output_')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Question_index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Asking_therapy",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Given_biomarker",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Question_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Is_there_an_approval",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Groundtruth_answers",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Groundtruth_therapies",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "matching_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "missing_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "hallucinating_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "no_output_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "RAGLLM_drug_output_0",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_2",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_3",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_4",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_full_output_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_4",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_4",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "8e45e410-d283-48a8-b931-1f1562daaece",
       "rows": [
        [
         "0",
         "q0",
         "What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "erdafitinib",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    "
        ],
        [
         "1",
         "q1",
         "Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    "
        ],
        [
         "2",
         "q2",
         "Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    "
        ],
        [
         "3",
         "q3",
         "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: olaparib; abiraterone, olaparib, and prednisone; enzalutamide and talazoparib; abiraterone acetate and niraparib; and rucaparib.",
         "[{'olaparib'}, {'prednisone', 'olaparib', 'abiraterone'}, {'talazoparib', 'enzalutamide'}, {'abiraterone acetate', 'niraparib'}, {'rucaparib'}]",
         "3",
         "2",
         "0",
         "0",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Prostate Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    "
        ],
        [
         "4",
         "q4",
         "For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "TDM-1 (ado-trastuzumab emtansine (Kadcyla))",
         "[{'ado-trastuzumab emtansine'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    "
        ],
        [
         "5",
         "q5",
         "For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, the TRK inhibitors Entrectinib and Larotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No known acquired resistance mutation, no satisfactory standard therapy or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    "
        ],
        [
         "6",
         "q6",
         "For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",
         "[{'pembrolizumab'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    "
        ],
        [
         "7",
         "q7",
         "What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    "
        ],
        [
         "8",
         "q8",
         "What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    "
        ],
        [
         "9",
         "q9",
         "A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    "
        ],
        [
         "10",
         "q10",
         "A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    "
        ],
        [
         "11",
         "q11",
         "I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    "
        ],
        [
         "12",
         "q12",
         "My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    "
        ],
        [
         "13",
         "q13",
         "For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    "
        ],
        [
         "14",
         "q14",
         "Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    "
        ],
        [
         "15",
         "q15",
         "For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    "
        ],
        [
         "16",
         "q16",
         "For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    "
        ],
        [
         "17",
         "q17",
         "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.",
         "[{'talazoparib'}, {'capivasertib', 'fulvestrant'}, {'olaparib'}]",
         "0",
         "3",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    "
        ],
        [
         "18",
         "q18",
         "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "While this version of MOAlmanac does not directly curate HER2+ status as a biomarker, a number of FDA approvals and companion diagnostics include ERBB2 amplifications for approvals based on HER2+. For FDA approvals for patients with breast cancer: Ado-Trastuzumab Emtansine; Capecitabine + Trastuzumab + Tucatinib; Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab; Lapatinib; Margetuximab-cmkb + Chemotherapy; Neratinib; Neratinib + Capecitabine; Pertuzumab + Trastuzumab; Trastuzumab; Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
         "[{'ado-trastuzumab emtansine'}, {'trastuzumab', 'tucatinib', 'capecitabine'}, {'trastuzumab', 'hyaluronidase-zzxf', 'pertuzumab', 'chemotherapy'}, {'lapatinib'}, {'chemotherapy', 'margetuximab-cmkb'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'trastuzumab', 'pertuzumab', 'hyaluronidase-zzxf', 'docetaxel'}, {'trastuzumab', 'pertuzumab', 'docetaxel'}]",
         "2",
         "9",
         "0",
         "0",
         "{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    "
        ],
        [
         "19",
         "q19",
         "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "True",
         "Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.",
         "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]",
         "0",
         "2",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "{\n    \"Status\": \"no_match\",\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    "
        ],
        [
         "20",
         "q20",
         "If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 genetic alterations (e.g., c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Status\": \"success\",\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    "
        ]
       ],
       "shape": {
        "columns": 27,
        "rows": 21
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question_index</th>\n",
       "      <th>prompt</th>\n",
       "      <th>Asking_therapy</th>\n",
       "      <th>Given_biomarker</th>\n",
       "      <th>Question_category</th>\n",
       "      <th>Is_there_an_approval</th>\n",
       "      <th>Groundtruth_answers</th>\n",
       "      <th>Groundtruth_therapies</th>\n",
       "      <th>matching_cnt</th>\n",
       "      <th>missing_cnt</th>\n",
       "      <th>...</th>\n",
       "      <th>RAGLLM_full_output_0</th>\n",
       "      <th>RAGLLM_full_output_1</th>\n",
       "      <th>RAGLLM_full_output_2</th>\n",
       "      <th>RAGLLM_full_output_3</th>\n",
       "      <th>RAGLLM_full_output_4</th>\n",
       "      <th>RAGLLM_input_prompt_0</th>\n",
       "      <th>RAGLLM_input_prompt_1</th>\n",
       "      <th>RAGLLM_input_prompt_2</th>\n",
       "      <th>RAGLLM_input_prompt_3</th>\n",
       "      <th>RAGLLM_input_prompt_4</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>q0</td>\n",
       "      <td>What is the first-line treatment of metastatic...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>q1</td>\n",
       "      <td>Are PARP inhibitors used for patients with lei...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>PARP inhibitors are not yet approved for the t...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>q2</td>\n",
       "      <td>Are ALK inhibitors approved for use in TFCP2 f...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>No, no ALK inhibitors are currently approved f...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>q3</td>\n",
       "      <td>For a patient with cancer metastatic prostate ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The following therapy and combination therapie...</td>\n",
       "      <td>[{'olaparib'}, {'prednisone', 'olaparib', 'abi...</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>q4</td>\n",
       "      <td>For a patient with HER2+ breast cancer after n...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>TDM-1 (ado-trastuzumab emtansine (Kadcyla))</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>q5</td>\n",
       "      <td>For patients with advanced cancer and with NTR...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, the TRK inhibitors Entrectinib and Larotr...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>q6</td>\n",
       "      <td>For patients with advanced cancer and with hig...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, Keytruda (pembrolizumab) is approved by t...</td>\n",
       "      <td>[{'pembrolizumab'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>q7</td>\n",
       "      <td>What FDA-approved therapies exist for a Stage ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>While no drugs are approved for use by the US ...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>q8</td>\n",
       "      <td>What are available FDA-approved targeted thera...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>There are not currently approved therapies for...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>q9</td>\n",
       "      <td>A patient with localized Ewing sarcoma has a S...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any treatments...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>q10</td>\n",
       "      <td>A patient with relapsed high-risk neuroblastom...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>q11</td>\n",
       "      <td>I have a 3 year old patient with Neuroblastoma...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>q12</td>\n",
       "      <td>My 20 year old patient with ALK mutated Neurob...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>q13</td>\n",
       "      <td>For a 17-year-old osteosarcoma patient with 50...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>q14</td>\n",
       "      <td>Is there an optimal drug combination to minimi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>q15</td>\n",
       "      <td>For a 4 year old patient with medulloblastoma,...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>q16</td>\n",
       "      <td>For toddler with unresectable hepatoblastoma a...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>q17</td>\n",
       "      <td>I have a patient with de novo metastatic HR+ b...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>Two therapeutic hypotheses to consider for thi...</td>\n",
       "      <td>[{'talazoparib'}, {'capivasertib', 'fulvestran...</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>q18</td>\n",
       "      <td>I have a patient with an initial diagnosis of ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>While this version of MOAlmanac does not direc...</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}, {'trastuzumab'...</td>\n",
       "      <td>2</td>\n",
       "      <td>9</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>q19</td>\n",
       "      <td>I have a patient with metastatic HR-negative, ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>True</td>\n",
       "      <td>Either T-DXd or SG could be used; we generally...</td>\n",
       "      <td>[{'sacituzumab govitecan'}, {'trastuzumab deru...</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>q20</td>\n",
       "      <td>If a bladder cancer patient has FGFR3 mutation...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The US FDA has approved Erdafitnib for use for...</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>{\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>21 rows  27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Question_index                                             prompt  \\\n",
       "0              q0  What is the first-line treatment of metastatic...   \n",
       "1              q1  Are PARP inhibitors used for patients with lei...   \n",
       "2              q2  Are ALK inhibitors approved for use in TFCP2 f...   \n",
       "3              q3  For a patient with cancer metastatic prostate ...   \n",
       "4              q4  For a patient with HER2+ breast cancer after n...   \n",
       "5              q5  For patients with advanced cancer and with NTR...   \n",
       "6              q6  For patients with advanced cancer and with hig...   \n",
       "7              q7  What FDA-approved therapies exist for a Stage ...   \n",
       "8              q8  What are available FDA-approved targeted thera...   \n",
       "9              q9  A patient with localized Ewing sarcoma has a S...   \n",
       "10            q10  A patient with relapsed high-risk neuroblastom...   \n",
       "11            q11  I have a 3 year old patient with Neuroblastoma...   \n",
       "12            q12  My 20 year old patient with ALK mutated Neurob...   \n",
       "13            q13  For a 17-year-old osteosarcoma patient with 50...   \n",
       "14            q14  Is there an optimal drug combination to minimi...   \n",
       "15            q15  For a 4 year old patient with medulloblastoma,...   \n",
       "16            q16  For toddler with unresectable hepatoblastoma a...   \n",
       "17            q17  I have a patient with de novo metastatic HR+ b...   \n",
       "18            q18  I have a patient with an initial diagnosis of ...   \n",
       "19            q19  I have a patient with metastatic HR-negative, ...   \n",
       "20            q20  If a bladder cancer patient has FGFR3 mutation...   \n",
       "\n",
       "    Asking_therapy  Given_biomarker  \\\n",
       "0             True             True   \n",
       "1             True             True   \n",
       "2             True             True   \n",
       "3             True             True   \n",
       "4             True             True   \n",
       "5             True             True   \n",
       "6             True             True   \n",
       "7             True             True   \n",
       "8             True             True   \n",
       "9             True             True   \n",
       "10            True             True   \n",
       "11            True             True   \n",
       "12            True             True   \n",
       "13            True             True   \n",
       "14            True             True   \n",
       "15            True             True   \n",
       "16            True             True   \n",
       "17            True             True   \n",
       "18            True             True   \n",
       "19            True             True   \n",
       "20            True             True   \n",
       "\n",
       "                                    Question_category  Is_there_an_approval  \\\n",
       "0           given disease and biomarker, return drugs                  True   \n",
       "1           given disease and biomarker, return drugs                 False   \n",
       "2           given disease and biomarker, return drugs                 False   \n",
       "3           given disease and biomarker, return drugs                  True   \n",
       "4   given disease and biomarker, return drugs; HER...                  True   \n",
       "5           given disease and biomarker, return drugs                  True   \n",
       "6           given disease and biomarker, return drugs                  True   \n",
       "7           given disease and biomarker, return drugs                  True   \n",
       "8           given disease and biomarker, return drugs                 False   \n",
       "9           given disease and biomarker, return drugs                 False   \n",
       "10          given disease and biomarker, return drugs                 False   \n",
       "11          given disease and biomarker, return drugs                 False   \n",
       "12          given disease and biomarker, return drugs                 False   \n",
       "13          given disease and biomarker, return drugs                 False   \n",
       "14  given disease and biomarker, return drugs; not...                 False   \n",
       "15          given disease and biomarker, return drugs                 False   \n",
       "16          given disease and biomarker, return drugs                 False   \n",
       "17  given disease and biomarker, return drugs; HER...                  True   \n",
       "18  given disease and biomarker, return drugs; HER...                  True   \n",
       "19  given disease and biomarker, return drugs; not...                  True   \n",
       "20          given disease and biomarker, return drugs                  True   \n",
       "\n",
       "                                  Groundtruth_answers  \\\n",
       "0                                         erdafitinib   \n",
       "1   PARP inhibitors are not yet approved for the t...   \n",
       "2   No, no ALK inhibitors are currently approved f...   \n",
       "3   The following therapy and combination therapie...   \n",
       "4         TDM-1 (ado-trastuzumab emtansine (Kadcyla))   \n",
       "5   Yes, the TRK inhibitors Entrectinib and Larotr...   \n",
       "6   Yes, Keytruda (pembrolizumab) is approved by t...   \n",
       "7   While no drugs are approved for use by the US ...   \n",
       "8   There are not currently approved therapies for...   \n",
       "9   The US FDA has not yet approved any treatments...   \n",
       "10  The US FDA has not yet approved any biomarker-...   \n",
       "11  The US FDA has not yet approved any biomarker-...   \n",
       "12  The US FDA has not yet approved any biomarker-...   \n",
       "13  The US FDA has not yet approved any biomarker-...   \n",
       "14  The US FDA has not yet approved any biomarker-...   \n",
       "15  The US FDA has not yet approved any biomarker-...   \n",
       "16  The US FDA has not yet approved any biomarker-...   \n",
       "17  Two therapeutic hypotheses to consider for thi...   \n",
       "18  While this version of MOAlmanac does not direc...   \n",
       "19  Either T-DXd or SG could be used; we generally...   \n",
       "20  The US FDA has approved Erdafitnib for use for...   \n",
       "\n",
       "                                Groundtruth_therapies  matching_cnt  \\\n",
       "0                                   [{'erdafitinib'}]             1   \n",
       "1                                                  []             0   \n",
       "2                                                  []             0   \n",
       "3   [{'olaparib'}, {'prednisone', 'olaparib', 'abi...             3   \n",
       "4                     [{'ado-trastuzumab emtansine'}]             1   \n",
       "5                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "6                                 [{'pembrolizumab'}]             1   \n",
       "7                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "8                                                  []             0   \n",
       "9                                                  []             0   \n",
       "10                                                 []             0   \n",
       "11                                                 []             0   \n",
       "12                                                 []             0   \n",
       "13                                                 []             0   \n",
       "14                                                 []             0   \n",
       "15                                                 []             0   \n",
       "16                                                 []             0   \n",
       "17  [{'talazoparib'}, {'capivasertib', 'fulvestran...             0   \n",
       "18  [{'ado-trastuzumab emtansine'}, {'trastuzumab'...             2   \n",
       "19  [{'sacituzumab govitecan'}, {'trastuzumab deru...             0   \n",
       "20                                  [{'erdafitinib'}]             1   \n",
       "\n",
       "    missing_cnt  ...                               RAGLLM_full_output_0  \\\n",
       "0             0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "1             0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "2             0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "3             2  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "4             0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "5             0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "6             0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "7             0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "8             0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "9             0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "10            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "11            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "12            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "13            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "14            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "15            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "16            0  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "17            3  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "18            9  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "19            2  ...  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "20            0  ...  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "\n",
       "                                 RAGLLM_full_output_1  \\\n",
       "0   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "1   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "2   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "3   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "4   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "5   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "6   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "7   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "8   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "9   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "10  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "11  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "12  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "13  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "14  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "15  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "16  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "17  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "18  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "19  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "20  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "\n",
       "                                 RAGLLM_full_output_2  \\\n",
       "0   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "1   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "2   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "3   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "4   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "5   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "6   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "7   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "8   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "9   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "10  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "11  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "12  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "13  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "14  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "15  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "16  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "17  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "18  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "19  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "20  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "\n",
       "                                 RAGLLM_full_output_3  \\\n",
       "0   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "1   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "2   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "3   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "4   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "5   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "6   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "7   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "8   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "9   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "10  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "11  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "12  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "13  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "14  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "15  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "16  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "17  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "18  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "19  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "20  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "\n",
       "                                 RAGLLM_full_output_4  \\\n",
       "0   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "1   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "2   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "3   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "4   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "5   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "6   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "7   {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "8   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "9   {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "10  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "11  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "12  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "13  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "14  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "15  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "16  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "17  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "18  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "19  {\\n    \"Status\": \"no_match\",\\n    \"Message\": \"...   \n",
       "20  {\\n    \"Status\": \"success\",\\n    \"Treatment 1\"...   \n",
       "\n",
       "                                RAGLLM_input_prompt_0  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_1  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_2  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_3  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_4  \n",
       "0   \\n    Context information is below.\\n    -----...  \n",
       "1   \\n    Context information is below.\\n    -----...  \n",
       "2   \\n    Context information is below.\\n    -----...  \n",
       "3   \\n    Context information is below.\\n    -----...  \n",
       "4   \\n    Context information is below.\\n    -----...  \n",
       "5   \\n    Context information is below.\\n    -----...  \n",
       "6   \\n    Context information is below.\\n    -----...  \n",
       "7   \\n    Context information is below.\\n    -----...  \n",
       "8   \\n    Context information is below.\\n    -----...  \n",
       "9   \\n    Context information is below.\\n    -----...  \n",
       "10  \\n    Context information is below.\\n    -----...  \n",
       "11  \\n    Context information is below.\\n    -----...  \n",
       "12  \\n    Context information is below.\\n    -----...  \n",
       "13  \\n    Context information is below.\\n    -----...  \n",
       "14  \\n    Context information is below.\\n    -----...  \n",
       "15  \\n    Context information is below.\\n    -----...  \n",
       "16  \\n    Context information is below.\\n    -----...  \n",
       "17  \\n    Context information is below.\\n    -----...  \n",
       "18  \\n    Context information is below.\\n    -----...  \n",
       "19  \\n    Context information is below.\\n    -----...  \n",
       "20  \\n    Context information is below.\\n    -----...  \n",
       "\n",
       "[21 rows x 27 columns]"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_supp_df = pd.concat([real_rag_res_cnt_df_5, drug_output_df, full_output_df, input_df], axis=1)\n",
    "real_supp_df.to_csv(f\"./{base_model}_real_supp_df.csv\", index=False)\n",
    "real_supp_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "strategy=4\n",
    "input_df=create_selected_output_df(all_real_results[strategy], 'ragllm_input', 'RAGLLM_input_prompt_')\n",
    "full_output_df=create_selected_output_df(all_real_results[strategy], 'ragllm_output', 'RAGLLM_full_output_')\n",
    "\n",
    "pred_drug_output_ls = list()\n",
    "for i in range(len(all_real_results[strategy]['full'])):\n",
    "    pred_drug_output_ls.append(all_real_results[strategy]['full'][i]['pred_drugs_generic_set_ls'])\n",
    "\n",
    "drug_output_df=pd.DataFrame(pred_drug_output_ls).T.add_prefix('RAGLLM_drug_output_')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Question_index",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Asking_therapy",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Given_biomarker",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Question_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Is_there_an_approval",
         "rawType": "bool",
         "type": "boolean"
        },
        {
         "name": "Groundtruth_answers",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Groundtruth_therapies",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "matching_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "missing_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "hallucinating_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "no_output_cnt",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "RAGLLM_drug_output_0",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_2",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_3",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_drug_output_4",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "RAGLLM_full_output_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_full_output_4",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_0",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_2",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_3",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "RAGLLM_input_prompt_4",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "33ba43a7-ffed-4cc0-b20b-abd7e32e8bff",
       "rows": [
        [
         "0",
         "q0",
         "What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "erdafitinib",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 (c.746C>G or p.S249C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? \n     \n    "
        ],
        [
         "1",
         "q1",
         "Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "{frozenset({'olaparib'})}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t\t\n \t: \n \t{\n \t}\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \n  :\n  \"Treatment 1\" \n  }\n",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t\"Leiomyosarcoma is not mentioned in the provided context, and there are no FDA-approved PARP inhibitors specifically indicated for leiomyosarcoma with mutations in DNA damage repair genes based on the given information.\"\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t\"Treatment 1\"\n \t}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \n  :\n  {\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"Deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n} \n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?\n     \n    "
        ],
        [
         "2",
         "q2",
         "Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",
         "[]",
         "0",
         "0",
         "4",
         "0",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "set()",
         "set()",
         "set()",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or refractory, systemic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, recurrent, or refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, recurrent, or refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    }\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t{\n \t}\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r  \r",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or refractory, systemic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, recurrent, or refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, recurrent, or refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?\n     \n    "
        ],
        [
         "3",
         "q3",
         "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: olaparib; abiraterone, olaparib, and prednisone; enzalutamide and talazoparib; abiraterone acetate and niraparib; and rucaparib.",
         "[{'olaparib'}, {'prednisone', 'olaparib', 'abiraterone'}, {'talazoparib', 'enzalutamide'}, {'abiraterone acetate', 'niraparib'}, {'rucaparib'}]",
         "3",
         "2",
         "0",
         "0",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n        \"Disease Phase or Condition\": \"Advanced Stage (most often stage IV, but some stage III or earlier potentially)\",\n        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n     \n    "
        ],
        [
         "4",
         "q4",
         "For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "TDM-1 (ado-trastuzumab emtansine (Kadcyla))",
         "[{'ado-trastuzumab emtansine'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{frozenset({'ado-trastuzumab emtansine'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-positive, metastatic breast cancer\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy.\",\n        \"Genomic Features\": \"Copy number in gene ERBB2\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Residual disease after neoadjuvant chemotherapy and surgery\",\n        \"Drug Name\": \"Ado-Trastuzumab Emtansine\",\n        \"Prior Treatment or Resistance Status\": \"Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n     \n    "
        ],
        [
         "5",
         "q5",
         "For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, the TRK inhibitors Entrectinib and Larotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?\n     \n    "
        ],
        [
         "6",
         "q6",
         "For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",
         "[{'pembrolizumab'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?\n     \n    "
        ],
        [
         "7",
         "q7",
         "What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.",
         "[{'entrectinib'}, {'larotrectinib'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Have progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK gene fusion without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated Approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation\n     \n    "
        ],
        [
         "8",
         "q8",
         "What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.",
         "[]",
         "0",
         "0",
         "2",
         "0",
         "{frozenset({'futibatinib'}), frozenset({'pemigatinib'})}",
         "{frozenset({'futibatinib'}), frozenset({'pemigatinib'})}",
         "{frozenset({'futibatinib'}), frozenset({'pemigatinib'})}",
         "{frozenset({'futibatinib'}), frozenset({'pemigatinib'})}",
         "{frozenset({'futibatinib'}), frozenset({'pemigatinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Intrahepatic Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Futibatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 rearrangements\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Pemigatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 fusion or rearrangement\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Intrahepatic Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Futibatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 rearrangements\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Pemigatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 fusion or rearrangement\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Intrahepatic Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Futibatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 rearrangements\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Pemigatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 fusion or rearrangement\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Intrahepatic Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Futibatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 rearrangements\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Pemigatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 fusion or rearrangement\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Intrahepatic Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Futibatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 rearrangements\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Cholangiocarcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Pemigatinib\",\n        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n        \"Genomic Features\": \"FGFR2 fusion or rearrangement\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?\n     \n    "
        ],
        [
         "9",
         "q9",
         "A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "set()",
         "set()",
         "set()",
         "set()",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Ewing sarcoma\",\n        \"Disease Phase or Condition\": \"Relapsed\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"STAG2 mutation\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Ewing sarcoma\",\n        \"Disease Phase or Condition\": \"Relapsed\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"STAG2 mutation\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t\t\n \t: \n \t{\n \t}\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Ewing sarcoma\",\n        \"Disease Phase or Condition\": \"Relapsed\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"STAG2 mutation\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Ewing sarcoma\",\n        \"Disease Phase or Condition\": \"Relapsed\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"STAG2 mutation\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?\n     \n    "
        ],
        [
         "10",
         "q10",
         "A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "4",
         "0",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{frozenset({'ceritinib'}), frozenset({'alectinib'}), frozenset({'crizotinib'}), frozenset({'lorlatinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, Recurrent, or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, Recurrent, or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or Third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for pediatric patients 1 year of age or older and young adults\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, Recurrent, or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, Recurrent, or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for adult and pediatric patients 1 year of age or older\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or Third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, Recurrent, or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, Recurrent, or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or Third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for pediatric patients 1 year of age or older and young adults\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, Recurrent, or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, Recurrent, or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for adult and pediatric patients 1 year of age or older\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or Third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Anaplastic Large Cell Lymphoma (ALCL)\",\n        \"Disease Phase or Condition\": \"Relapsed or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Relapsed or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for pediatric patients 1 year of age or older and young adults\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Alectinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Inflammatory Myofibroblastic Tumor (IMT)\",\n        \"Disease Phase or Condition\": \"Unresectable, Recurrent, or Refractory\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Unresectable, Recurrent, or Refractory\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved for adult and pediatric patients 1 year of age or older\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    },\n    \"Treatment 5\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Ceritinib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf\"\n    },\n    \"Treatment 6\": {\n        \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Lorlatinib\",\n        \"Prior Treatment or Resistance Status\": \"Second- or Third-line treatment\",\n        \"Genomic Features\": \"ALK-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?\n     \n    "
        ],
        [
         "11",
         "q11",
         "I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "1",
         "0",
         "{frozenset({'olaparib'})}",
         "{frozenset({'olaparib'})}",
         "{frozenset({'olaparib'})}",
         "{frozenset({'olaparib'})}",
         "{frozenset({'olaparib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Germline BARD1 mutation\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline BARD1 mutation\",\n        \"FDA-approval status\": \"Approved for other conditions with BARD1 mutation\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Germline BARD1 mutation\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline BARD1 mutation\",\n        \"FDA-approval status\": \"Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Germline BARD1 mutation\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline BARD1 mutation\",\n        \"FDA-approval status\": \"Approved for other conditions with BARD1 mutation\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Germline BARD1 mutation\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline BARD1 mutation\",\n        \"FDA-approval status\": \"Approved for other conditions with BARD1 mutation\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Germline BARD1 mutation\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline BARD1 mutation\",\n        \"FDA-approval status\": \"Approved for other conditions with BARD1 mutations\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?\n     \n    "
        ],
        [
         "12",
         "q12",
         "My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "[]",
         "0",
         "0",
         "1",
         "0",
         "{frozenset({'crizotinib'})}",
         "{frozenset({'crizotinib'})}",
         "{frozenset({'crizotinib'})}",
         "{frozenset({'crizotinib'})}",
         "{frozenset({'crizotinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Genomic Features\": \"ALK mutation\",\n        \"FDA-approval status\": \"Approved for treatment of pediatric patients 1 year of age or older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Genomic Features\": \"ALK mutation\",\n        \"FDA-approval status\": \"Approved for treatment of pediatric patients 1 year of age or older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Genomic Features\": \"ALK mutation\",\n        \"FDA-approval status\": \"Approved for treatment of pediatric patients 1 year of age or older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Genomic Features\": \"ALK mutation\",\n        \"FDA-approval status\": \"Approved for ALK-positive anaplastic large cell lymphoma (ALCL), ALK-positive non-small cell lung cancer (NSCLC), and ALK-positive inflammatory myofibroblastic tumor (IMT)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Neuroblastoma\",\n        \"Disease Phase or Condition\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Drug Name\": \"Crizotinib\",\n        \"Prior Treatment or Resistance Status\": \"Failed therapy with broad chemotherapy, radiation, and an ALK inhibitor\",\n        \"Genomic Features\": \"ALK mutation\",\n        \"FDA-approval status\": \"Approved for ALK-positive conditions in other cancers\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?\n     \n    "
        ],
        [
         "13",
         "q13",
         "For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma",
         "[]",
         "0",
         "0",
         "4",
         "0",
         "{frozenset({'pembrolizumab'}), frozenset({'selpercatinib'}), frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'pembrolizumab'}), frozenset({'selpercatinib'}), frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'pembrolizumab'}), frozenset({'selpercatinib'}), frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'pembrolizumab'}), frozenset({'selpercatinib'}), frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{frozenset({'pembrolizumab'}), frozenset({'selpercatinib'}), frozenset({'larotrectinib'}), frozenset({'entrectinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Selpercatinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"RET gene fusion\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, or NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1 or NTRK2 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"MSI-high\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Selpercatinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"RET gene fusion\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, or NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1 or NTRK2 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"MSI-high\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Selpercatinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"RET gene fusion\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, or NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1 or NTRK2 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"MSI-high\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Selpercatinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"RET gene fusion\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1, NTRK2 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"MSI-high\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Selpercatinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"RET gene fusion\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or surgical resection likely to result in severe morbidity\",\n        \"Drug Name\": \"Larotrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No satisfactory alternative treatments or have progressed following treatment\",\n        \"Genomic Features\": \"NTRK1, NTRK2, or NTRK3 gene fusions without a known resistance mechanism\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf\"\n    },\n    \"Treatment 3\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Metastatic or where surgical resection is likely to result in severe morbidity\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following treatment or have no satisfactory standard therapy\",\n        \"Genomic Features\": \"NTRK1 or NTRK2 gene fusions without a known acquired resistance mutation\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    },\n    \"Treatment 4\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and who have no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"MSI-high\",\n        \"FDA-approval status\": \"Accelerated approval\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?\n     \n    "
        ],
        [
         "14",
         "q14",
         "Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",
         "[]",
         "0",
         "0",
         "1",
         "0",
         "{frozenset({'ivosidenib', 'azacitidine'})}",
         "set()",
         "{frozenset({'ivosidenib', 'azacitidine'})}",
         "{frozenset({'ivosidenib', 'azacitidine'})}",
         "set()",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Acute Myeloid Leukemia (AML)\",\n        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C) or IDH1 (c.395G>A or p.R132H)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Acute Myeloid Leukemia (AML)\",\n        \"Disease Phase or Condition\": \"Post Hematopoietic Stem Cell Transplant (HSCT) Relapse\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"KMT2A rearranged\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Acute Myeloid Leukemia (AML)\",\n        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C) or IDH1 (c.395G>A or p.R132H)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Acute Myeloid Leukemia (AML)\",\n        \"Disease Phase or Condition\": \"Newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n        \"Drug Name\": \"Ivosidenib + Azacitidine\",\n        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n        \"Genomic Features\": \"IDH1 (c.394C>T or p.R132C) or IDH1 (c.395G>A or p.R132H)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Acute Myeloid Leukemia (AML)\",\n        \"Disease Phase or Condition\": \"Post Hematopoietic Stem Cell Transplant (HSCT) relapse\",\n        \"Drug Name\": \"There are no FDA-approved drugs for the provided context.\",\n        \"Prior Treatment or Resistance Status\": \"N/A\",\n        \"Genomic Features\": \"KMT2A rearranged\",\n        \"FDA-approval status\": \"N/A\",\n        \"Link to FDA-approved Label\": \"N/A\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?\n     \n    "
        ],
        [
         "15",
         "q15",
         "For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",
         "[]",
         "0",
         "0",
         "0",
         "1",
         "set()",
         "{frozenset({'vismodegib'})}",
         "set()",
         "set()",
         "set()",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t{\n \t}\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Medulloblastoma, SHH subtype\",\n        \"Disease Phase or Condition\": \"Not specified\",\n        \"Drug Name\": \"Vismodegib\",\n        \"Prior Treatment or Resistance Status\": \"Not specified\",\n        \"Genomic Features\": \"Germline PTCH1 mutation\",\n        \"FDA-approval status\": \"FDA-approved for basal cell carcinoma with PTCH1 mutation, but not specifically for medulloblastoma\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203388s015lbl.pdf\"\n    }\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t{\n \t}\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t{\n \t}\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: \n \t{\n \t}\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?\n     \n    "
        ],
        [
         "16",
         "q16",
         "For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "False",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",
         "[]",
         "0",
         "0",
         "1",
         "0",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "{frozenset({'pembrolizumab'})}",
         "set()",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High mutational burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High mutational burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High mutational burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Solid Tumors\",\n        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n        \"Drug Name\": \"Pembrolizumab\",\n        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment and no satisfactory alternative treatment options\",\n        \"Genomic Features\": \"High mutational burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n    }\n}",
         "{\n    \"There are no FDA-approved drugs for the provided context.\"\n  \t: {\n        \"Disease Name\": \"Unresectable hepatoblastoma\",\n        \"Disease Phase or Condition\": \"Unresectable\",\n        \"Drug Name\": \"None\",\n        \"Prior Treatment or Resistance Status\": \"None\",\n        \"Genomic Features\": \"CTNNB1 mutation\",\n        \"FDA-approval status\": \"None\",\n        \"Link to FDA-approved Label\": \"None\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?\n     \n    "
        ],
        [
         "17",
         "q17",
         "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.",
         "[{'talazoparib'}, {'capivasertib', 'fulvestrant'}, {'olaparib'}]",
         "2",
         "1",
         "0",
         "0",
         "{frozenset({'talazoparib'}), frozenset({'olaparib'})}",
         "{frozenset({'talazoparib'}), frozenset({'olaparib'})}",
         "{frozenset({'talazoparib'}), frozenset({'olaparib'})}",
         "{frozenset({'talazoparib'}), frozenset({'olaparib'})}",
         "{frozenset({'talazoparib'}), frozenset({'olaparib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative high risk early breast cancer\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Treated with neoadjuvant or adjuvant chemotherapy\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative locally advanced or metastatic\",\n        \"Drug Name\": \"Talazoparib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative high risk early breast cancer\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Treated with neoadjuvant or adjuvant chemotherapy\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative locally advanced or metastatic\",\n        \"Drug Name\": \"Talazoparib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative high risk early breast cancer\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Treated with neoadjuvant or adjuvant chemotherapy\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative locally advanced or metastatic\",\n        \"Drug Name\": \"Talazoparib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative high risk early breast cancer\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Treated with neoadjuvant or adjuvant chemotherapy\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative locally advanced or metastatic\",\n        \"Drug Name\": \"Talazoparib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative high risk early breast cancer\",\n        \"Drug Name\": \"Olaparib\",\n        \"Prior Treatment or Resistance Status\": \"Treated with neoadjuvant or adjuvant chemotherapy\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-negative locally advanced or metastatic\",\n        \"Drug Name\": \"Talazoparib\",\n        \"Prior Treatment or Resistance Status\": \"None specified\",\n        \"Genomic Features\": \"Germline BRCA2 mutation\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n     \n    "
        ],
        [
         "18",
         "q18",
         "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?",
         "True",
         "True",
         "given disease and biomarker, return drugs; HER2-related",
         "True",
         "While this version of MOAlmanac does not directly curate HER2+ status as a biomarker, a number of FDA approvals and companion diagnostics include ERBB2 amplifications for approvals based on HER2+. For FDA approvals for patients with breast cancer: Ado-Trastuzumab Emtansine; Capecitabine + Trastuzumab + Tucatinib; Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab; Lapatinib; Margetuximab-cmkb + Chemotherapy; Neratinib; Neratinib + Capecitabine; Pertuzumab + Trastuzumab; Trastuzumab; Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
         "[{'ado-trastuzumab emtansine'}, {'trastuzumab', 'tucatinib', 'capecitabine'}, {'trastuzumab', 'hyaluronidase-zzxf', 'pertuzumab', 'chemotherapy'}, {'lapatinib'}, {'chemotherapy', 'margetuximab-cmkb'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'trastuzumab', 'pertuzumab', 'hyaluronidase-zzxf', 'docetaxel'}, {'trastuzumab', 'pertuzumab', 'docetaxel'}]",
         "1",
         "10",
         "0",
         "0",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{frozenset({'pertuzumab', 'trastuzumab'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients who have received neoadjuvant treatment\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Received neoadjuvant TCHP and had 1cm of residual disease at surgery\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients who have received neoadjuvant treatment\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"HER2-positive breast cancer\",\n        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Patients who have received neoadjuvant therapy and have residual disease at surgery\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"HER2-positive, early stage, high risk of recurrence\",\n        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n        \"Prior Treatment or Resistance Status\": \"Received neoadjuvant TCHP and had 1cm of residual disease at surgery\",\n        \"Genomic Features\": \"HER2-positive\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n     \n    "
        ],
        [
         "19",
         "q19",
         "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",
         "True",
         "True",
         "given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",
         "True",
         "Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.",
         "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]",
         "2",
         "0",
         "0",
         "0",
         "{frozenset({'sacituzumab govitecan'}), frozenset({'trastuzumab deruxtecan'})}",
         "{frozenset({'sacituzumab govitecan'}), frozenset({'trastuzumab deruxtecan'})}",
         "{frozenset({'sacituzumab govitecan'}), frozenset({'t-dxd'})}",
         "{frozenset({'sacituzumab govitecan'}), frozenset({'trastuzumab deruxtecan'})}",
         "{frozenset({'sacituzumab govitecan'}), frozenset({'trastuzumab deruxtecan'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Trastuzumab Deruxtecan (T-DXd)\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761139s003lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Sacituzumab Govitecan\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s006lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Trastuzumab Deruxtecan (T-DXd)\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761139s003lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Sacituzumab Govitecan\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"T-DXd (Trastuzumab Deruxtecan)\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761139s000lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Sacituzumab Govitecan\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Trastuzumab Deruxtecan (T-DXd)\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761139s003lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Sacituzumab Govitecan\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s006lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Trastuzumab Deruxtecan (T-DXd)\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761139s003lbl.pdf\"\n    },\n    \"Treatment 2\": {\n        \"Disease Name\": \"Breast Cancer\",\n        \"Disease Phase or Condition\": \"Metastatic, HR-negative, HER2-low, PD-L1-negative, no germline BRCA mutation\",\n        \"Drug Name\": \"Sacituzumab Govitecan\",\n        \"Prior Treatment or Resistance Status\": \"Second line\",\n        \"Genomic Features\": \"HER2-low\",\n        \"FDA-approval status\": \"FDA-approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s006lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS  1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n     \n    "
        ],
        [
         "20",
         "q20",
         "If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",
         "True",
         "True",
         "given disease and biomarker, return drugs",
         "True",
         "The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",
         "[{'erdafitinib'}]",
         "1",
         "0",
         "0",
         "0",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{frozenset({'erdafitinib'})}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial Carcinoma\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy\",\n        \"Genomic Features\": \"FGFR3 genetic alterations (e.g., c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Urothelial carcinoma (Bladder cancer)\",\n        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n        \"Drug Name\": \"Erdafitinib\",\n        \"Prior Treatment or Resistance Status\": \"Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy\",\n        \"Genomic Features\": \"FGFR3 genetic alterations (e.g., c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)\",\n        \"FDA-approval status\": \"Approved\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\"\n    }\n}",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    ",
         "\n    Context information is below.\n    ---------------------\n    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']\n    ---------------------\n    \n    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?\n     \n    "
        ]
       ],
       "shape": {
        "columns": 27,
        "rows": 21
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question_index</th>\n",
       "      <th>prompt</th>\n",
       "      <th>Asking_therapy</th>\n",
       "      <th>Given_biomarker</th>\n",
       "      <th>Question_category</th>\n",
       "      <th>Is_there_an_approval</th>\n",
       "      <th>Groundtruth_answers</th>\n",
       "      <th>Groundtruth_therapies</th>\n",
       "      <th>matching_cnt</th>\n",
       "      <th>missing_cnt</th>\n",
       "      <th>...</th>\n",
       "      <th>RAGLLM_full_output_0</th>\n",
       "      <th>RAGLLM_full_output_1</th>\n",
       "      <th>RAGLLM_full_output_2</th>\n",
       "      <th>RAGLLM_full_output_3</th>\n",
       "      <th>RAGLLM_full_output_4</th>\n",
       "      <th>RAGLLM_input_prompt_0</th>\n",
       "      <th>RAGLLM_input_prompt_1</th>\n",
       "      <th>RAGLLM_input_prompt_2</th>\n",
       "      <th>RAGLLM_input_prompt_3</th>\n",
       "      <th>RAGLLM_input_prompt_4</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>q0</td>\n",
       "      <td>What is the first-line treatment of metastatic...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>q1</td>\n",
       "      <td>Are PARP inhibitors used for patients with lei...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>PARP inhibitors are not yet approved for the t...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>q2</td>\n",
       "      <td>Are ALK inhibitors approved for use in TFCP2 f...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>No, no ALK inhibitors are currently approved f...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>q3</td>\n",
       "      <td>For a patient with cancer metastatic prostate ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The following therapy and combination therapie...</td>\n",
       "      <td>[{'olaparib'}, {'prednisone', 'olaparib', 'abi...</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>q4</td>\n",
       "      <td>For a patient with HER2+ breast cancer after n...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>TDM-1 (ado-trastuzumab emtansine (Kadcyla))</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>q5</td>\n",
       "      <td>For patients with advanced cancer and with NTR...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, the TRK inhibitors Entrectinib and Larotr...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>q6</td>\n",
       "      <td>For patients with advanced cancer and with hig...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes, Keytruda (pembrolizumab) is approved by t...</td>\n",
       "      <td>[{'pembrolizumab'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>q7</td>\n",
       "      <td>What FDA-approved therapies exist for a Stage ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>While no drugs are approved for use by the US ...</td>\n",
       "      <td>[{'entrectinib'}, {'larotrectinib'}]</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>q8</td>\n",
       "      <td>What are available FDA-approved targeted thera...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>There are not currently approved therapies for...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>q9</td>\n",
       "      <td>A patient with localized Ewing sarcoma has a S...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any treatments...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>q10</td>\n",
       "      <td>A patient with relapsed high-risk neuroblastom...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>q11</td>\n",
       "      <td>I have a 3 year old patient with Neuroblastoma...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>q12</td>\n",
       "      <td>My 20 year old patient with ALK mutated Neurob...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>q13</td>\n",
       "      <td>For a 17-year-old osteosarcoma patient with 50...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>q14</td>\n",
       "      <td>Is there an optimal drug combination to minimi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>q15</td>\n",
       "      <td>For a 4 year old patient with medulloblastoma,...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>q16</td>\n",
       "      <td>For toddler with unresectable hepatoblastoma a...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>False</td>\n",
       "      <td>The US FDA has not yet approved any biomarker-...</td>\n",
       "      <td>[]</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"There are no FDA-approved drugs for th...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>q17</td>\n",
       "      <td>I have a patient with de novo metastatic HR+ b...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>Two therapeutic hypotheses to consider for thi...</td>\n",
       "      <td>[{'talazoparib'}, {'capivasertib', 'fulvestran...</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>q18</td>\n",
       "      <td>I have a patient with an initial diagnosis of ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; HER...</td>\n",
       "      <td>True</td>\n",
       "      <td>While this version of MOAlmanac does not direc...</td>\n",
       "      <td>[{'ado-trastuzumab emtansine'}, {'trastuzumab'...</td>\n",
       "      <td>1</td>\n",
       "      <td>10</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>q19</td>\n",
       "      <td>I have a patient with metastatic HR-negative, ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs; not...</td>\n",
       "      <td>True</td>\n",
       "      <td>Either T-DXd or SG could be used; we generally...</td>\n",
       "      <td>[{'sacituzumab govitecan'}, {'trastuzumab deru...</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>q20</td>\n",
       "      <td>If a bladder cancer patient has FGFR3 mutation...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>given disease and biomarker, return drugs</td>\n",
       "      <td>True</td>\n",
       "      <td>The US FDA has approved Erdafitnib for use for...</td>\n",
       "      <td>[{'erdafitinib'}]</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>{\\n    \"Treatment 1\": {\\n        \"Disease Name...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "      <td>\\n    Context information is below.\\n    -----...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>21 rows  27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Question_index                                             prompt  \\\n",
       "0              q0  What is the first-line treatment of metastatic...   \n",
       "1              q1  Are PARP inhibitors used for patients with lei...   \n",
       "2              q2  Are ALK inhibitors approved for use in TFCP2 f...   \n",
       "3              q3  For a patient with cancer metastatic prostate ...   \n",
       "4              q4  For a patient with HER2+ breast cancer after n...   \n",
       "5              q5  For patients with advanced cancer and with NTR...   \n",
       "6              q6  For patients with advanced cancer and with hig...   \n",
       "7              q7  What FDA-approved therapies exist for a Stage ...   \n",
       "8              q8  What are available FDA-approved targeted thera...   \n",
       "9              q9  A patient with localized Ewing sarcoma has a S...   \n",
       "10            q10  A patient with relapsed high-risk neuroblastom...   \n",
       "11            q11  I have a 3 year old patient with Neuroblastoma...   \n",
       "12            q12  My 20 year old patient with ALK mutated Neurob...   \n",
       "13            q13  For a 17-year-old osteosarcoma patient with 50...   \n",
       "14            q14  Is there an optimal drug combination to minimi...   \n",
       "15            q15  For a 4 year old patient with medulloblastoma,...   \n",
       "16            q16  For toddler with unresectable hepatoblastoma a...   \n",
       "17            q17  I have a patient with de novo metastatic HR+ b...   \n",
       "18            q18  I have a patient with an initial diagnosis of ...   \n",
       "19            q19  I have a patient with metastatic HR-negative, ...   \n",
       "20            q20  If a bladder cancer patient has FGFR3 mutation...   \n",
       "\n",
       "    Asking_therapy  Given_biomarker  \\\n",
       "0             True             True   \n",
       "1             True             True   \n",
       "2             True             True   \n",
       "3             True             True   \n",
       "4             True             True   \n",
       "5             True             True   \n",
       "6             True             True   \n",
       "7             True             True   \n",
       "8             True             True   \n",
       "9             True             True   \n",
       "10            True             True   \n",
       "11            True             True   \n",
       "12            True             True   \n",
       "13            True             True   \n",
       "14            True             True   \n",
       "15            True             True   \n",
       "16            True             True   \n",
       "17            True             True   \n",
       "18            True             True   \n",
       "19            True             True   \n",
       "20            True             True   \n",
       "\n",
       "                                    Question_category  Is_there_an_approval  \\\n",
       "0           given disease and biomarker, return drugs                  True   \n",
       "1           given disease and biomarker, return drugs                 False   \n",
       "2           given disease and biomarker, return drugs                 False   \n",
       "3           given disease and biomarker, return drugs                  True   \n",
       "4   given disease and biomarker, return drugs; HER...                  True   \n",
       "5           given disease and biomarker, return drugs                  True   \n",
       "6           given disease and biomarker, return drugs                  True   \n",
       "7           given disease and biomarker, return drugs                  True   \n",
       "8           given disease and biomarker, return drugs                 False   \n",
       "9           given disease and biomarker, return drugs                 False   \n",
       "10          given disease and biomarker, return drugs                 False   \n",
       "11          given disease and biomarker, return drugs                 False   \n",
       "12          given disease and biomarker, return drugs                 False   \n",
       "13          given disease and biomarker, return drugs                 False   \n",
       "14  given disease and biomarker, return drugs; not...                 False   \n",
       "15          given disease and biomarker, return drugs                 False   \n",
       "16          given disease and biomarker, return drugs                 False   \n",
       "17  given disease and biomarker, return drugs; HER...                  True   \n",
       "18  given disease and biomarker, return drugs; HER...                  True   \n",
       "19  given disease and biomarker, return drugs; not...                  True   \n",
       "20          given disease and biomarker, return drugs                  True   \n",
       "\n",
       "                                  Groundtruth_answers  \\\n",
       "0                                         erdafitinib   \n",
       "1   PARP inhibitors are not yet approved for the t...   \n",
       "2   No, no ALK inhibitors are currently approved f...   \n",
       "3   The following therapy and combination therapie...   \n",
       "4         TDM-1 (ado-trastuzumab emtansine (Kadcyla))   \n",
       "5   Yes, the TRK inhibitors Entrectinib and Larotr...   \n",
       "6   Yes, Keytruda (pembrolizumab) is approved by t...   \n",
       "7   While no drugs are approved for use by the US ...   \n",
       "8   There are not currently approved therapies for...   \n",
       "9   The US FDA has not yet approved any treatments...   \n",
       "10  The US FDA has not yet approved any biomarker-...   \n",
       "11  The US FDA has not yet approved any biomarker-...   \n",
       "12  The US FDA has not yet approved any biomarker-...   \n",
       "13  The US FDA has not yet approved any biomarker-...   \n",
       "14  The US FDA has not yet approved any biomarker-...   \n",
       "15  The US FDA has not yet approved any biomarker-...   \n",
       "16  The US FDA has not yet approved any biomarker-...   \n",
       "17  Two therapeutic hypotheses to consider for thi...   \n",
       "18  While this version of MOAlmanac does not direc...   \n",
       "19  Either T-DXd or SG could be used; we generally...   \n",
       "20  The US FDA has approved Erdafitnib for use for...   \n",
       "\n",
       "                                Groundtruth_therapies  matching_cnt  \\\n",
       "0                                   [{'erdafitinib'}]             1   \n",
       "1                                                  []             0   \n",
       "2                                                  []             0   \n",
       "3   [{'olaparib'}, {'prednisone', 'olaparib', 'abi...             3   \n",
       "4                     [{'ado-trastuzumab emtansine'}]             1   \n",
       "5                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "6                                 [{'pembrolizumab'}]             1   \n",
       "7                [{'entrectinib'}, {'larotrectinib'}]             2   \n",
       "8                                                  []             0   \n",
       "9                                                  []             0   \n",
       "10                                                 []             0   \n",
       "11                                                 []             0   \n",
       "12                                                 []             0   \n",
       "13                                                 []             0   \n",
       "14                                                 []             0   \n",
       "15                                                 []             0   \n",
       "16                                                 []             0   \n",
       "17  [{'talazoparib'}, {'capivasertib', 'fulvestran...             2   \n",
       "18  [{'ado-trastuzumab emtansine'}, {'trastuzumab'...             1   \n",
       "19  [{'sacituzumab govitecan'}, {'trastuzumab deru...             2   \n",
       "20                                  [{'erdafitinib'}]             1   \n",
       "\n",
       "    missing_cnt  ...                               RAGLLM_full_output_0  \\\n",
       "0             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "1             0  ...  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "2             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "3             2  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "4             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "5             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "6             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "7             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "8             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "9             0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "10            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "11            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "12            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "13            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "14            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "15            0  ...  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "16            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "17            1  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "18           10  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "19            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "20            0  ...  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "\n",
       "                                 RAGLLM_full_output_1  \\\n",
       "0   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "1   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "2   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "3   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "4   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "5   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "6   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "7   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "8   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "9   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "10  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "11  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "12  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "13  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "14  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "15  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "16  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "17  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "18  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "19  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "20  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "\n",
       "                                 RAGLLM_full_output_2  \\\n",
       "0   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "1   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "2   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "3   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "4   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "5   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "6   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "7   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "8   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "9   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "10  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "11  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "12  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "13  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "14  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "15  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "16  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "17  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "18  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "19  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "20  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "\n",
       "                                 RAGLLM_full_output_3  \\\n",
       "0   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "1   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "2   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "3   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "4   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "5   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "6   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "7   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "8   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "9   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "10  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "11  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "12  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "13  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "14  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "15  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "16  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "17  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "18  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "19  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "20  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "\n",
       "                                 RAGLLM_full_output_4  \\\n",
       "0   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "1   {\\n    \"There are no FDA-approved drugs for th...   \n",
       "2   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "3   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "4   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "5   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "6   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "7   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "8   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "9   {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "10  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "11  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "12  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "13  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "14  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "15  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "16  {\\n    \"There are no FDA-approved drugs for th...   \n",
       "17  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "18  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "19  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "20  {\\n    \"Treatment 1\": {\\n        \"Disease Name...   \n",
       "\n",
       "                                RAGLLM_input_prompt_0  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_1  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_2  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_3  \\\n",
       "0   \\n    Context information is below.\\n    -----...   \n",
       "1   \\n    Context information is below.\\n    -----...   \n",
       "2   \\n    Context information is below.\\n    -----...   \n",
       "3   \\n    Context information is below.\\n    -----...   \n",
       "4   \\n    Context information is below.\\n    -----...   \n",
       "5   \\n    Context information is below.\\n    -----...   \n",
       "6   \\n    Context information is below.\\n    -----...   \n",
       "7   \\n    Context information is below.\\n    -----...   \n",
       "8   \\n    Context information is below.\\n    -----...   \n",
       "9   \\n    Context information is below.\\n    -----...   \n",
       "10  \\n    Context information is below.\\n    -----...   \n",
       "11  \\n    Context information is below.\\n    -----...   \n",
       "12  \\n    Context information is below.\\n    -----...   \n",
       "13  \\n    Context information is below.\\n    -----...   \n",
       "14  \\n    Context information is below.\\n    -----...   \n",
       "15  \\n    Context information is below.\\n    -----...   \n",
       "16  \\n    Context information is below.\\n    -----...   \n",
       "17  \\n    Context information is below.\\n    -----...   \n",
       "18  \\n    Context information is below.\\n    -----...   \n",
       "19  \\n    Context information is below.\\n    -----...   \n",
       "20  \\n    Context information is below.\\n    -----...   \n",
       "\n",
       "                                RAGLLM_input_prompt_4  \n",
       "0   \\n    Context information is below.\\n    -----...  \n",
       "1   \\n    Context information is below.\\n    -----...  \n",
       "2   \\n    Context information is below.\\n    -----...  \n",
       "3   \\n    Context information is below.\\n    -----...  \n",
       "4   \\n    Context information is below.\\n    -----...  \n",
       "5   \\n    Context information is below.\\n    -----...  \n",
       "6   \\n    Context information is below.\\n    -----...  \n",
       "7   \\n    Context information is below.\\n    -----...  \n",
       "8   \\n    Context information is below.\\n    -----...  \n",
       "9   \\n    Context information is below.\\n    -----...  \n",
       "10  \\n    Context information is below.\\n    -----...  \n",
       "11  \\n    Context information is below.\\n    -----...  \n",
       "12  \\n    Context information is below.\\n    -----...  \n",
       "13  \\n    Context information is below.\\n    -----...  \n",
       "14  \\n    Context information is below.\\n    -----...  \n",
       "15  \\n    Context information is below.\\n    -----...  \n",
       "16  \\n    Context information is below.\\n    -----...  \n",
       "17  \\n    Context information is below.\\n    -----...  \n",
       "18  \\n    Context information is below.\\n    -----...  \n",
       "19  \\n    Context information is below.\\n    -----...  \n",
       "20  \\n    Context information is below.\\n    -----...  \n",
       "\n",
       "[21 rows x 27 columns]"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_supp_df = pd.concat([real_rag_res_cnt_df_4, drug_output_df, full_output_df, input_df], axis=1)\n",
    "real_supp_df.to_csv(f\"./{base_model}_real_4_supp_df.csv\", index=False)\n",
    "real_supp_df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
